"id_article","title","doi","detection_principle","testing_method_category","target","testing_method","testing_method_additional_info","reported_performance","sample_size","assay_type","peer_reviewed","notes","last_updated",
"1232"," A new and rapid approach for detecting COVID-19 based on S1 protein fragments.","10.1002/ctm2.90","ImmunoAssay-Antigen","Other","S1","new rapid detetion kit","colloidal gold immunochromatography assay for IgM/IgG antibodies against the receptor?binding domain of  SARS?CoV?2 S1 protein","IgM: sensitivity 90.67%, specificity 97.84%, and accuracy 95.33%.  IgG: sensitivity 69.33%, specificity 99.28%, and accuracy 88.79%; combination of IgM and IgG: sensitivity 92.00%, specificity  97.12% and accuracy 95.33%.","75 positive and 139 negative","","yes","","2021-05-27 10:17:26",
"1237"," Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalised COVID-19 patients.","10.1016/j.ijid.2021.01.038","ImmunoAssay-Antibody","Other Immuno assay","Ig","Abbott, Euroimmun, Snibe, Cellex, Getein, Innovita, Liming Bio, Leccurate, Medomics, Render, Sd, ","testing of semiquantitative (enzyme-linked immune-absorbent assays [ELISA] and chemiluminescence immunoassays [CLIA]) and qualitative assays (lateral flow immunoassays [LFIA]) from 11 different suppliers ","Specificity: 97.4% (Abbott, Euroimmun), 88.6% (Snibe), 76% (Cellex), 96% (Getein, SD, Leccurate), 97.1% (Innovita), 100% (Liming, Render), 95.8% (Medomics) ; Sensitivity: 87.9% (Abbott), 91.4% (Euroimmun), 90.6% (Snibe), 87.5% (Cellex), 83.3% (Getein, Innovita), 75% (Leccurate), 82.9% (Liming), 77.8% (Medomics), 80% (Render), 81.3% (SD) ; NPA: 99.3% (Abbott, Snibe, Getein, SD), 99.6% (Euroimmun), 99.1% (Cellex, Innovita, Leccurate, Medomics), 99.2% (Liming), 99% (Renger) ; PPV: 99.8% (Abbott, Euroimmun, Innovita), 99.3% (Snibe), 98.4% (Cellex), 99.7% (Getein, Leccurate, Medomics, SD), 100% (Liming, Renger) ; Remarks: all reported values are for combined Ig detection but single Ig detection values are also available. Sensitivity values are for more than 21 days since symptoms onset but values for earlier determinations are also available. Reported NPA and PPA values are calculated on 3% and 95% population prevalence, respectively, but other values are also available.","126 patients","","yes","","2021-05-27 10:17:34",
"1233"," Validation of COVID-19 serologic tests and large scale screening of asymptomatic healthcare workers.","10.1016/j.clinbiochem.2021.01.004","ImmunoAssay-Antibody","ELISA","IgG, IgM, IgA","Ortho-Clinical Diagnostics VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack and University of Maryland Medical Center Enzyme Linked Immunosorbant Assay (UMMC ELISA)","evaluation of serological tests using RT-PCR tested samples","Sensitivity: 100% (VITROS), 97.6% (ELISA) ; Specificity: 99.3% (VITROS), 100% (ELISA); PPA: 82.2% (VITROS), 100% (ELISA), 100% (combined) ; NPA: 100% (VITROS), 99.9% (ELISA), 100% (combined) ; Concordance: 98.8%","288 samples","","yes","","2021-05-27 10:17:28",
"1132",""No dose"" lung ultrasound correlation with ""low dose"" CT scan for early diagnosis of SARS-CoV-2 pneumonia"","10.1007/s00134-020-06058-7","mixed","In_silico","ground glass opacities (GGOs), consolidation and crazy-paving pattern"," lung  ultrasonography performed in close temporal relationship to the chest CT"," ","Remark: Lung  ultrasonography  may  be  considered  a  useful  alternative  to  low-dose  chest  CT  for  diagnosis  and  management  of  COVID-19  given  its  ease  of use, repeatability, reproducibility, absence of radiation","1 patient"," ","yes","","2021-05-27 10:14:08",
"1","2019 Novel Coronavirus can be detected in urine, blood, anal swabs and oropharyngeal swabs samples","10.1101/2020.02.21.20026179","NucleicAcid-PCR based","Other PCR method(s)","Not specified","Other method","","Not reported","9 samples","","no","","2021-05-27 09:42:17",
"475","2019 novel coronavirus disease (Covid-19): Detection and diagnosis system using iot based smart glasses","/","Others"," ","/","detection of suspected covid-19 cases using smart glasses to detect high body temperature ","Full article available at: http://sersc.org/journals/index.php/IJAST/article/download/10105/5507/","/","/","","yes","","2021-05-27 09:54:17",
"901","2019-nCoV: The identify-isolate-inform (3I) Tool applied to a novel emerging coronavirus","10.5811/westjem.2020.1.46760","Others","In_silico","symptoms and epidemiological risk factors","Identify-Isolate-Inform (3I) Tool","the 3I Tool assists clinicians in managing persons with suspected or confirmed 2019-nCoV","/","/"," ","yes","","2021-05-27 10:07:27",
"1091","A blueprint for the implementation of a validated approach for the detection of SARS-Cov2 in clinical samples in academic facilities","10.12688/wellcomeopenres.15937.2","NucleicAcid-PCR based","RT-PCR","ORF1","RT-PCR in house","setting up research lab facilities and validation of testing method for virus detection","100% correlation between the test results initially generated by the diagnostic laboratory and the research laboratory","40 samples","","yes","","2021-05-27 10:12:44",
"121","A blueprint for the implementation of a validated approach for the detection of SARS-Cov2 in clinical samples in academic facilities","10.1101/2020.04.14.041319","NucleicAcid-PCR based","Other PCR method(s)","Not specified","In-house method","","100% correlation between diagnostic and research tests ","30 samples","","no","","2021-05-27 09:45:04",
"166","A case of SARS-CoV-2 carrier for 32 days with several times false negative nucleic acid tests","10.1101/2020.03.31.20045401","NucleicAcid-PCR based","PCR_KIT","RdRp-region, E-gene, N-gene, S-gene","Multiple-kits","Kits: various suppliers","Not reported","1 patient","","no","","2021-05-27 09:45:57",
"501","A case-based reasoning framework for early detection and diagnosis of novel coronavirus","10.1016/j.imu.2020.100395","Others","In_silico","Patient medical records","Case-based Reasoning framework","","Accuracy: 94.54%","71 patients","","yes","","2021-05-27 09:55:09",
"595","A combined oropharyngeal/nares swab is a suitable alternative to nasopharyngeal swabs for the detection of SARS-CoV-2","10.1016/j.jcv.2020.104442","NucleicAcid-PCR based","PCR_KIT","E, RdRP (In house); ORF1ab, E (Cobas); E, N2 (Xpert)","kit & in-house","Cobas 6800 system (Roche Diagnostics) & laboratory-developed test (LDT) designed at the British Columbia Centre for Disease Control (BCCDC) (Vancouver, BC) & Xpert Xpress SARS-CoV-2 assay (Cepheid)","Specificity: 100% (all); Sensitivity: 94.4% (LDT, NasoPharingeal swabs), 100% ( commercial kit, NP swabs), 91.7 (LDT, OroPharingeal swabs), 88.9% (commercial kit, OP swabs)","190 samples","","yes","","2021-05-27 09:57:53",
"406","A comparison of health care worker-collected foam and polyester nasal swabs in convalescent COVID-19 patients","10.1101/2020.04.28.20083055","Others"," ","S Gene, ORF1ab, and N Gene","PCR method used only for swabs comparison","Comparison between polyester and foam nasal swabs","Sensitivity: 86% (polyester swabs in saline), 72.4% (dry polyester swabs)  ","139","","no","","2021-05-27 09:52:01",
"978","A deep learning approach to characterize 2019 coronavirus disease (COVID-19) pneumonia in chest CT images","10.1007/s00330-020-07044-9","Imaging-CT scan","In_silico","CT-scans","CT-scan","deep learning model for automatic detection of abnormalities in chest CT images from COVID-19 patients","sensitivity: 100% ; remarks: more detailed performance data in tables","14435 patients","","yes","","2021-05-27 10:09:22",
"810","A deep learning based hybrid approach for covid-19 disease detections","10.18280/ts.370313","Imaging-X-ray","Other","X-ray","","deep learnin hybrid based approach","Accuracy: 96.30%","700 images","","yes","","2021-05-27 10:04:47",
"714","A Deep Learning System to Screen Novel Coronavirus Disease 2019 Pneumonia","10.1016/j.eng.2020.04.010","Imaging-CT scan"," ","CT images","deep learning","early screening model to distinguish COVID-19 from IAVP and healthy cases through pulmonary CT images using deep learning techniques","overall accuracy rate: 86.7%","618 images","","yes","","2021-05-27 10:01:36",
"1129","A diagnostic model for coronavirus disease 2019 (COVID-19) based on radiological semantic and clinical features: a multi-center study","10.1007/s00330-020-06829-2","Imaging-CT scan","In_silico","1745 lesions and 67 clinical features","To identify differences in CT imaging and clinical manifestations between pneumonia patients with and without COVID-19, and to develop and validate a diagnostic model for COVID-19 based on radiological semantic and clinical features alone."," ","Remark: Three diagnostic models achieved an area under the curve value as high as 0.986 (95% CI 0.966~1.000). The clinical and radiological semantic models provided a better diagnostic performance and more considerable net benefits."," 70 patients with covid and 66 patients with pneumonia"," ","yes","","2021-05-27 10:14:02",
"265","A field indoor air measurement of SARS-CoV-2 in the patient rooms of the largest hospital in Iran","10.1016/j.scitotenv.2020.138401","NucleicAcid-PCR based","PCR_KIT","RdRp-region, E-gene, S-gene ","Individual-kit","Kit: ModularDx, Life Science, Berlin, Germany","Not reported","","","yes","","2021-05-27 09:48:15",
"718","A fully automated centrifugal microfluidic system for sample-to-answer viral nucleic acid testing","10.1007/s11426-020-9800-6","NucleicAcid-PCR based","LAMP","ORF1ab, N, E","LAMP","fully automated centrifugal microfluidic system with sample-in-answer-out capability","LOD: 2 copies per reaction (for armored RNA particles) ","spiked samples","","yes","","2021-05-27 10:01:42",
"167","A High Through-put Assay for Circulating Antibodies Directed against the S Protein of Severe Acute Respiratory Syndrome Corona virus 2","10.1101/2020.04.14.20059501","ImmunoAssay-Antibody"," ","Total antibody on S-protein","ELISA individual-kit","Kit: Luminex binding Ab assay","Not reported","8 patients","","no","","2021-05-27 09:45:59",
"1055","A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation","10.1101/2020.05.21.109546","ImmunoAssay-Antibody","Other Immuno assay","Ab ","fluorescence-based high-throughput neutralization assay","The assay was built on a stable mNeonGreen (mNG) SARS-CoV-2 where the mNG gene was engineered at the ORF7 of the viral genome","Remark: NT50 values comparable to the conventional PRNT assay","120 samples (clinical evaluation), 150 samples (cross reactivity)","","yes","","2021-05-27 10:11:30",
"566","A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation","10.1038/s41467-020-17892-0","ImmunoAssay-Antibody"," ","Not specified","mNG","A high-throughput fluorescence-based neutralization assay (mNG)","Specificity: 100%; Remark: mNG SARS-CoV-2 assay has a higher sensitivity than the conventional PRNT assay ","60 positive & 60 negative & 150 samples (cross reactivity)","","yes","","2021-05-27 09:57:01",
"168","A Highly Scalable and Rapidly Deployable RNA Extraction-Free COVID-19 Assay by Quantitative Sanger Sequencing","10.1101/2020.04.07.029199","NucleicAcid-PCR based","WHO method(s)","N-gene","WHO-3","WHO-3 used in qSanger","LOD: 10-20 genome copy equivalent","Synthetic control","","no","","2021-05-27 09:46:01",
"694","A Hybrid COVID-19 Detection Model Using an Improved Marine Predators Algorithm and a Ranking-Based Diversity Reduction Strategy","10.1109/ACCESS.2020.2990893","Imaging-X-ray"," ","Lung ","Imaging-X-ray","a new hybrid model to detect the COVOD-19 using an improved marine predators algorithm (IMPA) and a ranking-based diversity reduction (RDR) strategy ","The performance of the proposed IMPA algorithm is shown to outperform all other investigated algorithms in the fitness values, Std, and a range of threshold metrics. In addition, the performance of the proposed model and EO was shown to be convergent on all the thresholds level in SSIM and UQI metrics."," "," ","yes","","2021-05-27 10:00:59",
"1082","A machine learning algorithm to increase COVID-19 inpatient diagnostic capacity","10.1371/journal.pone.0239474","Others","Other","erritin, lactate dehydrogenase [LDH], C-reactive protein, among others absolute lymphocyte count"," Machine learning algoritm ","Blood markers","Sensitivity: 0.93; Specificity: 0.64","392 blood samples","","yes","","2021-05-27 10:12:25",
"1097","A method to prevent SARS-CoV-2 IgM false positives in gold immunochromatography and enzyme-linked immunosorbent assays","10.1128/JCM.00375-20","ImmunoAssay-Antibody","GICA","IgM","GICA and ELISA","interference factors causing false-positive reactivity with the two methods were analyzed,and the urea dissociation test was employed to dissociate the SARS-CoV-2 IgM-positive serum ","after urea dissociation,  false positive: GICA 1/86; ELISA: 3/86 ","86 serum samples (19 covid)","","yes","","2021-05-27 10:12:56",
"497","A new COVID-19 Patients Detection Strategy (CPDS) based on hybrid feature selection and enhanced KNN classifier","10.1016/j.knosys.2020.106270","Others","In_silico","chest CT","Corona Patients Detection Strategy (CPDS)","","Accuracy:96%","/","","yes","","2021-05-27 09:55:01",
"389","A new role for Biofoundries in rapid prototyping, development, and validation of automated clinical diagnostic tests for SARS-CoV-2","10.1101/2020.05.02.20088344","NucleicAcid-Others","Mixed","N gene","RT-PCR CDC, CRISPR, LAMP","tested on automated platform for diagnosis with multiple methods","/","/","","no","","2021-05-27 09:51:26",
"518","A Novel Amplification-free SARS-CoV-2 Point-of-care Nucleic Acid Detection System based on Hybrid Capture Fluorescence Immunoassay","10.21203/rs.3.rs-33170/v1","NucleicAcid-Others"," ","ORF1ab, N, E","hybrid capture fluorescence immunoassay (HC-FIA) ","Performance evaluation vs RT-PCR","Sensitivity: 88.61% (all samples), 87.69% (throat swabs), 91.94% (sputum), 100% (HC-FIA and RT-PCR all samples); Specificity: 94.92%(all samples), 95.01% (throat swabs), 92.41% (sputum), 98.18% (HC-FIA and RT-PCR all samples).","734 samples from 670 subjects","","No","","2021-05-27 09:55:37",
"1071","A novel comparative study for detection of Covid-19 on CT lung images using texture analysis, machine learning, and deep learning methods","10.1007/s11042-020-09894-3","Imaging-CT scan","In_silico","CT scan","deep learning","Convolutional Neural Network (CNN), one of the deep learning methods, was used which suggested automatic classification of CT images of lungs for early diagnosis of Covid-19 disease. In addition, k-Nearest Neighbors (k-NN) and Support Vector Machine (SVM) was used to compare the classification successes of deep learning with machine learning.","sensitivity: 91.97% (2-fold cross-validation), 94.04% (10-fold cross-validation); specificity: 98.91% (2-fold cross-validation), 99.01% (10-fold cross-validation); accuracy: 94.73% (2-fold cross-validation), 95.99% (10-fold cross-validation); F-1 score: 90.58% (2-fold cross-validation), 92.84% (10-fold cross-validation); AUC values: 98.88% (2-fold cross-validation), 99.03% (10-fold cross-validation)  ","1396 images","","yes","","2021-05-27 10:12:03",
"169","A novel high specificity COVID-19 screening method based on simple blood exams and artificial intelligence","10.1101/2020.04.10.20061036","Others","In_silico","","","","","","","no","","2021-05-27 09:46:03",
"848","A Novel Medical Diagnosis model for COVID-19 infection detection based on Deep Features and Bayesian Optimization","10.1016/j.asoc.2020.106580","Imaging-X-ray","In_silico"," "," convolution neural network","Algorithm  automatically reveals discriminative features on chest X-ray images"," accuracy: 98.97%;  sensitivity: 89.39%;   specificity: 99.75%;  F-score: 96.72%","2905 images"," ","yes","","2021-05-27 10:05:54",
"915","A novel multiplex qrt-pcr assay to detect sars-cov-2 infection: High sensitivity and increased testing capacity","10.3390/microorganisms8071064","NucleicAcid-PCR based","RT-PCR","N gene","in house RT-qPCR and multiplex RT-qPCR based on WHO-7 (N1 and N2 targets)","direct (no prior RNA extraction) and multiplex RT-qPCR assay evaluation","Sensitivity: 100% (multiplex and N2), 90% (N1) ; specificity: 100% (multiplex)","27 patients","","yes","","2021-05-27 10:07:50",
"364","A novel reverse transcription loop-mediated isothermal amplification method for rapid detection of sars-cov-2","10.3390/ijms21082826","NucleicAcid-PCR based","LAMP","N gene","In-house LAMP","Novel LAMP assay shows high sensitivity, no cross reactivity with 17 common viruses, fast detection speed","LOD: 118.6 copies per 25 ?L reaction; positive rate: 63.4%; concordance rate: 92.9% (with RT-PCR)","56 samples","","yes","","2021-05-27 09:50:41",
"804","A Novel Scoring System for Prediction of Disease Severity in COVID-19","10.3389/fcimb.2020.00318","Others","In_silico"," 48 indicators","","use of logistic regression to select the risk factors to build a scoring system for prediction","AUC scoring: 0.906; sensitivity: 70.8%; specificity: 89.3%","22 patients","","yes","","2021-05-27 10:04:36",
"2","A one-enzyme RT-qPCR assay for SARS-CoV-2, and procedures for reagent production","10.1101/2020.03.29.013342","NucleicAcid-PCR based","WHO method(s)","N-gene","WHO-7","","None tested","Not reported","","no","","2021-05-27 09:42:19",
"922","A one-step, one-tube real-time RT-PCR based assay with an automated analysis for detection of SARS-CoV-2","10.1016/j.heliyon.2020.e04405","NucleicAcid-PCR based","RT-PCR","N1 and N2","in house method","development of a rapid and accurate one-step multiplex TaqMan probe-based real-time RT-PCR assay, along with a computational tool to systematically analyse the data.","LOD: 15 copies; sensitivity: 100%; specificity: 100%","26 clinical samples","","yes","","2021-05-27 10:08:02",
"20","A Peptide-based Magnetic Chemiluminescence Enzyme Immunoassay for Serological Diagnosis of Corona Virus Disease 2019 (COVID-19)","10.1101/2020.02.22.20026617","ImmunoAssay-Antibody"," ","IgM/IgG on S-protein","ELISA in-house-method","Peptide-based luminescent immunoassay","Sensitivity: 71.4% (IgG), 57.2% (IgM), 81, 5% (IgG+IgM)","276 patient","","no","","2021-05-27 09:42:47",
"818","A Peptide-Based Magnetic Chemiluminescence Enzyme Immunoassay for Serological Diagnosis of Coronavirus Disease 2019","10.1093/infdis/jiaa243","ImmunoAssay-Antibody","Other Immuno assay","IgG, IgM","MCLIA (magnetic chemiluminescence enzyme immuno assay)"," ","detection rate: 71.4% (IgG), 57.2% (IgM), 81.5% (IgG+IgM)","276 patients"," ","yes","","2021-05-27 10:05:01",
"405","A possible role of immunopathogenesis in COVID-19 progression","10.1101/2020.04.28.20083089","Others"," ","circulating immune cells,  antigen specific T-cells, and humoral immunity ","Flow citometry","immunoprofiling","/","53","","no","","2021-05-27 09:51:59",
"1073","A predictive score for COVID-19 diagnosis using clinical, laboratory and chest image data","10.1016/j.bjid.2020.06.009","mixed","Mixed","CT scan","","CT scan, leukopenia and LDH values to forecast coronavirusq","Leukocytes count: <7.7x10e3mme-3; LDH : >273 U/L; Sensitivity: 96%; Specificity: 73.5%","100 patients","","yes","","2021-05-27 10:12:07",
"1210","A preliminary study on analytical performance of serological assay for SARS-CoV-2 IgM/IgG and application in clinical practice","10.1101/2020.05.05.20092551","ImmunoAssay-Antibody","Mixed","IgM and IgG targeting N+ORF1a/b or N+S1; or S; or S1","IgM and IgG Shenzhen YHLO Biotech, TISENC, Wondfo"," ","Postive Rate Detection Yahuilong IgG: 91.67%; Postive Rate Detection Yahuilong IgM: 33.33%; Positive Rate Detection TISENC IgG: 83.33%, Positive Rate Detection TISENC IgM: 8.33%; Positive Rate Detection of Ab Wondfo: 83.33% ","419 patients","","no","","2021-05-27 10:16:41",
"21","A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients","10.1101/2020.03.06.20031856","ImmunoAssay-Antibody"," ","IgM/IgG on N-protein","ELISA individual-kit","","Specificity: tested ; Sensitivity: 81.5% (11 dpo), 20% (0-5 dpo)","238 patients ","","no","","2021-05-27 09:42:50",
"577","A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients","10.1016/j.micinf.2020.05.008","ImmunoAssay-Antibody"," ","IGm IgG vs N (ELISA); ORF1ab, N (PCR)","ELISA and RT-PCR kit","ELISA kit: Lizhu, Zhuhai, China; PCR kit: Daan, Guangzhou, China","Specificity: 100% (control subjects), 94.3% (patients); sensitivity: 93% (>11 dpo)","238 patients & 50 controls","","yes","","2021-05-27 09:57:20",
"1278","A Public Website for the Automated Assessment and Validation of SARS-CoV-2 Diagnostic PCR Assays.","10.1093/bioinformatics/btaa710","Others","In_silico","/","/","website for the automated assessment and validation of SARS-CoV-2 diagnostic PCR assays","/","/","","yes","","2021-05-27 10:18:58",
"908","A quantitative and radiomics approach to monitoring ards in COVID-19 patients based on chest CT: A retrospective cohort study","10.7150/ijms.48432","Imaging-CT scan","In_silico","","","monitor ARDS from CT images using radiomics or traditional quantitative analysis in COVID-19","Specificity: 97% (traditional quantitative model), 86% (radiomics model), 98% (combined model) ; sensitivity: 55% (traditional quantitative model), 82% (radiomics model), 58% (combined model)","86 patients (352 CT images)","","yes","","2021-05-27 10:07:39",
"290","A Rapid COVID-19 RT-PCR Detection Assay for Low Resource Settings","10.1101/2020.04.29.069591","NucleicAcid-PCR based","WHO method(s)","N1, N2","In-house rapid test with CDC oligos","12 minutes test","Not specified","Not specified","","no","","2021-05-27 09:48:50",
"1259","A Rapid High-Sensitivity SARS-CoV-2 Nucleocapsid Immunoassay to Aid Diagnosis of Acute COVID-19 at the Point of Care: A Clinical Performance","10.1007/s40121-021-00413-x","ImmunoAssay-Antigen","Other","nucleocapside protein","LumiraDx SARS-CoV-2 antigen","microfluidic immunoassay to detect the nucleocapsid protein of SARS-CoV-2. Comparison to rt-PCR Roche cobas 6800 platform","nasal swab test: sensitivity 97.6% specificity96.6%. nasopharyngeal swab: sensitivity 97.5%; specificity 97.7% ","512 patients","","yes","","2021-05-27 10:18:19",
"306","A rapid, low cost, and highly sensitive SARS-CoV-2 diagnostic based on whole genome sequencing","10.1101/2020.04.25.061499","NucleicAcid-PCR based","NGS","","Whole-genome sequencing of SARS-CoV-2","","LoD of 84 genome equivalents per milliliter","10 samples","","no","","2021-05-27 09:49:23",
"674","A Rapid, Simple, Inexpensive, and Mobile Colorimetric Assay COVID-19-LAMP for Mass On-Site Screening of COVID-19","10.3390/ijms21155380","NucleicAcid-PCR based","LAMP","ORF3a, E","in house","one-step colorimetric reverse-transcriptional loop-mediated isothermal amplification assay (COVID-19-LAMP) for detection of SARS-CoV-2","sensitivity: 95.07% (LAMP 60 min), 98.21% (LAMP, 90 min), 96.88%-98.96% (NP swabs), 94.03%-97.02% (sputum/deep throat saliva), 93.33%-98.33% (throat swab); specificity: 100%; LOD: 42 copies/reaction","366 samples","","yes","","2021-05-27 10:00:18",
"123","A report of three COVID-19 cases with prolonged viral RNA detection in anal swabs","10.1016/j.cmi.2020.04.010","NucleicAcid-PCR based","PCR_KIT","ORF1ab-gene, N-gene","Individual-kit","Kit: Biogerm,  Shanghai,  China","Not reported","3 samples","","yes","","2021-05-27 09:45:06",
"764","A reverse-transcription recombinase-aided amplification assay for the rapid detection of N gene of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","10.1016/j.virol.2020.07.006","NucleicAcid-PCR based","RT-PCR","N gene","in house","a real-time reverse-transcription recombinase-aided amplification assay (RT-RAA) ","LOD: 10 cpr; kappa value: 0.959","150 specimens","","yes","","2021-05-27 10:03:16",
"326","A RT-PCR Assay for the Detection of Coronaviruses from Four Genera","10.1016/j.jcv.2020.104391","NucleicAcid-PCR based","Other PCR method(s)","","","","LOD 4 to 4x10e2 copies/reaction","192 samples","","yes","","2021-05-27 09:50:02",
"849","A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction","10.1038/s41587-020-0631-z","ImmunoAssay-Antibody","ELISA","total immunodominant neutralizing antibodies targeting the S protein","in house ELISA"," test  based on antibody-mediated blockage of the interaction between the ACE2 receptor protein and the receptor-binding domain","specificity: 99.93%, sensitivity: 95-100%","60 samples"," ","yes","","2021-05-27 10:05:56",
"418","A SARS-CoV-2 vaccine candidate would likely match all currently circulating strains","10.1101/2020.04.27.064774","Others","In_silico","/","/","sequence diversity analysis","/","5700 sequenced samples","","no","","2021-05-27 09:52:26",
"170","A Scalable, Easy-to-Deploy, Protocol for Cas13-Based Detection of SARS-CoV-2 Genetic Material","10.1101/2020.04.20.052159","NucleicAcid-Others","CRISPR","Multiple targets on N-gene","WHO-7","","LOD: 10 cpu","Not reported","","no","","2021-05-27 09:46:05",
"1110","A serological assay to detect SARS-CoV-2 antibodies in at-home collected finger-prick dried blood spots","10.1038/s41598-020-76913-6","ImmunoAssay-Antibody","Other Immuno assay","antibodies against S1 protein","modified Antibody Detection by Agglutination-PCR (ADAP) ","dried blood spot collection kit containing spot card for self testing","Specificity: 100% ; sensitivity: 100% ; PPV: 100% ; NPV: 100%","111 samples","","yes","","2021-05-27 10:13:23",
"23","A serological assay to detect SARS-CoV-2 seroconversion in humans","10.1101/2020.03.17.20037713","ImmunoAssay-Antibody"," ","S-protein ","ELISA in-house-method","","Not reported","4 patients","","no","","2021-05-27 09:42:52",
"171","A simple colorimetric molecular detection of novel coronavirus (COVID-19), an essential diagnostic tool for pandemic screening","10.1101/2020.04.10.20060293","NucleicAcid-Others","LAMP","N-gene, ORF gene","Other method","","LOD: 10 cpr (N gene), 100 cpr (ORF)","Not reported","","no","","2021-05-27 09:46:07",
"1041","A simple magnetic nanoparticles-based viral RNA extraction method for efficient detection of SARS-CoV-2","10.1101/2020.02.22.961268","NucleicAcid-PCR based","RT-PCR","ORF1ab, N gene","Magnetic Nano Particles RNA extraction","viral RNA extraction by Magnetic NanoParticles and RT-PCR","sensitivity: 10 copies/reaction","","","no","","2021-05-27 10:11:01",
"904","A simple method for detection of a novel coronavirus (SARS-CoV-2) using one-step RT-PCR followed by restriction fragment length polymorphism","10.1002/jmv.26171","NucleicAcid-PCR based","RT-PCR","RdRP, E-gene","in house RT-PCR + RFLP","assays were designed to target conserved regions of the RdRP gene and E gene","sensitivity: 95%; specificity: 100%","50 samples"," ","yes","","2021-05-27 10:07:31",
"25","A Single and Two-Stage, Closed-Tube, Molecular Test for the 2019 Novel Coronavirus (COVID-19) at Home, Clinic, and Points of Entry","10.26434/chemrxiv.11860137.v1","NucleicAcid-PCR based","LAMP","ORF1ab-gene","Other method","","Specificity: tested","No clinical samples","","no","","2021-05-27 09:42:54",
"1282","A Streamlined Approach to Rapidly Detect SARS-CoV-2 Infection Avoiding RNA Extraction: Workflow Validation.","10.1155/2020/8869424","NucleicAcid-PCR based","RT-PCR","E","RT-PCR without RNA extraction","fast and cost-effective viral genome isolation method that, combined with quantitative RT-PCR assay, detects SARS-CoV-2 RNA","LOD: 10 viral copies/sample; Sensitivity: 90%; Specificity: 100%","60 patients","","yes","","2021-05-27 10:19:07",
"172","A streamlined approach to rapidly detect SARS-CoV-2 infection, avoiding RNA extraction","10.1101/2020.04.06.20054114","NucleicAcid-PCR based","PCR_KIT","E-gene","Individual-kit","Kit: Roche with ddPCR for validation","LOD: 10 cpr","500 swabs","","no","","2021-05-27 09:46:09",
"854","A systematic review of CT chest in COVID-19 diagnosis and its potential application in a surgical setting","10.1111/codi.15252","Imaging-CT scan","Other"," ","review","literature study into the sensitivity and utility of chest CT in diagnosing COVID-19","performance of 17 methods listed in table 1","/"," ","yes","","2021-05-27 10:06:05",
"533","A throughput serological Western blot system using whole virus lysate for the concomitant detection of antibodies against SARS-CoV-2 and human endemic Coronaviridae","10.1101/2020.07.31.20165019","ImmunoAssay-Antibody"," ","IgG","Western blot","Bead based Western Blot system (DigiWest)","Sensitivity: 87.2 %;  specificity: 100 % ","263 samples","","no","","2021-05-27 09:56:02",
"483","Accuracy and reproducibility of low-dose submillisievert chest CT for the diagnosis of COVID-19","10.1148/ryct.2020200196","Others"," ","chest CT ","Low-dose submillisievert chest CT ","/","sensitivity: 86.7%; specificity: 93.6%; positive predictive value:91.1%; negative predictive value:90.3%; accuracy: 90.2%","192 patients","","yes","","2021-05-27 09:54:32",
"1069","Accuracy of a nucleocapsid protein antigen rapid test in the diagnosis of SARS-CoV-2 infection","10.1016/j.cmi.2020.09.057","ImmunoAssay-Antigen","Other Immuno assay","NP","Fluorescence immunochromatography (FIC)","A rapid method was developed based on fluorescence immunochromatographic (FIC) assay to detect the SARS-CoV-2 NP antigen.","sensitivity: 75.6%; specificity:100%; percent agreement: 80.5%","251 patients","","yes","","2021-05-27 10:11:58",
"3","Accurate Identification of SARS-CoV-2 from Viral Genome Sequences using Deep Learning","10.1101/2020.03.13.990242","Others","In_silico","","","","","","","no","","2021-05-27 09:42:21",
"173","Accurate Prediction of COVID-19 using Chest X-Ray Images through Deep Feature Learning model with SMOTE and Machine Learning Classifiers","10.1101/2020.04.13.20063461","Others","In_silico","","","","","","","no","","2021-05-27 09:46:11",
"4","Ad hoc laboratory-based surveillance of SARS-CoV-2 by real-time RT-PCR using minipools of RNA prepared from routine respiratory samples","10.1101/2020.03.30.20043513","NucleicAcid-PCR based","WHO method(s)","E-gene","WHO-5","","LOD: 48 cpr","5 labs tested the pool approach","","no","","2021-05-27 09:42:23",
"803","Ad hoc laboratory-based surveillance of SARS-CoV-2 by real-time RT-PCR using minipools of RNA prepared from routine respiratory samples","10.1016/j.jcv.2020.104381","NucleicAcid-PCR based","RT-PCR","","","focus on pooling strategy for samples (minipools of 10 samples each)","/","700 samples","","yes","","2021-05-27 10:04:34",
"383","ai-corona: Radiologist-Assistant Deep Learning Framework for COVID-19 Diagnosis in Chest CT Scans","10.1101/2020.05.04.20082081","Others","In_silico","CT scan","ai-corona (deep learning framework)","use of Convolutional Neural Networks (CNN) to detect covid infection in CT scan","sensitivity: 92.4%; specificity: 98.3%","2121","","no","","2021-05-27 09:51:14",
"490","AI4COVID-19: AI enabled preliminary diagnosis for COVID-19 from cough samples via an app","10.1016/j.imu.2020.100378","Others","In_silico","Cough","Artificial intelligence screening solution","Deep Transfer Learning-based Multi Class classifier (DTL-MC); Classical Machine Learning-based Multi Class classifier (CML-MC); Deep Transfer Learning-based Binary Class classifier (DTL-BC)","Accuracy: 92.64% (DTL-MC), 88.76% (CML-MC), 92.85% (DTL-BC); sensitivity: 89.14% (DTL-MC), 91.71 (CML-MC), 94.57 (DTL-BC); specificity: 96.67% (DTL-MC), 95.27 (CML-MC), 91.14% (DTL-BC); precision:89.91% (DTL-MC), 86.60% (CML-MC), 91.43 (DTL-BC)","543 cough samples (96 bronchitis, 130 pertussis, 70 COVID, 247 normal coughts)","","yes","","2021-05-27 09:54:46",
"26","All-in-One Dual CRISPR-Cas12a (AIOD-CRISPR) Assay: A Case for Rapid, Ultrasensitive and Visual Detection of Novel Coronavirus SARS-CoV-2 and HIV virus","10.1101/2020.03.19.998724","NucleicAcid-Others","CRISPR","N-gene","Proof of concept","","LOD: 1.2 cpr (DNA), 4.6 cpr (RNA)","Not reported","","no","","2021-05-27 09:42:56",
"593","Alltest rapid lateral flow immunoassays is reliable in diagnosing SARS-CoV-2 infection from 14 days after symptom onset: A prospective single-center study","10.1016/j.jcv.2020.104473","ImmunoAssay-Antibody"," ","IgM, IgG","kit (LFIA)","AllTest COVID-19 IgG/IgM","Specificity: 100%; Sensitivity: 64.4% (overall), 88% (14 dpo)","90 positive & 100 negative samples","","yes","","2021-05-27 09:57:49",
"340","An acceptable method to evaluate the analytical performance of real-time fluorescent RT-PCR targeting SARS-CoV-2","10.1101/2020.05.18.20105247","NucleicAcid-PCR based","PCR_KIT","ORF1ab, N ","Sansure Biotech kit","Analytical performance evaluation of RT-PCR vs template preparation, transport medium, storage temperature","Not reported ","Not specified","","no","","2021-05-27 09:50:27",
"124","An alternative workflow for molecular detection of SARS-CoV-2 - escape from the NA extraction kit-shortage, Copenhagen, Denmark, March 2020","10.2807/1560-7917.es.2020.25.14.2000398","NucleicAcid-PCR based","PCR_KIT","E-gene","Multiple-kits and other method","Kit: Altona Diagnostics, Hamburg, Germany. Other method SensiFAST","Sensitivity: 97.4% (sensiFAST) ; Specificity: 100% (sensiFAST) ; Accuracy: 98.3% (sensiFAST) ; Remark: RealStar kit inhibited","87 patients","","yes","","2021-05-27 09:45:08",
"658","An approach to a perceived risk of venous thromboembolism in non-ICU COVID-19 patients in Singapore","10.1177/2010105820943904","Others"," ","","","Short communication: correlation with Covid-19 with coagulation activation and venous thromoembolism (VTE)","","","","yes","","2021-05-27 09:59:45",
"371","An assessment of real-time RT-PCR kits for SARS-CoV-2 detection","10.7883/yoken.JJID.2020.108","NucleicAcid-PCR based","Other PCR method(s)","N1, N2","in house RT-PCR","Comparison of a developed test assay with the LightMix Modular SARS and Wuhan CoV E-gene (LN S&W-E), Cov N-gene (LM S&W-N) and Cov RdRP gene (LM W-RdRP) assay ","Remark: LM W-RdRP set was less sensitive than the others, LM S&W-E and LM S&W-N kits show high sensitivities, in house developed test N2 set is more sensitive than the N set ","25 samples","","yes","","2021-05-27 09:50:51",
"1035","An automated Residual Exemplar Local Binary Pattern and iterative ReliefF based corona detection method using lung X-ray image","10.1016/j.chemolab.2020.104054","Imaging-X-ray","In_silico","x-ray","deep learning","a novel intelligent computer vision method to automatically detect the Covid-19 virus isproposed, detect Covid-19 by using a computer vision method (without human).","accuracy: 99.69% (ResExLBP); 100%(IRF)","321 images","","yes","","2021-05-27 10:10:48",
"1111","An enhanced isothermal amplification assay for viral detection","10.1038/s41467-020-19258-y","NucleicAcid-PCR based","Other PCR method(s)","S and N genes","eRPA enhanced recombinase polymerase amplification","development of RT-RPA assay combined with a commercial lateral flow assay (LFA) for saliva testing","","","","yes","","2021-05-27 10:13:25",
"889","An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection","10.1016/j.antiviral.2020.104882","ImmunoAssay-Others","ELISA","S protein","in house in-cell ELISA","novel enzyme-based immunodetection assay that directly quantifies the amount of de novo synthesized viral spike protein within fixed and permeabilized cells","","","","yes","","2021-05-27 10:07:04",
"691","An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment","10.1038/s41467-020-17317-y","ImmunoAssay-Antibody"," ","IgA, IgG, IgM, multiple targets","kits","a) Wantai Ig total ELISA, (b) Wantai IgM ELISA, (c) Euroimmun IgG ELISA, (d) Euroimmun IgA ELISA, (e)  DiaSorin Liaison XL IgG chemiluminescence immunoassay, (f) Cellex IgM/IgG, (g) InTec IgM/IgG, (h) Orient gene/Healgen IgM/IgG compared to an in-house plaque-reduction neutralization test (PRNT50) used as a reference ","Specificity: 99% (Wantai Ig tot), 99% (Wantai IgM), 99% (Euroimmun IgG), 94% (Euroimmun IgA), 90% (Liaison), 99% (Cellex), 85% (Intec), 88% (Orient/Healgen); Sensitivity: 99% (Wantai Ig tot), 90% (Wantai IgM), 81% (Euroimmun IgG), 97% (Euroimmun IgA), 81% (Liaison), 89% (Cellex), 90% (Intec), 100% (Orient/Healgen). Remark: Wantai ELISA detecting total Ig has the best overall characteristics to detect functional antibodies in different stages and severity of disease","147 samples (187 samples sensitivity)","","yes","","2021-05-27 10:00:53",
"28","An ultrasensitive, rapid, and portable coronavirus SARS-CoV-2 sequence detection method based on CRISPR-Cas12","10.1101/2020.02.29.971127","NucleicAcid-Others","CRISPR","ORF1ab-gene","WHO-7, WHO-3, WHO-1","","LOD:  10 cpu (WHO-1)","No clinical samples","","no","","2021-05-27 09:42:58",
"602","Analysis of adjunctive serological detection to nucleic acid test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection diagnosis","10.1016/j.intimp.2020.106746","ImmunoAssay-Antibody","Mixed","IgM, IgG and ORF1ab/N","kits","SARS-CoV-2 ORF1ab/N PCR detection kit (GeneoDx Biotech, Shanghai, China), and SARS-CoV-2 antibody detection kit (YHLO Biotech, Shenzhen, China). ","Positive rate of detection: 65.9% (RT-PCR, moderate cases), 71.2% (RT-PCR, severe cases), and 67.6% (RT-PCR, critical cases),  79.5% (IgM, moderate cases), 93.2% (IgG, moderate cases), 82.7% (IgM, severe cases), 100% (IgG, severe cases), 73.0% (IgM, critical cases), 97.3% (IgG, critical cases)","133 patients","","yes","","2021-05-27 09:58:03",
"1157","Analysis of COVID-19 convalescent plasma for SARS-CoV-2 IgG using two commercial immunoassays","10.1016/j.jim.2020.112837","ImmunoAssay-Antibody","ELISA","IgG vs N (Epitope), IgG vs S1-RBD (Euroimmun)","kits (Epitope, Euroimmun)","Epitope Diagnostics Inc. (EDI) (San Diego, CA)  and Euroimmun ELISA (Lubeck, Germany)","Sensitivity:  84.8% (Epitope), 91.8% (Euroimmun); Specificity: 99.1% (Epitope), 96.8% (Euroimmun)","228 samples (102 PCR positive, 20 other respiratory viruses, 106 pre-pandemic samples)","","yes","","2021-05-27 10:14:56",
"125","Analysis of factors associated early diagnosis in coronavirus disease 2019 (COVID-19)","10.1101/2020.04.09.20059352","NucleicAcid-PCR based","Other PCR method(s)","Not specified","Not specified","","Sensitivity: 68% (1 time test), 92% (3 time test)","315 patients","","no","","2021-05-27 09:45:10",
"993","Analysis of novel coronavirus nucleic acid detection in different specimens of COVID-19 patients after treatment in Tianjin","10.3760/cma.j.cn112309-20200324-00138","","","","","","","","","yes (paper not in English)","","2021-05-27 10:09:49",
"1270","Analysis of SARS-CoV-2 antibodies in COVID-19 convalescent blood using a coronavirus antigen microarray.","10.1038/s41467-020-20095-2","ImmunoAssay-Antibody","Other","IgG, IgM vs S, N, RBD, S1, S2, PLpro","microarray","A coronavirus antigen microarray (COVAM) was constructed containing 61 antigens that are causes of acute respiratory infections, including 11 antigens from SARS-CoV-2. ","Sensitivity: 56.29% (IgG vs S1), 58.94% (IgM vs RBD), 87.8% (combination of IgG and IgM, >7 dpo); Specificity: 98.49% (IgG vs S1), 98.73% (IgM vs RBD), 98.9% (combination of IgG and IgM, >7 dpo) ","188 samples","","yes","","2021-05-27 10:18:42",
"1274","Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Plasma using a Coronavirus Antigen Microarray.","10.1101/2020.04.15.043364","ImmunoAssay-Antigen","Other Immuno assay","spike protein (S), including the receptor-binding (RBD), S1, and S2 domains and the whole protein (S1?+?S2), nucleocapsid protein (NP), and papain-like protease (PLpro)","ONCYTE AVID nitrocellulose-coated slides (Grace Bio-Labs, Bend","validation of a coronavirus antigen microarray containing immunologically significant antigens from SARS-CoV-2, in addition to SARS-CoV, MERS-CoV, common human coronavirus strains, and other common respiratory viruses. ","IgG SARS.CoV.2.S1.mFcTag Sensitivity: 0.5629; Specificity: 0.9849; IgM SARS.CoV.2.Spike.RBD.rFc Sensitivity: 0.5894; Specificity: 0.9873; Combination of IgG and IgM  sensitivity: 87.8%; Specificity: 98.9%","135 blood specimens","","yes","","2021-05-27 10:18:50",
"5","Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray","10.1101/2020.03.24.006544","ImmunoAssay-Antigen"," ","Multiple"," "," ","Not reported","Not reported","antigen micro array","no","","2021-05-27 09:42:25",
"618","Analysis of the diagnostic value of serum specific antibody testing for coronavirus disease 2019","10.1002/jmv.26230","ImmunoAssay-Antibody"," ","IgM, IgG","kit","Axceed 260 (Bioscience, Tianjin, China) magnetic particle-based chemiluminescence immunoanalyzer","Remark: study aiming at exploring the dynamic changes of serum immunoglobulin antibody","802 patients","","yes","","2021-05-27 09:58:32",
"1185","Analytical and Clinical Comparison of Three Nucleic Acid Amplification Tests for SARS-CoV-2 Detection","10.1128/JCM.01134-20","NucleicAcid-PCR based","PCR_KIT","Fusion: ORF1ab; Aptima: ORF1ab;Biofire: ORF1ab and ORF8","kits: the Hologic Panther Fusion SARS-CoV-2 assay (Fusion), the Hologic Aptima SARS-CoV-2 assay (Aptima), and the BioFire Defense COVID-19 test (BioFire)","comparative study","LOD: Fusion: 62.5 copies/ml;  Aptima:  62.5 copies/ml; Biofire: 125 copies/ml. Sensitivity:  Fusion: 98.7%;  Aptima:  94.7%; Biofire: 98.7%. Specificity: Fusion: 100%;  Aptima:  100%; Biofire: 100%.","150 samples","","yes","","2021-05-27 10:15:51",
"562","Analytical and Clinical Evaluation of the Automated Elecsys Anti-SARS-CoV-2 Antibody Assay on the Roche cobas e602 Analyzer","10.1093/ajcp/aqaa155","ImmunoAssay-Antibody"," ","IgA/IgG","Kit","Elecsys Anti-SARS-CoV-2 immunoassay (Roche Diagnostics) vs Euroimmun IgA/IgG","Sensitivity: 95% (>14 days post positive PCR), 77.5% (0-13 days post positive PCR); specificity: 100%; Concordance with ELISA: 100%; PPV: 100%; NPV: 98.83%; accuracy: 98.88 (0-13 days post positive PCR), 99.74% (>14 days post positive PCR)","66 samples (method comparison) & 77 samples (cross reactivity) & 78 samples (clinical performance)","","yes","","2021-05-27 09:56:53",
"531","Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity","10.1101/2020.08.01.20166546","ImmunoAssay-Antibody"," ","IgG","Kits (CLIA and ELISA)","CLIA: Abbott SARS-Cov-2 IgG, Roche Elecsys anti-SARS-CoV-2, Ortho SARS-CoV-2 total and IgG; ELISA: Diesse ENZY-WELL SARS-CoV-2 IgG. Compared with the neutralization activity achieved using the plaque reduction neutralization test (PRNT)","Sensitivity: from 78.5 to 87.8%( overall), 95.2 (>12 dpo, VITROassay);  specificity: from 97.6 to 100% (overall).","184 samples (130 positive & 54 negative)","","no","","2021-05-27 09:55:58",
"1279","Analytical and Clinical Validation for RT-qPCR Detection of SARS-CoV-2 Without RNA Extraction.","10.3389/fmed.2020.567572","NucleicAcid-PCR based","RT-PCR","RdRP (LightMix); E, N (multiplex)","kits (LightMix Modular Wuhan CoV RdRP-gene kit, Roche; SARS-CoV-2/SARS-CoV Multiplex REAL-TIME PCR Detection Kit, DNA-Technology) ","validation results for an RT-qPCR protocol without prior RNA extraction","Concordance: 94%","180 samples","","yes","","2021-05-27 10:19:01",
"754","Analytical and clinical validation of an ELISA for specific SARS-CoV-2 IgG, IgA, and IgM antibodies","10.1002/jmv.26303","ImmunoAssay-Antibody","","IgM, IgG, IgA and total Ab","ELISA kits","The NovaLisa SARS?CoV?2 IgG, IgA, IgM test (NovaTec)  and the Platelia SARS?CoV?2 Total Ab test (Bio?Rad) ","sensitivity:  94.9% (NovaLisa, IgG), 89.7% (NovaLisa, IgA),  48.7% (NovaLisa, IgM), 94.9% (Platelia, total Ab); specificity: 96.2% (NovaLisa, IgG), 98.7% (NovaLisa, IgA),  98.7% (NovaLisa, IgM), 97.4% (Platelia, total Ab) ","208 samples","","yes","","2021-05-27 10:02:56",
"563","Analytical comparisons of SARS-COV-2 detection by qRT-PCR and ddPCR with multiple primer/probe sets","10.1080/22221751.2020.1772679","NucleicAcid-PCR based","Mixed","ORF1ab, N","ddPCR and RT-PCR","8 primer and probe sets (Chinese CDC)","Remark: none of 8 primer/probe sets used in qRT-PCR could significantly distinguish true negatives and positives with low viral load. False positive reports of qRT-PCR with UCDC-N1, N2 and CCDC-N primers/probes sets were observed. ddPCR showed significantly better performance in general for low viral load samples compared to qRT-PCR","/","","yes","","2021-05-27 09:56:55",
"1212","Analytical performance of lateral flow immunoassay for SARS-CoV-2 exposure screening on venous and capillary blood samples","10.1101/2020.05.13.20098426","ImmunoAssay-Antibody","LFIA","IgM and IgG","Biolidics 2019-nCoV IgG/IgM Detection Kit lateral flow immunoassay","Validation of the lateral flow immunoassay (LFI) for rapid sxcreeninf and qualitative detection of anti-SARS-CoV2","Specificity IgM: 92%; Specificity IgG: 100%; Specificity IgM and IgG: 92%; Day 0 Sensitivity IgM: 29%; D0 Sensitivity IgG: 21%; Day 0 Sensitivty IgM and IgG: 29%; Day7 Sensitivity IgM: 54%; D7 Sensitivity IgG: 88%; D7 Sensitivity IgM and IgG: 92% ; Plasma Sensitivity IgM: 59%; Plasma Sensitivity IgG: 86%; Plasma Sensitivity IgM and IgG: 95%; Whole Blood Sensitivity IgM: 55%; Whole Blood Sensitivity : 86%; Whole Blood Sensitivity IgM and IgG: 95%; Capillary Sensitivity IgM: 43%; Capillary Sensitivity IgG: 68%; Capillary Sensitivity Igm and IgG: 93%; ","62 patients","","yes","","2021-05-27 10:16:45",
"126","Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics","10.1515/cclm-2020-0443","ImmunoAssay-Antibody"," ","IgM/IgG","CLIA individual-kit","Kit: MAGLUMI 2000 Plus","Remark: analytical validation of CLIA  IgM and IgG kinetics. Sensitivity:  100% (IgG),  88% (IgG)","87 samples","","yes","","2021-05-27 09:45:12",
"30","Analytical sensibility and specificity of two RT-qPCR protocols for SARS-CoV-2 detection performed in an automated workflow","10.1101/2020.03.07.20032326","NucleicAcid-PCR based","WHO method(s)","See individual methods","WHO-5, WHO-7","","Specificity: tested ; LOD: 21 cpr (N1), 141 cpr (E gene) ; Sensitivity: 93.4% (N1),  86% (E gene)","60 patients","","no","","2021-05-27 09:43:00",
"31","Analytical sensitivity and efficiency comparisons of SARS-COV-2 qRT-PCR assays","10.1101/2020.03.30.20048108","NucleicAcid-PCR based","WHO method(s)","See individual methods","WHO-1, WHO-7, WHO-5, WHO-3","","None tested","12 patients","","no","","2021-05-27 09:43:02",
"710","Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT-qPCR primer-probe sets","10.1038/s41564-020-0761-6","NucleicAcid-PCR based","PCR_KIT","E, RdRP (Charitè); ORF1, N (HKU, China CDC); N1, N2, N3 (US CDC)","kits & CDC","independent evaluations of primer–probe sets used in four common SARS-CoV-2 diagnostic assays (Charitè, HKU, China CDC, US CDC)","LOD: 500 RNA cpr; Remark: The exception for this is the RdRp-SARSr (Charité) confirmatory primer–probe set which has low sensitivity","172 samples","","yes","","2021-05-27 10:01:30",
"1257","Analytical Sensitivity and Specificity of Two RT-qPCR Protocols for SARS-CoV-2 Detection Performed in an Automated Workflow.","10.3390/genes11101183","NucleicAcid-PCR based","PCR_KIT","N1, E, RdRP (modified)","kits (Charité and Centers for Disease Control (CDC)","","LOD: 21 cpr (N1), 141 cpr (E), 350 cpr (RdRP), 33.7 cpr (RdRP modified); PPA: 91.3% (RdRP vs N1), 96% (E vs N1); NPA: 99.6% (RdRP vs N1), 99.8% (E vs N1)","60 samples, 968 samples (accuracy)","","yes","","2021-05-27 10:18:15",
"174","Analytical Validation of a COVID-19 qRT-PCR Detection Assay Using a 384-well Format and Three Extraction Methods","10.1101/2020.04.02.022186","NucleicAcid-PCR based","WHO method(s)","Multiple targets on N-gene","WHO-7","","LOD: 5 cpu ; Sensitivity: 100% ; Specificity: 100%","20 samples ","","no","","2021-05-27 09:46:13",
"115","Antibodies in Infants Born to Mothers With COVID-19 Pneumonia","10.1001/jama.2020.4861","ImmunoAssay-Antibody"," ","IgM/IgG","LFIA individual-kit","Kit: YHLO","Sensitivity: 88.2% (IgM), 97.8% (IgG) ; Specificity: 99.0% (IgM), 97.9% (IgG)","9 patients","","no","","2021-05-27 09:45:00",
"1167","Antibody Detection and Dynamic Characteristics in Patients with COVID-19","10.1093/cid/ciaa461","ImmunoAssay-Antibody","ELISA","IgM, IgG vs N","kit (Zhuhai)","The serum SARS-CoV-2 antibodies (IgM and IgG) of the subjects were detected using a sandwich enzyme linked immunosorbent assay (ELISA kits, Livzon Inc, Zhuhai, P.R.China)","sensitivity: 77.3% (IgM, confirmed COVID patients), 87.5% (IgM, suspected COVID patients) 83.3% (IgG, confirmed COVID patients), 70.8% (IgG, suspected COVID patients);  specificity: 100% (IgM, confirmed COVID patients), 100% (IgM, suspected COVID patients), 95% (IgG, confirmed COVID patients), 96.6% (IgG, suspected COVID patients); PPV: 100% (IgM, confirmed COVID patients), 100% (IgM, suspected COVID patients), 94.8% (IgG, confirmed COVID patients), 85% (IgG, suspected COVID patients); NPV: 80% (IgM, confirmed COVID patients), 95.2% (IgM, suspected COVID patients), 83.8% (IgG, confirmed COVID patients), 89.1% (IgG, suspected COVID patients); consistency rate: 88.1%(IgM, confirmed COVID patients), 96.4% (IgM, suspected COVID patients), 88.9% (IgG, confirmed COVID patients), 88.1% (IgG, suspected COVID patients)","109 patients (8 confirmed, 24 suspected)","","yes","","2021-05-27 10:15:14",
"402","Antibody Profiling and Prevalence in the US population during the SARS-CoV2 Pandemic","10.1101/2020.04.29.20085068","ImmunoAssay-Antibody"," ","IgM, IgA, IgG vs S1, RBD, S2, N","protein microarray technology","","sensitivity: 98.1% (overall); specificity:98.6% (overall); Remark: single Ab sensitivity and specificity data are provided in table 4","158 cases & 1418 controls","","no","","2021-05-27 09:51:53",
"1147","Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by 4 automated immunoassays and 3 ELISAs","10.1016/j.cmi.2020.07.038","ImmunoAssay-Antibody","Other Immuno assay","total Ig antibodies (Roche) or IgG (Abbott, Diasorin, Snibe, Euroimmun, Mikrogen) ","kits (Roche, Abbott, Diasorin, Snibe, Euroimmun, Mikrogen)","determine the antibody response against SARS-CoV-2 spike protein and nucleoprotein using four automated immunoassays and three ELISAs for the detection of total Ig antibodies (Roche) or IgG (Abbott, Diasorin, Snibe, Euroimmun, Mikrogen) ","Sensitivity: 100% (all assays); Specificity:  94-100% (variations among assays). Remark: Calculated at the cut-offs that corresponded to a specificity of 95% and 97.5%, Roche had the highest sensitivity (85.0% and 81.1%)","233 samples","","yes","","2021-05-27 10:14:37",
"1108","Antibody response using six different serological assays in a completely PCR-tested community after a COVID-19 outbreak - the CoNAN study","10.1016/j.cmi.2020.11.009","ImmunoAssay-Antibody","Other Immuno assay","IgG","EDI Novel Coronavirus SARS-CoV-2 IgG ELISA kit (Epitope Diagnostics Inc., San Diego, USA), SARS-CoV-2 IgG ELISA kit (Euroimmun, Lübeck, Germany), SARS-CoV-2 S1/S2 IgG CLIA kit (DiaSorin, Saluggia, Italy), 2019-nCoV IgG kit (Snibe Co., Ltd., Shenzhen, China), SARS-CoV-2 IgG CMIA kit (Abbott, Chicago, USA) and Elecsys Anti-SARS-CoV-2 kit (Roche, Basel Switzerland)","two enzyme-linked immunosorbent assays (EfimmunLISA) and four chemiluminescence-based immunoassays (CLIA/CMIA). ","","620 patients","","yes","","2021-05-27 10:13:19",
"6","Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice","10.1101/2020.03.18.20038018","ImmunoAssay-Antibody"," ","IgM/IgG on N-protein, S-protein","Unclear","","Remark: Study focusses on seroconversion time","449 patients","","no","","2021-05-27 09:42:27",
"108","Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 pneumonia","10.1093/cid/ciaa344/5812996","ImmunoAssay-Antibody"," ","Total antibody","Individual-kit","Kit: Beijing Watai Biological Pharmacy Enterprise","Specificity: 99.1% (Total Ab), 98.6% (IgM), 99% (IgG) ;  Sensitivity: 93.1% (Total Ab), 82.7% (IgM), 64.7% (IgG)","173 patients","","yes","","2021-05-27 09:44:49",
"666","Antibody responses to SARS-CoV-2 in patients with COVID-19","10.1038/s41591-020-0897-1","ImmunoAssay-Antibody"," ","IgG, IgM","kit (MCLIA)","magnetic chemiluminescence enzyme immunoassay (MCLIA) supplied by Bioscience Co. (approved by the China National Medical Products Administration; approval numbers 20203400183(IgG) and 20203400182(IgM))","Sensitivity: 100% (IgG, 17-19 dpo), 94.1 % (IgM, 20-22 dpo)","285 patients","","yes","","2021-05-27 10:00:01",
"315","Antibody tests in detecting SARS-CoV-2 infection: a meta-analysis","10.1101/2020.04.22.20074914","ImmunoAssay-Antibody","Mixed","IgM/IgG","ELISA, CLIA, FIA, LFIA"," ","Sensitivity: 90-94% (ELISA and CLIA), 80-86% (LFIA and FIA) ; specificity: 91.4-99.4% (all methods) ; Remark: performance across 38 studies with different sample size","7848 patients from 38 studies","","no","","2021-05-27 09:49:41",
"742","Antibody tests in detecting SARS-CoV-2 infection: A meta-analysis","10.3390/diagnostics10050319","Review"," ","IgG, IgM","review and metanalysis","Enzyme-linked immunosorbent assay (ELISA), Chemiluminescence Enzyme Immunoassays (CLIA), Fluorescence Immunoassays (FIA), and the Lateral Flow Immunoassays (LFIA)","Specificity: 99% (ELISA, LFIA); Sensitivity: 90%-94% (ELISA, CLIA), 80%-89% (LFIA, FIA)","7848 individuals (38 studies)","","yes","","2021-05-27 10:02:31",
"32","Application and optimization of RT-PCR in diagnosis of SARS-CoV-2 infection","10.1101/2020.02.25.20027755","NucleicAcid-PCR based","WHO method(s)","RdRp-region, E-gene, N-gene, S-gene","WHO-5","","Not reported","568 patients (1674 samples)","","no","","2021-05-27 09:43:04",
"970","Application of deep learning for fast detection of COVID-19 in X-Rays using nCOVnet","10.1016/j.chaos.2020.109944","Imaging-X-ray","In_silico","X-ray","x-ray","algorithm nCOVnet detects COVID-19 patients using X-ray images","accuracy: 88% (overall) ; specificity: 78.57% ; sensitivity: 97.62%","337 images","","yes","","2021-05-27 10:09:08",
"918","Application of deep learning technique to manage COVID-19 in routine clinical practice using CT images: Results of 10 convolutional neural networks","10.1016/j.compbiomed.2020.103795","Imaging-CT scan","Other","CT imaging ","artificial intelligence","Ten well-known convolutional neural networks were used to distinguish infection of COVID-19 from non-COVID-19 groups","sensitivity: 100%; specificity: 99.02%; accuracy: 99.51%","194 patients","","yes","","2021-05-27 10:07:54",
"1106","Application of deep learning techniques for detection of COVID-19 cases using chest X-ray images: A comprehensive study","10.1016/j.bspc.2020.102365","Imaging-X-ray","In_silico","X-ray","X-ray","automated COVID-19 screening method using chest X-ray images. Models VGG-16, AlexNet, GoogleNet, MobileNet-V2, SqueezeNet, ResNet-34, ResNet-50 and Inception-V3 are compared.","Precision: 96.77% ; Specificity: 96.67% ; Accuracy: 98.33% ; Sensitivity: 100% ; Remarks: best performing method ResNet-34","406 images","","yes","","2021-05-27 10:13:15",
"960","Application of nanomaterials in treatment, anti-infection and detection of coronaviruses.","10.2217/nnm-2020-0117","review","Other","mixed ","nanoparticle based assays","paper reviews applications of nanoparticles as vaccine, cure, detection method for COVID19","table 3 lists applications of nanoparticles in developing coronaviruses sensors with their LOD","/"," ","yes","","2021-05-27 10:08:49",
"175","Artificial intelligence for rapid identification of the coronavirus disease 2019 (COVID-19)","10.1101/2020.04.12.20062661","Others","In_silico","","","","","","","no","","2021-05-27 09:46:15",
"871","Artificial intelligence–enabled rapid diagnosis of patients with COVID-19","10.1038/s41591-020-0931-3","Imaging-CT scan","Other","CT imaging ","AI","artificial intelligence (AI) algorithms to integrate chest CT findings with clinical symptoms, exposure history and laboratory testing to rapidly diagnose patients who are positive for COVID-19","sensitivity of AI: 84.3%;","279 patients","","yes","","2021-05-27 10:06:36",
"945","Assay Techniques and Test Development for COVID-19 Diagnosis.","10.1021/acscentsci.0c00501","review","Mixed","mixed","multiple","paper gives an overview of current Nucleic acid & Immunological detection methods.","tables 1-3 list many detection methods with their time-to-results","/"," ","yes","","2021-05-27 10:08:43",
"1080","Assessing a novel, lab-free, point-of-care test for SARS-CoV-2 (CovidNudge): a diagnostic accuracy study","10.1016/S2666-5247(20)30121-X","NucleicAcid-PCR based","RT-PCR","drp1, rdrp2, e-gene, n-gene, n1, n2, and n3","CovidNudge point-of-care real-time RT-PCR platform (DnaNudge, UK)","development and clinical assessment of a highly sensitive and specific rapid point-of-care platform for the detection of SARS-CoV-2, validated in frontline clinical settings during the first peak of the COVID-19 pandemic","Sensitivity: 94%; Specificity: 100%","386 patients","","yes","","2021-05-27 10:12:21",
"1194","Assessment of immune response to SARS-CoV-2 withfully automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays","10.1515/cclm-2020-0473","ImmunoAssay-Antibody","Other Immuno assay","IgG, IgM","MAGLUMI 2019-nCoV","compared with results from Anti-SARS-CoV-2 IgA and IgG enzyme-linked immunosorbent assays (ELISAs; Euroimmun AG, Luebeck, Germany)","Remarks: overall concordance of each test is 90%, more detailed info in the text","131 patients","","yes","","2021-05-27 10:16:08",
"1276","Assessment of sample pooling for SARS-CoV-2 molecular testing for screening of asymptomatic persons in Tunisia.","10.1016/j.diagmicrobio.2020.115125","NucleicAcid-PCR based","RT-PCR","N, ORF1ab","RT-PCR","Hong Kong RT-PCR assay used for evaluation of sample pooling","Remark: a single positive specimen can still be detected in pools of up to 10","120 pools","","yes","","2021-05-27 10:18:54",
"995","Assessment of SARS-CoV-2 in human semen - a cohort study","10.1016/j.fertnstert.2020.05.028","NucleicAcid-PCR based","RT-PCR","","","","no RNA detected ","18 patients","","yes (paper not in English)","","2021-05-27 10:09:53",
"590","Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech)","10.1016/j.jcv.2020.104511","ImmunoAssay-Antibody"," ","IgG (Abbott), IgG/IgA (Euroimmun), IgG-IgM (NG Biotech)","kits","ELISA (Euroimmun), CLIA(Abbott), LFIA(NG Biotech)","Sensitivity: 100% (IgG overall, >15 dpo); Specificity: 98% (IgG CLIA and LFIA), 95.8% (IgG ELISA), 78.9% (IgA ELISA), 95.8% (IgM LFIA)","293 samples","","yes","","2021-05-27 09:57:42",
"176","Assessment of Specimen Pooling to Conserve SARS CoV-2 Testing Resources","10.1101/2020.04.03.20050195","NucleicAcid-PCR based","WHO method(s)","Multiple targets on N-gene","WHO-7","","Remark: focus on sample pooling strategy","25 pools of 5 samples","","no","","2021-05-27 09:46:18",
"464","Assessment of Specimen Pooling to Conserve SARS CoV-2 Testing Resources","10.1093/ajcp/aqaa064","NucleicAcid-PCR based","WHO method(s)","N1 and N2","WHO-7 (CDC)","pools of 5 samples","/","60 samples","","yes","","2021-05-27 09:53:55",
"403","Assessment of the outbreak risk, mapping and infestation behavior of COVID-19: Application of the autoregressive and moving average (ARMA) and polynomial models","10.1101/2020.04.28.20083998","Others","In_silico","/","/","application of autoregressive  and  moving average (ARMA) and polynomial models for risk assessment and mapping","/","/","","no","","2021-05-27 09:51:55",
"7","Association between Clinical, Laboratory and CT Characteristics and RT-PCR Results in the Follow-up of COVID-19 patients","10.1101/2020.03.19.20038315","NucleicAcid-PCR based","Other PCR method(s)","Not specified","Other method","","Not reported","52 patients","","no","","2021-05-27 09:42:29",
"1094","Association between COVID-19 diagnosis and presenting chief complaint from New York City triage data","10.1016/j.ajem.2020.11.006","Others","Other","","patient complaints analysis","patients complaints in relation of RT-PCR results (no test info available) and disease development","info about recurrence of sympthoms/complaints reported","11992 hospital visits","","yes","","2021-05-27 10:12:50",
"1120","Automated Deep Transfer Learning-Based Approach for Detection of COVID-19 Infection in Chest X-rays","10.1016/j.irbm.2020.07.001","Imaging-X-ray","In_silico","X-ray images","deep transfer learning-based detection model","table 1 and 2 also list performance parameters of competing image processing models","Accuracy : 0.974068; F-measure: 0.969697; Sensitivity: 0.970921;  Specificity: 0.972973; Kappa statistics: 0.971924","open source image set"," ","yes","","2021-05-27 10:13:44",
"860","Automated detection and quantification of COVID-19 pneumonia: CT imaging analysis by a deep learning-based software","10.1007/s00259-020-04953-1","Imaging-CT scan","Other","CT imaging ","Deep learning based software","uAI Intelligent Assistant Analysis System can accurately evaluate pneumonia in COVID-19 patients.","Multiple lesions: 90%, Primarly  ground glass opacity GGO: 94%","2460 images","","yes","","2021-05-27 10:06:17",
"730","Automated detection of COVID-19 cases using deep neural networks with X-ray images","10.1016/j.compbiomed.2020.103792","Imaging-X-ray"," ","chest X-rays","deep neural networks","DarkCovidNet model","accuracy: 98.08% (binary), 87.02% (multi-classes)","127 images","","yes","","2021-05-27 10:02:07",
"432","Automated Diagnosis of COVID-19 Using Deep Learning and Data Augmentation on Chest CT","10.1101/2020.04.24.20078998","Others","In_silico","/","Chest CT","deep learning on chest CT for automated diagnosis","AUC: 0.9689; Sensitivity: 90.52%; Specificity: 91.58%; Accuracy: 91.21%","1042","","no","","2021-05-27 09:52:53",
"1100","Automatic detection of COVID-19 from chest radiographs using deep learning","10.1016/j.radi.2020.10.018","Imaging-X-ray","In_silico","X-ray","X-ray","chest radiography performances in two classes (covid positive and negative) and three classes (covid positive and negative and bacterial pneumonia positive) cases","accuracy: 92.53% (3 classes), 96% (two classes) ; sensitivity: 92.64% (two classes), 87.7% (three classes) ; specificity: 97.27% (two classes), 95.1% (three classes)","1428 images","","yes","","2021-05-27 10:13:02",
"391","Automatic Detection of COVID-19 Using X-ray Images with Deep Convolutional Neural Networks and Machine Learning","10.1101/2020.05.01.20088211","Others","In_silico","Chest x ray","DCNN","deep convolutional neural networks for automatic detection of covid using x-ray","Accuracy: >96%","3520","","no","","2021-05-27 09:51:30",
"782","Automatic distinction between COVID-19 and common pneumonia using multi-scale convolutional neural network on chest CT scans","10.1016/j.chaos.2020.110153","Imaging-CT scan","","CT scan","AI","multi-scale convolutional neural network","sensitivity: 89.1%; specificity: 85.7%; accuracy: 87.5%","828 patients (7987 CT slice)","","yes","","2021-05-27 10:03:51",
"1027","Benchmarking Methodology for Selection of Optimal COVID-19 Diagnostic Model Based on Entropy and TOPSIS Methods","10.1109/ACCESS.2020.2995597","Imaging-X-ray","In_silico","X-ray","","","","50 images","","yes","","2021-05-27 10:10:32",
"398","Beyond the Spike: identification of viral targets of the antibody response to SARS-CoV-2 in COVID-19 patients","10.1101/2020.04.30.20085670","ImmunoAssay-Antibody"," ","N, ORF3b, ORF8 (LIPS), IgG vs S, N (ELISA)","ELISA, LIPS","Luciferase Immunoprecipitation System (LIPS) vs ELISA (IgG)","sensitivity: 93.3% (N),86.6%(ORF3b), 100%(ORF8), 100% (N+ORF3b+ORF8); specificity: 100% (all)","26","","no","","2021-05-27 09:51:45",
"224","Blockchain and artificial intelligence technology for novel coronavirus disease-19 self-testing","10.3390/diagnostics10040198","Others","In_silico","","","","","","","no","","2021-05-27 09:47:36",
"488","Blood Plasma Microfluidic Device: Aiming for the Detection of COVID-19 Antibodies Using an On-Chip ELISA Platform","10.1007/s41403-020-00123-9","ImmunoAssay-Antibody"," ","IgM, IgG vs S protein","ELISA","Microfluidic ELISA on lab on chip platform","/","/","","yes","","2021-05-27 09:54:42",
"629","Boosting SARS-CoV-2 qRT-PCR detection combining pool sample strategy and mathematical modeling","10.1101/2020.08.16.20167536","NucleicAcid-PCR based","In_silico","Not specified","pooling strategy for RT-PCR","pooling strategy","/","/","","no","","2021-05-27 09:58:54",
"477","Breathe analyser for respiratory diseases: A review","/","Others"," ","/","review on invasive and non-invasive detection techniques for respiratory diseases","Full article available at: http://sersc.org/journals/index.php/IJAST/article/view/9086/5017","/","/","","yes","","2021-05-27 09:54:22",
"865","Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays","10.1016/j.jcv.2020.104480","ImmunoAssay-Antibody","Mixed","IgG","Abbott Architec i2000, Roche cobas, 411 analyzer, LIAISON®XL platform, VIRCLIA® automation system, Euroimmun SARS-CoV-2 IgG, Virotech SARS-CoV-2 IgG ELISA, in-house developed plaque reduction neutralization test (PRNT)","Two commercially available ELISA assays, four automated immunoassays and a plaque reduction neutralization test (PRNT)) focusing on the detection and neutralization capacity of IgG antibodies in follow up serum or plasma samples of individuals with PCR-diagnosed infections with SARS-CoV-2","sensitivity: 66.7% (Virotech), 75.6% (Elecsys), 77.8% (Abbott), 71.1% (Euroimmun), 75.6% (Liaison, 91.1% (Virclia), 93.3% (PRNT) ; Specificity: 94.6% (Abbott, Liaison, Virotech, PRNT), 91.7% (Elecsys), 93.9% (Virclia), 100% (Euroimmun)","82 samples","","yes","","2021-05-27 10:06:27",
"772","Brief validation of the novel GeneXpert Xpress SARS-CoV-2 PCR assay","10.1016/j.jviromet.2020.113925","NucleicAcid-PCR based","PCR_KIT","E, N2 (Xpert); E, ORF1ab (Cobas)","kit","evaluation of performance of the new available Xpert Xpress SARS-CoV-2 (Cepheid) comparing the assay against the cobas SARS-CoV-2 assay (Roche) on the COBAS 6800 system (Roche)","Sensitivity: 100%; Specificity: 100%","19 samples","","yes","","2021-05-27 10:03:32",
"661","Can AI Help in Screening Viral and COVID-19 Pneumonia?","10.1109/ACCESS.2020.3010287","Others","In_silico","","","AI for detecting difference in X-ray and CT of lung: healthy patients, Covid patients and Pneumonia patients","accuracy 99.7%, precision 99.7%, sensitivity 99.7% and specificity99.55%","23 COVID-19, 1485 viral pneumonia, and 1579 normal chest X-ray images","","yes","","2021-05-27 09:59:51",
"1051","Capillary Electrophoresis of PCR fragments with labelled primers for testing the SARS-Cov-2","10.1101/2020.05.16.099242","NucleicAcid-PCR based","Other sequencing method(s)","2 fragments of the SARS-CoV-2","in house method","The cDNA was synthesised and two fragments of the SARS-Cov-2 were amplified. One of the primers for each pair was 5’-end fluorochrome labelled. The amplifications were subjected to capillary electrophoresis in ABI3130 sequencers to visualize the fluorescent peaks. Alternative method to identify the SARS-Cov-2 genome that could be scaled to the analysis of approximately 100 samples in less than 5 hours. By combining a standard PCR with capillary electrophoresis our approach would overcome the limits imposed to many labs by the qtPCR (lack of reactive and real-time PCR equipment) and increase the testing capacity.","Remark: Two SARS-Cov-2 fragments successfully amplified in the positive samples, while no fluorescent peaks in the negative samples. Screening  of 96  samples  in  less  than  5  hours."," naso-pharingeal RNA from 20 positive and 10 negative samples","","no","","2021-05-27 10:11:21",
"511","Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2","10.3390/v12060582","","Mixed","","","Review on diagnostic tests commercially available","Remark: review on different methods reporting performances","/","","yes","","2021-05-27 09:55:27",
"802","Challenges in use of saliva for detection of SARS CoV-2 RNA in symptomatic outpatients","10.1016/j.jcv.2020.104567","NucleicAcid-PCR based","RT-PCR","N1, N2","Emergency Use Authorized laboratory developed assay based on the Centers for Disease Control and Prevention protocol","comparison of saliva and nasal swab for COVID testing (paired samples analysed)","sensitivity: 94.3% (nasal swab), 85.7% (saliva)124 samples","","","yes","","2021-05-27 10:04:32",
"753","Characteristics and roles of severe acute respiratory syndrome coronavirus 2-specific antibodies in patients with different severities of coronavirus 19","10.1111/cei.13500","ImmunoAssay-Antibody","","IgM, IgG, IgA vs S","kit","Kaeser 6600 automatic chemiluminescence immunoanalyzer and matching reagents kit (Guangzhou Kangrun Biotech Co. Ltd, Guangzhou, China)","positive rate: 95%-100% (IgA vs IgM), 96%-100% (IgA vs IgG), 92%-100% (IgM vs IgG). Remark: IgA–IgG combined antibodies are more effective for diagnosing COVID?19","104 patients (359 samples)","","yes","","2021-05-27 10:02:54",
"395","Characteristics of lymphocyte subsets and their predicting values for the severity of COVID-19 patients","10.1101/2020.05.01.20086421","NucleicAcid-PCR based","PCR_KIT","/","/","count of T-cells in severe/moderate/mild patients","/","16","","no","","2021-05-27 09:51:39",
"1139","Characteristics of patients with coronavirus disease (COVID?19) confirmed using an IgM?IgG antibody test","10.1002/jmv.25930","mixed","Mixed","IgM/IgG vs E, N and ORF1ab, N","Chemiluminescence immunoassay and RT-PCR","","Remark: the virus?specific antibody test had a significantly higher positive result rate than the nucleic acid test. The combination of nucleic acid testing and the IgM?IgG antibody test is the optimal method for diagnosing SARS?CoV?2 infection","56 patients","","yes","","2021-05-27 10:14:23",
"456","Characterization of intra-host SARS-CoV-2 variants improves phylogenomic reconstruction and may reveal functionally convergent mutations","10.1101/2020.04.22.044404","Others","In_silico","whole genomes","/","phylogenesis analysis","/","22 samples","","no","","2021-05-27 09:53:38",
"1045","Chest computed tomography (CT) scan findings in patients with COVID-19: a systematic review and meta-analysis","10.1101/2020.04.22.20075382","Imaging-CT scan","In_silico","CT-scans","CT scan meta analysis","review and meta-analysis of CT-scans for covid diagnosis in literature","CT-scans patterns and features are reported ","4183 patients","","no","","2021-05-27 10:11:09",
"519","Chest computed tomography for the diagnosis of patients with coronavirus disease 2019 (COVID-19): a rapid review and meta-analysis","10.21037/atm-20-3311","Others","In_silico","CT scan","","meta-analysis on chest CT scan for diagnosis","Sensitivity: 99% (overall), 66% (in patients <18y)","5673 patients","","yes","","2021-05-27 09:55:39",
"985","Chest CT accuracy in diagnosing COVID-19 during the peak of the Italian epidemic: A retrospective correlation with RT-PCR testing and analysis of discordant cases","10.1016/j.ejrad.2020.109192","Imaging-CT scan","Mixed","CT-scan and ","CT-scan and RT-PCR (GeneFinderTM COVID-19 Plus RealAmp Kit or Allplex™ 2019-nCoV Assay)","assess chest computed tomography (CT) diagnostic accuracy in clinical practice using RT-PCR as standard of reference","sensitivity: 90.7% ; specificity: 78.8% ; PPV: 86.4% ; NPV: 85.1% ; accuracy: 85.9%","773 patients","","yes","","2021-05-27 10:09:35",
"1079","Chest CT accuracy in the diagnosis of SARS-CoV-2 infection: initial experience in a cancer center","10.1590/0100-3984.2020.0040","Imaging-CT scan","Mixed","CT scan","","Evaluation of accuracy of chest computed tomography ","Sensitivity: 92%; Specificity: 62.1%; Accuracy: 70.3%","91 patients","","yes","","2021-05-27 10:12:19",
"797","Chest CT Features of COVID-19 in Rome, Italy","10.1148/radiol.2020201237","Imaging-CT scan","Other","","CT scan, RT-PCR as comparison","comparison of the accuracy of CT analysis with that of RT-PCR","sensitivity: 97%, specificity: 56%","158 patients","","yes","","2021-05-27 10:04:22",
"1016","Chest CT for detecting COVID-19: a systematic review and meta-analysis of diagnostic accuracy","10.1007/s00330-020-06934-2","review","Other","CT scan","CT scan","","remarks: sensitivity and specificity from many studies reported in tables","","","yes","","2021-05-27 10:10:14",
"943","Chest CT for early detection and management of coronavirus disease (COVID-19): a report of 314 patients admitted to Emergency Department with suspected pneumonia","10.1007/s11547-020-01256-1","Imaging-CT scan","Mixed","CT scans","CT scans and RT-PCR","agreement between CT findings and RT-PCR and between two images readers","","314 patients","","yes","","2021-05-27 10:08:39",
"851","Chest CT for triage during COVID-19 on the emergency department: myth or truth?","10.1007/s10140-020-01821-1","Mixed","Mixed"," ","CO-RADS classification (CT images); CE-IVD kit GeneFinder TM COVID-19 Plus (RT-PCR kit)","using RT-PCR as reference standard, the diagnostic performance of chest CT using the CO-RADS score is assessed","sensitivity: 90.2% (Chest CT+RT-PCR), 89.3% (CO-RADS); specificity: 88.2% (Chest CT+RT-PCR), 93.4% (CO-RADS); PPV: 84.5%  (Chest CT+RT-PCR), 90.8% (CO-RADS); NPV:  92.7% (Chest CT+RT-PCR), 92.3% (CO-RADS);","404 patients"," ","yes","","2021-05-27 10:05:59",
"981","Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis","10.1007/s00330-020-07033-y","Imaging-CT scan","Other","CT-scan","CT-scan","correlation of CT-based semi-quantitative score of pulmonary involvement in COVID-19 pneumonia with clinical staging of disease and laboratory findings","remarks: image findings distribution available in tables","130 patients","","yes","","2021-05-27 10:09:26",
"979","Chest X-ray features of SARS-CoV-2 in the emergency department: a multicenter experience from northern Italian hospitals","10.1016/j.rmed.2020.106036","Imaging-X-ray","Mixed","x-ray, CT scan","x-ray, CT-scan and RT-PCR","","remarks: distribution of images findings available in tables","468 patients","","yes","","2021-05-27 10:09:24",
"693","Classification of Covid-19 coronavirus, pneumonia and healthy lungs in CT scans using Q-deformed entropy and deep learning features","10.3390/E22050517","Imaging-CT scan"," ","CT lungs","image segmentation","discriminating COVID-19 coronavirus, pneumonia and healthy CT lung scan","accuracy: 99.68%","321 patients"," ","yes","","2021-05-27 10:00:57",
"924","Classification of COVID-19 patients from chest CT images using multi-objective differential evolution–based convolutional neural networks","10.1007/s10096-020-03901-z","Imaging-CT scan","","CT imaging literature review","deep learning-based prediction technique","a convolutional neural networks (CNN) is used to classify the COVID-19-infected patients as infected (+ve) or not (?ve).","","/","","yes","","2021-05-27 10:08:06",
"338","Clinical And Analytical Performance Of An Automated Serological Test That Identifies S1/S2 Neutralizing IgG In Covid-19 Patients Semiquantitatively","10.1101/2020.05.19.105445","ImmunoAssay-Antibody"," ","IgG vs S1, S2 ","Automated Chemiluminescent assay","LIAISON® SARS-CoV-2 S1/S2 IgG assay","sensitivity: 91.3%(>5 dpo), 95.7% (?15 dpo); specificity: 97%-98.5% ","1609","","no","","2021-05-27 09:50:23",
"1078","Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey","10.1136/thoraxjnl-2020-215732","ImmunoAssay-Antibody","LFIA","IgM and IgG","Guangzhou Wondfo Biotech (Guangzhou, China) SARS- CoV-2 Antibody test (lateral flow method); Menarini (Orientgene) Zhejiang Orient Gene Biotech Co Ltd REF; BIOPANDA COVID-19 Rapid Ab test Product Number: RAPG- COV-019 Separate IgM and IgG Target: S and N proteins Fortress Diagnostics COVID- 19 TOTAL Ab Device Product Code: COVID010 / COVID020 Separate IgM and IgG Target antigen: S protein and N protein; BIOPANDA COVID-19 Rapid Ab test Product Number: RAPG- COV-019 Separate IgM and IgG Target: S and N proteins; BIOSURE (Mologic)* COVID-19 Self-Test IgG only Target: N protein","Comparison of 5 commercially available kit ","Specificity: 98.6%; Sensitivity: 84%; ","276 patients","","yes","","2021-05-27 10:12:17",
"965","Clinical and radiological characteristics of pediatric patients with COVID-19: focus on imaging findings","10.1007/s11604-020-01003-6","Imaging-CT scan","Other","CT scans ","CT scan and RT-PCR","","sensitivity: 66.67%","27 patients","","yes","","2021-05-27 10:09:00",
"226","Clinical and virological data of the first cases of COVID-19 in Europe: a case series","10.1016/S1473-3099(20)30200-0","NucleicAcid-PCR based","WHO method(s)","RdRp-region, E-gene","WHO-5","","Not reported","5 patients","","no","","2021-05-27 09:47:38",
"826","Clinical application of Chemiluminescence Microparticle Immunoassay for SARS-CoV-2 infection diagnosis","10.1016/j.jcv.2020.104576","ImmunoAssay-Others","Other","Chemiluminescence Microparticle Immunoassay (CMIA) IgM and total Antibodies ","Xiamen InnoDx Biotech Co., Ltd., China (Xiamen, China). ","CMIA has high sensitivity and specificity for the detection of serum samples, especially the durations from symptom onset to this serological test was more than 7 days","specificity: 99.3% (IgM), 98.9% (TotalAb )","206 patients","","yes","","2021-05-27 10:05:18",
"581","Clinical application of rapid diagnostic test kit for SARS-CoV-2 antibodies into the field of patient care","10.1016/j.jmii.2020.07.003","ImmunoAssay-Antibody"," ","IgG, IgM vs S","kit","RDT kits using lateral flow immunoassay principle were assembled at Korea (Wells Bio Inc., Seoul, Korea","Remark: reported sensitivity: 88.66%; specificity: 90.63%","29 patients","","yes","","2021-05-27 09:57:28",
"117","Clinical characteristics of the recovered COVID-19 patients with re-detectable positive RNA test","10.1101/2020.03.26.20044222","ImmunoAssay-Antibody"," ","IgM/IgG","ELISA individual-kit","Kit: Sangon Biotech","Not reported","262 patients","","no","","2021-05-27 09:45:02",
"413","Clinical classifiers of COVID-19 infection from novel ultra-high-throughput proteomics","10.1101/2020.04.27.20081810","Others"," ","proteins","LC-MS","short-gradient high-flow liquid chromatography and low-cost high-throughput mass spectrometry","/","199","","no","","2021-05-27 09:52:16",
"33","Clinical diagnosis of 8274 samples with 2019-novel coronavirus in Wuhan","10.1101/2020.02.12.20022327","NucleicAcid-PCR based","PCR_KIT","Not specified","Multiple-kits","Kits: Bioperfectus, Taizhou,  China ","Not reported","8274 patients","","no","","2021-05-27 09:43:06",
"227","Clinical diagnostic value of CT imaging in COVID-19 with multiple negative RT-PCR testing","10.1016/j.tmaid.2020.101627","NucleicAcid-PCR based","WHO method(s)","ORF1ab-gene","WHO-1","","Not reported","1 patient","","no","","2021-05-27 09:47:40",
"1024","Clinical Evaluation and Utilization of Multiple Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2","10.1093/ajcp/aqaa097","NucleicAcid-PCR based","PCR_KIT","S, ORF1ab, RdRp regions","Abbott ID NOW COVID-19 (Abbott ID NOW), DiaSorin Molecular Simplexa COVID-19 Direct (DiaSorin Simplexa), and Roche cobas 6800 SARS-CoV-2 (Roche cobas)","clinical performance of 3 molecular assays ","positive percent agreement: 91% (Abbott), 100% (DiaSorin and Roche) ; negative percent agreement: 100%","184 samples","","yes","","2021-05-27 10:10:28",
"331","Clinical evaluation of a rapid colloidal gold immunochromatography assay for SARS-Cov-2 IgM/IgG"," PMC7191168","ImmunoAssay-Antibody"," ","IgG, IgM","Colloidal gold immunochromatography assay kit","RT-qPCR to confirm positive and negative cases","Sensitivity: 71.1% (PCR positive cases), 95.2% (patients with symptoms more than 14 days), 86% (patients with severe clinical condition) ; specificity: 96.2% (positive cases), 100% (negative cases) ; remarks: compared to qPCR results","150 sympthomatic patiens, 26 healthy patients","","yes","","2021-05-27 09:50:12",
"1204","Clinical evaluation of a rapid colloidal gold immunochromatography assay for SARS-Cov-2 IgM/IgG","PMID:32355546","ImmunoAssay-Antibody","GICA","IgM and IgG","colloidal gold immunochromatography antibody detection kit (Shanghai Outdo Biotech Co. Ltd, China, LOT: 20200101","To evaluate the diagnostic performance and clinical utility of the colloidal gold immunochromatography assay for SARS-Cov-2 specific IgM/IgG anti-body detection in suspected COVID-19 cases.","Sensitivity: 71.1%; specificity: 96.2%","150 patients","","yes","","2021-05-27 10:16:28",
"479","Clinical evaluation of a rapid colloidal gold immunochromatography assay for SARS-Cov-2 IgM/IgG","/","ImmunoAssay-Antibody","GICA","IgG, IgM","Shanghai Outdo Biotech Co. Ltd, China, LOT: 20200101","Full article available at: http://www.ajtr.org/files/ajtr0110318.pdf","sensitivity 71.1% [95% CI 0.609-0.797]; specificity 96.2% [95% CI 0.859-0.993]. In patients with symptoms more than 14 days, sensitivity was higher at 95.2% [95% CI 0.741-0.998] and in patients with severe clinical condition sensitivity was 86.0% [95% CI 0.640-0.970].","150 patients with covid symptoms, 26 healthy blood donors","","yes","","2021-05-27 09:54:26",
"846","Clinical evaluation of a SARS-CoV-2 RT-PCR assay on a fully automated system for rapid on-demand testing in the hospital setting","10.1016/j.jcv.2020.104390","NucleicAcid-PCR based","RT-PCR","E gene","Gene-LDT assay setup (NeuMoDx 96 system)","fully automated T system for rapid on-demand testing","LOD: 95.55 copies/ml, Positive agreement: 100%, Negative agreement: 99.2% Invalid rate: 6.3%","176 patients","","yes","","2021-05-27 10:05:50",
"177","Clinical evaluation of a SARS-CoV-2 RT-PCR assay on a fully automated system for rapid on-demand testing in the hospital setting","10.1101/2020.04.07.20056234","NucleicAcid-PCR based","Other PCR method(s)","Not specified","Multiple-kits","Kits: Sarbeco-Lab Developed Test assay, cobas6800-based assay","LOD: 95.55 cpm ;  positive agreement:  100% ; negative agreement: 99.2%","176 patients","","no","","2021-05-27 09:46:20",
"314","Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19","10.1101/2020.04.22.20075564","ImmunoAssay-Antibody","Mixed","IgM/IgG","Immunochromatography and CT assays","","Sensitivity: 27.8% (IgM 1 week), 48% (IgM 1-2 weeks), 95.8% (IgM >2 weeks), 3.3% (IgG 1 week), 8% (IgG 1-2 weeks), 62.5% (IgG >2 weeks), 57.9% (CT asymptomatic), 68.4% (CT combined with IC asymptomatic), 74.3% (CT symptomatic), 82.4% (CT combined with IC symptomatic) ","112 patients with COVID-19 and 48 non-COVID-19 patients","","yes","","2021-05-27 09:49:39",
"355","Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19","10.1016/j.jcv.2020.104393","ImmunoAssay-Antibody"," ","IgG, IgM and chest scan","immunochromatographic (IC) assay and chest CT scan","One Step Novel Coronavirus (COVID-19) IgM/IgG Antibody Test (Artron, Burnaby, Canada)","Sensitivity: 43.2% (IC assay), 57.9% (CT scan in asymptomatic patients), 74.3% (CT scan in symptomatic patients), 68.4% (IC assay+CT scan for asymptomatic patients), 82.4% (IC assay + CT scan for symptomatic patients); Specificity:98.0% (IC assay)","139 samples from 112 patients & 48 controls","","yes","","2021-05-27 09:50:31",
"916","Clinical evaluation of AusDiagnostics SARS-CoV-2 multiplex tandem PCR assay","10.1016/j.jcv.2020.104448","NucleicAcid-PCR based","RT-PCR","E, N and S genes","AusDiagnostics SARS-CoV-2 multiplex tandem PCR T assay","Evaluation of the clinical performance of AusDiagnostics respiratory multiplex tandem PCR assay including SARS-CoV-2","Concordance 98.4%","7839 (127% positive)","","yes","","2021-05-27 10:07:52",
"647","Clinical evaluation of BD VeritorTMSARS-CoV-2 point-of-care test performance compared to PCR-based testing and versus the Sofia®2 SARS Antigen point-of-care test","10.1128/JCM.02338-20","ImmunoAssay-Antigen"," ","Not specified","kit","BD Veritor™ System for Rapid Detection of SARS-CoV-2 nucleocapsid antigen (Veritor) compared to Lyra PCR and to Sofia2 antigen test","PPA: 81.8%-87.5% (Veritor vs Lyra),97.4% (Veritor vs Sofia2); NPA: 98.1% (Veritor vs Sofia2); OPA: 98.1% (Veritor vs Sofia2)","251 (vs Lyra) &  361 (vs Sofia2) patients","","yes","","2021-05-27 09:59:23",
"862","Clinical evaluation of five different automated SARS-CoV-2 serology assays in a cohort of hospitalized COVID-19 patients","10.1016/j.jcv.2020.104549","ImmunoAssay-Others","Mixed","IgG IgM","Anti-SARS-CoV-2 ELISA (IgG)EUROIMMUN; LIAISON SARS-CoV-2 S1/S2 IgG DiaSorin S; Elecsys Anti-SARS-CoV-2 Roche Diagnostics; WANTAI SARS-CoV-2 Ab ELISA Beijing Wantai Biological Pharmacy Enterprise Co; Atellica IM SARS-CoV-2 Total (COV2T) Siemens Healthcare Gmbh","Comparison of 5 different commercial methods for detecting coronavirus ","Positivity assay Diasorin: 68.4 %, Positivity assay Euroimmun: 70.3 %, Positivity assay Siemens: 73.7 %, Positivity assay  Roche: 79.0 %, Positivity assay Wantai: 81.6 %. Specificity Euroimmun: 99,1% Specificity Diasorin: 99.1 %, Specificity Wantai: 99.4 %, Specificity Roche: 99.7 %, Specificity: Siemens 100 %","75 confirmed ","","yes","","2021-05-27 10:06:21",
"1081","Clinical evaluation of four commercial immunoassays for the detection of antibodies against established SARS-CoV-2 infection","10.1016/j.pathol.2020.09.003","ImmunoAssay-Antibody","Other Immuno assay"," IgG","1)The Elecsys Anti-SARS-CoV-2 assay (Roche Diagnostics, Germany) 2) The Liaison SARS-CoV-2 S1/S2 IgG assay (DiaSorin, Italy) 3) The Access SARS-CoV-2 IgG assay (Beckman Coulter, USA) 4) ","Comparison of clinical performance of 4 available antibody kits","1) Elycsis Sensitivity: 98.84% ; Specificity: 100%; 2)Liaison Sensitivity: 96.51% ; Specificity: 97.89% ; 3) Access assay Sensitivity: 88.84%; Specificity: 98.95%; 4) Vitro assays Sensitivity: 97.67%; Specificity: 100%","190 sera","","yes","","2021-05-27 10:12:23",
"525","Clinical evaluation of self-collected saliva by RT-qPCR, direct RT-qPCR, RT-LAMP, and a rapid antigen test to diagnose COVID-19","10.1128/jcm.01438-20","NucleicAcid-PCR based","Mixed","N1, N2 (LDT); other targets not specified","Kits & in house","Laboratory developed test (LDT), Cobas, 3 RT-PCR kits (A, B on CDC method, C on LDT), LAMP (Loopamp 2019-SARS-CoV-2 kit) and immunochromatographic assay (Espline SARS-CoV-2)","Sensitivity: 81.6% (LDT), 80.6% (cobas), 78.6% (direct RT-qPCR method B), 76.7% (method A), 70.9% (RT-LAMP), 50.5% (method C)","103 saliva samples","","yes","","2021-05-27 09:55:49",
"1146","Clinical evaluation of serological IgG antibody response on the Abbott Architect for established SARS-CoV-2 infection","10.1016/j.cmi.2020.05.036","ImmunoAssay-Antibody","Other Immuno assay","IgG","kit (Abbott)","Abbott Architect SARS-CoV-2 IgG assay","Specificity: 100%; Sensitivity: 8.6% (?6 dpo), 43.6% (7–13 dpo), 84.0% (14–20 dpo), 84.4% (?21 dpo)","340 samples","","yes","","2021-05-27 10:14:35",
"669","Clinical evaluation of the BioFire® Respiratory Panel 2.1 and detection of SARS-CoV-2","10.1016/j.jcv.2020.104538","NucleicAcid-PCR based","PCR_KIT","M, S","kit","BioFire® Respiratory Panel 2.1 (RP2.1) against three other SARS CoV-2 EUA assays.","PPA: 98 % ; NPA: 100 % ","100 samples","","yes","","2021-05-27 10:00:07",
"1269","Clinical Evaluation of the cobas SARS-CoV-2 Test and a Diagnostic Platform Switch during 48 Hours in the Midst of the COVID-19","10.1128/JCM.00599-20","NucleicAcid-PCR based","PCR_KIT","ORF1, E genes","cobas 6800 SARS-CoV-2 (Roche Molecular Systems, Branchburg, NJ)","Cobas 6800 compared with  LightMix Modular SARS and Wuhan CoV E-gene kit (Tib100 Molbol, Berlin Germany) ","Overall agreement: 98.1% (compared to LightMix E gene)","502 samples","","yes","","2021-05-27 10:18:40",
"366","Clinical Evaluation of Three Sample-To-Answer Platforms for the Detection of SARS-CoV-2","10.1128/JCM.00783-20","NucleicAcid-PCR based","PCR_KIT","N2, E (Cepheid Xpert); RdRP (Abbott ID NOW); N gene (GenMark ePlex); ORF1ab (Hologic)","Kits","Evaluation of three platforms using Hologic Panther Fusion as reference: Cepheid Xpert® Xpress SARS-CoV-2 [Xpert Xpress], Abbott ID NOW COVID-19 [ID NOW], GenMark ePlex® SARS-CoV-2 Test [ePlex]","LOD: 20,000 copies/mL (ID NOW), 1,000 copies/mL (ePlex), 100 copies/mL (Xpert Xpress); Positive Percent Agreement: 98.3% (Xpert), 91.4% (ePlex), 87.9% (ID NOW); Negative Percent Agreement: 100% ","108 samples","","yes","","2021-05-27 09:50:45",
"476","Clinical features and chest CT findings of coronavirus disease 2019 in infants and young children","10.7499/j.issn.1008-8830.2020.03.007","Others"," ","/","cinical data and CT images of 9 infected children","/","/","/","","yes (paper not in English)","","2021-05-27 09:54:19",
"1265","Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective interventional","10.1016/S2213-2600(20)30454-9","NucleicAcid-PCR based","PCR_KIT & other","ORF1b, E (QIAstat); E, RdRP (PCR)","kit (QIAstat-Dx), and laboratory PCR at POC","QIAstat-Dx Respiratory SARS-CoV-2 Panel & PCR at POC","Sensitivity: 99.4% (QIAstat), 85.9% (PCR); Specificity: 98.6% (QIAstat), 99% (PCR); Accuracy: 98.9% (QIAstat), 94% (PCR)","499 patients & 55 controls","","yes","","2021-05-27 10:18:32",
"178","Clinical meanings of rapid serological assay in patients tested for SARS-Co2 RT-PCR","10.1101/2020.04.03.20052183","ImmunoAssay-Antibody"," ","IgM/IgG","LFIA individual-kit","Kit: Viva-Diag test, Jiangsu Medomics Medical Technologies","Sensitivity: 30% ; Specificity: 89%(<8 dpo) ; Remark: Both improve after 10 dpo","191 patients","","no","","2021-05-27 09:46:22",
"1095","Clinical performance and sample freeze-thaw stability of the cobas 6800 SARS-CoV-2 assay for the detection of SARS-CoV-2 in oro-/nasopharyngeal swabs and lower respiratory specimens","10.1016/j.jcv.2020.104686","NucleicAcid-PCR based","PCR_KIT","E, RdRp genes","Cobas6800 assay (Roche Diagnostics, Switzerland) and LDA based on Sarbeco method","comparison of clinical performance of Cobas 6800 assay and lab developed assay.","","377 samples","","yes","","2021-05-27 10:12:52",
"1150","Clinical performance of a rapid test compared to a microplate test to detect total anti SARS-CoV-2 antibodies directed to the spike protein","10.1016/j.jcv.2020.104528","ImmunoAssay-Antibody","Mixed","total Ab vs S","kits (Wantai ELISA and Rapid test)","2 serological assays that detect total anti-SARS-CoV-2 antibodies. One is a rapid immunochromatographic test (SARS-CoV-2 Ab Rapid Test, Beijing Wantai Biological Pharmacy Ent, Bejing, China) and the other is a microplate assay (SARS-CoV-2 Ab ELISA, Beijing Wantai Biological Pharmacy Ent, Bejing, China).","Specificity: 100% (both); Sensitivity 87 % (Rapid test, overall), 93% (Rapid test, >15 dpo), 100 % (ELISA, overall), 100% (ELISA, >15dpo)","99 samples","","yes","","2021-05-27 10:14:43",
"743","Clinical performance of different SARS-CoV-2 IgG antibody tests","10.1002/jmv.26145","ImmunoAssay-Antibody","Mixed","IgG, S and N proteins","Euroimmun (ELISA), Vircell (ELISA), IFA (in-house), Assure Tech (Rapid test), PRNT (in-house)","FaStep (COVID?19 IgG/IgM) rapid test cassettes (COV?W32M, Assure Tech), Euroimmun SARS?CoV?2 IgG ELISA, Vircell COVID?19 ELISA IgG, ","Specificity: 95.7% (Euroimmun), 95.2% (Vircell), 100% (IFA and Assure Tech); Sensitivity: 58.8% (Euroimmun, 5-9days after positive PCR(da+PCR)), 70.6% (Vircell, 5-9da+PCR), 76.5% (IFA and PRNT, 5-9da+PCR), 62.5% (Assur Tech, 5-9da+PCR), 93.8% (Euroimmun and Assure Tech 10-18da+PCR), 100% (Vircell, IFA and PRNT 10-18da+PCR)","33 plasma samples","","yes","","2021-05-27 10:02:33",
"680","Clinical performance of sars-cov-2 molecular tests","10.1128/JCM.00995-20","NucleicAcid-PCR based"," ","Depending on kit: E gene, N2 gene, ORF1ab, RdRp","kit","determine the clinical performance characteristics of SARS-CoV-2 molecular assays for diagnosis and stratification of COVID-19 patients and to determine the dynamics of SARS-CoV-2 molecular assay results over time in a large data set from multiple hospital locations in the New York City area","sensitivity: between 58% and 96%, depending on the unknown number of false-negative results in single-tested patients","27,377 samples from 22,338 patients","","yes","","2021-05-27 10:00:30",
"1170","Clinical Performance of the Elecsys Electrochemiluminescent Immunoassay for the Detection of SARS-CoV-2 Total Antibodies","10.1093/clinchem/hvaa131","ImmunoAssay-Antibody","Other Immuno assay","Total Ab vs N","kit (Roche Elecsys )","Elecsys anti-SARS-CoV-2 from Roche Diagnostics","Sensitivity: 91.7% (diagnostic), 100% (optimal cutoff), 91.1% (>14 dpo), 95.1% (>14 dpo, optimal cutoff), 96.7% (>28 dpo), 100% (> 28 dpo, optimal cutoff). Remark: sensitivity for samples <14 dpo was not sufficient to be reliable in clinical practice","140 samples","","yes","","2021-05-27 10:15:21",
"844","Clinical performance of the luminex nxtag cov extended panel for sars-cov-2 detection in nasopharyngeal specimens from covid-19 patients in Hong Kong","10.1128/JCM.00936-20","NucleicAcid-PCR based","PCR_KIT & other","ORF1ab, N, and E genes","NxTAG CoV","Luminex NxTAG CoV compared with COVID-19 reverse transcription-PCR (RT-PCR) protocol with a LightMix SarbecoV E-gene kit and an in-house RdRp/Hel RT-PCR assay","sensitivity: 97.8%; specificity: 100%; low-viral load specimens sensitivity: 85.71%.","214 patients","","yes","","2021-05-27 10:05:46",
"1171","Clinical Performance of the Roche SARS-CoV-2 Serologic Assay","10.1093/clinchem/hvaa132","ImmunoAssay-Antibody","Other Immuno assay","nucleocapside protein","Roche Elecsys Anti-SARS-CoV-2 assay compared to two serologic assays [Abbott and EUROIMMUN (EI)] ","Comparison performance of Roche Elecsys, Abbot and Euroimmun serologic assay to PCR assay","Specificity compared to PCR: Roche 98.69%; Abbot 99.34%; EI: 94.77%. Sensitivity >14d post symptoms: Roche 89.36%; Abbott: 93.76%; EI: 85.42%. ","153 negative, 102 positive samples","","yes","","2021-05-27 10:15:23",
"1169","Clinical Performance of Two SARS-CoV-2 Serologic Assays","10.1093/clinchem/hvaa120","ImmunoAssay-Antibody","Mixed","IgG vs N (Abbott), IgG vs S1 (Euroimmun)","kits (Abbott, Euroimmun)","Abbott SARS-CoV-2 IgG assay and EI SARS-CoV-2 IgG assay (EUROIMMUN)","specificity: 99.4% (Abbott), 94.8-96.7% (Euroimmun); sensitivity: 0.0% (Abbott, <3 dpo), 30% (Abbott, 3-7 dpo) , 47.8% (Abbott, 8–13 dpo), 93.8% (Abbott, ?14dpo), 0.0% (Euroimmun, <3 dpo), 25% (Euroimmun, 3-7 dpo) , 56.7% (Euroimmun, 8–13 dpo), 85.4% (Euroimmun, ?14dpo); qualitative concordance: 0.83 ","256 samples","","yes","","2021-05-27 10:15:19",
"1144","Clinical performances of an ELISA for SARS-CoV-2 antibody assay and correlation with neutralization activity","10.1016/j.cca.2020.08.024","ImmunoAssay-Antibody","ELISA","IgA, IgM, IgG","kit (NovaTec)","Novalisa NovaTec Immunodiagnostica, Dietzenbach, Germany","diagnostic performances (AUC): 0.943 (IgA), 0.856 (IgM), 0.934 (IgG); Sensitivity: 69% (IgA, 11 NTU), 80.6% (IgA, 6NTU), 48.8% (IgM, 11 NTU), 72.9% (IgM, 5 NTU), 79.8% (IgG, 11 NTU), 83.7% (IgG, 9 NTU); Specificity: 100% (IgA, 11 Novatec Threshould Units), 97.6% (IgA, 6NTU), 97.6% (IgM, 11 NTU), 88% (IgM, 5 NTU), 100% (IgG, 11 NTU), 97.6% (IgG, 9 NTU)","171 samples","","yes","","2021-05-27 10:14:33",
"1058","Clinical predictors and timing of cessation of viral RNA shedding in patients with COVID-19","10.1016/j.jcv.2020.104577","review","PCR_KIT","not specified","retrospective review on data collected using SARS-CoV-2 qualitative assays using the cobas 6800 / 8800 systems (Roche Molecular Systems), the Abbott m2000 system (Abbott) or a SARS-CoV-2 laboratory-developed test that has received emergency use authorization from the Food and Drug Administration","retrospectively reviewed laboratory-confirmed COVID-19 adult symptomatic cases, eventually achieving cessation of viral RNA shedding (CVS), defined as two consecutive negative SARS-CoV-2 PCR results on nasopharyngeal swabs collected at least 24?h apart","cumulative CVS rate: 13.5% (2 weeks from symptom onset), 43.8% (3 weeks post symptom onset). Remark: Repeating a SARS-CoV-2 PCR test within 21 days of a laboratory-confirmed COVID-19 diagnosis is considered unnecessary","251 patients","","yes","","2021-05-27 10:11:36",
"1123","Clinical Samples for SARS-CoV-2 Detection: Review of the Early Literature","10.1016/j.clinmicnews.2020.07.001","review","Other","N/A","N/A","review compares suitability of different samples (eg. Blood, urine, saliva, stool, etc)","/","/"," ","yes","","2021-05-27 10:13:50",
"546","Clinical Sensitivity and Interpretation of PCR and Serological COVID-19 Diagnostics for Patients Presenting to the Hospital","10.1101/2020.06.19.20135723","NucleicAcid-PCR based","Mixed","N; ORF1a, E; N, E (PCR); IgG, IgA, IgM vs RBD (ELISA)","Kits & in house","LDT , cobas® SARS-CoV-2 (Roche), Xpert Xpress; ELISA","PCR Sensitivity: 90% (<5 dpo), 70-71% (9-11 dpo), 30% (>21 dpo); serological sensitivity: >50% (>7 dpo), >80% (>12 dpo), 100% (>21 dpo)","209 patients (with several tests each)","","no","","2021-05-27 09:56:29",
"890","Clinical significance of a high SARS-CoV-2 viral load in the Saliva","10.3346/JKMS.2020.35.E195","NucleicAcid-PCR based","RT-PCR","E and RdRP","rRT-PCR was performed using CFX96 real-time PCR detection system (Bio-rad, Hercules, CA, USA) and PowerChek 2019-nCoV real-time PCR kit (Kogenebiotech, Seoul, Korea)","","Viral load nasophrynx patient 1: 8.41 log10 copies/ml; Viral load nasophrynx patient 2: 7.49 log10 copies/ml. Viral load in saliva patient 1: 6.63 log10 copies/ml;  Viral load in saliva patient 2: 7.10 log10 copies/ml","2 patients","","yes","","2021-05-27 10:07:06",
"34","Clinical significance of IgM and IgG test for diagnosis of highly suspected COVID-19 infection","10.1101/2020.02.28.20029025","ImmunoAssay-Antibody"," ","IgM/IgG","TRFICA individual-kit","Kit: Beijing Diagreat Biotechnologies","Sensitivity: 72.73% (IgM), 87.50% (IgG)","57 patients","","no","","2021-05-27 09:43:08",
"1141","Clinical usefulness of fully automated chemiluminescent immunoassay for quantitative antibody measurements in COVID-19 patients","10.1002/jmv.26430","ImmunoAssay-Antibody","Other Immuno assay","IgG, IgM vs N, S","kit (MAGLUMI)","Snibe 2019?Novel Coronavirus (nCoV) Kit, a CE?IVD marked assay on MAGLUMI 800 (Shenzhen New Industries Biomedical Engineering [Snibe] Co., Ltd., Shenzhen, China),","specificity: 100%; PPV: 100%; Sensitivity: 95.5% (15-25 dpo); LOD: 0.03 AU/mL (IgG), 0.58 AU/mL (IgM). Remark: table 3 and 4 present performance assessment of the method","276 samples","","yes","","2021-05-27 10:14:27",
"534","Clinical Utility of a Highly Sensitive Lateral Flow Immunoassay as determined by Titer Analysis for the Detection of anti-SARS-CoV-2 Antibodies at the Point-of-Care","10.1101/2020.07.30.20163824","ImmunoAssay-Antibody"," ","IgG/IgM ","LFIA kits vs ELISA and viral neutralization assay","LFIA kits: Pinnacle Biolabs SARS CoV-2 IgG/IgM One Step Rapid Test Device (Pinnacle); Wuhan EasyDiagnosis Biomedicine Co., Ltd COVID-19 (SARS-CoV-2) IgM/IgG Antibody Test Kit, reference SA-2-D (EDiagnostics); SafeCare Bio-Tech COVID-19 IgG/IgM Rapid Test Device (WB/S/P) ref NCO-4022 (SafeCare), AcroBiotech 2019-nCoV IgG/IgM Rapid Test Cassette reference INCP-402 (AcroBiotech); LumiQuick Diagnostics Quick Profile 2019 nCoV IgG/IgM Test Card ref 71108B (LumiQuick); Cellex qSARS-COV-2 IgG/IgM Rapid Test (Cellex); CALTH Care Health AllCheck COVID-19 IgG/IgM reference CHR09E (AllCheck); and Healgen COVID-19 IgG/IgM (Whole Blood/Serum/Plasma) Rapid Test Device reference GCCOV-402a (Healgen). Coronavirus (SARS-CoV-2) IgG Test Kit ref CG-COV-IgG (RayBiotech IgG), and Coronavirus (SARS-CoV-2) IgM Test Kit ref CG-CoV-IgM-FP (RayBiotech IgM) ","Remark: RayBiotech and EDiagnostics, showed similar analytical sensitivity to the ELISA ","27 patients & 7 controls","","no","","2021-05-27 09:56:04",
"557","Clinical Utility of Buccal Swabs for Severe Acute Respiratory Syndrome Coronavirus 2 Detection in Coronavirus Disease 2019-Infected Children","10.1093/jpids/piaa068","NucleicAcid-PCR based","PCR_KIT","E gene","in house","method described by Corman et al ","Remark: Viral loads in buccal specimens were substantially lower than those in nasopharyngeal specimens","11 patients","","yes","","2021-05-27 09:56:47",
"1165","Clinical validation and performance evaluation of the automated Vitros Total Anti-SARS-CoV-2 Antibodies assay for screening of serostatus in COVID-19","10.1093/ajcp/aqaa157","ImmunoAssay-Antibody","Other Immuno assay","total Ab vs S","kit (Vitros)","Vitros Anti–SARS-CoV-2 Total (CoV2T) assay for qualitative serologic testing of SARS-CoV-2 antibodies.","NPA: 100%; PPA: 71%; concordance with PCR: 97% (>7 dpo); Specificity: 100%; Sensitivity: 100%","136 subjects","","yes","","2021-05-27 10:15:12",
"1241","Clinical validation of an automated reverse transcription-insulated isothermal PCR assay for the detection of severe","10.1016/j.jmii.2021.01.005","NucleicAcid-PCR based","RT-PCR","ORF1ab","POCKIT Central SARS-CoV-2 (orf 1 ab)  Premix Reagent, GeneReach Biotech (RT-iiPCR assay)","POCKIT compared to real-time RT-PCR assay developed by Corman et al.","sensitivity: 96.8%; specificity: 97.1%","31 positive and 69 negative","","yes","","2021-05-27 10:17:42",
"1140","Clinical validation of an immunochromatographic SARS-Cov-2 IgM/IgG antibody assay with Japanese cohort","10.1002/jmv.26363","ImmunoAssay-Antibody","GICA","IgG, IgM","Kit (INNOVITA)","colloidal gold immunochromatography assay for SARS?Cov?2 IgM/IgG 2019?nCoV Ab Test Cassette (Colloidal Gold) (Innovita) ","sensitivity: 79.7% (IgM, 8 dpo),  86.1% (IgG, 8 dpo);specificity: 100%","151 samples","","yes","","2021-05-27 10:14:25",
"1203","Clinical Validity of Serum Antibodies to SARS-CoV-2: A Case-Control Study","10.7326/M20-2889","ImmunoAssay-Antibody","ELISA","IgG and IgA againt  S1 protein","IgA and IgG antibodies against S1 protein SARS-CoV-2 ELISA Euroimmun","Case study and clinical validity of serum antibodies against SARS-CoV2","Sensitivity IgG: 0.976: Sensitivity IgA: 0.988; ","11066 tested persons","","yes","","2021-05-27 10:16:26",
"994","Clinical value of anal swab positive in COVID-19 patients","10.3760/cma.j.cn112309-20200425-00228","","","","","","","","","yes (paper not in English)","","2021-05-27 10:09:51",
"695","Clinically Applicable AI System for Accurate Diagnosis, Quantitative Measurements, and Prognosis of COVID-19 Pneumonia Using Computed Tomography","10.1016/j.cell.2020.04.045","Imaging-CT scan"," ","lung  ","Ct scan","AI system that can diagnose sars-cov-2 and differentiate it from other common pneumonia and normal controls","accuracy: 92.49%; sensitivity: 94.93%; specificity: 91.13% ","database from 3,777 patients","","yes","","2021-05-27 10:01:01",
"711","Clinically practiced and commercially viable nanobio engineered analytical methods for COVID-19 diagnosis","10.1016/j.bios.2020.112361","Review"," ","","","review","remark: review on diagnostic assays reporting performance","/","","yes","","2021-05-27 10:01:32",
"615","Closing the Serological Gap in the Diagnostic Testing for COVID-19: The Value of Anti-SARS-CoV-2 IgA Antibodies","10.1002/jmv.26422","ImmunoAssay-Antibody"," ","ELISA: IgA, IgG (S1); CLIA: IgM, IgG (S+N)","Kits (CLIA and ELISA)","chemiluminescent assay (YHLO Biotech Co Ltd ,Shenzhen, China) and ELISA (Euroimmun Medizinische Labordiagnostika AG Luebeck, Germany)","Remark: The inclusion of SARS?CoV?2 IgA antibodies may increase the diagnostic sensitivity of the serological tests for COVID?19","30 patients","","yes","","2021-05-27 09:58:28",
"1104","CNN-based transfer learning–BiLSTM network:Anovel approach for COVID-19 infection detection","10.1016/j.asoc.2020.106912","Imaging-CT scan","In_silico","CT scans","CT scans","","Accuracy: 98.7%","2905 images","","yes","","2021-05-27 10:13:11",
"466","Co-infection with SARS-CoV-2 and influenza A virus","10.1016/j.idcr.2020.e00775","Others"," ","/","/","case report of influenza A and SARS-CoV-2 co-infection","/","/","","yes","","2021-05-27 09:53:59",
"677","Co-Infection with SARS-COV-2 and Parainfluenza in a young adult patient with pneumonia: Case Report","10.1016/j.idcr.2020.e00762","Others"," ","","","Report case of co-infection with SARS-COV-2 andParainfluenza 4 virus ","","1 patient","","yes","","2021-05-27 10:00:24",
"632","Colorimetric Test for Fast Detection of SARS-CoV-2 in Nasal and Throat Swabs","10.1101/2020.08.15.20175489","ImmunoAssay-Antigen"," ","spike, envelope, and membrane proteins","in house","colorimetric biosensor based on gold nanoparticle (AuNP)","sensitivity: 96%; specificity: 98%","94 samples","","yes","","2021-05-27 09:59:00",
"1131","Combination of CT and RT-PCR in the screening or diagnosis of COVID-19","10.7189/jogh.10.010347","mixed","In_silico"," ","CT imaging and RT-PCR in parallel or in series","We recommend that parallel tests are used in screening, while series tests should be used for diagnosis confirmation of COVID-19. Parallel tests perform RT-PCR and CT imaging at the same time and the results are cross-referenced to make the diagnosis. Serial test employs as a secondary screening test which is performed only if the result of initial screening test is positive.","Sensitivity of chest CT imaging: 97%; specificity: 25%, with RT-PCR as a diagnosis criterion. Sensitivity of RT-PCR testing: 65%; specificity 83%, if chest CT as a reference of diagnosis standard.  Remark: If both sensitivity and specificity were taken into account simultaneously, neither chest CT nor RT-PCR testing alone is accurate enough for the diagnosis of COVID-19 infection.","1014 patients"," ","yes","","2021-05-27 10:14:06",
"35","Combination of RT-qPCR testing and clinical features for diagnosis of COVID-19 facilitates management of SARS-CoV-2 outbreak.","10.1002/jmv.25721","NucleicAcid-PCR based","Mixed","Unclear","Unclear","","Not reported","Not reported","","no","","2021-05-27 09:43:10",
"580","Combination of serological total antibody and RT-PCR test for detection of SARS-COV-2 infections","10.1016/j.jviromet.2020.113919","ImmunoAssay-Antibody","Mixed","ORF1ab, N (RT-PCR); ","Kits (CMIA and RT-PCR)","chemiluminescence microparticle immunoassay kit (CMIA) :Xiamen Wantai Kairui Biological Technology Co., Ltd, China; RT-PCR kit: Shanghai BioGerm Medical Technology Co.","Sensitivity: 92.2% (RT-PCR), 95.7% (CMIA), 98.6% (combined); Specificity: 100% (RT-PCR), 98.7% (CMIA), 98.7% (combined)","375 patients & 234 controls","","yes","","2021-05-27 09:57:26",
"409","Commercial stocks of SARS-CoV-2 RNA may report low concentration values, leading to artificially increased apparent sensitivity of diagnostic assays","10.1101/2020.04.28.20077602","NucleicAcid-PCR based","PCR_KIT","/","kit and RT-dPCR","CDC RT-PCR and dPCR test on commercial nucleic acid stocks (synthetic RNA, plasmid DNA and genomic RNA)","Remark: identification of discrepancies in the analytical sensitivity  (LOD) of the CDC?recommended RT?qPCR protocol. RT?dPCR revealed  there are likely errors in the supplier?reported concentrations of the nucleic acid stocks.","/","","no","","2021-05-27 09:52:07",
"36","Comparative analysis of primer-probe sets for the laboratory confirmation of SARS-CoV-2","10.1101/2020.02.25.964775","NucleicAcid-PCR based","WHO method(s)","See individual methods","WHO-1, WHO-7, WHO-3, WHO-5, WHO-4, WHO-6","","LOD: 15 cpr  (ORF1ab), 33 cpr (N targets) ; Remark: PCR Efficiency tested","None","","no","","2021-05-27 09:43:12",
"530","Comparative Evaluation of Three Serologic Assays for the Identification of SARS-CoV-2 Antibodies","10.1101/2020.08.04.20167643","ImmunoAssay-Antibody"," ","IgG","kits","Liaison SARS-CoV-2 S1/S2 IgG, Elecsys anti-SARS-CoV-2 total antibody, Access SARS-CoV-2 IgG","Inter-tests agreement: 96% (overall), 100% (negative PCR patients), 88% (early positive patients), 100% (14 days post positive PCR) ","113 samples","","no","","2021-05-27 09:55:56",
"857","Comparative in silico design and validation of GPS™ CoVID-19 dtec-RT-qPCR test","10.1111/jam.14781","NucleicAcid-PCR based","PCR_KIT"," ","GPS TM COVID-19 dtec-RT-qPCR kit (Alicante, Spain)"," ","LOD: 10 copies; LOQ: 10 copies; specificity: tested","41 samples"," ","yes","","2021-05-27 10:06:11",
"37","Comparative performance of four nucleic acid amplification tests for SARS-CoV-2 virus","10.1101/2020.03.26.010975","NucleicAcid-PCR based","PCR_KIT","ORF1ab-gene, N-gene","Multiple-kits","Kits: Daan, Sansure, Hybribio, and Bioperfectus","Specificity: tested ; LOD: 3000 cpm (Sansure, Hybribio, Daan), 4000 cpm (Bioperfectus) ; Sensitivity: 100% (Daan, Sansure and Hybribio),  81.25% (Bioperfectus)","46 samples","","no","","2021-05-27 09:43:14",
"1029","Comparative performance of SARS-CoV-2 detection assays using seven different primer-probe sets and one assay kit","10.1128/JCM.00557-20","NucleicAcid-PCR based","RT-PCR","N, RdRp, E genes","WHO-5, WHO-7, in house UW RdRp","","LOD: 790 ge/reaction (UW RdRp, N), 316 ge/reaction (RdRp, E)","300 samples","","yes","","2021-05-27 10:10:36",
"38","Comparative Performance of SARS-CoV-2 Detection Assays using Seven Different Primer/Probe Sets and One Assay Kit","10.1101/2020.03.13.20035618","NucleicAcid-PCR based","WHO method(s)","RdRp-region, see individual methods ","WHO-7, WHO-5, other method, kit","Kit: BGI RT-PCR detection kit","Remark: LOD given but expressed in dilution rather than copies","300 samples","","no","","2021-05-27 09:43:16",
"975","Comparison analysis of different swabs and transport mediums suitable for SARS-CoV-2 testing following shortages","10.1016/j.jviromet.2020.113947","NucleicAcid-PCR based","WHO method(s)","E gene","WHO-5","different swab media tested","remarks: no meaningful difference in viral yield from different swabs and most transport mediums for the collection and detection of SARS-CoV-2","","","yes","","2021-05-27 10:09:16",
"762","Comparison and Application of Different Immunoassay Methods for the Detection of SARS-CoV-2","10.1002/jmv.26187","ImmunoAssay-Antibody","","IgM, IgG","kits (CLIA and colloidal gold)","SARS?CoV?2 IgM and IgG antibody chemiluminescence detection kits were from Maccura Biotechnology Co, Ltd and Bioscience (Tianjin) Diagnostic Technology Co, Ltd; SARS?CoV?2 colloidal gold test kits came from Innovita (Tangshan) Biological Technology Co, Ltd and Zhuhai Livzon Diagnostics Inc","positive rate: 50% (IgM, CLIA, <7 dpo), 40% (IgM, colloidal gold, <7 dpo), 90% (IgM, CLIA, 14 dpo), 80% (IgM, colloidal gold, 14 dpo), 100% (IgM, CLIA & colloidal gold, >21dpo), 45% (IgG, CLIA, <7 dpo), 30% (IgG, colloidal gold, <7 dpo), 90% (IgG, CLIA, 14 dpo), 60% (IgG, colloidal gold, 14 dpo), 95% (IgG, CLIA & colloidal gold, >21dpo)","169 patients","","yes","","2021-05-27 10:03:12",
"492","Comparison five primer sets from different genome region of COVID-19 for detection of virus infection by conventional RT-PCR","10.18502/ijm.v12i3.3234","NucleicAcid-PCR based","PCR_KIT","N, E, RdRp, S, ORF1ab","in house RT-PCR and kit","In house PCR tested versus two reference kits: TIB (TIB MOLBIOL, Germany) and Sansure (Sansure Biotech, China)","Sensitivity: 95.7% (RdRp), 96.6% (N), 66.7% (E), 85.7% (S), 96% (ORF1ab); Specificity: 88.9% (RdRp), 100% (N), 66.7% (E), 50% (S), 100% (ORF1ab); PPV: 95.7% (RdRp), 100% (N), 88.9% (E), 96% (S), 100% (ORF1ab); NPV: 88.9% (RdRp), 50% (N), 33.3% (E), 20% (S), 83.3% (ORF1ab); Accuracy: 47% (RdRp), 31.3% (N), 29.3% (E), 27.3% (S), 40.7% (ORF1ab); LOD: 10 copies/mL (TIB), 200 copies/mL (Sansure)","30 positive & 15 negative samples","","yes","","2021-05-27 09:54:50",
"1222","Comparison of 12 molecular detection assays for SARS-CoV-2","10.1101/2020.06.24.170332","NucleicAcid-PCR based","PCR_KIT & other","E, RdRP, N","WHO-4, WHO-5, WHO-7, LightMix® Modular assays (Roche), 2019-nCoV kit (BGI Biotechnology, China), TaqPath™ COVID-19 Combo Kit (ThermoFisher), ","a total of 12 molecular diagnostic assays were compared","specificity: 100% (all assays); sensitivity: 98.5% (CDC N1), 100% (CDC N2), 100% (NIID N2), 95.6% (NIID N2 with EAV), 98.5% (Corman E), 69.1% (Corman N), 86.8% (Roche E),  42.6% (Roche RdRP), 67.6% (Roche N),  85.3% (Thermo),  88.2% (BGI), 80.9% (LAMP)","155 samples"," ","no","","2021-05-27 10:17:05",
"891","Comparison of a laboratory-developed test targeting the envelope gene with three nucleic acid amplification tests for detection of SARS-CoV-2","10.1016/j.jcv.2020.104427","NucleicAcid-PCR based","RT-PCR","E, S, N and ORF1ab","high complexity laboratory-developed rRT-PCR EUA from Stanford Health Care (SHC) targeting the SARS-CoV-2 envelope (E) ; Atila isothermal amplification assay targeting the nucleocapsid (N) gene; Atila isothermal amplification assay targeting open reading frame 1ab (ORF1ab); pike (S) multiplex, real-time RT-PCR, and the US Centers for Disease Control; Prevention (CDC) N1 and N2 rRT-PCRs.","Comparing high complexity laboratory-developed rRT-PCR EUA from Stanford Health Care (SHC)  with other kits","PPA with the SHC EUA reference assay: 82.8 % (95 % confidence interval (CI) 65.0 to 92.9); PPA for Atila: 86.7 % (95 % CI 69.7 to 95.3); PPA for the Altona E: 86.7 % (95 % CI 69.7 to 95.3);  PPA for Altona S targets:c90.0 % (95 % CI 73.6 to 97.3)","8 patients","","yes","","2021-05-27 10:07:08",
"1180","Comparison of a Point-of-Care Assay and a High-Complexity Assay for Detection of SARS-CoV-2 RNA","10.1093/jalm/jfaa135","NucleicAcid-PCR based","PCR_KIT","envelope (E) gene and nucleocapsid (N) gene (N2 region) ","Cepheid Xpert Xpress SARS-CoV-2 assay and Hologic Panther Fusion SARS-CoV-2 assay","A diagnostic comparison study was performed to evaluate the performance of the Cepheid Xpert Xpress SARS-CoV-2 assay compared to the Hologic Panther Fusion SARS-CoV-2 assay","sensitivity: 98.1%, specificity: 100%","54 positive and 50 negative","","yes","","2021-05-27 10:15:41",
"1087","Comparison of a rapid immunochromatographic test with a chemiluminescence immunoassay for detection of anti-SARS-CoV-2 IGM and IGG","10.11613/BM.2020.030901","ImmunoAssay-Antibody","LFIA","IgM IgG","1) IOSYNEX COVID-19 BSS IgM/IgG test 2) MAGLUMI CLIA (IgM and IgG) ","Comparison of a rapid immunochromatographic test with a chemiluminescence immunoassay for detection of anti-SARS-CoV-2 IgM and IgG","Biosynex Covid-19 BSS vs MAGLUMI 2019-nCov for IgM, Sensitivity: 83%; Specificity: 88%, PPV: 83%; NPV: 88%; Likehood ratio: 6.79; C-k - Cohen’s kappa: 0.71. Biosynex Covid-19 BSS vs MAGLUMI 2019-nCov for IgG, Sensitivity: 82; Specificity: 93%; PPV: 95%; NPV: 75%; Likehood ratio: 10.63; C-k cohen's kappa: 0.71","70 patients","","yes","","2021-05-27 10:12:36",
"365","Comparison of Abbott ID Now and Abbott m2000 methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from symptomatic patients","10.1128/JCM.00798-20","NucleicAcid-PCR based","LAMP","Not specified","In-house LAMP","Comparison between LAMP assay (ID NOW COVID IDNCOV) and Abbott RT-PCR COVID (ACOV)","LOD: 3,225 copies/mL (IDNCOV); positive agreement: 75%; negative agreement: 99%","524 samples","","yes","","2021-05-27 09:50:43",
"1126","Comparison of abbott id now, diasorin simplexa, and CDC fda emergency use authorization methods for the detection of sars-cov-2 from nasopharyngeal and nasal swabs from individuals diagnosed with covid-19","10.1128/JCM.00760-20","NucleicAcid-PCR based","Mixed","mixed"," ID Now (Abbott, USA), Simplexa (DiaSorin, Italy), WHO7 (CDC, modified)","letter to the editor","Percent positive agreement: 94% (ID now), 96% (Simplexa)","96 samples"," ","no","","2021-05-27 10:13:56",
"645","Comparison of automated SARS-CoV-2 antigen test for COVID-19 infection with quantitative RT-PCR using 313 nasopharyngeal swabs, including from seven serially followed patients","10.1016/j.ijid.2020.08.029","ImmunoAssay-Antigen"," ","Not specified","kit","LUMIPULSE antigen test (chemiluminescence enzyme immunoassay)","sensitivity: 55.2% (vs RT-PCR); specificity: 99.6% (vs RT-PCR), overall agreement rate: 91.4% (vs RT-PCR), 100% (vs RT-PCR in samples >100 viral copies), 85% (vs RT-PCR in samples 0-100 viral copies)","313 samples","","yes","","2021-05-27 09:59:21",
"318","Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the Rapid Detection of SARS-CoV-2","10.1101/2020.04.22.055327","NucleicAcid-PCR based","PCR_KIT","ORF1ab, NS, E, N2, RdRp genes","Cobas, ID Now, Xpert kits compared","Agreement of Xpert and ID Now with other methods measured","Not specified","113 patients (plus 25 negative specimens)","","yes","","2021-05-27 09:49:48",
"869","Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the Rapid Detection of SARS-CoV-2","10.1016/j.jcv.2020.104428","NucleicAcid-PCR based","RT-PCR","E, N and ORF1 a/b","Cepheid Xpert Xpress and Abbott ID Now to Roche cobas","Cepheid Xpert Xpress SARS-CoV-2 and Abbott ID Now SARS-CoV-2, to the Roche cobas SARS-CoV-2 assay for samples with low, medium, and high viral concentrations.","Positive agreement compared to Cobas for ID Now: 73.9%, Positive agreement compared to Cobas for Cepheid Xpert Xpress: 98.9%. Negative agreement  compared to Cobas for ID NOW: 100%, Negative agreement  compared to Cobas for  Cepheid Xpert Xpress: 92.0%  for medium and high concentration. Ct values >30 positive agreement ID NOW: 34.3%, Ct values >30 positive agreement Cepheid Xpress Xpert:97.1%"," ","","yes","","2021-05-27 10:06:31",
"961","Comparison of commercial lateral flow immunoassays and ELISA for SARS-CoV-2 antibody detection","10.1016/j.jcv.2020.104529","ImmunoAssay-Antibody","ELISA","IgA, IgM and IgG","Euroimmun, Hangzhou Alltest Biotech, Wuhan UNscience Biotechnology and Guangzhou Wondfo Biotech.","Compare IgA and IgG Euroimmun vs LFI Hangzhou Alltest Biotech, Wuhan UNscience Biotechnology and Guangzhou Wondfo Biotech","Sensitivity IgA: 81,5%; Sensitivity IgG: 93.1%; Specificity IgA: 100%; Specificity IgG: 80.6%","152 sera","","yes","","2021-05-27 10:08:51",
"741","Comparison of commercial realtime reverse transcription PCR assays for the detection of SARS-CoV-2","10.1016/j.jcv.2020.104510","NucleicAcid-PCR based","PCR_KIT","multiple targets","kits","Altona Diagnostics (RealStar SARS-CoV2 1.0: E, S); Tibmolbiol (LightMix Sarbeco-E/SARS-CoV-2 RdRp: E, RdRp); ThermoFisher (Taqman 2019-nCoV Assay kit v1: ORF1ab, S, N); DAAN Gene (	Detection Kit for 2019-nCoV: ORF1ab, N); Kogene Biotech (Powercheck 2019-nCoV: ORF1ab, E); Liferiver	(2019-nCoV realtime multiplex RT-PCR: ORF1ab, N); Maccura Biotechnology (SARS-CoV2 fluorescent PCR: ORF1ab, E, N); R-Biopharm (Ridagene SARS-CoV2: E); Sansure Biotech (2019-nCoV nucleic acid diagnostic kit: ORF1ab, N); Sentinel Diagnostics B (RUO) (STAT-NAT COVID19 B RUO: E, RdRp, N); Sentinel Diagnostics B (CE-IVD)	(STAT-NAT COVID19 B CE-IVD: E, RdRp, N); Sentinel Diagnostics HK (RUO)	(STAT-NAT COVID19 HK: ORF1ab, N); Sentinel Diagnostics HK (CE-IVD) (STAT-NAT COVID19 HK CE-IVD: ORF1ab, N); XABT (RT PCR kit for detection of 2019-nCoV: ORF1ab, E, N); Hecin Scientific (SARS-CoV-2 Realtime PCR assay kit: RdRp, N); Reference assay	(Corman et al.: E, RdRp)","Sensitivity: 3.3 copies (Altona), 25-100 cpoies (TibMolbiol), 3.3-33 copies (Thermofisher), 3.3 copies (Daan Gene), 33-100 copies (Kogene), 3.3-33 copies (Liferiver), 3.3 copies (Maccura), 50 copies (R-Biopharm), 3.3 copies (Sansure), 33-330 copies (Sentinel Diagnostic B RUO and CEIVD, Sentinel Diagnostic HK RUO), 33 copies (Sentinel Diagnostic HK CEIVD), 3.3 copies (XABT), 25 copies (Hecin), 3.3-25 copies (reference). Remark: None but the Kogene Biotech E gene PCR detected other coronaviruses, which detected also MERS","dilution series of virus stock","","yes","","2021-05-27 10:02:29",
"317","Comparison of commercial RT-PCR diagnostic kits for COVID-19","10.1101/2020.04.22.056747","NucleicAcid-PCR based","PCR_KIT","E, S, ORF1ab, N, RdRp genes","7 commercial RT-PCR kits compared","","PCR efficiency: >96% (all tests) ; sensitivity: 13/16 (R-Biopharm AG), 12/16 (BGI, KH Medical, Seegene), 11/16 (CerTest BioTec), 10/16 (Altona Diagnostic, PrimerDesign) ; LOD95%: 3.8 cpu (Altona Diagnostic E- and S-gene), 23 cpu (PrimerDesign), 0.91 cpu (in-house Corman E-gene), 4.3 cpu (BGI and R-Biopharm AG, KH Medical S-gene), 4.8 cpu (CerTest Biotec N-gene, KH Medical ORF1ab/RdRp), 18 cpu (CerTest Biotec Orf1ab/RdRp) ","16 patients Covid19 positive, 6 patients other respiratory viral infections","","no","","2021-05-27 09:49:46",
"309","Comparison of Commercially Available and Laboratory Developed Assays for in vitro Detection of SARS-CoV-2 in Clinical Laboratories","10.1101/2020.04.24.20074559","NucleicAcid-PCR based","PCR_KIT","Cepheid E-gene and N2, ","Comparison of the analytical performance of a laboratory developed test (LDT) developed based on CDC primer sets with other 4 kits","UW CDC LDT and Cepheid Xpert Xpress SARS-CoV-2 assays having the best and similar sensitivity, followed by the Roche Cobas 6800, DiaSorin Simplexa, and Panther Fusion SARS-CoV-2 assays.","","169 samples","","no","","2021-05-27 09:49:29",
"370","Comparison of Commercially Available and Laboratory Developed Assays for in vitro Detection of SARS-CoV-2 in Clinical Laboratories","10.1128/JCM.00821-20","NucleicAcid-PCR based","Other PCR method(s)","N1, N2, RdRP (UW CDC LDT)","in house RT-PCR on CDC primers (UW CDC LDT)","Comparison of in house Laboratory Developed Test with commercial kits Cepheid, DiaSorin, Hologic Panther, and Roche Cobas","Specificity: 100% (all); Remark: all the tested assays show good sensitivity (UW CDC LDT and Cepheid Xpert Xpress the best, followed by the Roche Cobas 6800, DiaSorin Simplexa, and Panther Fusion SARS-CoV-2 assays ","169 samples","","yes","","2021-05-27 09:50:49",
"1092","Comparison of copan ESwab and FLOQSwab for COVID-19 diagnosis: working around a supply shortage","10.1128/JCM.00669-20","NucleicAcid-PCR based","RT-PCR","UTR and envelope","; Corman et al. on the Rotor-gene Q (Qiagen, Germany)","comparison of specimens collected with FLOQSwab  preserved in universal transport medium (Copan UTM system)and flocked regular nylon tip swab preserved in liquid Amies (ESwab collection system; Copan). using two distinct extraction/real-time reverse transcription-PCR (rRT-PCR): ExK TNA-2 extraction strip and detection; NucliSENS EasyMAG (bioMérieux, France) and detection  performed on the Rotor-gene Q (Qiagen, Germany). ","BD Max sensitivity:100%; specificity: 100%. Rotor geneQ: sensitivity:97,1%; specificity: 100%","94 patients","","yes","","2021-05-27 10:12:46",
"983","Comparison of diagnostic accuracies of rapid serological tests and ELISA to molecular diagnostics in patients with suspected coronavirus disease 2019 presenting to the hospital","10.1016/j.cmi.2020.05.028","mixed","Mixed","","LFAs (Boson Biotech, Cellex, Dynamiker Biotechnology, Orient Gene Biotech, Prometheus Bio and Wantai Rapid Test), ELISA (Wantai SARS-CoV-2 Ab ELISA kit), RT-PCR (CE-IVD kit GeneFinder™ COVID-19 Plus RealAmp Kit and WHO-5)","assessment of diagnostic performance of rapid LFAs compared with an ELISA and NATs in individuals with suspected COVID-19","sensitivity: 43% (Orient Gene Biotech LFA), 62% (Wantai ELISA) ; specificity: 98% (both kits) ; remarks: more detailed performance data for each kits available in tables","228 patients","","yes","","2021-05-27 10:09:30",
"39","Comparison of different samples for 2019 novel coronavirus detection by nucleic acid amplification tests","10.1016/j.ijid.2020.02.050","NucleicAcid-PCR based","PCR_KIT","Not specified","Multiple-kits","Kit: GeneoDx GZ-TRM, China, Maccura Sichuan China, Life-river W-RR-0479-02 China","Not reported","19 patients","","yes","","2021-05-27 09:43:18",
"864","Comparison of different serological assays for SARS-CoV-2 in real life","10.1016/j.jcv.2020.104569","ImmunoAssay-Antigen","mixed","ABBOTT: Nucloecapsid, BIORAD Spike1, LIAISON Spike1/2, WATAI RBD ","SARS-CoV-2 nucleocapsid for ABBOTT and BIORAD, Spike 1 for EUROIMMUN, Spike 1 and 2 for LIAISON and receptor binding domain (RBD) for WANTAI","Comparison of different serological assays for SARS-CoV-2 in real life","Sensitivity for hospitalized patients WANTAI: 100%, Sensitivity for hospitalized patients BIORAD: 100%, Sensitivity for hospitalized patients EUROIMMUN: 100%, Sensitivity for hospitalized patients ABBOTT: 100%, Sensitivity for hospitalized patients LIAISON: 100%.  31 days after the PCR sample, the different techniques showed a positive signal for 100 % of patients with WANTAI and EUROIMMUN (21/21), 95 % with BIORAD and LIAISON (20/21) and 90 % with ABBOTT (19/21)","168 patients","","yes","","2021-05-27 10:06:25",
"1047","Comparison of Four Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2 in Nasopharyngeal Specimens","10.1101/2020.04.17.20069864","NucleicAcid-PCR based","PCR_KIT","N, N1, N2, S, ORF1ab regions","New York SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic EUA Panel (Modified WHO-7), DiaSorin Molecular Simplexa COVID-19 Direct EUA, GenMark ePlex SARS-CoV-2 EUA panel, Hologic Panther Fusion SARS-CoV-2 EUA","","LOD: 779±27 copies/ml (modified WHO-7), 39±23 copies/ml (DiaSorin Molecular), 1000 copies/ml (GenMark), 83±36 copies/ml (Hologic) ; sensitivity: 100% (modified WHO-7, DiaSorin Molecular, Hologic), 96% (GenMark) ; specificity: 100% (GenMark, DiaSorin Molecular), 98% (modified WHO-7), 96% (Hologic) ","104 samples","","no","","2021-05-27 10:11:13",
"732","Comparison of four molecular in vitro diagnostic assays for the detection of sars-cov-2 in nasopharyngeal specimens","10.1128/JCM.00743-20","NucleicAcid-PCR based","PCR_KIT","N1, N2 (modified CDC); ORF1ab, S (Simplexa); N (GenMark); ORF1ab (Hologic)","kits","the New York SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Panel (modified CDC) assay, the Simplexa COVID-19 Direct (Diasorin Molecular) assay, GenMark ePlex SARS-CoV-2 (GenMark) assay, and the Hologic Panther Fusion SARS-CoV-2 (Hologic) assay","LOD: 779 copies/ml (modified CDC), 39 copies/ml (Diasorin), 1000 copies/ml (GenMark), 83 copies/ml (Hologic); PPA: 100% (Diasorin, Hologic, modified CDC), 96% (GenMark); NPA: 100% (GenMark, Diasorin), 96% (Hologic), 98% (modified CDC)","104 samples","","yes","","2021-05-27 10:02:11",
"325","Comparison of four new commercial serologic assays for determination of SARS-CoV-2 IgG","10.1016/j.jcv.2020.104394","ImmunoAssay-Antibody"," ","IgG","kit","Euroimmun is validated in Germany","Sensitivity:  86.4% (Euroimmun), 100% (EDI), 86.4% (Mikrogen), 77.3% (Viramed); specificity: 96.2% (Euroimmun), 88.7% (EDI), 100% (Mikrogen), 100% (Viramed)","75 samples","","yes","","2021-05-27 09:50:00",
"876","Comparison of nasopharyngeal and oropharyngeal swabs for SARS-CoV-2 detection in 353 patients received tests with both specimens simultaneously","10.1016/j.ijid.2020.04.023","NucleicAcid-PCR based","RT-PCR","N and ORF1ab genes","","Comparison of nasopharyngeal and oropharyngeal swabs for SARS-CoV-2","73.1% of nasopharyngeal positive cases were negative in oropharyngeal swab, indicating false negative results may occur using oropharyngeal swab only. ","353 patients","","yes","","2021-05-27 10:06:44",
"1272","Comparison of nine different commercially available molecular assays for detection of SARS-CoV-2 RNA.","10.1007/s10096-021-04159-9","NucleicAcid-PCR based","PCR_KIT","E, S (Altona); E, ORF1a (Mikrogen); RdRP, E (gerbion); ORF1ab/N (Fast track); ORF1ab, N, E (Shangai Fosun); N, ORF1a (SolGent); RdRP, E (WELLS BIO)","kits","RealStar SARS-CoV-2 RT-PCR Kit RUO, Altona Diagnostics (Hamburg, Germany) ; Mikrogen diagnostic (Neuried, Germany) ; gerbion GmbH & Co KG (Kornwestheim, Germany); Primerdesign Ltd. (Camberley, UK); Fast Track Diagnostics (Esch-sur-Alzezze, Luxembourg); Shanghai Fosun Long March Medical Science Co., Ltd. (Shanghai, China); SolGent Co., Ltd. (Daejeon, Korea); WELLS BIO, INC. (Gangseo-gu, Republic of Korea); BGI (Wuhan, China)","LOD: 10cpr (Altona, E), 100cpr (Altona, S),  10cpr (Mikrogen, E), 10cpr (Mikrogen, ORF1a), 6000cpr (gerbion, RdRP), 60cpr (Gerbion, E), 80cpr (Primerdesign), 100cpr (Fast Track, ORF1ab/N), 100cpr (Shanghai Fosun, ORF1ab), 10cpr (Shanghai Fosun, N), 10cpr (Shanghai Fosun, E), 50cpr (SolGent, N), 50cpr (SolGent, ORF1a), 100cpr (WELLS BIO, RdRP),  10cpr (WELLS BIO, E), 10cpr (BGI); Sensitivity: 90% (Altona, E), 97% (Altona, S), 97% (Mikrogen, E), 97% (Mikrogen, ORF1a), 49% (gerbion, RdRP), 82% (Gerbion, E), 87%(Primerdesign), 100%(Fast Track, ORF1ab/N), 94% (Shanghai Fosun, ORF1ab), 100% (Shanghai Fosun, N), 94% (Shanghai Fosun, E), 97% (SolGent, N), 92% (SolGent, ORF1a), 66%(WELLS BIO, RdRP),  62% (WELLS BIO, E), 95% (BGI); Specificity: 100% (Altona, E), 100% (Altona, S),  100% (Mikrogen, E), 100% (Mikrogen, ORF1a), 100% (gerbion, RdRP), 100%(Gerbion, E), 100% (Primerdesign), 100% (Fast Track, ORF1ab/N), 100% (Shanghai Fosun, ORF1ab), 100% (Shanghai Fosun, N), 100% (Shanghai Fosun, E), 100% (SolGent, N), 100% (SolGent, ORF1a), 100% (WELLS BIO, RdRP),  100% (WELLS BIO, E), 100% (BGI)","different sample size for kit (up to 39 positive & 29 negative)","","yes","","2021-05-27 10:18:46",
"700","Comparison of SARS-CoV-2 detection from nasopharyngeal swab samples by the Roche cobas 6800 SARS-CoV-2 test and a laboratory-developed real-time RT-PCR test","10.1002/jmv.25988","NucleicAcid-PCR based","PCR_KIT","ORF1a, E (Cobas); N1, N2, N3 (LDT)","kit and in house","Roche Diagnostics cobas 6800 SARS?CoV?2 test and a laboratory?developed test (LDT) based on a modified CDC protocol","overall percent agreement: 95.8%; PPA: 94.2%","1006 samples","","yes","","2021-05-27 10:01:11",
"1224","Comparison of SARS-CoV-2 serological tests with different antigen targets","10.1101/2020.07.09.20149864","ImmunoAssay-Antibody","Mixed","IgG, IgM, IgA","EDI Novel Coronavirus COVID-19 ELISA (IgG kit & IgM kit), Anti-SARS-CoV-2 ELISA (IgG kit & IgA kit), SARS-CoV-2 NP ELISA (IgG kit & IgM kit), COVID-19 ELISA (IgG kit & IgM+IgA kit), SARS-CoV-2 IgG ELISA (IgG kit & IgM kit), 2019-nCOV IgG/IgM Rapid Test, NADAL® COVID-19 IgG/IgM Test, 2019-nCoV IgM/IgG Antibody kit, ISON® SARS-CoV-2 IgG kit, MAGLUMITM 2019-nCoV (IgG kit & IgM kit), Elecsys anti-SARS-CoV-2","comparison of 17 serological tests.","sensitivity: Supplementary Table S3 holds a very detailed breakdown of all sensitvity data over a range of days post infection.","182 sera"," ","yes","","2021-05-27 10:17:09",
"180","Comparison of SARS-CoV2 N gene real-time RT-PCR targets and commercially available mastermixes","10.1101/2020.04.17.047118","NucleicAcid-PCR based","WHO method(s)","Multiple targets on N-gene","WHO-7 and in-house-method","In-house method N geneTaq","LLOD: 1cpu (N1),  <1cpm (N2)","74 samples","","no","","2021-05-27 09:46:24",
"606","Comparison of serologic and molecular SARS-CoV 2 results in a large cohort in Southern Tuscany demonstrates a role for serologic testing to increase diagnostic sensitivity","10.1016/j.clinbiochem.2020.07.002","ImmunoAssay-Antibody","Mixed","IgM, IgG; E, RdRP, N","Multiple kits","Rapid IgM, IgG test: Acro Biotech, Inc.,Rancho Cucamonga, CA, USA). ; RT-PCR: Seegene Inc., Seoul, Korea","Specificity: 94% (Rapid serological test); sensitivity 37% (Rapid serological test); PPV: 51% (Rapid serological test); NPV: 94% (Rapid serological test)","516 patients","","yes","","2021-05-27 09:58:11",
"739","Comparison of seven commercial RT-PCR diagnostic kits for COVID-19","10.1016/j.jcv.2020.104412","NucleicAcid-PCR based","PCR_KIT","E, S (Altona); ORF1ab (BGI); ORF1ab, N (CerTest); RdRP, S (KH); RdRP (PrimerDesign); E (R-Biopharm); RdRP, E, N (Seegene); E, RdRP (in house)","kits & in house","Altona Diagnostics, BGI, CerTest Biotec, KH Medical, PrimerDesign, R-Biopharm AG, and Seegene","LOD95: 3.8 copies/mL (Altona), 4.3 (BGI), 4.8 (CerTest, N), 18 (CerTest, ORF1ab), 4.8 (KH, RdRP), 4.3 (KH, S), 23 (PrimerDesign), 4.3 (R-Biopharm), 4.8 (Seegene, E), 18 (Seegene, RdRP), 0.91 (in house PCR, E), 3.1 (in house PCR, RdRP). Remark: detection rate varies between kits,  none of the assays showed cross-reactivity with other respiratory (corona)viruses, except as expected for the SARS-CoV-1 E-gene.","19 samples","","yes","","2021-05-27 10:02:25",
"1225","Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories","10.1101/2020.07.30.20165373","ImmunoAssay-Antibody","Mixed","IgM, IgG, total antibody","Wantai/ELISA total-Ab, CUH/NOVO in-house ELISA total-Ab, Ortho/Vitros total-Ab, YHLO/iFlash-IgG, Ortho/Vitros-IgG, Siemens/Atellica total-Ab, Roche-Elecsys total-Ab, Abbott-Architect-IgG, Abbott/Alinity-IgG, Diasorin/LiaisonXL-IgG, Siemens/Vista total-Ab, Euroimmun/ELISA-IgG, Snibe/Maglumi-IgG ","comparison of 15 commercial and 1 in-house anti-SARS-CoV-2 assays in 16 laboratories","specificity: ? 99% (All except one),  97.2% (Diasorin/LiaisonXL-IgG ); sensitivity: 96.7% (Wantai/ELISA total-Ab), 96.0% (CUH/NOVO in-house ELISA total-Ab), 95.3% (Ortho/Vitros total-Ab), 94.0% (YHLO/iFlash-IgG), 93.3% (Ortho/Vitros-IgG), 93.2% (Siemens/Atellica total-Ab), 92.7% (Roche-Elecsys total-Ab), 90.0% (Abbott-Architect-IgG), 88.0% (Abbott/Alinity-IgG), 84.6% (Diasorin/LiaisonXL-IgG), 81.0% (Siemens/Vista total-Ab), 78.0% (Euroimmun/ELISA-IgG), 78.0% (Snibe/Maglumi-IgG).","150 samples"," ","no","","2021-05-27 10:17:12",
"607","Comparison of test performance of commercial anti-SARS-CoV-2 immunoassays in serum and plasma samples","10.1016/j.cca.2020.07.007","ImmunoAssay-Antibody"," ","IgG vs S (Euroimmun); IgG vs N (Epitope, Roche)","Multiple kits","ELISA kits: anti-SARS-CoV-2 IgG ELISA (Lot:E200429AG, Euroimmun, Germany), EDITM Novel Coronavirus COVID-19 IgG ELISA (Lot:P745U, Epitope Diagnostics, United States) ; ECLIA (electrochemiluminescence immunoassay) kit: Elecsys Anti-SARS-CoV-2 (Lot:496298, Roche, Germany).","Sensitivity: 92.3% (Roche), 96.2–100% (Euroimmun), 100% (Epitope); specificity: 100% (Roche), 100% (Euroimmun), 84–86% (Epitope)","51 samples","","yes","","2021-05-27 09:58:13",
"805","Comparison of the accula sars-cov-2 test with a laboratory-developed assay for detection of sars-cov-2 RNA in clinical nasopharyngeal specimens","10.1128/JCM.01072-20","NucleicAcid-PCR based","PCR_KIT","N gene","Accula SARS-CoV-2 POCT (Mesa Biotech, Inc., San Diego, CA)","Performances of Accula test (RT-PCR targeting N gene read out on lateral flow) on samples tested with WHO-5 method targeting E gene","Overall percent agreement: 84.0% ; Positive Percentage Agreement: 68.0% ; Negative Percentage agreement: 100% ; Remarks: Accula test compared to RT-PCR results ","100 samples","","yes","","2021-05-27 10:04:38",
"777","Comparison of the analytical sensitivity of seven commonly used commercial SARS-CoV-2 automated molecular assays","10.1016/j.jcv.2020.104578","NucleicAcid-PCR based","PCR_KIT","multiple targets","kits","Abbott Molecular RealTime SARS-CoV-2 assay (Abbott Molecular, Des Plaines, Il), NeuMoDx SARS-CoV-2 assay (NeuMoDx, Ann Arbor, Michigan), Roche Cobas SARS-CoV-2 assay, Becton Dickinson BD Max reagents (Becton Dickinson, Sparks, MD), Hologic Aptima SARS-CoV-2 assay (Hologic, Bedford, MA), Cepheid Xpert Xpress SARS-CoV-2 test (Cepheid, Sunnyvale, CA), GenMark ePlex SARS-CoV-2 test (GenMark, Carlsbad, CA)","Sensitivity: 100% (Abbott), 100% (NeuMoDx, high conc), 30%-80% (NeuMoDx, low conc), 100% (roche cobas), 100% (BD max, high conc), 50%-87.5% (BD max, low conc), 100% (Hologic, high conc), 87.5% (Hologic, low conc), 100% (Xpert, high conc), 66.67%-100% (Xpert, low conc), 100% (GenMark, high conc), 33.33% (GenMark, low conc)","10 replicates","","yes","","2021-05-27 10:03:41",
"982","Comparison of the computed tomography findings in COVID-19 and other viral pneumonia in immunocompetent adults: a systematic review and meta-analysis","10.1007/s00330-020-07018-x","review","Other","CT-scan","CT-scan","review of CT findings for covid-19 and other viral pneumonia","","","","yes","","2021-05-27 10:09:28",
"1152","Comparison of the diagnostic sensitivity of SARS-CoV-2 nucleoprotein and glycoprotein-based antibody tests","10.1016/j.jcv.2020.104544","ImmunoAssay-Antibody","Mixed","IgG (Abbott, Novatec, Virotech, Euroimmun and Mediagnost); Variuos Ab (ECLIA from Roche and the MIA from Siemens); Ab vs N (Abbott, Roche, Novatec and Virotech); Ab vs S1, RBD (Siemens, Euroimmun and Mediagnost); ","kits","Roche Elecsys Anti-SARS-CoV-2, Abbott Architect SARS-CoV-2 IgG, Novatec Novalisa SARS-CoV-2 IgG ELISA, Virotech SARS-CoV-2 IgG ELISA, Euroimmun Anti-SARS-CoV-2-ELISA (IgG), Mediagnost Anti-SARS CoV-2 ELISA, and Siemens Atellica IM COV2T.","Sensitivity: 80% (Roche, 2-3 weeks), 80% (Abbott,  2-3 weeks), 72% (Novatec,  2-3 weeks), 64% (Virotech,  2-3 weeks), 80%(Siemens,  2-3 weeks), 72% (Euroimmun,  2-3 weeks), 52% (Mediagnost,  2-3 weeks), 95.8% (Roche, >4weeks), 83.3% (Abbott, >4 weeks), 66.7% (Novatec,  >4 weeks), 66.7% (Virotech,  >4 weeks), 100% (Siemens,  >4 weeks), 89.6% (Euroimmun,  >4 weeks), 70.8% (Mediagnost,  >4 weeks), 90.4% (Roche, overall), 82.2% (Abbott, overall), 68.5% (Novatec,  overall), 65.8% (Virotech,  overall), 93.2% (Siemens,  overall), 83.6% (Euroimmun,  overall), 64.4% (Mediagnost,  overall)","73 samples","","yes","","2021-05-27 10:14:45",
"931","Comparison of the Elecsys® Anti-SARS-CoV-2 immunoassay with the EDI™ enzyme linked immunosorbent assays for the detection of SARS-CoV-2 antibodies in human plasma","10.1016/j.cca.2020.05.049","ImmunoAssay-Antibody","ELISA","IgM and IgG"," Elecsys Anti-SARS-CoV-2 assay EDITM ELISAs","Comparison Elecys and EDITM ELISA","Positivity rate Elecys: 100%; Positivity rate EDITM IgM: 94%; Positivity rate EDITM IgG: 100% ; ","256 samples","","yes","","2021-05-27 10:08:18",
"910","Comparison of the Panther Fusion and a laboratory-developed test targeting the envelope gene for detection of SARS-CoV-2","10.1016/j.jcv.2020.104383","NucleicAcid-PCR based","RT-PCR","ORF1ab and E gene","Hologic Panther Fusion SARS-CoV-2 and EUA from Stanford Health Care (SHC) ","Comparison between two kits ","Percent agreement: 98,3%  (95 % confidence interval (CI) 95.2–99.7) and kappa coefficient was 0.97 (95 % CI 0.93–1.0)","184 patients","","yes","","2021-05-27 10:07:41",
"40","Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-Cov-2) infected pneumonia (COVID-19)","10.1101/2020.02.21.20026187","NucleicAcid-PCR based","PCR_KIT","ORF1ab-gene, N-gene","Individual-kit","Kit: Shanghai ZJ Bio-Tech Co Ltd","Not reported","52 patients","","no","","2021-05-27 09:43:20",
"132","Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-Cov-2)-infected pneumonia (COVID-19)","10.1515/cclm-2020-0187","NucleicAcid-PCR based","PCR_KIT","ORF1ab-gene,  N-gene ,  E- gene","Individual-kit","Kit Shanghai ZJ Bio-Tech Co Ltd","Not reported","52 patients","","yes","","2021-05-27 09:45:14",
"671","Comparison of two commercial molecular tests and a laboratory-developed modification of the CDC 2019-ncov reverse transcriptase PCR assay for the detection of sars-cov-2","10.1128/JCM.00938-20","NucleicAcid-PCR based","PCR_KIT","N gene(LDT test); N, RdRP (ACOV); RdRP (IDNOW)","kit & in house","2 commercial molecular amplification assays (RealTime SARS-CoV-2 on the m2000 [abbreviated ACOV; Abbott] and ID Now COVID-19 [abbreviated IDNOW; Abbott]) and a laboratory-developed test (modified CDC 2019-nCoV reverse transcriptase PCR [RT-PCR] assay ","overall agreement: 83.5%; PPA: 75.2%-100%; NPA: 92.4%-100%","200 samples","","yes","","2021-05-27 10:00:12",
"541","Comparison of two commercial platforms and a laboratory developed test for detection of SARS-CoV-2 RNA","10.1101/2020.07.03.20144758","NucleicAcid-PCR based","PCR_KIT","N gene (LDT); ORF1ab, E (Cobas); ORF1ab, N (AmpliDiag) ","kit & in house","LDT , cobas® SARS-CoV-2 (Roche), Amplidiag® COVID-19 (Mobidiag)","PPA: 100% (Cobas), 98.9% (AmpliDiag and LDT); NPA:89.4% (Cobas), 98.8% (AmpliDiag), 100% (LDT) ","183 samples","","no","","2021-05-27 09:56:18",
"379","Comparison of Two High-Throughput Reverse Transcription-Polymerase Chain Reaction Systems for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2","10.1128/JCM.00890-20","NucleicAcid-PCR based","PCR_KIT","ORF1ab-gene, N-gene (Cobas); ORF1ab (Panther fusion); N2, E (Xpert)","Kits","Performance analysis of cobas 6800 and Panther Fusion against Xpert (Cepheid)","overall percent agreement: 96.4%","389 samples","","yes","","2021-05-27 09:51:06",
"1115","Comparison of various serological assays for novel SARS-COV-2","10.1007/s10096-020-04091-4","ImmunoAssay-Antibody","Other Immuno assay","IgG, IgM, IgA","The StrongStep®SARS-CoV-2 IgG/IgM kit, AllTest COV-19 IgG/IgM kit, Wondfo® SARS-CoV-2 Antibody, Covid-19 VIRCLIA IgM+IgA monotest and Covid-19 VIRCLIA IgG monotest (Vircell, S.L.).","","remarks: positive rates in different sample groups are reported","50 samples","","yes","","2021-05-27 10:13:33",
"438","Comprehensive Investigation and Isolation have Effectively Suppressed the Spread of COVID-19","10.1101/2020.04.24.20077933","Others","In_silico","/","/","transmission dynamic model","/","/","","no","","2021-05-27 09:53:05",
"575","Concordance between two rapid diagnostic tests for the detection of antibodies against SARS-CoV-2","10.1016/j.semerg.2020.06.009","ImmunoAssay-Antibody"," ","IgM, IgG","kit","c-RTD (combined): Wondfo® SARS-COV-2 (Lateral Flow Method) of GUANGZHOU WONDFO BIOTECH CO LTD; d-RTD (differentiated): All Test® 2019-nCoV IgG/IgM Rapid Test Cassette of HANGZHOU ALL TEST BIOTECH CO LTD.","Specificity: 100% (both); sensitivity: 56.5% (d-RTD), 63% (c-RTD)","58 patients & 52 controls","","yes","","2021-05-27 09:57:16",
"8","Conjunctival polymerase chain reaction-tests of 2019 novel coronavirus in patients in Shenyang,China","10.1101/2020.02.23.20024935","NucleicAcid-PCR based","PCR_KIT","Not specified","Individual-kit","Kit: not specified","Not reported","19 patients","","no","","2021-05-27 09:42:31",
"267","Consistency analysis of COVID-19 nucleic acid tests and the changes of lung CT","10.1016/j.jcv.2020.104359","NucleicAcid-PCR based","WHO method(s)","ORF1ab-gene, N-gene","WHO-5","","Not reported","69 patients ","","yes","","2021-05-27 09:48:17",
"41","Consistent detection of 2019 novel coronavirus in saliva","10.1093/cid/ciaa149","NucleicAcid-PCR based","Other PCR method(s)","S-gene","Other method","","Sensitivity: 91.7%","12 samples","","yes","","2021-05-27 09:43:22",
"335","CONTAIN: An open-source shipping container laboratory optimisedfor automated COVID-19 diagnostics","10.1101/2020.05.20.106625","NucleicAcid-PCR based","PCR_KIT","N1, RNase P","CDC kit","Validation of a workflow for automated RT-qPCR testing into a container laboratory","Not specified","30 samples","","no","","2021-05-27 09:50:16",
"410","Controlling the SARS-CoV-2 outbreak, insights from large scale whole genome sequences generated across the world","10.1101/2020.04.28.066977","Others","In_silico","whole genome","/","collection of genome sequences from NCBI and GISAID ","/","5349 whole genomes","","no","","2021-05-27 09:52:09",
"934","Convolutional capsnet: A novel artificial neural network approach to detect COVID-19 disease from X-ray images using capsule networks","10.1016/j.chaos.2020.110122","Imaging-X-ray","In_silico","x-rays images","deep learning models","a novel artificial neural network, Convolutional CapsNet for the detection of COVID-19 disease is proposed by using chest X-ray images with capsule networks. The proposed approach is designed to provide fast and accurate diagnostics for COVID-19 diseases with binary classification (COVID-19, and No-Findings), and multi-class classification (COVID-19, and No-Findings, and Pneumonia). ","accuracy: 97.24%(binary class); 84.22% (multi-class)","1420 x-ray","","yes","","2021-05-27 10:08:25",
"898","Coronavirus (COVID-19): A Review of Clinical Features, Diagnosis, and Treatment.","10.7759/cureus.7355","review","Mixed","mixed","multiple","paper reviews Diagnostic Testing for covid19","table 1 gives an overview of 28 Commercial SARS-CoV-2 in Vitro Diagnostic Assays"," "," ","yes","","2021-05-27 10:07:23",
"682","Coronavirus disease 2019 (COVID-19) pneumonia incidentally detected on coronary CT angiogram: a do-not-miss diagnosis","10.1007/s10140-020-01802-4","Imaging-CT scan"," ","coronary CT angiography","","Case study of discovery of covid-19 patiens with coronary CT angiography","","3 patients","","yes","","2021-05-27 10:00:34",
"659","Coronavirus disease 2019 (SARS-CoV-2) and colonization of ocular tissues and secretions: a systematic review","10.1038/s41433-020-0926-9","NucleicAcid-PCR based"," ","","","Review:Coronavirus and colonization of ocular tissues and secretions detection.The prevalence of ocular conjunctivitis complicating the course of COVID-19","","","","yes","","2021-05-27 09:59:47",
"482","Coronavirus Disease 2019: Initial Detection on Chest CT in a Retrospective Multicenter Study of 103 Chinese Subjects","10.1148/ryct.2020200092","Others"," ","CT scan","multi-slice CT systems","/","sensitivity: 93% (85-97%); specificity: 53% (27-77%); PPV: 92% (83-96%); NPV: 42% (18-70%)","103 patients","","yes","","2021-05-27 09:54:30",
"798","CoroNet: A deep neural network for detection and diagnosis of COVID-19 from chest x-ray images","10.1016/j.cmpb.2020.105581","Imaging-X-ray","In_silico","","deep neural network","Deep Convolutional Neural Network model to automatically detect COVID-19 infection from chest X-ray images","accuracy: 89.6%; precision: 93%","1251 images","","yes","","2021-05-27 10:04:24",
"686","Correlation between Chest Computed Tomography and Lung Ultrasonography in Patients with Coronavirus Disease 2019 (COVID-19)","10.1016/j.ultrasmedbio.2020.07.003","Imaging-CT scan"," ","chest CT and LUS","","correlation between lung ultrasonography (LUS) findings and chest CT in patients ","sensitivity: 100.0%; specificity: 78.6%; PPV: 92.5%; NPV: 100.0%. Remark: LUS exhibited similar accuracy compared with chest CT in the detection of lung abnormalities in COVID-19 patients","51 patients","","yes","","2021-05-27 10:00:42",
"473","Correlation Between Relative Nasopharyngeal Virus RNA Load and Lymphocyte Count Disease Severity in Patients with COVID-19","10.1089/vim.2020.0062","NucleicAcid-PCR based","PCR_KIT","dual target","RT-PCR Daan kit","viral load measured by RT-PCR compared to clinical data","/","76 patients","","yes","","2021-05-27 09:54:13",
"230","Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases","10.1148/radiol.2020200642","NucleicAcid-PCR based","Other PCR method(s)","Not specified","Not specified","","Remark: Comparison with Chest CT scan","1014 patients","","yes","","2021-05-27 09:47:42",
"540","Correlation of ELISA based with random access serologic immunoassays for identifying adaptive immune response to SARS-CoV-2","10.1101/2020.07.06.20145938","ImmunoAssay-Antibody"," ","IgG, IgM, IgA vs N, S","kits","ELISA based assay by AnshLabs (IgG and IgM) and random access immunoassay (RAIA) by DiaSorin, Roche, and Abbott","Specificity: 99.4 (IgG AnshLabs), 100% (IgM AnshLabs); concordance for positive results: 93.3 % (AnshLabs with Diasorin and Abbott), 100% (AnshLabs with Roche); concordance for negative results: 69.7% (AnshLabs with Diasorin and Roche), 73% (AnshLabs with Abbott).","167 samples","","no","","2021-05-27 09:56:16",
"297","Cotton tipped plastic swabs for SARS-CoV-2 RT-qPCR diagnosis to prevent supplies shortage","10.1101/2020.04.28.20079947","NucleicAcid-PCR based","PCR_KIT","N1, N2, RdRP","Kit","CDC EUA Kit from IDT","Not specified","44 samples (33 positive &11 negative)","","no","","2021-05-27 09:49:04",
"1046","CoV2ID: Detection and Therapeutics Oligo Database for SARS-CoV-2","10.1101/2020.04.19.048991","NucleicAcid-PCR based","In_silico","primers and probes from PCR based methods","in silico tool","in silico evaluation of a database of primers and probes from literature and WHO methods","","","","no","","2021-05-27 10:11:11",
"507","COVID 19 diagnostic multiplicity and its role in community surveillance and control","10.14293/S2199-1006.1.SOR-.PPA94RC.v1","Others","Mixed","N gene, E gene, S gene, RdRP, ORF1","review of clinical and radiological, molecular based (laboratory based and point-of-care), Immunoassay based (ELISA, rapid antigen and antibody detection tests) and digital diagnostics (artificial intelligence based algorithms): Altona Diagnostics; BGI Health (HK) Co. Ltd; Boditech Med. Inc; DAAN Gene Co. Ltd; GeneFirst Limited; KH Medical Co. Ltd; SD Biosensor Inc.; Tip Molbiol.","","Altona Diagnostics: E and S genes: sensitivity 92%, specificity 100%; BGI Health (HK) Co. Ltd: ORF1 gene, N gene: sensitivity 100% both, specificity 99% and 100% respectively; Boditech Med. Inc: E gene, RdRP: sensitivity 100 % and 90% respectively, specificity 100 % both; DAAN Gene Co. Ltd: ORF1 gene, N gene: sensitivity 100% both, specificity 96% and 96% respectively; GeneFirst Limited: ORF1 gene, N gene: sensitivity 100 % and 98% respectively, specificity 99% and 100% respectively; KH Medical Co. Ltd: S gene, RdRP gene: sensitivity 100% both, specificity 100% both; SD Biosensor Inc.: E gene, ORF1 gene: sensitivity 100% both, specificity 97% and 99% respectively; Tip Molbiol: E gene: sensitivity 100%, specificity 100%.","/","","yes","","2021-05-27 09:55:21",
"809","COVID faster R-CNN: A novel framework to Diagnose Novel Coronavirus Disease (COVID-19) in X-Ray images","10.1016/j.imu.2020.100405","Imaging-X-ray","Other","X-ray","","VGG-16 (Visual Geometry Group, also called OxfordNet) Network-based Faster Regions with Convolutional Neural Networks (Faster R–CNN)","accuracy: 97.36%, Sensitivity: 97.65%, Precision: 99.28%. ","224 images","","yes","","2021-05-27 10:04:45",
"181","COVID-19 Antibody Seroprevalence in Santa Clara County, California","10.1101/2020.04.14.20062463","ImmunoAssay-Antibody"," ","IgM/IgG","CLIA individual-kit","Kit: Premier Biotech, Minneapolis, MN","Sensitivity: 91, 8% ; Specificity: 99, 5%","3300 patients","","no","","2021-05-27 09:46:26",
"662","COVID-19 detection using deep learning models to exploit Social Mimic Optimization and structured chest X-ray images using fuzzy color and stacking approaches","10.1016/j.compbiomed.2020.103805","Imaging-CT scan","In_silico","","","Deep learn methods on CT imaging","99.7% accuracy","","","yes","","2021-05-27 09:59:53",
"182","COVID-19 diagnosis and study of serum SARS-CoV-2 specific IgA, IgM and IgG by a quantitative and sensitive immunoassay","10.1101/2020.04.17.20064907","ImmunoAssay-Antibody"," ","IgM/IgG, IgA on N-protein, RBD-domain of S-protein","Review of multiple-kits","Review of different kits without mentioning companies","Sensitivity:  98.6% (IgA), 96.8% (IgM), 96.8% (IgG) ; Specificity: 98.1% ; Remark : IgA and IgM dpo =16-20 days IgG dpo+21-25 days ","570 patients","","no","","2021-05-27 09:46:28",
"183","COVID-19 diagnosis prediction in emergency care patients: a machine learning approach","10.1101/2020.04.04.20052092","Others","In_silico","","","","","","","no","","2021-05-27 09:46:30",
"769","COVID-19 diagnostics for resource-limited settings: Evaluation of unextracted qRT-PCR","10.1002/jmv.26328","NucleicAcid-PCR based","RT-PCR","N1, N2, N3 (CDC) and RNaseP","US CDC","the approach replaces RNA extraction/purification with a heat?inactivation step of viral transport media (VTM), followed by direct inoculationminto PCR master mixes.","PPA (non extraction vs extraction): 95% (N1, unconcentrated samples), 95% (N3, unconcentrated samples), 100% (RP, unconcentrated samples), 32.5% (N2, unconcentrated samples), 95% (N1, concentrated samples), 100% (N3, concentrated samples), 100% (RP, concentrated samples), 85.4% (N2, concentrated samples); NPA: 95% (N1, unconcentrated samples), 97% (N3, unconcentrated samples), 100% (N2, unconcentrated samples), 97% (N1, concentrated samples), 95% (N3, concentrated samples), 100% (N2, concentrated samples)","41 samples","","yes","","2021-05-27 10:03:26",
"1229","COVID-19 Experience: First Italian Survey on Healthcare Staff Members from a Mother-Child Research Hospital Using Combined Molecular and Rapid Immunoassay Tests","10.2139/ssrn.3592658","mixed","Mixed","mixed","the Wantai SARS-Antibody: CoV-2 Ab Rapid Test, (Beijing Wantai Biological Pharmacy Enterprise, China), the 2019-nCoV IgG/IgM Rapid Test Cassette (Acro Biotech,  USA), SARS-CoV-2 IgM/IgG Antibody-Colloidal Gold (KHB, China); RT-PCR: NeoPlexTM COVID-19 Detection Kit","immunological response survey in healthcare workers.","/","727 patients"," ","no","","2021-05-27 10:17:20",
"457","COVID-19 Fatality and Comorbidity Risk Factors among Confirmed Patients in Mexico","10.1101/2020.04.21.20074591","Others","In_silico","/","survival analysis methods","estimate of fatality risk","/","7497","","no","","2021-05-27 09:53:40",
"800","COVID-19 identification in chest X-ray images on flat and hierarchical classification scenarios","10.1016/j.cmpb.2020.105532","Imaging-X-ray","In_silico","","algorithmic classification","","F1 score: 0.65 (multi class approach), 0.85 (hierarchal classification)","1144 images","","yes","","2021-05-27 10:04:28",
"470","COVID-19 in Children: Clinical Approach and Management","10.1007/s12098-020-03292-1","NucleicAcid-PCR based","PCR_KIT","/","RT-PCR kits approved by ICMR in India","/","sensitivity: 93% (BAL), 72% (sputum), 63% (nasal swab), 46% (bronchoscopic brush biopsy), 32% (pharyngeal swab), 29% (feces), 1% (blood), 0% urine","nd","","yes","","2021-05-27 09:54:07",
"1031","COVID-19 paraclinical diagnostic tools: Updates and future trends","10.1016/j.retram.2020.06.001","review","Mixed","","","diverse diagnostic tools reviewed and relative performances reported","","","","yes","","2021-05-27 10:10:40",
"944","COVID-19 pneumonia diagnosis using a simple 2d deep learning framework with a single chest CT image: Model development and validation","10.2196/19569","Imaging-CT scan","Mixed","CT scan","2D deep learning framework of FCONet, ResNet-50 ","rapidly develop an AI technique to diagnose COVID-19 pneumonia in CT images and differentiate it from non–COVID-19 pneumonia and nonpneumonia diseases.","Sensitivity: 99.58%; Specificity: 100%; Accuracy: 99,87%","3993 images","","yes","","2021-05-27 10:08:41",
"1068","COVID-19 pneumonia: high diagnostic accuracy of chest CT in patients with intermediate clinical probability","10.1007/s00330-020-07346-y","Imaging-CT scan","Other","CT scan","CT scan ","Two independent chest radiologists blinded to clinical information and RT-PCR results retrospectively reviewed and classified images on a 1–5 confidence level scale for COVID-19 pneumonia. PCR Seegene Allplex, Eurobio","PPV: 95.9% (Radiologist 1),  94.3%(Radiologist 2); NPV: 84.4% (Radiologist 1), 77.1% (Radiologist 2)","319 patients","","yes","","2021-05-27 10:11:56",
"505","COVID-19 prediction and detection using deep learning","/","Others","In_silico","Chest x ray datasets","Deep convolutional neural network and prediction models (PA, ARIMA, LSTM)","Full text available at: https://www.researchgate.net/profile/Abdelwadood_Mesleh/publication/341980921_COVID-19_Prediction_and_Detection_Using_Deep_Learning/links/5edc1eb592851c9c5e8aee88/COVID-19-Prediction-and-Detection-Using-Deep-Learning.pdf","Remark: the system is useful in detecting COVID-19 and accurate in prediction of diagnosis confirmation, recoveries and deaths","1000 Imaging-X-ray","","yes","","2021-05-27 09:55:17",
"972","Covid-19 s: A new proposal for diagnosis and structured reporting of covid-19 on computed tomography imaging","10.5152/dir.2020.20351","Imaging-CT scan","Mixed","CT scans","Biospeedy SARS CoV?2 qPCR Detection Kit, Bioeksen, Turkey","clinical, laboratory and radiological findings for the differential diagnosis of non–SARS?CoV?2 viruses from COVID?19","","112 patients","","yes","","2021-05-27 10:09:12",
"812","COVID-19 Screening with Chest CT in Acute Stroke Imaging: A Clinical Decision Model","10.1111/jon.12746","Imaging-CT scan","In_silico"," ","CT scan, mathematical decision model","in patients scheduled for (any) CT scan, is it worthwhile to do an additinal scan for COVID while you're at it.","QALM: 12 (doing extra CT), 11.99 (not doing extra CT)","/"," ","yes","","2021-05-27 10:04:51",
"652","COVID-19 Serological Tests: How Well Do They Actually Perform?","10.3390/diagnostics10070453","Review"," ","","","Review on serological assays","Remark: review on different serological assays reporting performances","/","","yes","","2021-05-27 09:59:33",
"481","COVID-19 Special Column: Principles Behind the Technology for Detecting SARS-CoV-2, the Cause of COVID-19","/","Others","Mixed","S protein, N protein, E protein, ORF1ab segment for PCR; IgG, IgM, IGA for serological tests","39 molecular diagnostic tests: QIAstat-Dx Respiratory SARS-CoV-2 Panel (QIAGEN GmbH); NeuMoDx SARS-CoV-2 Assay (NeuMoDx Molecular, Inc.); NxTAG CoV Extended Panel Assay (Luminex Molecular Diagnostics, Inc.); ID NOW COVID-19 (Abbott Diagnostics Scarborough, Inc.); Real-Time Fluorescent RT-PCR Kit for Detecting SARS-2019-nCoV (BGI Genomics Co. Ltd); AvellinoCoV2 test (Avellino Lab USA, Inc.); PerkinElmer New Coronavirus Nucleic Acid Detection Kit (PerkinElmer, Inc.); Accula SARS-Cov-2 Test (Mesa Biotech Inc.); BioFire COVID-19 Test (BioFire Defense, LLC); Xpert Xpress SARS-CoV-2 test (Cepheid); Primerdesign Ltd COVID-19 genesig Real-Time PCR assay (Primerdesign Ltd.); ePlex SARS-CoV-2 Test (GenMark Diagnostics, Inc.); Simplexa COVID-19 Direct assay (DiaSorin Molecular LLC); Abbott RealTime SARS-CoV-2 assay (Abbott Molecular); Quest SARS-CoV-2 rRT-PCR (Quest Diagnostics Infectious Disease, Inc.); Lyra SARS-CoV-2 Assay (Quidel Corporation); COVID-19 RT-PCR Test (Laboratory Corporation of America); Panther Fusion SARS-CoV-2 (Hologic, Inc.); TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific, Inc.); cobas SARS-CoV-2 (Roche Molecular Systems, Inc.); New York SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Panel (Wadsworth Center, New York State Department of Public Health's); CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel (CDC) (Centers for Disease Control and Prevention's). 18 high complexity molecular-based laboratory developed tests: UDX SARS-CoV-2 Molecular assay (Ultimate Dx Laboratory); SARS-CoV-2 Assay (AIT Laboratories); COVID-19 Key (Southwest Regional PCR Laboratory LLC. dba MicroGen DX); SARS-CoV-2 PCR Test (Diatherix Eurofins Laboratory); SARS-CoV-2 Molecular Detection Assay (Mayo Clinic Laboratories, Rochester, MN); CDI Enhanced COVID-19 Test (Hackensack University Medical Center (HUMC) Molecular Pathology Laboratory; CirrusDx SARS-CoV-2 Assay (CirrusDx Laboratories); Childrens-Altona-SARS-CoV-2 Assay (Infectious Diseases Diagnostics Laboratory (IDDL), Boston Children's Hospital); SARS-CoV-2 Assay (Exact Sciences Laboratories); SARS-CoV-2 Assay (Integrity Laboratories); COVID-19 RT-PCR Test (Pathology/Laboratory Medicine Lab of Baptist Hospital Miami); Orig3n 2019 Novel Coronavirus (COVID-19) Test (Orig3n, Inc.); ThermoFisher - Applied Biosystems TaqPath COVID-19 Combo Kit (Rutgers Clinical Genomics Laboratory-Rutgers University); SDI SARS-CoV-2 Assay (Specialty Diagnostic (SDI) Laboratories); UNC Health SARS-CoV-2 real-time RT-PCR test (University of North Carolina Medical Center); Stanford SARS-CoV-2 assay (Stanford Health Care Clinical Virology Laboratory); Viracor SARS-CoV-2 Assay (Viracor Eurofins Clinical Diagnostics); MGH COVID-19 qPCR assay (Massachusetts General Hospital); SARS-CoV-2 RT-PCR test (Infectious Disease Diagnostics Laboratory- Children's Hospital of Philadelphia); SARS-CoV-2 PCR test (Yale New Haven Hospital, Clinical Virology Laboratory). 7 serological diagnostic tests: (NCT04261426 [China];36 NCT04264858 [China];37 NCT04332380 [Colombia];38 NCT04332835 [Colombia]; 39 NCT04323800 [US, Johns Hopkins];40 NCT04325672 [US, Mayo Clinic];41 NCT04333251 [US, Baylor])","Full article available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226308/","/","from 1 to 288 (see Table 1 for molecular diagnostic tests)","","yes","","2021-05-27 09:54:28",
"796","COVID-19 symptoms predictive of healthcare workers' SARS-CoV-2 PCR results","10.1371/journal.pone.0235460","Mixed","Mixed"," ","CDC 2019-Novel RT-PCR; Roche Cobas SARS-CoV-2; Abbott Real Time SARS-CoV-2","study aims to find telephonic reported symptoms with most predictive power among health care workers","","592 patients","","yes","","2021-05-27 10:04:20",
"833","COVID-19 target: A specific target for novel coronavirus detection","10.1016/j.genrep.2020.100740","NucleicAcid-PCR based","RT-PCR","ORF8","none","bioinformatic identification of a new detection target & primer/probde design for said target","/","/"," ","yes","","2021-05-27 10:05:28",
"1057","COVID-19 Testing","10.1093/ajcp/aqaa141","review","In_silico","mixed","meta-analysis","Impact of Prevalence, Sensitivity, and Specificity on Patient Risk and Cost","Sensitivity: 86% (molecular tests),  61% (Antigen), 68% (Antibody); Specificity:  95.8% (molecular tests),  98.2% (Antigen), 95.6% (Antibody). Remark: Molecular and antigen tests are relevant in the acute phase only. Serologic assays detect antibodies to SARS-CoV-2 in the recovering and recovered phase","/","","yes","","2021-05-27 10:11:34",
"610","COVID-19: a meta-analysis of diagnostic test accuracy of commercial assays registered in Brazil","10.1016/j.bjid.2020.04.003","Others","In_silico","IgM/IgG","kits","A total of 16 tests for detection of COVID-19 registered in the Brazilian Health Regulatory Agency (ANVISA) online platform","remark: review and metanalysis on commercially available tests","/","","yes","","2021-05-27 09:58:19",
"823","Covid-19: automatic detection from X-ray images utilizing transfer learning with convolutional neural networks","10.1007/s13246-020-00865-4","Imaging-CT scan","In_silico","","X-ray images, Deep Learning"," a dataset of X-ray images from patients with common bacterial pneumonia, confirmed Covid-19 disease, and normal incidents, was utilized for the automatic detection of the Coronavirus disease. the procedure called Transfer Learning was adopted","accuracy: 96.78%,; sensitivity: 98.66%; specificity: 96.46% ","1442 images","","yes","","2021-05-27 10:05:12",
"654","COVID-19: Progress in diagnostics, therapy and vaccination","10.7150/thno.47987","Review","Mixed","","","Review on diagnostic tests","Remark: review on different methods reporting performances","","","yes","","2021-05-27 09:59:37",
"521","COVID19 antibody detection using lateral flow assay tests in a cohort of convalescent plasma donors","10.1186/s13104-020-05212-0","ImmunoAssay-Antibody"," ","IgG, IgM","Lateral Flow Assay","Clungene SARS-CoV-2 (COVID-19) IgG/IgM Rapid Test Cassettes","Remark: IgG results are consistent with the manufacturer’s 97.4% clinical performance data ","63 samples","","yes","","2021-05-27 09:55:43",
"681","CovidGAN: Data Augmentation Using Auxiliary Classifier GAN for Improved Covid-19 Detection","10.1109/ACCESS.2020.2994762","Imaging-CT scan","In_silico","","","based model called CovidGAN that generates synthetic CXR image","accuracy 95%","403 COVID-CXR images and 721 Normal-CXR images","","yes","","2021-05-27 10:00:32",
"991","COVIDiag: a clinical CAD system to diagnose COVID-19 pneumonia based on CT findings","10.1007/s00330-020-07087-y","Imaging-CT scan","In_silico","CT-scans","CT-scan","clinical computer-aided diagnosis (CAD) system using CT features to automatically discriminate COVID-19 from non-COVID-19 pneumonia patients","sensitivity: 93.54% ; specificity: 90.32% ; accuracy: 91.94%","612 patients","","yes","","2021-05-27 10:09:45",
"781","COVIDiagnosis-Net: Deep Bayes-SqueezeNet based diagnosis of the coronavirus disease 2019 (COVID-19) from X-ray images","10.1016/j.mehy.2020.109761","Imaging-X-ray","","X-rays","deep learning","COVID-19 detection AI model, COVIDiagnosis-Net, based on deep SqueezeNet with Bayes optimization","accuracy: 98.3% (among Normal, Pneumonia and Covid cases), 100% (single recognition of COVID-19 among other classes)","5310 images","","yes","","2021-05-27 10:03:49",
"386","COVIDier: A Deep-learning Tool For Coronaviruses Genome And Virulence Proteins Classification","10.1101/2020.05.03.075549","Others","In_silico","genome","/","deep learning-based software that is enabled to classify the different genomes","accuracy: 99%","/","","no","","2021-05-27 09:51:20",
"429","CovidNLP: A Web Application for Distilling Systemic Implications of COVID-19 Pandemic with Natural Language Processing","10.1101/2020.04.25.20079129","Others","In_silico","/","/","application of natural language processing to develop a CovidNLP dashboard","/","/","","no","","2021-05-27 09:52:47",
"663","CovXNet: A multi-dilation convolutional neural network for automatic COVID-19 and other pneumonia detection from chest X-ray images with transferable multi-receptive feature optimization","10.1016/j.compbiomed.2020.103869","Imaging-X-ray"," ","chest X-rays","CNN","deep convolutional neural network (CNN) based architecture (CovXNet)","accuracy: 97.4% (COVID/Normal), 96.9% (COVID/Viral pneumonia), 94.7% (COVID/Bacterial pneumonia), 90.2% (multiclass COVID/normal/Viral/Bacterial pneumonias)","5856 images","","yes","","2021-05-27 09:59:55",
"9","CRISPR-based COVID-19 surveillance using a genomically-comprehensive machine learning approach","10.1101/2020.02.26.967026","NucleicAcid-Others","CRISPR","Not specified","Other method","","LOD: 10 cpu","Not reported","","no","","2021-05-27 09:42:33",
"134","CRISPR-Cas12-based detection of SARS-CoV-2.","10.1038/s41587-020-0513-4","NucleicAcid-Others","CRISPR","E-gene, N-gene, S-gene","Other method","","Sensitivity: 95% ; Specificity: 100% ; LOD: 10 cpu","78 (38 covid 19 positive)","","yes","","2021-05-27 09:45:16",
"1054","CRISPR/cas systems redefine nucleic acid detection: Principles and methods.","10.1016/j.bios.2020.112430","review","CRISPR","mixed","mulitple CRISPR-Cas9 based detection systems","overview of applications of CRISPR-Cas9 as detection tool","table 1 lists Biosensing assays based on Cas9","/"," ","yes","","2021-05-27 10:11:27",
"1122","Critical appraisal on salivary diagnostic for COVID-19","10.1016/j.oraloncology.2020.104926","Others","Other","N/A","N/A","letter to the editor, a critique of saliva based sampling raising several issues","/","/"," ","no","","2021-05-27 10:13:48",
"1178","Cross-Comparison of a Chemiluminescent Platform and a Commercial Receptor Binding Domain-Based ELISA Assay for Detecting SARS-CoV-2 IgG","10.1093/jalm/jfaa133","ImmunoAssay-Antibody","Other Immuno assay","IgG, IgM ","Abbott Architect IgG assay, GenScript SARS-CoV-2 Spike S1-RBD IgG ELISA","Parallel Architect and ELISA analyses were performed","Architect specificity: serum 100%; plasma 98.8%. ELISA treshold 1 specificity: serum 85.7%;  plasma 93.5% ; treshold 2: serum 66.7%; plasma 92.9%. Architect sensitivity: serum 90.5%; plasma 93.5%. ELISA treshold 1 sensitivity: serum 85.7%;  plasma 93.5%; treshold 2: serum 66.7%; plasma 82.6%","230 serum + 238 plasma","","yes","","2021-05-27 10:15:37",
"10","Cross-reaction of sera from COVID-19 patients with SARS-CoV assays","10.1101/2020.03.17.20034454","ImmunoAssay-Antibody"," ","IgM/IgG","ELISA, IIFT","ELISA: Ksiazek et al; IIFT Kit: Euroimmun","Sensitivity: 15.4% (0-7 dpo), 46.5% (8-14 dpo), 88.9% (15-21 dpo), 100% (22+ dpo)","17 patients ","","no","","2021-05-27 09:42:35",
"522","CT differential diagnosis of COVID-19 and non-COVID-19 in symptomatic suspects: a practical scoring method","10.1186/s12890-020-1170-6","Others","In_silico","CT scan","","Combined CT image features analysis for hierarchical diagnosis","Sensitivity: 56.67% (score?>4), 100% (score >0), 86.67% (score >2); specificity 95.35% (score?>4), 23.26% (score?>0), 67.44% (score?>2).","91 patients","","yes","","2021-05-27 09:55:45",
"921","CT in relation to rt-PCR in diagnosing covid-19 in the netherlands: A prospective study","10.1371/journal.pone.0235844","Imaging-CT scan","","CT imaging ","","investigating the diagnostic accuracy of CT using RT-PCR for SARS-CoV-2 as reference standard ","sensitivity: 89.2%; specificity: 68.2%","193 patients","","yes","","2021-05-27 10:08:00",
"454","CT in relation to RT-PCR in diagnosing COVID-19 in the Netherlands: a prospective study","10.1101/2020.04.22.20070441","Others"," ","chest CT, RdRP, E","CT scan, RT-PCR","evaluation of chest CT diagnostic accuracy vs RT-PCR","sensitivity: 89.2%; specificity: 68.2%","193 patients","","no","","2021-05-27 09:53:34",
"939","CT manifestations of coronavirus disease-2019: A retrospective analysis of 73 cases by disease severity","10.1016/j.ejrad.2020.108941","Imaging-CT scan","Other","CT scans","CT scans","","remarks: lung abnormalities distribution available in tables","73 patients","","yes","","2021-05-27 10:08:33",
"780","CT radiomics can help screen the Coronavirus disease 2019 (COVID-19): a preliminary study","10.1007/s11432-020-2849-3","Imaging-CT scan","","CT scan","radiomic signature","radiomic signature to screen COVID-19 from CT images","AUC: 0.862 (training set),  0.826 (test set)","75 patients","","yes","","2021-05-27 10:03:47",
"813","CT Scanning in Suspected Stroke or Head Trauma: Is it Worth Going the Extra Mile and Including the Chest to Screen for COVID-19 Infection?","10.3174/ajnr.A6607","Imaging-CT scan","In_silico"," ","CT scan evaluation","restults from patietns that where scheduled for (any) CT and were also screened for COVID","sensitivity: 85.7%; specificity: 75%; negative predictive value: 93.8%; positive predictive value: 54.6%","27 patients"," ","yes","","2021-05-27 10:04:53",
"407","Curbing the AI-induced enthusiasm in diagnosing COVID-19 on chest X-Rays: the present and the near-future","10.1101/2020.04.28.20082776","Others","In_silico","/","chest x-ray","use of AI in chest x-ray for covid diagnosis","/","/","","no","","2021-05-27 09:52:03",
"773","Current and Future Point-of-Care Tests for Emerging and New Respiratory Viruses and Future Perspectives","10.3389/fcimb.2020.00181","Review","In_silico","","review","review on point of care testing for various coronaviruses ","/","/","","yes","","2021-05-27 10:03:35",
"571","Current and Perspective Diagnostic Techniques for COVID-19","10.1021/acsinfecdis.0c00365","Others","Mixed","","","Review on diagnostic tests","Remark: review on different methods reporting performances","/","","yes","","2021-05-27 09:57:08",
"775","Current diagnostic tools for coronaviruses-From laboratory diagnosis to POC diagnosis for COVID-19","10.1002/btm2.10177","Review","","","review","review on current diagnostic assays reporting performance","Remark: review on diagnostic assays reporting performance","/","","yes","","2021-05-27 10:03:39",
"1074","Data science and the role of Artificial Intelligence in achieving the fast diagnosis of Covid-19","10.1016/j.chaos.2020.110182","Imaging-Others","Mixed","CT scan X-ray","","Chest X-ray and CT scan images amalgamating with AI to identify the Covid-19","Accuracy: 93%; Precision score: 88%","297 images","","yes","","2021-05-27 10:12:09",
"564","ddPCR: a more accurate tool for SARS-CoV-2 detection in low viral load specimens","10.1080/22221751.2020.1772678","NucleicAcid-PCR based"," ","ORF1ab, N","ddPCR vs RT-PCR","Chinese CDC","Sensitivity: 40% (RT-PCR), 94% (ddPCR); Specificity: 100% (RT-PCR, ddPCR); PPV: 100% (RT-PCR, ddPCR); NPV: 16% (RT-PCR), 63% (ddPCR); accuracy: 47% (RT-PCR), 95% (ddPCR)","77 patients","","yes","","2021-05-27 09:56:57",
"42","ddPCR: a more sensitive and accurate tool for SARS-CoV-2 detection in low viral load specimens","10.1101/2020.02.29.20029439","NucleicAcid-PCR based","WHO method(s)","ORF1ab-gene, N-gene","WHO-1 in ddPCR","","LOD: 2.1 cpr (ORF1ab ddPCR), 1.8 cpr(N ddPCR), 1039  cpr (ORF1ab RT-PCR), 873.2 cpr (N RT-PCR)","57 patients","","no","","2021-05-27 09:43:25",
"791","Deep learning applications in pulmonary medical imaging: recent updates and insights on COVID-19","10.1007/s00138-020-01101-5","Review","","images","deep learning","review of the development of deep learning applications in medical image analysis targeting pulmonary imaging ","/","/","","yes","","2021-05-27 10:04:10",
"942","Deep learning COVID-19 detection bias: accuracy through artificial intelligence","10.1007/s00264-020-04609-7","Imaging-X-ray","Other","X rays","deep learning model","Deep learning model to improve accuracyof reported cases and precisely predict the disease from chest X-ray","Accuracy: 96.3%; ","181 patients","","yes","","2021-05-27 10:08:37",
"928","Deep learning system to screen coronavirus disease 2019 pneumonia","10.1007/s10489-020-01714-3","Others","","","","retracted article","","","","Yes (full text NOT available)","","2021-05-27 10:08:14",
"736","Deep Learning-Based Decision-Tree Classifier for COVID-19 Diagnosis From Chest X-ray Imaging","10.3389/fmed.2020.00427","Imaging-X-ray"," ","chest X-rays","deep learning"," two-dimensional CNN algorithm with a PyTorch frame","accuracy: 95%","324 images","","yes","","2021-05-27 10:02:19",
"1030","Deep throat saliva as an alternative diagnostic specimen type for the detection of SARS-CoV-2","10.1002/jmv.26258","NucleicAcid-PCR based","PCR_KIT","E gene","lightMix Modular SARS?CoV (COVID19) E?gene detection kit (TIB Molbiol, Berlin, Germany)","comparability of deep throat saliva (DTS) to nasopharyngeal swab (NPS) for the detection of SARS?CoV?2 by RT?PCR","Positive RT-PCR: 51% (DTS), 45% (NPS) ; Negative RT-PCR: 44% (DTS), 50% (NPS) ; overall agreement: 78.9%","157 samples","","yes","","2021-05-27 10:10:38",
"783","Deep-COVID: Predicting COVID-19 from chest X-ray images using deep transfer learning","10.1016/j.media.2020.101794","Imaging-X-ray","","X-rays","deep transfer learning","end-to-end deep learning framework which directly predicts the COVID-19 disease from raw images without any need of feature extraction","sensitivity: 98%; specificity: 90%","5000 images","","yes","","2021-05-27 10:03:53",
"758","Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression","10.1080/22221751.2020.1766382","ImmunoAssay-Antibody","GICA","IgM","SARS-CoV-2 IgM GICA kit (Shanghai Outdo Biotech Co., China)","","Positive rate: 82.2% (from the RT-qPCR confirmed positive cases)","185 patients","","yes","","2021-05-27 10:03:04",
"683","Deploying Machine and Deep Learning Models for Efficient Data-Augmented Detection of COVID-19 Infections","10.3390/v12070769","Imaging-Others"," ","CT and X-ray images","deep learning","the Convolutional Neural Network (CNN) and the Convolutional Long Short-Term Memory (ConvLSTM)-based deep learning models (DADLMs)","remark: average increases of 4% to 11% in COVID-19 detection accuracy are reported in favour of the proposed data-augmented deep learning models relative to the machine learning techniques","/","","yes","","2021-05-27 10:00:36",
"363","Detection and analysis of nucleic acid in various biological samples of COVID-19 patients","10.1016/j.tmaid.2020.101673","NucleicAcid-PCR based","PCR_KIT","Not specified","CDC China kit (BioGerm)","positive rate of 2019-nCoV nucleic acid in sputum was higher than that of nasopharyngeal swabs","Not specified","132 patients","","yes","","2021-05-27 09:50:39",
"43","Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR","10.2807/1560-7917.ES.2020.25.3.2000045","NucleicAcid-PCR based","WHO method(s)","RdRp-region, E-gene, N-gene, S-gene","WHO-5","","Specificity: tested ; LOD: 3.9 cpr (E gene),  3.6 cpr (RdRp)","75 patients","","yes","","2021-05-27 09:43:27",
"756","Detection of coronavirus disease (COVID-19) based on deep features and support vector machine","10.33889/IJMEMS.2020.5.4.052","Imaging-X-ray","","X-ray","deep learning","deep feature plus support vector machine (SVM) based methodology","Accuracy: 95.33%; Sensitivity: 95.33%","381 images","","yes","","2021-05-27 10:03:00",
"785","Detection of COVID-19 Infection from Routine Blood Exams with Machine Learning: A Feasibility Study","10.1007/s10916-020-01597-4","Others","In_silico","hematochemical values","machine learning","two machine learning classification models using hematochemical values from routine blood exams","accuracy: 82%-86%; sensitivity: 92%-95%","279 patients","","yes","","2021-05-27 10:03:57",
"451","Detection of COVID-19 Infection from Routine Blood Exams with Machine Learning: a Feasibility Study","10.1101/2020.04.22.20075143","Others","In_silico","","machine learning","two models to discriminate between positive and negative patients","accuracy: 82%-86%; sensitivity: 92%-95%","279 patients","","no","","2021-05-27 09:53:30",
"499","Detection of COVID-19: A review of the current literature and future perspectives","10.1016/j.bios.2020.112455","Others","Mixed","","","Review on diagnostic tests commercially available","Remark: review on different methods reporting performances","/","","yes","","2021-05-27 09:55:05",
"484","Detection of IgM and IgG antibodies against SARS-CoV-2 in patients with autoimmune diseases","10.1016/S2665-9913(20)30128-4","ImmunoAssay-Antibody"," ","IgM, IgG vs N, S","Colloidal gold immunochromatography assay kit","Innovita Biotechnology Co, Tangshan, China ","Sensitivity: 89%; Specificity: 91%","290 samples (serum from autoimmune disease patients)","","yes","","2021-05-27 09:54:34",
"626","Detection of IgM and IgG antibodies in patients with coronavirus disease 2019","10.1002/cti2.1136","ImmunoAssay-Antibody"," ","IgM, IgG","Kit","anti?SARS?CoV?2 CLIA?YHLO kit","Sensitivity: 82.57% (IgM), 93.11% (IgG); Specificity: 98.67% (IgM), 92% (IgG)","338 patients","","yes","","2021-05-27 09:58:48",
"840","Detection of low levels of SARS-CoV-2 RNA from nasopharyngeal swabs using three commercial molecular assays","10.1016/j.jcv.2020.104387","NucleicAcid-PCR based","PCR_KIT","Lightmix®assay (E gene); Xpert®(N2 and E genes)","","comparison of Xpert®Xpress SARS-CoV-2with the cobas®SARS-CoV-2 and the Lightmix®assay","concordance: 100% (between ct 30?33.9); discordance 23% (ct>34)","37 swabs","","yes","","2021-05-27 10:05:40",
"234","Detection of novel coronaviruses in bats in Myanmar","10.1371/journal.pone.0230802","NucleicAcid-PCR based","Other PCR method(s)","RdRp-region","Not specified","","Not reported","Not reported","","yes","","2021-05-27 09:47:44",
"320","Detection of Nucleocapsid Antibody to SARS-CoV-2 is More Sensitive than Antibody to Spike Protein in COVID-19 Patients","10.1101/2020.04.20.20071423","ImmunoAssay-Antibody"," ","Nucleocapsid and spike proteins","LIPS","","Sensitivity: 100% (nucleocapsid), 91% (spike) ; specificity: 100% (both)","81 patients","","no","","2021-05-27 09:49:52",
"987","Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients","10.1016/j.jinf.2020.05.077","ImmunoAssay-Antibody","Mixed","IgM, IgA, IgG","ID.Vet, ID screen SARS-CoV-2-N IgG indirect (ID.Vet, Montpellier, France), SARS-CoV-2 IgA and IgG (EUROIMMUN, Lubeck, Germany), AccuBioTech Co, Ltd. Accu-Tell COVID-19 IgG/IgM Rapid Test, Zhuhai Livzon Pharmaceutical Group Inc. 2019-nCoV IgM/IgG Antibody Test Kit, Chongqing iSIA BIO-Technology Co., Ltd. 2019-nCoV IgM/IgG Diagnostic Test Kit (Chongqing, China), UNscience Biotechnology Co., Ltd. COVID-19 IgG/IgM Rapid Test Kit (Wuhan, China), Acro Biotech, Inc., 2019-nCoV IgM/IgG Rapid Test (Rancho Cucomonga CA, USA), Guangdong Hecin Biotech Co., Ltd. 2019-nCoV IgM Antibody Test Kit, (Guangzhou, China)","","remarks: detailed performance data for each kit available in tables","58 patients","","yes","","2021-05-27 10:09:37",
"361","Detection of SARS-CoV-2 by RT-PCR in anal from patients who have recovered from coronavirus disease 2019","10.1002/jmv.25875","NucleicAcid-PCR based","PCR_KIT","ORF1a/b","CDC China kit (BioGerm)","Letter to the editor","Remark: anal swabs vs nasopharyngeal swabs","4 patients","","yes","","2021-05-27 09:50:35",
"1049","Detection of SARS-CoV-2 from raw patient samples by coupled high temperature reverse transcription and amplification","10.1101/2020.05.19.20103150","NucleicAcid-PCR based","RT-PCR","ORF1ab, N","in house assay: We have developed a thermostable DNA polymerase, which can mediate DNA synthesis from  both  RNA  as  well  as  DNA  templates  (Sauter  &  Marx,  2006).  By  targeted modifications, we have further improved the accuracy and processivity of this enzyme (Blatter, Bergen et al., 2013), which lays the foundation of the commercialized Volcano3G formulations. ","Improved nucleic-acid-based approach to detect SARS-CoV-2, which alleviates the need to purify RNA, reduces handling steps, minimizes costs, and  allows  evaluation  by  non-specialized  equipment.  The  use  of unprocessed  swap samples and the ability to detect as little as three viral genome equivalents is enabled by employing a heat-stable RNA- and DNA-dependent DNA polymerase, which performs the double task of stringent reverse transcription of RNA at elevated temperatures as well as PCR amplification of a SARS-CoV-2 specific target gene. As results are obtained within 2 hours and can be read-out by a hand-held LED-screen. ","Performance evaluated in parallel with a commercial in vitro diagnostic kit (Allplex, Seegene): consistency with regard to positive and negative outcomes, increased sensitivity might be due to the fact that the high temperature reverse transcription step involves several cycles, which allow initial highly stringent amplification of viral target genes. Though the high temperature RT-PCR with Volcano3G was slightly more sensitive, the results correlated extremely well over a wide range of cq-values with the results obtained by the commercial assay  (r2=0.980,  p<0.0001,  Fig.  2D).","43 samples","","yes","","2021-05-27 10:11:17",
"1191","Detection of SARS-CoV-2 IgG Targeting Nucleocapsid or Spike Protein by Four High Throughput Immunoassays Authorized for Emergency Use","10.1128/JCM.01742-20","ImmunoAssay-Antibody","Other Immuno assay","IgG","Abbott Architect immunoassay, DiaSorin Liaison, Ortho Vitros, Euroimmun","comparison of results obtained using 4 high-throughput SARS-CoV-2 IgG EUA immunoassays (chemiluminescent immunoassays, chemiluminescent microparticles immunoassays and enzyme-linked immunosorbent assay)","PPA: 99.7% (Abbott), 94.3% (Diasorin), 100% (Ortho), 99.8% (Euroimmun) ; NPA: 97.7% (Abbott), 97.5% (Diasorin), 100% (Ortho), 96.7% (Euroimmun)","1200 samples","","yes","","2021-05-27 10:16:02",
"44","Detection of SARS-CoV-2 in Different Types of Clinical Specimens.","10.1001/jama.2020.3786","NucleicAcid-PCR based","WHO method(s)","ORF1a/b","WHO1 (CDC China)","comparison of results from different types of samples from COVID+ patients","mean Cq value : >30 (all specimens), 24.3 (nasal swabs)","205 patients","","yes","","2021-05-27 09:43:29",
"673","Detection of SARS-CoV-2 in formalin-fixed paraffin-embedded tissue sections using commercially available reagents","10.1038/s41374-020-0464-x","Others"," ","ACDBio SARS-CoV-2 RNA (21631–23303), Bioss Recombinant SARS-CoV-2 Nucleocapsid protein (His-tag), Bioss Recombinant SARS Nucleocapsid protein (no tag), Thermo SARS nucleoprotein preparation","","staining protocol with a list of commercially available antibodies for detection of SARS-CoV-2 on human formalin-fixed, paraffin-embedded tissue","","8 autopsy lungs, 1 placenta, and 10 kidney biopsies","","yes","","2021-05-27 10:00:16",
"938","Detection of SARS-CoV-2 in Human Retinal Biopsies of Deceased COVID-19 Patients","10.1080/09273948.2020.1770301","NucleicAcid-PCR based","RT-PCR","E, ORF nCoV, RdRP genes","Taqman RT-PCR","","LOD: 5.2 copies/reaction (E), 3.8 copies/raction (RdRP), 8.3 copies/reaction (ORF nCoV) ; remarks: in human retina","14 patients","","yes","","2021-05-27 10:08:31",
"1033","Detection of SARS-CoV-2 in nasal swabs using MALDI-MS","10.1038/s41587-020-0644-7","Others","Other","/","mass spectrometry (MALDI-MS)","method to detect SARS-CoV-2 in nasal swabs using matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) and machine learning analysis","accuracy: 93.9% ( 7% false positives and 5% false negatives)","362 samples","","yes","","2021-05-27 10:10:44",
"327","Detection of SARS-CoV-2 RNA and Antibodies in Diverse Samples: Protocol to Validate the Sufficiency of Provider-Observed, Home-Collected Blood, Saliva, and Oropharyngeal Samples","10.2196/19054","Others"," ","N, S, ORF1, IgM, IgA, IgG","qPCR, ELISA","Protocol for self-collecting specimens","Not specified","Not specified","","yes","","2021-05-27 09:50:04",
"675","Detection of SARS-CoV-2 RNA by direct RT-qPCR on nasopharyngeal specimens without extraction of viral RNA","10.1371/journal.pone.0236564","NucleicAcid-PCR based","PCR_KIT","E gene","kits","protocol for direct RT-qPCR to detect SARS-CoV-2 in nasopharyngeal swabs without RNA extraction. samples were processed by several commercial and laboratory-developed methods and tested by RT-qPCR assays without RNA extraction ","sensitivity: 95%; specificity: 99%; accuracy: 98.5%; LOD: 6.6x10^3 copy/ml","132 samples","","yes","","2021-05-27 10:00:20",
"715","Detection of SARS-CoV-2 RNA residue on object surfaces in nucleic acid testing laboratory using droplet digital PCR","10.1016/j.scitotenv.2020.140370","NucleicAcid-PCR based","PCR_KIT & other","ORF1ab, N","kit & CDC","ddPCR on Chinese CDC and Novel Coronavirus (2019-nCoV) Nucleic Acid Diagnostic Kit (Sansure Biotech, Cat: 20203400064)","Remark: Test results for all samples were negative by qRT-PCR. In contrast, 13 out of 61 samples were positive by ddPCR","61 surface samples","","yes","","2021-05-27 10:01:38",
"235","Detection of serum IgM and IgG for COVID-19 diagnosis","10.1007/s11427-020-1688-9","ImmunoAssay-Antibody"," ","IgM/IgG on N-protein, S-protein","ELISA in-house-method, CLIA in-house-method","","Sensitivity: 97.9% (rN IgG) ;  97.9%  (rN IgM), 95.7% (rS IgG), 89.1%  (rS IgM), 95.6% (CHEMIL IgG),  97.7% (CHEMIL IgM) ; Specificity: 99.7% (rN  IgM), spec 99.7%  (rN IgG), 85.7% (rS IgG), 99.0% (rS IgM), 96.6% (CHEMIL IgG), 95.2% (CHEMIL IgM)","47 patients & 300 controls","","yes","","2021-05-27 09:47:46",
"556","Detection of serum immunoglobulin M and immunoglobulin G antibodies in 2019 novel coronavirus infected patients from different stages","10.1097/cm9.0000000000000820","ImmunoAssay-Antibody"," ","IgG, IgM","CLIA, GICA, ELISA","chemiluminescent immunoassay (CLIA), gold immunochromatographic assay (GICA), and enzyme-linked immunosorbent assay (ELISA) ","Remark: GICA possessed a relatively higher positive rate in serum IgM detection and ELISA exhibited a comparatively higher positive rate in serum IgG testing ","22 patients","","yes","","2021-05-27 09:56:45",
"510","Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by Mass Spectrometry","10.3390/v12080849","NucleicAcid-Others","Mixed","MS: N1, N2, N3, ORF1ab; RT-PCR: RdRP (ORF1ab), E","Mass spectrometry & RT-PCR","Comparison between rt-PCR (virellaSARS-CoV-2 seqc rRT-PCR kit) and MS","remark: the two methods were in concordance for all samples","22 positive & 22 negative samples","","yes","","2021-05-27 09:55:25",
"755","Detection of spike protein of SARS-CoV-2 by surface enhanced Raman spectroscopy ","10.11884/HPLPB202032.200145","ImmunoAssay-Antigen","","S protein","SERS","surface enhanced Raman spectroscopy (SERS)","/","/","","yes (paper not in English)","","2021-05-27 10:02:58",
"787","Detection profile of SARS-CoV-2 using RT-PCR in different types of clinical specimens: A systematic review and meta-analysis","10.1002/jmv.26349","Review","In_silico","","meta-analysis","","positive rate: 71.3% (lower respiratory tract (LRT) specimens), 91.8% (Bronchoalveolar lavage fluid (BLF) specimen), 87.8% (rectal swabs), 68.1% (sputum), 7.6% (oropharyngeal swabs),   1.0% (blood), 0% (urine samples), 32.8% (feces), 45.5% (Nasopharyngeal swab)","8136 samples","","yes","","2021-05-27 10:04:01",
"1105","Development  of  a  SERS-based  lateral  flow  immunoassay  for rapid and ultra-sensitive detection of anti-SARS-CoV-2 IgM/IgG in clinical samples","10.1016/j.snb.2020.129196","ImmunoAssay-Others","Other Immuno assay","IgG, IgM","surface-enhanced Raman scattering-based lateral flow immunoassay (SERS-LFIA)","","Accuracy: 100% ; specificity: 100%","68 samples","","yes","","2021-05-27 10:13:13",
"625","Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis","10.1002/jmv.25727","ImmunoAssay-Antibody"," ","IgG, IgM","kit","Point of Care (POC) rapid SARS?CoV?2 IgG?IgM combined antibody test designed by Jiangsu Medomics Medical Technologies, located in Nanjing, China (Lateral flow immunoassay)","Sensitivity: 88.66%; specificity: 90.63%","397 positive & 128 negative patients","","yes","","2021-05-27 09:58:46",
"46","Development and Evaluation of A CRISPR-based Diagnostic For 2019-novel Coronavirus","10.1101/2020.02.22.20025460","NucleicAcid-Others","CRISPR","ORF1ab-gene","Other method","","Specificity: tested ; Sensitivity: 100%","114 samples","","no","","2021-05-27 09:43:31",
"713","Development and Evaluation of a Duo SARS-CoV-2 RT-qPCR Assay Combining Two Assays Approved by the World Health Organization Targeting the Envelope and the RNA-Dependant RNA Polymerase (RdRp) Coding Regions","10.3390/v12060686","NucleicAcid-PCR based","PCR_KIT","E, RdRP","in house (WHO-5 + WHO-2)","2 mono-target assays recommended by WHO (WHO-5: E-Sarbeco, enveloppe gene, Charite University, Berlin, Germany and WHO-2: RdRp-IP4 RdRp, Institut Pasteur, Paris, France) were selected and combined in a unique robust test","LOD95: 29.3 RNA copies/µL (E-Sarbeco assay), 7.9 RNA copies/µL (RdRp-IP4) ","69 samples","","yes","","2021-05-27 10:01:34",
"880","Development and Evaluation of Novel and Highly Sensitive Single-Tube Nested Real-Time RT-PCR Assays for SARS-CoV-2 Detection","10.3390/ijms21165674","NucleicAcid-PCR based","RT-PCR","RdRp/Hel and N genes","in house single tube nested RT-PCR","evaluation of two in house single tube nested RT-PCR and comparison with in house non-nested RT-PCR and WHO-4","sensitivity: 100% ; specificity: 100% ; LOD: 1.8 × 10?1 TCID50/mL","213 specimens","","yes","","2021-05-27 10:06:48",
"184","Development and Multicenter Performance Evaluation of The First Fully Automated SARS-CoV-2 IgM and IgG Immunoassays","10.1101/2020.04.16.20067231","ImmunoAssay-Antibody"," ","IgM/IgG","CLIA in-house-method","","Sensitivity:  85.88% (IgM), 96.62% (IgG) ; Specificity:  97.33% (IgM, hospitalized patients), 99.49% (IgM, normal population), 97.42% (IgG, hospitalized patients), 99.15% (IgG, normal population)","1558 patiens","","no","","2021-05-27 09:46:32",
"308","Development and potential usefulness of the COVID-19 Ag Respi-Strip diagnostic assay in a pandemic context","10.1101/2020.04.24.20077776","ImmunoAssay-Antigen"," ","nucleoprotein","","Analytical and clinical performance of a non-fluorescent ICT","Sensitivity 74.2%, specificity: 100%","60 samples","","no","","2021-05-27 09:49:27",
"751","Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context","10.3389/fmed.2020.00225","ImmunoAssay-Antigen"," ","nucleoprotein","kit","Ag Respi-Strip results were compared with qRT-PCR as golden standard for COVID-19 diagnostics.","sensitivity: 57.6%; specificity:99.5%; reproducibility between-observer disagreement: 1.7%; robustness: 98%","328 nasopharyngeal samples","","yes","","2021-05-27 10:02:50",
"11","Development and utilization of an intelligent application for aiding COVID-19 diagnosis","10.1101/2020.03.18.20035816","Others","In_silico","","","","","","","no","","2021-05-27 09:42:37",
"185","Development and Validation of a Diagnostic Nomogram to Predict COVID-19 Pneumonia","10.1101/2020.04.03.20052068","Others","In_silico","","","","","","","no","","2021-05-27 09:46:34",
"47","Development and validation of a rapid single-step reverse transcriptase loop-mediated isothermal amplification (RT-LAMP) system potentially to be used for reliable and high-throughput screening of COVID-19","10.1101/2020.03.15.20036376","NucleicAcid-Others","LAMP","ORF1ab-gene, N-gene","Other method, multiple-kit","Kits: Daan, Shanghai BioGerm Medical Biotechnology","Specificity: tested ; Sensitivity: 91.4% ; LOD: 500 cpm","260 samples","","no","","2021-05-27 09:43:33",
"990","Development and Validation of a Rapid, Single-Step Reverse Transcriptase Loop-Mediated Isothermal Amplification (RT-LAMP) System Potentially to Be Used for Reliable and High-Throughput Screening of COVID-19","10.3389/fcimb.2020.00331","NucleicAcid-PCR based","LAMP","N gene","in house LAMP, SARS-CoV-2 kit from Shanghai BioGerm Medical Biotechnology Co. Ltd, DAAN Gene Co., Ltd","","specificity: 100% (serial dilutions), 99.5% (clinical samples) ; sensitivity: 500 copies/ml (serial dilutions), 91.4% (clinical samples) ; PPV: 97.7% ; NPV: 98.1%","260 patients","","yes","","2021-05-27 10:09:43",
"295","Development and validation of an automated radiomic CT signature for detecting COVID-19","10.1101/2020.04.28.20082966","Others"," ","","Chest CT","AI system to detect covid using chest CT","Sensitivity: 78.94%; Specificity: 91.09%","181 covid & 1200 controls","","no","","2021-05-27 09:49:00",
"289","Development and validation of direct RT-LAMP for SARS-CoV-2","10.1101/2020.04.29.20075747","NucleicAcid-PCR based","LAMP","S, RdRP, ORF1ab","In-house LAMP","","PPA: 97.62% (Sgene), 91.97% (S and RdRP); NPA: 98.72% (Sgene), 100% (S and RdRP)  ","120 samples","","no","","2021-05-27 09:48:48",
"1218","Development and validation of IMMUNO-COVâ„¢: a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2","10.1101/2020.05.26.117549","ImmunoAssay-Antibody","Other Immuno assay","Antibodies vs S","IMMUNO-COV ","high-throughput clinical test","specificity: 100%; sensitivity:  "it is difficult to conclusively define an assay sensitivity""; clinical agreement: ""excellent"""","230 samples"," ","no","","2021-05-27 10:16:57",
"1255","Development and Validation of the Elecsys Anti-SARS-CoV-2 Immunoassay as a Highly Specific Tool for Determining Past Exposure to","10.1128/JCM.01694-20","ImmunoAssay-Antibody","Other Immuno assay","IgA, IgG vs N","kit (Elecsys)","Elecsys Anti-SARS-CoV-2 immunoassay (Roche Diagnostics, electrochemiluminescence), evaluated vs pseudoneutralization","Sensitivity: 99.5% (>14 days post positive PCR), 85.3% (7-13 days post positive PCR), 60.2% (0-6 days post positive PCR); Specificity: 99.8% (overall), 99.81% (diagnostic samples), 99.78% (blood donor samples), 99.5% (overall in cross reactvity samples); PPA: 86.4%; NPA: 100%; overall agreement: 87.0%","496 samples (sensitivity), 10453 samples (specificity), 792 samples (cross reactivity)","","yes","","2021-05-27 10:18:11",
"339","Development and Validation of Two In-house  Low-Cost SARS-CoV-2 Detection Assays"," 10.1101/2020.05.18.20105510","NucleicAcid-PCR based","Other PCR method(s)","S-gene, ORF1a (PCR); N, S, E, RdRp, RNase P (SYBRgreen)","in house RT-PCR ","PCR and SYBRgreen assays","LOD: 10 copies/?L","40 patients","","no","","2021-05-27 09:50:25",
"1249","Development and validation of viral load assays to quantitate SARS-CoV-2.","10.1016/j.jviromet.2021.114100","NucleicAcid-PCR based","RT-PCR","N, S genes","in house","validation of in-house RT-PCR compared with CDC RT-PCR targeting n1 and n2 genes","PPA: 100% ; NPA: 100% ; LOD 375 cp/ml ; specificity: 100%","113 samples","","yes","","2021-05-27 10:17:59",
"135","Development of a dual-gene loop-mediated isothermal amplification (LAMP) detection assay for SARS-CoV-2: A preliminary study","10.1101/2020.04.08.20056986","NucleicAcid-Others","LAMP","ORF1a-gene, N-gene","Other method","","Sensitivity: 95%  ;  Specificity: 100%","70 (45 covid positive)","","no","","2021-05-27 09:45:18",
"1032","Development of a fully automated high throughput PCR for the detection of SARS-CoV-2: The need for speed","10.1080/21505594.2020.1798041","NucleicAcid-PCR based","RT-PCR","E gene","NeuMoDx N96 system","fully automated, random access high-throughput real-time PCR-based diagnostic platform for the detection of SARS-CoV-2. ","Specificity: 100%","spiked samples","","yes","","2021-05-27 10:10:42",
"627","Development of a high-throughput homogeneous AlphaLISA drug screening assay for the detection of SARS-CoV-2 Nucleocapsid","10.1101/2020.08.20.258129","ImmunoAssay-Antibody"," ","IgG, IgM vs N ","in house","homogeneous cell-based HTS system using AlphaLISA detection technology","Remark: high sensitivity and large dynamic range","/","","yes","","2021-05-27 09:58:50",
"48","Development of a Laboratory-safe and Low-cost Detection Protocol for SARS-CoV-2 of the Coronavirus Disease 2019 (COVID-19)","10.5607/en20009","NucleicAcid-PCR based","WHO method(s)","","WHO-7, other method","","Specificty: tested ; Remark: notes false positive problems with WHO-7","12 patients","","yes","","2021-05-27 09:43:35",
"721","Development of a lateral flow immunoassay strip for rapid detection of IgG antibody against SARS-CoV-2 virus","10.1039/d0an00629g","ImmunoAssay-Antibody"," ","IgG","in house LFIA","development of a point-of-care (POC) serological assay for the detection of IgG antibody","sensitivity: 69.1%; Specificity: 100%","89 samples","","yes","","2021-05-27 10:01:48",
"49","Development of a Novel Reverse Transcription Loop-Mediated Isothermal Amplification Method for Rapid Detection of SARS-CoV-2","10.1007/s12250-020-00218-1","NucleicAcid-Others","LAMP","ORF1ab","Other method, individual-kit","Kit: Liferiver Novel","Specificity: tested ; LOD: 3 cpr","24 samples","","yes","","2021-05-27 09:43:37",
"269","Development of a novel, genome subtraction-derived, sars-cov-2-specific covid-19-nsp2 real-time rt-pcr assay and its evaluation using clinical specimens","10.3390/ijms21072574","NucleicAcid-PCR based","Other PCR method(s)","NSP2-domain","In-house method","","LOD: 1.8 50%-tissue-culture-infective-doses per ml","14 patients","","yes","","2021-05-27 09:48:19",
"636","Development of a portable, ultra-rapid and ultra-sensitive cell-based biosensor for the direct detection of the SARS-COV-2 S1 spike protein antigen","10.3390/s20113121","ImmunoAssay-Antigen","Biosensor","Spike S1 Protein","in house","Vero/anti-S1 cell-based biosensor","LOD: 1 fg/mL; ","/","","yes","","2021-05-27 09:59:06",
"565","Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2","10.1080/22221751.2020.1756698","NucleicAcid-PCR based","LAMP","N gene","In house LAMP","","LOD: 100 cpr; Remark: high specificity and sensitivity","14 samples","","yes","","2021-05-27 09:56:59",
"548","Development of a SARS-CoV-2 total antibody assay and the dynamics of antibody response over time in hospitalized and non-hospitalized patients with COVID-19","10.1101/2020.06.17.20133793","ImmunoAssay-Antibody"," ","IgG, IgA, IgM on RBD, NP","in house","Bridging assay","Specificity 99% (total Ab), 98.1-99.3% (RDB-Ab), 93.7-97.5% (NP-Ab)","591 samples","","no","","2021-05-27 09:56:33",
"843","Development of an automatic integrated gene detection system for novel severe acute respiratory syndrome-related coronavirus (SARS-CoV2)","10.1080/22221751.2020.1782774","NucleicAcid-PCR based","RT-PCR","S gene","in house","combination fo qRT-PCR assay with a new automatic nucleic acid detection system","LOD: 365 copies/ml;  specificity:100%; sensitivity: 97.62% ","266 patients","","yes","","2021-05-27 10:05:44",
"50","Development of Genetic Diagnostic Methods for Novel Coronavirus 2019 (nCoV-2019) in Japan","10.7883/yoken.jjid.2020.061","NucleicAcid-PCR based","WHO method(s)","See individual methods","WHO-5, WHO-4","","Specificity: tested","none tested ","","yes","","2021-05-27 09:43:39",
"794","Development of indigenous IgG ELISA for the detection of anti-SARS-CoV-2 IgG","10.4103/ijmr.IJMR_2232_20","ImmunoAssay-Antibody","ELISA","whole virus?","in house ELISA","virus was grown in viro, purified, inactivated and bound to elisa plates.","sensitivity: 93.27%; specificity: 97.9%; positive predictive value: 94.44: negative predicitive value: 98.14","513 samples","","yes","","2021-05-27 10:04:16",
"1281","Development of machine learning models to predict RT-PCR results for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients","10.1186/s13049-020-00808-8","Others","In_silico","/","Artificial intelligence- machine learning","properly trained artificial intelligence algorithms may be able to predict correct results in RT-PCR for SARS-COV-2, using basic clinical data","accuracy: 91.4%; sensitivity:94.1%; specificity: 88.7%","199 patients","","yes","","2021-05-27 10:19:05",
"51","Development of Reverse Transcription Loop-mediated Isothermal Amplification (RT-LAMP) Assays Targeting SARS-CoV-2","10.1101/2020.03.09.983064","NucleicAcid-Others","LAMP","N-gene, S-gene, ORF8-gene","Other method","","Specificity: tested ; LOD: 100 cpr","No clinical samples","","no","","2021-05-27 09:43:41",
"768","Development of Reverse Transcription Loop-Mediated Isothermal Amplification Assays Targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)","10.1016/j.jmoldx.2020.03.006","NucleicAcid-PCR based","LAMP","Nsp3, Spike, ORF8, N gene","LAMP","in house RT-LAMP","LOD: 100 copies RNA; remark: Cross-reactivity of RT-LAMP assays to other human coronaviruses was not observed","dilution of standard and viral RNA","","yes","","2021-05-27 10:03:24",
"500","Development of two TaqMan real-time reverse transcription-PCR assays for the detection of severe acute respiratory syndrome coronavirus-2","10.1016/j.bsheal.2020.07.009","NucleicAcid-PCR based"," ","N-gene, ORF1b gene","in house RT-PCR","","LOD: 1 cpr (N), 10 cpr (ORF1b) ","23 patients","","yes","","2021-05-27 09:55:07",
"946","Diagnosing COVID-19: The Disease and Tools for Detection.","10.1021/acsnano.0c02624","review","Mixed","mixed","multiple","paper gives an overview of current an potential detection methods.","table 2 lists emerging diagnostics","/"," ","yes","","2021-05-27 10:08:45",
"808","Diagnosis and detection of infected tissue of COVID-19 patients based on lung x-ray image using convolutional neural network approaches","10.1016/j.chaos.2020.110170","Imaging-X-ray","Other","X-ray lung ","","Two methods of deep learning: 1) deep neural network (DNN) on the fractal feature of images and 2) convolutional neural network (CNN) methods ","1) DNN Accuracy: 83.4%; Sensitivity: 86% 2) CNN Accuracy: 93.2%; Sensitivity: 96.1% ","682 images","","yes","","2021-05-27 10:04:42",
"186","Diagnosis and Prediction Model for COVID19 Patients Response to Treatment based on Convolutional Neural Networks and Whale Optimization Algorithm Using CT Images","10.1101/2020.04.16.20063990","Others","In_silico","","","","","","","no","","2021-05-27 09:46:36",
"53","Diagnosis of Acute Respiratory Syndrome Coronavirus 2 Infection by Detection of Nucleocapsid Protein","10.1101/2020.03.07.20032524","ImmunoAssay-Antigen"," ","N-protein"," ","","Sensitivity: 73.6% (in urine)","239 patients","Lateral flow device","no","","2021-05-27 09:43:43",
"270","Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT?","10.1016/j.ejrad.2020.108961","NucleicAcid-PCR based","Other PCR method(s)","Not specified","Not specified","","Remark: Retrospective comparison of CT and PCR results","36 patients","","yes","","2021-05-27 09:48:21",
"622","Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience","10.1002/jmv.25932","ImmunoAssay-Antibody"," ","IgM, IgG","kit","iFlash1800 CLIA analyzer from YHLO biotechnology Co (LTD, Shenzhen, China)","sensitivity: 73.3%(IgM), 76.7% (IgG); specificity: 92.2% (IgM), 100% (IgG). Remark: results improve modifying cutoff","61 patients & 64 controls","","yes","","2021-05-27 09:58:40",
"858","Diagnostic accuracy of Augurix COVID-19 IgG serology rapid test","10.1111/eci.13357","ImmunoAssay-Antibody","Mixed","IgG, IgM","RDT kit (Augurix SARS-CoV-2 IgM/IgG); in-house rFIA; ELISA kit (Euroimmun SARS-CoV-2 IgG)","Augurix performance is assessed vs in house rFIA and ELISA kit","sensitivity: 88% (RDT), specificity: 98% (RDT), PPV: 97% (RDT), NPV: 94% (RDT)","91 patients"," ","yes","","2021-05-27 10:06:13",
"502","Diagnostic Accuracy of North America Expert Consensus Statement on Reporting CT Findings in Patients with Suspected COVID-19 Infection: An Italian Single Center Experience","10.1148/ryct.2020200312","Others"," ","CT scan","","Diagnostic accuracy of the four categories for CT reporting: “typical”, “indeterminate”, “atypical” and “negative” vs Real-Time PCR","sensitivity:71.6% (typical pattern); specificity: 91.6%(typical pattern); PPV: 87.8%(typical pattern)","460 patients","","yes","","2021-05-27 09:55:11",
"523","Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis","10.1136/bmj.m2516","ImmunoAssay-Antibody"," ","IgG, IgM","ELISA, LFIA, CLIA","review and meta-analysis on serological tests","Remark: Pooled sensitivity:  84.3% (ELISAs IgG or IgM), 66% (LFIAs), 97.8% (CLIAs). Pooled specificities ranged from 96.6% to 99.7%. Among LFIAs, pooled sensitivity of commercial kits (65.0%, 49.0% to 78.2%) was lower than that of non-commercial tests (88.2%, 83.6% to 91.3%). Heterogeneity was seen in all analyses. Sensitivity was higher at least three weeks after symptom onset (ranging from 69.9% to 98.9%) compared with within the first week (from 13.4% to 50.3%).","/","","yes","","2021-05-27 09:55:47",
"1221","Diagnostic accuracy of six commercial SARS-CoV-2 IgG/total antibody assays and identification of SARS-CoV-2 neutralizing antibodies in convalescent sera","10.1101/2020.06.15.20131672","ImmunoAssay-Antibody","ELISA","IgG","Abbott SARS-CoV-2 IgG; Diasorin Liaison® SARS-CoV-2 S1/2 IgG; Epitope EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit; Euroimmun Anti-SARS-CoV-2 ELISA (IgG); Mikrogen recomWell SARS-CoV-2 IgG; Roche Elecsys Anti-SARS-CoV-2"," ","sensitivity: 97.1 (Abbott), 82.4 (Diasorin), 82.4 (Epitope), 79.4 (Euroimmun), 88.2 (Mikrogen), 88.2 (Roche); specificity: 99.0 (Abbott), 96.0 (Diasorin), 100.0 (Epitope), 97.0 (Euroimmun), 98.0 (Mikrogen), 99.0 (Roche); accuracy: 98.5 (Abbott), 92.5 (Diasorin), 95.5 (Epitope), 92.5 (Euroimmun), 95.5  (Mikrogen), 96.3 (Roche) ","34 sera"," ","no","","2021-05-27 10:17:03",
"749","Diagnostic accuracy of the FebriDx host response point-of-care test in patients hospitalised with suspected COVID-19","10.1016/j.jinf.2020.06.051","Mixed"," ","Myxovirus resistance protein A (MxA) and C reactive protein (CRP)","FebriDx","detection of the antiviral host response protein MxA using the FebriDx point-of-care test","Specificity: 86%; Overall accuracy:  90%; detection for identification of COVID-19: 93%","248 (118 positive por rt-pcr)","","yes","","2021-05-27 10:02:46",
"517","Diagnostic accuracy of two commercially available rapid assays for detection of IgG and IgM antibodies to SARS-CoV-2 compared to ELISA in a low-prevalence population","10.21203/rs.3.rs-50887/v1","ImmunoAssay-Antibody"," ","IgG, IgM","POC tests vs ELISA","NADAL® COVID-19 IgG/IgM Rapid Test and mo?-screen 2019-NCOV Corona Virus Test","Sensitivity: 100% (NADAL), 90.9% (mo-screen); specificity: 98.8% (NADAL), 98.8% (mo-screen); PPV: 76.9% (NADAL), 76.9% (mo-screen); NPV: 100% (NADAL), 99.6% (mo-screen); accuracy: 98.8% (NADAL), 98.5% (mo-screen).","130 samples","","No","","2021-05-27 09:55:35",
"619","Diagnostic efficacy of anti-SARS-CoV-2 IgG/IgM test for COVID-19: A meta-analysis","10.1002/jmv.26211","ImmunoAssay-Antibody","In_silico","IgG, IgM","","meta-analysis on immunoassays","remark: meta-analysis on commercially available tests","/","","yes","","2021-05-27 09:58:34",
"503","Diagnostic efficacy of three test kits for SARS-CoV-2 nucleic acid detection","10.3785/j.issn.1008-9292.2020.03.09","NucleicAcid-PCR based","PCR_KIT","Not specified (article in Chinese)","Kits","Sansure Biotech, Jiangsu Bioperfectus Technologies and BGI Genomics","sensitivity: 95% (Sansure), 90% (Bioperfectus), 82.50% (BGI); specificity: 87.50% (Sansure), 87.50% (Bioperfectus), 81.25% (BGI); PPV: 95.00% (Sansure), 94.74 (Bioperfectus), 91.67% (BGI); NPV: 87.50% (Sansure), 77.78% (Bioperfectus), 65% (BGI); kappa value: 0.825 (Sansure), 0.747 (Bioperfectus), 0.593 (BGI)","40 cases & 16 controls","","yes (paper not in English)","","2021-05-27 09:55:13",
"55","Diagnostic Indexes of a Rapid IgG/IgM Combined Antibody Test for SARS-CoV-2","10.1101/2020.03.26.20044883","ImmunoAssay-Antibody"," ","IgM/IgG","Unclear"," Kit: manufactured by a Chinese biotechnology company","Specificity: 91 % ; Sensitivity: 85.6 %","179 patients","","no","","2021-05-27 09:43:45",
"613","Diagnostic methods and potential portable biosensors for coronavirus disease 2019","10.1016/j.bios.2020.112349","Others"," ","","","Review on diagnostic tests","Remark: review on different methods reporting performances","/","","yes","","2021-05-27 09:58:23",
"750","Diagnostic performance between CT and initial real-time RT-PCR for clinically suspected 2019 coronavirus disease (COVID-19) patients outside Wuhan, China","10.1016/j.rmed.2020.105980","Others"," ","lung","CT scan","compare the performance of CT and initial RT-PCR for clinically suspected COVID-19 patients","sensitivity: 79% (RT-PCR), 77% (Chest CT); specificity: 100% (RT-PCR), 96% (chest CT) ","82(34 positive)","","yes","","2021-05-27 10:02:48",
"1182","Diagnostic Performance of a Rapid Point-of-care Test for SARS-CoV-2 in an Urban Emergency Department Setting","10.1111/acem.14039","NucleicAcid-PCR based","PCR_KIT","/","ID NOW SARS?CoV?2 Assay","retrospective analysis of data to evaluate the Performance of ID NOW SARS?CoV?2 Assay Compared to the m2000 (Abbott Molecular)","sensitivity: 78.8% ; specificity: 98.7%","597 samples","","yes","","2021-05-27 10:15:45",
"1195","Diagnostic performance of a SARS-CoV-2 IgG/IgM lateral flow immunochromatography assay in symptomatic patients presenting to the emergency department","10.1515/cclm-2020-0635","ImmunoAssay-Antibody","LFIA","IgG and IgM","Maccura LFIA (SARS-CoV-2 IgM/IgG, Maccura Biotechnology, Chengdu, China)","LFIA compared to SARS-CoV-2 RT-PCR (Seegene Inc., Seoul, Republic of Korea)","PPV: 81% IgM and/or IgG), 100% (double positive IgM and IgG)","315 samples","","yes","","2021-05-27 10:16:10",
"1063","Diagnostic performance of chest CT to differentiate COVID-19 pneumonia in non-high-epidemic area in Japan","10.1007/s11604-020-00958-w","Imaging-CT scan","Other","Chest CT scan","CT scan","evaluation of the diagnostic performance of the five CT criteria: (1) ground glass opacity (GGO)-predominant lesions, (2) GGO- and peripheral-predominant lesions, (3) bilateral GGO-predominant lesions; (4) bilateral GGO- and peripheral-predominant lesions, and (5) bilateral GGO- and peripheral-predominant lesions without nodules, airway abnormalities, pleural effusion, and mediastinal lymphadenopathy.","Remark: The five CT criteria showed moderate to excellent diagnostic performance with area under the curves (AUCs) ranging 0.77–0.88 for Radiologist 1 and 0.78–0.92 for Radiologist 2","21 patients","","yes","","2021-05-27 10:11:46",
"478","Diagnostic performance of COVID-19 serology assays","/","ImmunoAssay-Antibody","GICA","total antibody, IgG and IgM separately, antigen","SARS-CoV-2 Antibody test (Biologix Corporation); WONDFO One Step COVID-19 (SARS-CoV-2 Antibody Test) (Guangzhou Wondfo Biotech); Diagnostic kit for IgM/IgG Antibody to Coronavirus (SARS-CoV-2) (Zhuhai Livzon Diagnostic Inc.); Eugene SARS-CoV-2 (COVID-19) IgG/IgM Rapid Test (Shanghai Eugene Biotech); COVID-19 IgG/IgM Rapid Test (Healgen Scientific); COVID-19 IgM/IgG Ab Rapid Test (Qi ngdao hightop Biotech Co., Ltd); VivaDiag COVID-19 IgM/IgG Rapid Test (VivaChek Laboratories); Standard Q COVID-19 IgM/IgG Duo Test (SD Biosensor); COVID-19 IgG/IgM Rapid Test (PureCheck).","Full article available at: http://www.mjpath.org.my/2020/v42n1/COVID-19-serology.pdf","total antibody: sensitivity  86.4% to 90.6%; specificity >99%. IgM/IgG tests: sensitivity: 72.7% to 100%; specificity: 98.7% to 100%; positive coincidence rate: 37.5% to 97.1% and negative coincidence rate: 96% to 100%. ","","","yes","","2021-05-27 09:54:24",
"506","Diagnostic performance of COVID-19 serology assays","/","ImmunoAssay-Antibody"," ","","","Full text available at: http://www.mjpath.org.my/2020/v42n1/COVID-19-serology.pdf ; Review on serological methods","Remark: review on different serological methods reporting performances","/","","yes","","2021-05-27 09:55:19",
"620","Diagnostic performance of immunochromatography assay for rapid detection of IgM and IgG in coronavirus disease 2019","10.1002/jmv.26060","ImmunoAssay-Antibody"," ","IgG, IgM","kit","Immunochromatography?based COVID?19 IgG/IgM rapid test PCL COVID?19 IgG/IgM Rapid Gold (PCL, Inc, Seoul, Korea)","Sensitivity: 92.9% (IgM or IgG); specificity: 96.2% (IgM or IgG); PPV: 95.6%; NPV: 93.8%","149 subjects","","yes","","2021-05-27 09:58:36",
"1124","Diagnostic performance of initial blood urea nitrogen combined with D-dimer levels for predicting in-hospital mortality in COVID-19 patients","10.1016/j.ijantimicag.2020.106110","Others","Other","blood urea nitrogen, D-Dimer","Colorimetry, hematology","study aims to predict in-hospital mortality","AUC: 0.88 (BUN), 0.88 (D-Dimer), 0.87 (CRP); sensitivity: 0.85% (D-Dimer+BUN); specificity: 91% (D-Dimer+BUN)","305 patients"," ","yes","","2021-05-27 10:13:52",
"746","Diagnostic performance of serological assays in the detection of SARS-CoV-2: A review","10.3390/app10134506","Review"," ","IgM and IgG","review, 10 different types of serological tests","specificity and sensitivity for each assay is reported","","212 papers","","yes","","2021-05-27 10:02:39",
"605","Diagnostic performance of seven rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients","10.1016/j.cmi.2020.05.023","ImmunoAssay-Antibody"," ","IgG/IgM and IgG/IgA","Multiple kits","7 rapid IgG/IgM tests (LFA lateral flow assays) and the Euroimmun IgA/IgG ELISA","Specificity: ?91.3% (LFA, IgM), ?90.3% (LFA, IgG), ?85.4% (LFA, IgM OR IgG), 96.1% (ELISA, IgG), 73.8% (ELISA, IgA); Sensitivity: 92.1%-100% ( IgG LFA, 14-25 dpo), 89.5% (IgG ELISA, 14-25 dpo)","103 samples (specificity), 167 samples (sensitivity)","","yes","","2021-05-27 09:58:09",
"551","Diagnostic performances and thresholds: the key to harmonization in serological SARS-CoV-2 assays?","10.1016/j.cca.2020.05.050","ImmunoAssay-Antibody"," ","IgM IgG vs S and N (Maglumi); IgG vs S1/S2 (Liaison); IgG, IgM vs NP and S (iFlash); IgG, IgA vs S (Euroimmun); total Ab vs RBD (Wantai)","CLIA, ELISA kits","CLIA assays: Maglumi (Snibe), Liaison (Diasorin), iFlash (Yhlo); ELISA kit : Euroimmun (Medizinische Labordiagnostika AG), Wantai (Wantai Biological Pharmacy)","Sensitivity: 93.8% (Maglumi), 97.1% (Liaison), 97.2% (iFlash); specificity: 93.3% (Maglumi), 88.9% (Liaison), 85.9%% (iFlash); overall agreement:90.3% (CLIA), 98.4% (ELISA)","271 subjects","","yes","","2021-05-27 09:56:39",
"496","Diagnostic techniques for COVID-19 and new developments","10.1016/j.talanta.2020.121392","Others","Mixed","","","Review on diagnostic tests commercially available","Remark: review on different methods reporting performances","/","","yes","","2021-05-27 09:54:59",
"328","Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus-2: A Narrative Review","10.7326/M20-1301","Others"," ","Not specified","Not specified","Review on diagnostic tests commercially available","Not specified","Not specified","","yes","","2021-05-27 09:50:06",
"239","Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19","10.1002/jmv.25770","Others","In_silico","","","","","","","yes","","2021-05-27 09:47:48",
"604","Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019","10.1016/j.ijid.2020.03.065","ImmunoAssay-Antibody"," ","IgG, IgM vs N, S","Kit (CLIA)","Chemiluminiscence assay (CLIA) Shenzhen YHLO Biotech Co., Ltd (China)","Sensitivity: 48.1% (IgM), 88.9% (IgG); Specificity: 100% (IgM), 90.9% (IgG)","76 patients","","yes","","2021-05-27 09:58:07",
"494","Diagnostic value of combined nucleic acid and antibody detection in suspected COVID-19 cases","10.1016/j.puhe.2020.07.011","ImmunoAssay-Antibody","Mixed","IgM and IgG ; ORF1ab and N gene","Kit","antibody kits: Beijing Diagreat Biotechnologies Co., Ltd. ; rt-PCR: GeneoDx and Sansure Biotech","Positive detection rate: 63.38% (combined nucleic acid and antibody detection), 46.48% (single nucleic acid detection), 42.25% (single specific antibody detection)","71 patients","","yes","","2021-05-27 09:54:54",
"498","Diagnostics for SARS-CoV-2 detection: A comprehensive review of the FDA-EUA COVID-19 testing landscape","10.1016/j.bios.2020.112454","Others","Mixed","","","Review on diagnostic tests commercially available","Remark: review on different methods reporting performances","/","","yes","","2021-05-27 09:55:03",
"1164","Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients","10.1080/22221751.2020.1756699","mixed","Mixed","IgM, IgG vs N, S","kits (RT-PCR: BGI; IgM, IgG: Innovita) ","RT–PCR kit (BGI Genomics, Beijing, China);  gold immunochromatography assay supplied by Innovita Co., LTd, China","/","21 subjects","","yes","","2021-05-27 10:15:10",
"896","Differential diagnosis of illness in patients under investigation for the novel coronavirus (SARS-CoV-2), Italy, February 2020","10.2807/1560-7917.ES.2020.25.8.2000170","NucleicAcid-PCR based","WHO method(s)"," ","WHO5 (Charité), QIAstat-Dx respiratory panel (QIAGEN), diagnostic algorithm","Method aims to distinguish COVID19 from common infections such as influenza and other respiratory tract diseases","53.2% patients were covid, others could be excluded","126 patients"," ","yes","","2021-05-27 10:07:19",
"817","Differentiating pneumonia with and without COVID-19 using chest CT images: From qualitative to quantitative","10.3233/XST-190689","Imaging-CT scan","Other"," ","CT scan evaluation","3 radiologists determined the scores for all patients","sensitivity: 98%; specificity: 61%","61 patients"," ","no","","2021-05-27 10:04:59",
"692","Direct on-the-spot detection of SARS-CoV-2 in patients","10.1177/1535370220941819","NucleicAcid-Others","LAMP","N gene"," ","comparison of results with two kits (Allplex 2019-nCoV (Seegene) and BGI). NO RNA purification steps","specificity at 40': 96.8%; sensitivity:  80.7%","83 patients"," ","yes","","2021-05-27 10:00:55",
"895","Discrimination of False Negative Results in RT-PCR Detection of SARS-CoV-2 RNAs in Clinical Specimens by Using an Internal Reference","10.1007/s12250-020-00273-8","NucleicAcid-PCR based","PCR_KIT","ORF1, N genes","WHO-1 RT-PCR (Bojie Ltd, Shanghai, China)","identification of Ct cutoff values for internal reference RPP30 RT-PCR which predicted false negative results for SARS-CoV-2 RT-PCR","Sensitivity: 95.03% (ORF1ab, sputum), 95.10% (N, sputum), 95.26% (ORF1ab, throat swab), 95.14% (N, throat swab) ; Specificity: 91.40% (ORF1ab, sputum), 88.16% (N, sputum), 83.72% (ORF1ab, throat swab), 98.55% (N, throat swab)","161 patients","","yes","","2021-05-27 10:07:17",
"187","Distinct early IgA profile may determine severity of COVID-19 symptoms: an immunological case series","10.1101/2020.04.14.20059733","ImmunoAssay-Antibody"," ","IgM/IgG, IgA","Immune-phenotyping and peptide microarray in-house-methods","","Not reported","5 patients","","no","","2021-05-27 09:46:38",
"412","Distinguishing between COVID-19 and the common cold in a primary care setting - comparison of patients with positive and negative SARS-CoV-2 PCR results","10.1101/2020.04.27.20081877","Others","In_silico","/","/","predictive characteristics for postiive PCR result","/","374","","no","","2021-05-27 09:52:14",
"611","DNA nanoscaffold-based SARS-CoV-2 detection for COVID-19 diagnosis","10.1016/j.bios.2020.112479","NucleicAcid-Others","Other PCR method(s)","Not specified","DNHCR","a DNA nanoscaffold hybrid chain reaction (DNHCR)-based nucleic acid assay","Remark: new method proposal ","/","","yes","","2021-05-27 09:58:21",
"878","Double-quencher probes improve detection sensitivity toward Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a reverse-transcription polymerase chain reaction (RT-PCR) assay","10.1016/j.jviromet.2020.113926","NucleicAcid-PCR based","RT-PCR","N1 and N2","2019-nCoV RUO Kit","Double-quencher(YCH-N1) probes improve detection sensitivity comparison with NIID","Positive percentage agreement NIID-N1: 56%, Positive percentage agreement YCH-N1:61%, Positive percentage agreement YCH-N2: 94%","66 nasopharyngeal swabs","","yes","","2021-05-27 10:06:46",
"57","Double-Quencher Probes Improved the Detection Sensitivity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by One-Step RT-PCR","10.1101/2020.03.17.20037903","NucleicAcid-PCR based","WHO method(s)","See individual methods","WHO-7, WHO-4, multiple-kits","Kits: CDC, IDT 2019-nCoV RUO","Sensitivity: tested","None","","no","","2021-05-27 09:43:47",
"1065","Dual-Functional Plasmonic Photothermal Biosensors for Highly Accurate Severe Acute Respiratory Syndrome Coronavirus 2 Detection","10.1021/acsnano.0c02439","Others","Biosensor","multiple targets (RdRP, ORF1ab, E)","plasmonic biosensor","a dual-functional plasmonic biosensor combining the plasmonic photothermal (PPT) effect and localized surface plasmon resonance (LSPR) sensing transduction. The two-dimensional gold nanoislands (AuNIs) functionalized with complementary DNA receptors can perform a sensitive detection of the selected sequences from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) through nucleic acid hybridization","LOD: 0.22pM","/","","yes","","2021-05-27 10:11:50",
"767","Dynamic Changes of Antibodies to SARS-CoV-2 in COVID-19 Patients at Early Stage of Outbreak","10.1007/s12250-020-00268-5","ImmunoAssay-Antibody","","IgG, IgM vs N","in house ELISA","In-house anti-SARS-CoV-2 IgG and IgM ELISA kits were developed using SARSr-CoV Rp3 nucleocapsid protein (NP) as antigen","sensitivity: 92.5% (IgG ELISA), 70.8% (IgM ELISA) ","226 samples","","yes","","2021-05-27 10:03:22",
"1018","Dynamic Changes of CT Findings in Pneumonia Patients with Coronavirus Disease 19","10.12182/20200560506","Imaging-CT scan","Other","CT scan","CT scan","","","","","yes (paper not in English)","","2021-05-27 10:10:18",
"586","Dynamic profile for the detection of anti-SARS-CoV-2 antibodies using four immunochromatographic assays","10.1016/j.jinf.2020.04.033","ImmunoAssay-Antibody"," ","IgG, IgM","kits","Biotime, Autobio, ISIA and Biolidics tests","sensitivity:  9%-24% (5 dpo), 67%-82%  (10 dpo),  100% (15 dpo), 81.82% (Autobio 10 dpo), 70.59% (Biotime, 10 dpo), 68.18% (ISIA, 10 dpo), 66.67% (Biolidics, 10 dpo); ","22 patients","","yes","","2021-05-27 09:57:36",
"465","Dynamic profile of RT-PCR findings from 301 COVID-19 patients in Wuhan, China: a descriptive study","10.1016/j.jcv.2020.104346","NucleicAcid-PCR based","PCR_KIT","ORF1ab and N","/","Period of viral infection and the contagious stage","/","75 samples","","yes","","2021-05-27 09:53:57",
"656","Dynamic surveillance of SARS-CoV-2 shedding and neutralizing antibody in children with COVID-19","10.1080/22221751.2020.1772677","NucleicAcid-PCR based"," ","","","Comparison of nasopharyngeal swabs, stool samples oropharyngeal swabs .In children, nasopharyngeal swabs appear to be a more sensitive specimen type for the diagnosis of COVID-19 compared with oropharyngeal swabs. ","","9 children","","yes","","2021-05-27 09:59:41",
"463","Dynamics of anti-SARS-Cov-2 IgM and IgG antibodies among COVID-19 patients","10.1016/j.jinf.2020.04.019","ImmunoAssay-Antibody","Mixed","IgM, IgG  and E, N, RdRP","CDC kit (RT-PCR), LFIA (antibodies)","letter to the editor on dynamics of antibodies response to clinical manifestation","sensitivity: 90.9% (IgM); ,specificity: 97% (IgM); accuracy: 95.9% (IgM)","14 patients & 28 controls","","yes","","2021-05-27 09:53:53",
"1050","Early antibody response to SARS-CoV-2","10.1101/2020.05.19.20099317","ImmunoAssay-Antibody","Other Immuno assay","IgM, IgG","Maglumi  800 Analyzer  (Snibe, Shenzen, China)","two step chemiluminescence immunoassay using magnetic microbeads  coated  with  anti-human  Immunoglobulins  (IgM  and  IgG)  and  2019-nCoV recombinant antigen labelled with luminescence substrate (MAGLUMI 2019-nCoV IgM and MAGLUMI  2019-nCoV  IgG  respectively)","true positive results: 60.8% (IgM, symptomatic patients), 85.1% (IgG, symptomatic patients)","46 patients (77 samples)","","no","","2021-05-27 10:11:19",
"1130","Early chest computed tomography to diagnose COVID-19 from suspected patients: A multicenter retrospective study","10.1016/j.ajem.2020.04.051","Imaging-CT scan","In_silico","ground glass opacities (GGOs), crazy-paving pattern and air bronchogram","To identify differences in CT imaging and clinical manifestations between pneumonia patients with and without COVID-19"," ","Remark: Sensitivity and specificity: The typical CT imaging features of the positive group were ground glass opacities (GGOs), the crazy-paving pattern and air bronchogram. The lesions were mostly distributed bilaterally and close to the lower lungs or the pleura. When features were combined, GGOs with bilateral pulmonary distribution and GGOs with pleural distribution were more common among the positive patients, 57.4% and 55.6%, respectively. The combinations were almost all statistically significant (P < .05), except for the combination of GGOs with consolidation. Most combinations presented relatively low sensitivity but extremely high specificity. The average specificity of these combinations was approximately 90%. "," 54 patients positive to covid and 76 patients negative"," ","yes","","2021-05-27 10:14:04",
"1017","Early CT findings of coronavirus disease 2019 (COVID-19) in asymptomatic children: A single-center experience","10.3348/kjr.2020.0231","Imaging-CT scan","Other","CT scan","CT scan","","remarks: distribution of image finding rported","4 patients","","yes","","2021-05-27 10:10:16",
"821","Early detection of SARS-CoV-2 antibodies in COVID-19 patients as a serologic marker of infection","10.1093/cid/ciaa523","ImmunoAssay-Antibody","ELISA"," ","in house ELISA"," ","specificity: 97.5%; sensitivity: 97.1%; accuracy: 97.3%","412 samples"," ","yes","","2021-05-27 10:05:07",
"448","Early detection of superspreaders by mass group pool testing can mitigate COVID-19 pandemic","10.1101/2020.04.22.20076166","Others","In_silico","/","/","stochastic social-epidemiological SEIAR model, where S-suspected, E-exposed, I-infectious, A-admitted, R-recovered","/","/","","no","","2021-05-27 09:53:26",
"394","Early phases of COVID-19 are characterized by a reduction of lymphocyte populations and the presence of atypical monocytes","10.1101/2020.05.01.20087080","Others"," ","/","/","evaluation of immunological changes in blood in covid","/","63","","no","","2021-05-27 09:51:36",
"397","Early trends for SARS-CoV-2 infection in central and north Texas and impact on other circulating respiratory viruses","10.1101/2020.04.30.20086116","NucleicAcid-PCR based","PCR_KIT","ORF1, N, E","PCR kit","Luminex Aries system, NxTAG platform ","/","3571 nasopharyngeal specimens","","no","","2021-05-27 09:51:43",
"404","Early viral clearance and antibody kinetics of COVID-19 among asymptomatic carriers","10.1101/2020.04.28.20083139","ImmunoAssay-Antibody","Mixed","RNA, IgG, IgA, IgM","RT-PCR,  CMIA, Ab-ELISA","GeneoDX Co.,Ltd., Shanghai, China (RT-PCR kit); Chemiluminescence Microparticle Immuno Assay (CMIA); Wantai (ELISA kits)","/","75","","no","","2021-05-27 09:51:57",
"443","eCovSens-Ultrasensitive Novel In-House Built Printed Circuit Board Based Electrochemical Device for Rapid Detection of nCovid-19","10.1101/2020.04.24.059204","ImmunoAssay-Antigen"," ","nCovid-19 spike antigen","in-house built biosensor device (eCovSens)","immunosensors","Sensitivity: 1 fM to 1 µM; LOD: 90 fM (eCOVSens), 120 fM (potentiostst on saliva)","/","","no","","2021-05-27 09:53:15",
"1200","EDTA-Anticoagulated Whole Blood for SARS-CoV-2 Antibody Testing by Electrochemiluminescence Immunoassay (ECLIA) and Enzyme-Linked Immunosorbent Assay (ELISA)","10.3390/diagnostics10080593","ImmunoAssay-Antibody","Mixed","IgG, IgA (Euroimmun); Total Ab vs N (Elecsys)","kits (Elecsys, Euroimmun)","evaluation of EDTA-anticoagulated whole blood as an alternative sample material for antibody testing against SARS-CoV-2 by electro-CLIA (ECLIA Elecsys Anti-SARS-CoV-2 assay (Roche Diagnostics, Rotkreuz, Switzerland)) and ELISA (IgG and IgA; Euroimmun, Germany)","Sensitivity: 88% (IgG ELISA serum), 78% (IgA ELISA serum), 97% (ECLIA serum),  93% (IgG ELISA Whole Blood Corrected for Hematocrit), 84% (IgA ELISA Whole Blood Corrected for Hematocrit), 96% (ECLIA Whole Blood Corrected for Hematocrit); Specificity: 99% (IgG ELISA serum), 93% (IgA ELISA serum), 100% (ECLIA serum), 97% (IgG ELISA Whole Blood Corrected for Hematocrit), 89% (IgA ELISA Whole Blood Corrected for Hematocrit), 99% (ECLIA Whole Blood Corrected for Hematocrit); Diagnostic accuracy: : 0.987 (ECLIA serum), 0.973 (ECLIA whole blood), 0.973 (ECLIA whole blood corrected for hematocrit), 0.969 (IgG ELISA serum), 0.971 (IgG ELISA whole blood), 0.971 (IgG ELISA whole blood corrected for hematocrit), 0.939 (IgA ELISA serum), 0.935 (IgA ELISA whole blood), 0.936 (IgA ELISA whole blood corrected for hematocrit)","223 individuals","","yes","","2021-05-27 10:16:20",
"1025","Effect of heat inactivation of blood samples on the efficacy of three detection methods of SARS-CoV-2 antibodies","10.12122/j.issn.1673-4254.2020.03.03","ImmunoAssay-Antibody","","","","","","","","yes (paper not in English)","","2021-05-27 10:10:30",
"337","Effect of Heat inactivation on Real-Time Reverse Transcription PCR of the SARS-COV-2 Detection","10.1101/2020.05.19.20101469","NucleicAcid-PCR based","PCR_KIT","ORF1ab, N ","bioperfectus technologies PCR kit","Effect of heat inactivation on RT-PCR","Not reported ","14 samples","","no","","2021-05-27 09:50:21",
"913","Efficacy of a novel SARS-CoV-2 detection kit without RNA extraction and purification","10.1016/j.ijid.2020.06.074","NucleicAcid-PCR based","PCR_KIT","","nCoV-DK; Shimadzu Corporation, Kyoto, Japan","comparison of nCoV-DK kit and direct PCR without RNA extraction and purification","Concordance rate: 95.2% (nasopharyngeal swabs), 95.5% (saliva), 85.7% (sputum) ; Specificity: 74.6% (direct PCR), 77.5% (nCoV-DK)","9 patients (71 samples)","","yes","","2021-05-27 10:07:47",
"189","Efficient and Practical Sample Pooling High-Throughput PCR Diagnosis of COVID-19","10.1101/2020.04.06.20052159","Others","In_silico","","","","","","","no","","2021-05-27 09:46:40",
"635","Efficient Deep Network Architecture for COVID-19 Detection Using Computed Tomography Images","10.1101/2020.08.14.20170290","Others","In_silico","CT scan","Deep convolutional neural network and prediction models","","accuracy: 97.78%; recall: 96.78%; specificity: 98.77%","2482 images","","no","","2021-05-27 09:59:04",
"969","Efficient gan-based chest radiographs (CXR) augmentation to diagnose coronavirus disease pneumonia","10.7150/ijms.46684","Imaging-Others","Mixed","X-ray and CT images","Deep Learning"," impactful applications of Deep Learning to fighting the Covid-19 from Chest X-Ray/CT Images GAN-based Chest Radiographs (CXR) augmentation to diagnose coronavirus disease pneumonia","Accuracy: 89%","32000 images","","yes","","2021-05-27 10:09:06",
"190","Efficient high throughput SARS-CoV-2 testing to detect asymptomatic carriers","10.1101/2020.04.14.20064618","Others","In_silico","","","","","","","no","","2021-05-27 09:46:42",
"474","Electrochemical biosensors for pathogen detection","10.3390/mi10040222","Others"," ","food borne pathogens","nothing related to covid-19","/","/","/","","yes","","2021-05-27 09:54:15",
"1004","Electrochemical biosensors for pathogen detection.","10.1016/j.bios.2020.112214","Others","Biosensor","mixed","biosensor","overview of biosensors for pathogen detection ","Table 1-2 list pathogen biosensors and their LOD","/"," ","yes","","2021-05-27 10:10:05",
"1117","Emerging Technologies for Use in the Study, Diagnosis, and Treatment of Patients with COVID-19","10.1007/s12195-020-00629-w","review","In_silico","mixed","multiple emerging technologies","focus on artificial intelligence, Big Data,Internet of Things, mathematical modeling, nanotechnology, telemedicine, 3D-printing","/","/"," ","yes","","2021-05-27 10:13:37",
"963","End-to-end automatic differentiation of the coronavirus disease 2019 (COVID-19) from viral pneumonia based on chest CT","10.1007/s00259-020-04929-1","Imaging-CT scan","In_silico","CT-scans","CT-scans and Jiangsu Shuoshi Biotechnology Co., Ltd. (Taizhou, China), Huada Biotechnology Co., Ltd. (Wuhan, China) RT-PCR kits","automatic differentiation method based on CT images to identify COVID-19 pneumonia patients in real time.","sensitivity: 80% ; specificity: 75%","201 patients","","yes","","2021-05-27 10:08:55",
"628","End-to-End Protocol for the Detection of SARS-CoV-2 from Built Environments","10.1101/2020.08.16.20172668","NucleicAcid-PCR based","PCR_KIT & other","Not specified","kit","RT-LAMP and RT-qPCR assays","Remark: evaluation of virus from environments. E2E protocol required a minimum of 1,000 viral particles per 25 cm2 to successfully detect virus from test surfaces.","368 environmental samples","","yes","","2021-05-27 09:58:52",
"137","Enhancement of trans-cleavage activity of Cas12a with engineered crRNA enables amplified nucleic acid detection","10.1101/2020.04.13.036079","NucleicAcid-Others","CRISPR","N-gene","Other method","","Not reported","No clinical samples","","no","","2021-05-27 09:45:20",
"1085","Enhancing sensitivity of lateral flow assay with application to SARS-CoV-2","10.1063/5.0021842","ImmunoAssay-Antibody","LFIA","IgG IgM","We use the SARS-CoV-2 IgG (Anti-Covid 19?+?SARS COV S Glycoprotein Human IgG1","Improvement of sensitivity of the AuNP LFA test ","Sensitivity 01. ng/ml ","","","yes","","2021-05-27 10:12:31",
"296","Enzyme immunoassay for SARS-CoV-2 antibodies in dried blood spot samples: A minimally-invasive approach to facilitate community- and population-based screening","10.1101/2020.04.28.20081844","ImmunoAssay-Antibody"," ","IgG on RBD","ELISA","2 protocols for dried blood spot testing","Not specified","9 positive & 5 controls","","no","","2021-05-27 09:49:02",
"431","Epidemiological and clinical characteristics of the early phase of the COVID-19 epidemic in Brazil","10.1101/2020.04.25.20077396","Others","In_silico","/","/","epidemiology","/","/","","no","","2021-05-27 09:52:51",
"439","Epidemiological characteristics of novel coronavirus infection: A statistical analysis of publicly available case data","10.1101/2020.04.24.20077800","Others","In_silico","/","/","estimation of disease incidence in hotspots","/","/","","no","","2021-05-27 09:53:07",
"469","Era of molecular diagnosis for pathogen identification of unexplained pneumonia, lessons to be learned","10.1080/22221751.2020.1738905","NucleicAcid-Others","Mixed","","CRISPR, RT-PCR, sequencing","/","/","1 patient","","yes","","2021-05-27 09:54:05",
"360","Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2","10.1080/22221751.2020.1743767","Others"," ","S-gene","Pseudovirus based neutralization assay","Optimization of key parameters for neutralization assay(cell types, cell numbers, virus inoculum). Showing high neutralizing potency against the SARS-CoV-2 pseudovirus, underscores its potential as therapeutics. ","LOD: 22.1 (Human serum), 42.3 (mouse serum)","74 human & 46 mouse samples","","yes","","2021-05-27 09:50:33",
"433","Estimating COVID-19 Antibody Seroprevalence in Santa Clara County, California. A re-analysis of Bendavid et al.","10.1101/2020.04.24.20078824","Others","In_silico","/","/","use of Bayesan model for estimating antibodies prevalence","/","/","","no","","2021-05-27 09:52:55",
"460","Estimating COVID-19 Prevalence in the United States: A Sample Selection Model Approach","10.1101/2020.04.20.20072942","Others","In_silico","/","mathematical model","estimate of population infection rate","/","/","","no","","2021-05-27 09:53:46",
"138","Estimating false-negative detection rate of SARS-CoV-2 by RT-PCR","10.1101/2020.04.05.20053355","Others","In_silico","","","","","","","no","","2021-05-27 09:45:22",
"440","Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors","10.1101/2020.04.24.20075291","ImmunoAssay-Antibody"," ","IgM, IgG ","commercial lateral flow test","measurement of infection fatality rate in blood donors","Specificiy:  99.54%; Sensitivity:  82.58%;","806 plasma samples","","no","","2021-05-27 09:53:09",
"1207","Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study.","10.1101/2020.04.26.20079822","ImmunoAssay-Antibody","Other Immuno assay","IgG","","cross-sectional study to estimate seroprevalence of SARS-CoV-2 infection.","/","1000 serum","","no","","2021-05-27 10:16:35",
"1109","Evaluating SARS-CoV-2 spike  and nucleocapsid proteins as  targets  for  antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay ","10.1016/j.jviromet.2020.114025","ImmunoAssay-Antibody","Other Immuno assay","IgG, IgM, IgA","Luminex","Luminex bead-based assay","Specificity: 99% ; sensitivity: 96% ; remarks: more performance values in severe and mild cases and with using multiplex and/or single antigen are also reported","296 samples","","yes","","2021-05-27 10:13:21",
"925","Evaluating the use of posterior oropharyngeal saliva in a point-of-care assay for the detection of SARS-CoV-2","10.1080/22221751.2020.1775133","NucleicAcid-PCR based","PCR_KIT","E and N2 genes","Xpert Xpress SARS-CoV-2 assay","assessment of the use of posterior oropharyngeal saliva as specimens for the detection of SARS-CoV-2 in an automated point-of-care molecular assay","detection rate: N2 (NPS 94.8%) (Saliva 93.1%); E (Saliva: 89.7%( (saliva: 82.8%) ","58 patients","","yes","","2021-05-27 10:08:08",
"329","Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2","10.1080/20008686.2020.1754538","ImmunoAssay-Antibody"," ","IgG, IgM","Commercially available serological kit","qPCR to confirm positive/negative cases","Sensitivity: 69% (IgM), 93.1% (IgG) ; specificity: 100% (IgM), 99.2% (IgG) ; remarks: compared to qPCR results","29 PCR-confirmed COVID-19 cases and 124 negative controls","","yes","","2021-05-27 09:50:08",
"665","Evaluation of a high-speed but low-throughput RT-qPCR system for detection of SARS-CoV-2","10.1016/j.jhin.2020.05.025","NucleicAcid-PCR based","PCR_KIT","not specified","kit","GeneSoC, a compact high-speed reciprocal flow quantitative reverse transcription polymerase chain reaction system, for the detection of SARS-CoV-2","LOD: 10 copies/reaction; Sensitivity: 92%; Specificity: 100%","78 samples","","yes","","2021-05-27 09:59:59",
"589","Evaluation of a novel multiplexed assay for determining IgG levels and functional activity to SARS-CoV-2","10.1016/j.jcv.2020.104572","ImmunoAssay-Antibody"," ","IgG vs S, RBD, N","kit","multiplexed solid-phase chemiluminescence assay (Meso Scale Discovery), Rockville, MD","Specificity:  97.4 % (IgG vs S), 92.3% (IgG vs RBD), 92.8% (IgG vs N) ; sensitivity:  96.2 % (IgG vs S, 14 dpo), 91% (IgG vs RBD, 14 dpo), 84.6% (IgG vs N, 14 dpo), 97.9 %  (IgG vs S, 21 dpo), 93.6% (IgG vs RBD, 21 dpo),  87.2% (IgG vs N, 21 dpo)","196 positive samples &194 control samples","","yes","","2021-05-27 09:57:40",
"58","Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system","10.2807/1560-7917.ES.2020.25.9.2000152","NucleicAcid-PCR based","WHO method(s)","E-gene","WHO-5","","Specificity: tested ; LOD: 689.3 cpm","88 samples","","yes","","2021-05-27 09:43:49",
"649","Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2 Antigen in Nasopharyngeal Swabs","10.1128/JCM.00977-20","ImmunoAssay-Antigen"," ","highly conserved nucleoprotein antigens","kit","COVID-19 Ag Respi-Strip (Coris BioConcept, Gembloux, Belgium) based on a nitrocellulose membrane technology with colloidal gold nanoparticles","Specificity: 100%; sensitivity: 50%","138 samples","","yes","","2021-05-27 09:59:27",
"731","Evaluation of a rapid igm-igg combined antibody test for sars-cov-2 infection: Single italian center study","10.3844/ajidsp.2020.85.88","ImmunoAssay-Antibody"," ","IgG, IgM","kit","2019-nCOV/COVID-19 IgG/IgM Rapid Test Device (Hangzhou Realy Tech Co., Ltd)","sensitivity: 95.5%; specificity: 96.8% ","132 cases","","yes","","2021-05-27 10:02:09",
"1179","Evaluation of an electrochemiluminescent SARS-CoV-2 antibody assay","10.1093/jalm/jfaa134","ImmunoAssay-Antibody","Other Immuno assay","IgG, IgM ","Roche anti-SARS-CoV-2 assay","evaluation of the Roche anti-SARS-CoV-2 assay on Cobas immunoassay analyzers ","sensitivity: 97.1% 14?days after PCR positivity and 100% at ?21?days. specificity: 99.86%","349 positive, 715 other","","yes","","2021-05-27 10:15:39",
"1197","Evaluation of an ELISA for SARS-CoV-2 antibody testing: clinical performances and correlation with plaque reduction neutralization titer","10.1515/cclm-2020-1096","ImmunoAssay-Antibody","ELISA","IgA, IgG and IgM","ELISA (ENZY-WELL SARS-CoV-2)","performance of ELISA method compared to RT-PCR test results (E gene)","Sensitivity: 82.2% (IgA), 66.4% (IgM), 86.8% (IgG) ; specificity: 100% (IgG), 97.5% (IgM), 96.3% (IgA)","314 samples","","yes","","2021-05-27 10:16:14",
"139","Evaluation of antibody testing for SARS-Cov-2 using ELISA and lateral flow immunoassays","10.1101/2020.04.15.20066407","ImmunoAssay-Antibody"," ","IgM/IgG; ELISA on S-protein","LFIA multiple-kits, ELISA individual-kit","9 commerical LFIA kits and 1 ELISA kit","Sensitivity: 85% (ELISA), 55-70% (LFIA), 65-85% (RT-PCR) ; Specificity: 100% (ELISA), 95-100% (LFIA),  93-100% (RT-PCR)","182 samples","","no","","2021-05-27 09:45:24",
"1199","Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples","10.2807/1560-7917.ES.2020.25.18.2000603","ImmunoAssay-Antibody","ELISA","IgG, IgA vs S1","kits (Euroimmun)","SARS-CoV-2 IgG and IgA ELISAs, Euroimmun, Lübeck, Germany","specificity: 91.9% (IgG), 73.0% (IgA)","37 samples","","yes","","2021-05-27 10:16:18",
"513","Evaluation of Commercial qPCR Kits for Detection of SARS-CoV-2 in Pooled Samples","10.3390/diagnostics10070472","NucleicAcid-PCR based","PCR_KIT","E, RdRP","Kits","Pooling strategy on kits:PowerCheck 2019-nCoV Real-Time PCR Kit (Kogene Biotech, Seoul, Korea), COVID-19 PCR Diatheva Detection Kit (Diatheva, Cartoceto, Italy), and 2019 nCoV CDC EUA KIT (IDT DNA, Coralville, IA, USA)","Remark: pooling up to 80 samples does not affect efficacy of kits","/","","yes","","2021-05-27 09:55:31",
"529","Evaluation of commercially available immuno-magnetic agglutination and enzyme-linked immunosorbent assays for rapid point-of-care diagnostics of COVID-19","10.1101/2020.08.15.20172080","ImmunoAssay-Antibody"," ","IgM/IgA or IgG (IMA); IgA/IgG (ELISA)","microfluidic quantitative immunomagnetic assay (IMA) and ELISA kit","microfluidic quantitative immunomagnetic assay (IMA)(ViroTrack Sero COVID IgM+IgA/IgG Ab, Blusense Diagnostics, Denmark) ; enzyme-linked immunosorbent assay ((ELISA) (EuroImmun Medizinische Labordiagnostika, Germany).","Sensitivity: 68% (IgA+IgM by IMA), 73% (IgG by IMA), 73% (IgG by ELISA), 90% (Ima and Elisa, >14 dpo); Specificity: 100% (IMA), 95% (ELISA IgA), 97.5% (ELISA IgG)","35 plasma from 22 patients & 40 controls","","no","","2021-05-27 09:55:54",
"59","Evaluation of COVID-19 RT-qPCR test in multi-sample pools","10.1101/2020.03.26.20039438","NucleicAcid-PCR based","WHO method(s)","RdRp-region, E-gene, N-gene, S-gene","WHO-5","","Not reported","72 samples","","no","","2021-05-27 09:43:51",
"1114","Evaluation of diagnostic accuracy of 10 serological assays for detection of SARS-CoV-2 antibodies","10.1007/s10096-020-04092-3","ImmunoAssay-Antibody","Other Immuno assay","IgG, IgM, IgA","VIRCLIA (IgG and IgM+A), ELISA (IgG and IgM+A), both from VIRCELL; EUROIMMUN ELISA (IgG and IgA); ABBOTT® chemiluminescence technique; Wondfo SARS-CoV-2 Antibody Test (Guangzhou Wondfo Biotech Co., Ltd), SGTi-flex COVID-19 IgM/IgG (Sugentech, Inc.), and Innovita 2019 n-CoV Ab Test Colloidal Gold (Biological Technology Co.);","different immunoassay kits tested and compared with RT-PCR results","Remarks: specificity, sensitivity, PPV and NPV for each Ig and for the Ig mix for each kit are reported","100 samples","","yes","","2021-05-27 10:13:31",
"885","Evaluation of eleven rapid tests for detection of antibodies against SARS-CoV-2","10.1515/cclm-2020-0628","ImmunoAssay-Antibody","Other Immuno assay","IgG, IgM","A: Acro 2019-nCoV IgG/IgM Rapid Test (Acro Biotech Inc, USA); B:OnSite Covid-19 IgG/IgM Rapid Test (CTK Biotech, Inc, USA); C: COVID-19 IgG/IgM Rapid Test Kit (WuHanUNscience Biotechnology Co., China); D: Rapid IgM-IgG Combined Antibody Test Kit for SARS-CoV-2 (Jiangsu Medomics medical technology Co., China); E: Wantai SARS-CoV-2 Ab Rapid Test Kit	(Beijing Wantai Biological Pharmacy Enterprise Co, China); F: Novel coronavirus 2019-nCov) IgM/IgG Antibody Combo Test Kit (Hangzhoue Laihe Biotech Co, China); G: Novel Coronavirus (SARS-CoV-2) IgM Antibody Detection (Ki RayBiotech, USA); H: Novel Coronavirus (SARS-CoV-2) IgG Antibody Detection Kit (RayBiotech, USA); I: Lumiratek COVID-19 IgG/IgM Hurtigtest kassett (Hangzhou Biotest Biotech Co., China); J: Covid-19 IgG/IgM Rapid Test Cassette (SureScreen Diagnostics, UK); K: SARS-CoV-2 IgG/IgM Rapid Test (Zhuhai Encode Medical Engineering Co., China).","evaluation of performances of 11 rapid tests","Remarks: all tests recovered IgM and IgG from hospitalized patients with varying sensitivity; in no-hospitalized participnts who had recovered from PCR-confirmed Covid-19, tests A, B, C, and D had higher IgG positivity rates than tests E, F, H I, and J; more detailed data available in tables.","92 patients","","yes","","2021-05-27 10:06:58",
"1216","Evaluation of ELISA tests for the qualitative determination of IgG, IgM and IgA to SARS-CoV-2","10.1101/2020.05.24.20111682","ImmunoAssay-Antibody","ELISA","IgG, IgM, and IgA","ENZY-WELL SARS-CoV-2 ELISA, DIESSE Diagnostica Senese S.p.a.","based on whole-virus antigens","sensitivity: 92.5% (IgG), 93.6% (IgA), 87.7% (IgM); specificity: 91.7% (IGG), 97.9%(IgA), 88.0% (IgG)","553 samples"," ","no","","2021-05-27 10:16:53",
"60","Evaluation of Enzyme-Linked Immunoassay and Colloidal Gold- Immunochromatographic Assay Kit for Detection of Novel Coronavirus (SARS-Cov-2) Causing an Outbreak of Pneumonia (COVID-19)","10.1101/2020.02.27.20028787","ImmunoAssay-Antibody"," ","IgM/IgG","ELISA individual-kit, GICA individual-kit","ELISA kit: Zhu Hai Liv Zon Diagnostics; GICA kit: Zhu Hai Liv Zon Diagnostics","Specificity: 100% (ELISA and GICA) ; Sensitivity: 44, 8% (IgM, ELISA), 82.5% (IgG, ELISA, 87.3 % (IgG+IgM, ELISA),  57.1% (IgM, GICA), 81.3% (IgG, GICA), 82.4% (IgG+IgM, GICA)","63 patients (ELISA),  91 patients (GICA)","","no","","2021-05-27 09:43:53",
"284","Evaluation of nCoV-QS (MiCo BioMed) for RT-qPCR detection of SARS-CoV-2 from nasopharyngeal samples using CDC FDA EUA qPCR kit as a gold standard: an example of the need of validation studies","10.1101/2020.05.01.20081034","NucleicAcid-PCR based","PCR_KIT","N1, N2, RdRp (CDC); ORF3a, N (MiCo BioMed)","Multiple kits","nCoV-QS (MiCo BioMed), CDC FDA EUA ","LOD: 20 cp/ul (CDC); PPA: 66.7% ","54 samples & 6 controls","","no","","2021-05-27 09:48:38",
"882","Evaluation of nCoV-QS (MiCo BioMed) for RT-qPCR detection of SARS-CoV-2 from nasopharyngeal samples using CDC FDA EUA qPCR kit as a gold standard: An example of the need of validation studies","10.1016/j.jcv.2020.104454","NucleicAcid-PCR based","RT-PCR","N1 and N2","CoV-QS(MiCoBioMed;SouthCorea)and2019-nCoV CDC EUA kit (IDT, USA)","the performance in terms of positive percent agreement(PPA) of nCoV-QS (MiCoBioMed;SouthCorea) and 2019-nCoV CDC EUA kit (IDT, USA)","Positive percentage agreement (PPA) for nCoV-QS: 66.7 % , MiCBioMedan PPA:70.5 %; Adapted CDC PPA: 62.5%","54 specimens","","yes","","2021-05-27 10:06:52",
"1280","Evaluation of NGS-based approaches for SARS-CoV-2 whole genome characterisation.","10.1093/ve/veaa075","NucleicAcid-Others","NGS","whole genome","4 sequencing protocols","Three used Illumina sequencing: an in-house metagenomic NGS (mNGS) protocol and two newly commercialised kits including a hybridisation capture method developed by Illumina (DNA Prep with Enrichment kit and Respiratory Virus Oligo Panel, RVOP), and an amplicon sequencing method developed by Paragon Genomics (CleanPlex SARS-CoV-2 kit). We also evaluated the widely used amplicon sequencing protocol developed by ARTIC Network and combined with Oxford Nanopore Technologies (ONT) sequencing.","Remark: For low viral loads, amplicon-based enrichment methods were the most sensitive techniques. All methods were highly concordant in terms of identity in complete consensus sequence","8 samples","","yes","","2021-05-27 10:19:03",
"140","Evaluation of nine commercial SARS-CoV-2 immunoassays","10.1101/2020.04.09.20056325","ImmunoAssay-Antibody"," ","IgM/IgG, IgA on S1-domain, RBD-domain of S-protein","Multiple-kits","8 different kits","Sensitivity: 93% (Wantai Total Ab ELISA), 93% ( Euroimmun IgA),  67% (IgG ELISAs), 90% (Dynamiker),  90% (CTK Biotech), 93% (AutoBio Diagnostics), 83% (Artron Laboratories), 80% (Acro Biotech), 100% (Alltest Biotech) ; Specificity:  100% (Wantai Total Ab ELISA), 93% ( Euroimmun IgA), 96% (IgG ELISAs), 100% (Dynamiker),  100% (CTK Biotech),  100% (AutoBio Diagnostics),  100% (Artron Laboratories), 80% (Acro Biotech),  87% (Alltest Biotech)","112 negative","","no","","2021-05-27 09:45:26",
"603","Evaluation of novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples","10.1016/j.ijid.2020.05.098","ImmunoAssay-Antigen"," ","Nucleocapsid protein","kit","RDT rapid antigen detection kit: fluorescence immunochromatographic SARS-CoV-2 antigen test (Bioeasy Biotechnology Co., Shenzhen, China)","Sensitivity: 93.9%; specificity: 100%","127 samples","","yes","","2021-05-27 09:58:05",
"242","Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2","10.1128/JCM.00461-20","ImmunoAssay-Antibody"," ","IgM/IgG on N-protein, S-protein","ELISA multiple-kits","ELISA rN kit; Lizhu, Zhuhai, China; ELISA rS kit: Hotgen, Beijing, China","Sensitivity: 77.1% (rS IgM), 74.3% (rS IgG), 68.2% (rN IgM),  70.1%  (rN IgG), 82.2% (rS IgG/gM), 80.4% ( rN IgG/IgM) ; Specificity: 100% ; Remark:  seven dpo groups= 0–5, 6–10, 11–15, 16–20, 21–30, 31–35, and >35 dpo","214 patients & 100 controls","","yes","","2021-05-27 09:47:50",
"1219","Evaluation of performance of two SARS-CoV-2 Rapid whole-blood finger-stick IgM-IgGCombined Antibody Tests","10.1101/2020.05.27.20112888","mixed","Mixed","antibody kit: IgM-IgG; RT-PCR: E-gene","antibody kit: COVID-PRESTO, COVID-DUO; RT-PCR: WHO2?","study to evaluate the performance of two RDTs compared to the gold standard of RT-PCR. ","sensitivity: 10% (0-5 dpo, COVID-PRESTO), 100% (>15 dpo, COVID-PRESTO), 35.71% (0-5 dpo, COVID DUO), 100% (>15 dpo, COVID-DUO); specificity: 100% (both)","238 patients"," ","no","","2021-05-27 10:16:59",
"592","Evaluation of rapid antigen test for detection of SARS-CoV-2 virus","10.1016/j.jcv.2020.104500","ImmunoAssay-Antigen"," ","not specified","kit","RAD (rapid antigen detection) BIOCREDIT COVID-19 Ag test vs RT-PCR","Remark: RAD was 105 fold less sensitive than RT-PCR. The RAD test detected between 11.1 % and 45.7 % of RT-PCR-positive samples","160 samples","","yes","","2021-05-27 09:57:47",
"664","Evaluation of rapid diagnosis of novel coronavirus disease (COVID-19) using loop-mediated isothermal amplification","10.1016/j.jcv.2020.104446","NucleicAcid-PCR based","LAMP","","kit","Loopamp® 2019-SARSCoV-2 Detection Reagent Kit","sensitivity: 100 %; specificity: 97.6 %; LOD: 10 copies/?L","76 samples","","yes","","2021-05-27 09:59:57",
"62","Evaluation of recombinant nucleocapsid and spike proteins for serological diagnosis of novel coronavirus disease 2019 (COVID-19)","10.1101/2020.03.17.20036954","ImmunoAssay-Antibody"," ","IgM/IgG on S-protein","GICA in-house-method","","Specificity: 99.39% ; Sensitivity: 86.89% (IgM), 99.39% (IgG)","814 patients","","no","","2021-05-27 09:43:55",
"1268","Evaluation of sample pooling for screening of SARS CoV-2.","10.1371/journal.pone.0247767","NucleicAcid-PCR based","RT-PCR","ORF1ab, N","kit (RT-PCR DAAN Gene)","evaluation of pooling approach with Novel Coronavirus 2019-nCov PCR Kit-fluorescent PCR method of DAAN Gene Co., Ltd, China","Remark: recommended sample pooling of 4 or 5 in 1, but NOT pooling of clinical samples when disease prevalence is greater than 7%","pooling strategy using 2 positive and 18 negative samples","","yes","","2021-05-27 10:18:38",
"733","Evaluation of SARS-CoV-2 viral RNA in fecal samples","10.1186/s12985-020-01359-1","NucleicAcid-PCR based","PCR_KIT","E, N, ORF1ab","kit","Novel Coronavirus (2019-nCoV) Real Time Multiplex RT-PCR kit from LifeRiver Ltd.","Remark: fecal samples remained positive for SARS-CoV-2 RNA longer time then respiratory tract samples","15 samples","","yes","","2021-05-27 10:02:13",
"1175","Evaluation of serological tests for SARS-CoV-2: Implications for serology testing in a low-prevalence setting","10.1093/infdis/jiaa467","ImmunoAssay-Antibody","Other Immuno assay","IgA, IgG, IgM","kits: OnSite COVID-19 IgG/IgM Rapid Test; VivaDiag COVID-19 IgM/IgG Rapid Test; Hangzhou AllTest COVID-19 test; Wondfo SARS-CoV-2 Antibody Test; and Hightop SARS-CoV-2 IgM/IgG Antibody Rapid Test; EuROIMMUN Anti-SARS-CoV-2 ELISA; Coronavirus Typing assay (AusDiagnostics)","Five PoCT are compared to EUROIMMUN Anti-SARS-CoV-2 ELISA and to PCR results.","ELISA overall sensitivity for IgA or IgG: 67.9%; specificity: 72.8%. sensitivity for samples collected >14 from symptoms onset: 93.8% . 5 PoCT devices with either an IgM or IgG: overall sensitivity 68.6%; specificity: 100.0%; sensitivity for samples collected >14 from symptoms onset: 93.8%.  (in the text are reported performance of single kits)","91 positive, 92 negative","","yes","","2021-05-27 10:15:31",
"1193","Evaluation of seven commercial SARS-CoV-2 RNA detection kits based on real-time polymerase chain reaction (PCR) in China","10.1515/cclm-2020-0271","NucleicAcid-PCR based","PCR_KIT","N, ORF1ab, E genes","kit A (BGI Biotech Co., Ltd, Wuhan, China), kit B (Outdo Biotech Co., Ltd, Shanghai, China), kit C (Sansure Biotech Inc., Changsha, China), kit D (Perkin Elmer Medical Diagnostic Products, Co., Ltd, Shanghai, China), kit E (Daan Gene Co., Ltd. Of Sun Yat-Sen University, Guangzhou, China), kit F (Jiangsu Bioperfectus Technologies Co., Ltd, Taizhou, China), and kit G (Fosun Long March Medical Science Co., Ltd, Shanghai, China). ","","PPV: 100% (all kits) ; sensitivity: 90.48% (A, F), 92.86% (B), 83.33% (C), 97.62% (D), 78.57% (E), 76.19% (G) ; Specificity: 100% (all) ; NPA: 98.04% (A,F), 98.52% (B), 96.62% (C), 99.50% (D), 95.69% (E), 95.24% (G)","242 specimens","","yes","","2021-05-27 10:16:06",
"829","Evaluation of simple nucleic acid extraction methods for the detection of SARS-CoV-2 in nasopharyngeal and saliva specimens during global shortage of extraction kits","10.1016/j.jcv.2020.104519","NucleicAcid-PCR based","RT-PCR","","","Three different methods for the extraction nucleic acid The first method involves incubating the specimen with proteinase K, and then heat treatment at 98?°C for 5?min (PKH); the second method involves heat treatment at 98?°C for 5?min without proteinase K pre-incubation (heat only); the third method involves no pre-processing steps (direct","PKH had significantly higher positive rate in SARS-CoV-2 RT-PCR (80 %) than those of heat only (58 %; P?=?0.001) or direct (56 %; P?=?0.002). The median Ct value was significantly earlier for PKH (median Ct: 37.0, IQR 31.7–40) than that of heat only (median Ct: 40, IQR 36.2–41; P?<?0.0001) and direct (median Ct, 37.5; IQR 33.9–41.0; P?=?0.0049). ","50 specimens, including 25 nasopharyngeal swab (NPS) and 25 posterior oropharyngeal saliva specimens","","yes","","2021-05-27 10:05:24",
"1189","Evaluation of six commercial mid to high volume antibody and six point of care lateral flow assays for detection of SARS-CoV-2 antibodies","10.1128/JCM.01361-20","ImmunoAssay-Antibody","Other Immuno assay","IgA, IgM, IgG","SARS-CoV-2 IgG assay (Abbott Laboratories, Abbott Park, IL, USA),  SARS-CoV-2 S1/S2 IgG (DiaSorin, Stillwater, MN, USA), COVID-19 IgM and IgG ELISA (Epitope Diagnostics Inc., supplied by Affinity Diagnostics Corp., Toronto, ON, Canada), COVID-19 IgM and IgG assay (DRG International Inc., supplied by Bio-Rad, Hercules, CA, USA), anti-SARS-CoV-2 ELISA IgA and IgG assay (Euroimmun, Mississauga, ON, Canada), ECLIA anti-SARS-CoV-2 (Roche Diagnostics, Indianapolis, IN, USA), Rapid Response (BTNX, Markham, Ontario, Canada), 2019 nCoV IgM/IgG detection kit (Biolidics Limited, Singapore), SARS-CoV-2 IgG/IgM Ab test kit (Anhui Deep Blue Medical Technology Co., Ltd., Anhui, China), Novel Coronavirus IgG/IgM test kit (Genrui; Genrui Biotech Inc., Shenzhen, China), One Step Test for Novel Coronavirus (Getein Biotech Inc., Nanjing, China), and the 2019-nCoV Ab test (Innovita Biological Technology Co. Ltd., Qian'an, Hebei, China)","Comparison of commercial chemiluminescence immunoassays (CLIA), enzyme-linked immunosorbent assays (ELISA), electrochemiluminescence immunoassay (ECLIA), point-of-care lateral flow tests (POCTs)","Sensitivity (all time points): 81% (Abbott), 68-95% (Affinity), 55-88% (Biorad),  62% (Diasorin), 63-83% (Euroimmun), 71% (Roche), 50-75% (BTNX), 18-78% (Biolidics), 53-70% (Deep Blue), 65-80% (Genrui), 3-64% (Getein), 20-45% (Innovita) ; Precision (all EIAs): 100% ; Reproducibility (all EIAs): 100% ; Remarks: sample size varies for different performance studies, percentages range among different target antibodies","96 samples","","yes","","2021-05-27 10:15:57",
"544","EVALUATION OF THE ABBOTT SARS-COV-2 IG-G ASSAY","10.1101/2020.06.28.20132498","ImmunoAssay-Antibody"," ","IgG","kit","Abbott SARS-CoV-2 IgG","Sensitivity: 90.9-100% (>14 days post PCR positive); Specificity: 100% (>14 days post PCR positive). Remark: no cross reactivity","54 patients (sensitivity) & 358 (specificity)","","no","","2021-05-27 09:56:24",
"828","Evaluation of the Aptima™ transcription-mediated amplification assay (Hologic®) for detecting SARS-CoV-2 in clinical specimens","10.1016/j.jcv.2020.104541","NucleicAcid-Others","Other","transcription-mediated amplification (TMA) ORF1ab","AptimaTM SARS-CoV-2 assay (Hologic Panther System)","","The AptimaTM and Panther FusionTM assays aCohen’s coefficient: ? = 0.978 [0.949–1.000], a positive percent agreement: 97.3 % [95.0–99.6 %], a negative percent agreement: 100 % [100?100%],  an overall percent agreement = 99.0 % [97.6–100 %]","200 respiratory specimens","","yes","","2021-05-27 10:05:22",
"1198","Evaluation of the automated cartridge-based ARIES SARS-CoV-2 Assay (RUO) against automated Cepheid Xpert Xpress SARS-CoV-2 PCR as gold standard","10.1556/1886.2020.00017","NucleicAcid-PCR based","PCR_KIT","ORF and N genes","ARIES SARS-CoV-2 Assay (Luminex)","automated cartridge-based PCR approach compared with Cepheid Xpert Xpress SARS-Cov-2 Assay","PPA: 100% ; NPA: 100% ; LoD (range): 10^3 DNA and virus copies/reaction, 10^3-10^4 free RNA copies/reaction","30 samples","","yes","","2021-05-27 10:16:16",
"623","Evaluation of the auxiliary diagnostic value of antibody assays for the detection of novel coronavirus (SARS-CoV-2)","10.1002/jmv.25919","ImmunoAssay-Antibody","Mixed","IgM, IgG; ORF1ab, N","Kits","Colloidal gold antibody test: GICA kits (Beijing Innovita Biological Technology Co Ltd); RT-PCR: SARS?CoV?2 nucleic acid detection kit (Shanghai BioGerm Medical Biotechnology Co Ltd)","Sensitivity: 73.6% (RNA from sputum), 36.8% (RNA from throat swab), 50% (IgM), 92.1% (IgG)","38 patients","","yes","","2021-05-27 09:58:42",
"886","Evaluation of the commercially available LightMix® Modular E-gene kit using clinical and proficiency testing specimens for SARS-CoV-2 detection","10.1016/j.jcv.2020.104476","NucleicAcid-PCR based","RT-PCR","E gene","LightMix Modular SARS and Wuhan CoV E-gene kit","Comparison of the  novel kit against the well-validated in house methods","LOD:  1.8 × 10?1 TCID50/mL; Sensitivity 51,6%; ","289 patients","","yes","","2021-05-27 10:07:00",
"1247","Evaluation of the COVID-19 IgG/IgM Rapid Test from Orient Gene Biotech.","10.1128/JCM.01233-20","ImmunoAssay-Antibody","LFIA","IgM, IgG (Orient OG); IgG (Abbott )","kits (Orient OG, Abbott )","performance characteristics of Orient Gene Biotech COVID-19 IgG/IgM Rapid Test Cassette (OG) and compare it to Abbott SARS-CoV-2 IgG immunoassay","Sensitivity: 95.8% (OG, 10 dpo),  90.5% (Abbott); Specificity: 100% (OG, Abbott)","102 patients","","yes","","2021-05-27 10:17:55",
"870","Evaluation of the COVID19 ID NOW EUA assay","10.1016/j.jcv.2020.104429","NucleicAcid-PCR based","RT-PCR","","ID NOW EUA assay","ID NOW performs well for strong and moderately positive samples but has reduced sensitivity for weakly positive samples"," Agreement: 78.7%, Sensitivity: 71.7%, Specificity: 100%","61 samples","","yes","","2021-05-27 10:06:33",
"1231","Evaluation of the Cue Health point-of-care COVID-19 (SARS-CoV-2 nucleic acid amplification) test at a community drive through collection","10.1016/j.diagmicrobio.2020.115307","NucleicAcid-Others","PCR_KIT","N gene","Cue COVID-19 test (Cue Health Inc., San Diego, CA)","Comparison of POC kit based on isothermal amplification with RT-PCR Hologic Aptima SARS-CoV-2 (Hologic, Marlborough MA) assay (targeting ORF1ab) and in-house developed Taqman RT-PCR (targeting N gene)","Positive percentage agreement: 91.7% ; Negative percentage agreement: 98.4% ; remarks: POC compared to Hologic Aptima test","292 samples","","yes","","2021-05-27 10:17:24",
"1143","Evaluation of the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 IgM and IgG antibodies in human plasma","10.1016/j.cca.2020.05.047","ImmunoAssay-Antibody","ELISA","IgG, IgM","kit (Epitope)","EDI Novel Coronavirus COVID-19 Enzyme Linked Immunosorbent Assays (ELISAs)","positivity rate: 5.9% (IgM, ? 5 dpo), 2.9% (IgG, ? 5 dpo),  31.7% (IgM, 5-10 dpo), 37.1% (IgG, 5-10 dpo),   76.4% (IgM, >10-15 dpo),  82.4% (IgG > 10–15 dpo); True positivity rate: 94.4% (IgM, >15-22 dpo),  100% (IgG > 15–22 dpo); false positivity rate: 0.5% (IgM in healthy blood donors), 1.0% (IgG in healthy blood donors), 1.6% (IgM in ICU patients), 1.2% (IgG in ICU patients)","520 samples","","yes","","2021-05-27 10:14:31",
"1149","Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies.","10.1016/j.jcv.2020.104468","ImmunoAssay-Antibody","ELISA","IgA, IgG vs S1","kit (EUROIMMUN)","EUROIMMUN enzyme-linked immunosorbent assay (ELISA) for semi-quantitative detection of IgA and IgG antibodies in serum and plasma samples using recombinant S1 domain of the SARS-CoV-2 spike protein as antigen.","agreement: 82.9% (IgA), 67.1% (IgG), 90.5% (IgA, ?4 days after positive PCR), 100% (IgG, ?4 days after positive PCR)","86 samples","","yes","","2021-05-27 10:14:41",
"368","Evaluation of the QIAstat-Dx Respiratory SARS-CoV-2 Panel, the first rapid multiplex PCR commercial assay for SARS-CoV-2 detection","10.1128/JCM.00630-20","NucleicAcid-PCR based","PCR_KIT","E, RdRP","Kit and WHO-5","Comparison with WHO recommended RT-PCR (WHO-5) and QIAstat-SARS","LOD: 1000 copies/mL; sensitivity: 100%; specificity: 93%","69 samples","","yes","","2021-05-27 09:50:47",
"1153","Evaluation of the Quotient® MosaiQ™ COVID-19 antibody microarray for the detection of IgG and IgM antibodies to SARS-CoV-2 virus in humans","10.1016/j.jcv.2020.104571","ImmunoAssay-Antibody","Other","Ab vs S","kit (MosaiQ COVID-19 Antibody test)","MosaiQ COVID-19 Antibody Microarray","Specificity: 100%; Sensitivity: 88% (overall), 71% (<14 dpo), 97% (14-20 dpo), 100% (>20 dpo), 98% (>14 dpo in non severe patients), 100% (>14 dpo in severe patients)","669 samples (68 accuracy, 101sensitivity, 500 specificity)","","yes","","2021-05-27 10:14:47",
"825","Evaluation of the RealStar® SARS-CoV-2 RT-PCR kit RUO performances and limit of detection","10.1016/j.jcv.2020.104520","NucleicAcid-PCR based","RT-PCR","E gene","RealStar SARS-CoV-2 assay","","LOD: 625 copies/ml, Sensitivity: 97.8%, Specificity: 97.3% ","83 clinical samples","","yes","","2021-05-27 10:05:16",
"542","EVALUATION OF THE ROCHE ELECSYS ANTI-SARS-COV-2 ASSAY","10.1101/2020.06.28.20142232","ImmunoAssay-Antibody"," ","Not specified","kit","Roche anti-SARS- CoV-2 sandwich immunoassay ","Sensitivity: 97.1% (14 days post PCR positivity), 100% (21 days post PCR positivity)","349 (sensitivity) & 714 (specificity) samples","","no","","2021-05-27 09:56:20",
"1172","Evaluation of Three Commercial Automated Assays for the Detection of anti-SARS-CoV-2 Antibodies","10.1093/clinchem/hvaa193","ImmunoAssay-Antibody","Other Immuno assay","Abbot: nucleocapside protein;Diasorin: spike protein; Roche:nucleocapside protein"," Abbott, Diasorin, and Roche assays for the detection of anti-SARS-CoV-2 antibodies.","Comparison of performance  Abbott, Diasorin, and Roche assays for the detection of anti-SARS-CoV-2 antibodies.","Comparison to PCR: Sensitivity: Abbott 95.31%; Diasorin 90.77%; Roche  95.38%. Specificity: Abbott 99.7%; Diasorin 97.67%; Roche  10.008%.","382 negative, 65 positive","","yes","","2021-05-27 10:15:25",
"1196","Evaluation of three fully-automated SARS-CoV-2 antibody assays","10.1515/cclm-2020-0975","ImmunoAssay-Antibody","Other Immuno assay","IgG and IgM","SARS-CoV-2-ELISA (IgG) (Euroimmun), Elecsys anti-SARS-CoV-2 (Roche), SARS-CoV-2 Total (COV2T) (Siemens Healthineers)","comparison of ELISA, ECLIA and CLIA commercial tests","Specificity: 100% ; sensitivity: 56.5% (0-6 days from+PCR, Siemens, Euroimmun), 65.2% 0-6 days after +PCR Roche), 90.3% (7-13 days after +PCR Siemens, Roche), 89.3% 7-13 days after +PCR Euroimmun), 97% (more than 14 days after +PCR Siemens), 89.4% (more than 14 days after +PCR Roche), 95.5% (more than 14 days after +PCR Euroimmun) ; remarks: using cut-off indeces some sensitivity values improve, but not specificity.","309 samples","","yes","","2021-05-27 10:16:12",
"1142","Evaluation of three immunochromatographic tests for rapid detection of antibodies against SARS-CoV-2","10.1007/s10096-020-04010-7","ImmunoAssay-Antibody","LFIA","IgM, IgG","kits (Sienna, Wondfo, Prometheus)","Wondfo, SARS-CoV-2 Antibody Test (Lateral flow method). (Luogang District, Guangzhou, China); T&D Diagnostics, Sienna, 2019-nCoV IgG/IgM Rapid Test Cassette (Halifax, Nova Scotia, Canada); Prometheus Bio Inc., 2019-nCoV IgG/IgM Test Cassette (Zhejiang, China).","Sensitivity: 64.4% (Sienna), 45.2% (Wondfo), 75.5% (Prometheus), 36.6% (Sienna, 0-7 dpo), 18.8% (Wondfo, 0-7 dpo), 68.6% (Prometheus, 0-7 dpo),  81.3% (Sienna, 8-14 dpo), 74.1%  (Wondfo, 8-14 dpo), 90.9% (Prometheus, 8-14 dpo), 100% (Sienna, >15 dpo), 83.3%  (Wondfo, >15 dpo), 100% (Prometheus, >15 dpo); specificity: 75% (Sienna), 81.8% (Wondfo), 12.5% (Prometheus); PPV: 85.5% (Sienna), 80.5% (Wondfo), 51.4% (Prometheus); NPV: 47.8% (Sienna), 47.4% (Wondfo), 29.4% (Prometheus); accuracy: 67.6% (Sienna), 59% (Wondfo), 47.2% (Prometheus)","145 samples","","yes","","2021-05-27 10:14:29",
"738","Evaluation of transport media and specimen transport conditions for the detection of sars-cov-2 by use of real-time reverse transcription-PCR","10.1128/JCM.00708-20","NucleicAcid-PCR based","PCR_KIT","N1, N3","kits","evalutation of transport media with QDID SARS-CoV-2 RNA qualitative real-time RT-PCR emergency use authorization (EUA) assay and Quest Diagnostics and the Roche Diagnostics cobas SARS-CoV-2 EUA tests","Remark: Specimens consistently yielded amplifiable RNA with mean cycle threshold differences of <3 over the various conditions assayed","specimens in different transport media","","yes","","2021-05-27 10:02:23",
"748","Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies","10.1016/j.jcv.2020.104413","ImmunoAssay-Antibody","Mixed","IgM and IgG","Maglumi2019-n-Cov IgG and IgM and Euroimmun Anti-SARS-CoV-2 IgG and IgA assays, 019-n-CoVIgG/IgMrapidtestcassette(LaboOnTime), 2019-n-CoV) antibody IgG/IgM assay(colloidal gold) (Avioq), QuickZen COVID-19 IgM/IgG Kit (QuickZen) ","assesstheperformanceoffiveimmunoassaysforthedetectionofSARS-CoV-2antibodies.","sensitivity at day 15: ELISA: IgA or IgG 93.93%, IgA 93.93%, IgG 90.9%;CLIA: IgM or IgG 93.75%, IgM 87.5%, IgG 87.5%; Lateral flow test: Avioq 93.93%, QuickZen 90.9%, LabOn Time 93.93%","200 samples","","yes","","2021-05-27 10:02:43",
"545","Evaluation of two commercial and two non-commercial immunoassays for the detection of prior infection to SARS-CoV-2","10.1101/2020.06.24.20139006","ImmunoAssay-Antibody"," ","IgM, IgG, IgA","Kits & in house","two commercial (Roche Diagnostics and Epitope Diagnostics IgM/IgG) and two non-commercial (Simoa and Ragon/MGH IgG) immunoassays","Sensitivity: 100% (Epitope IgG, Ragon, Roche, Simoa >21 dpo), 33.3% (Epitope IgM, >21 dpo), 67%-100% (9-14 dpo), 69%-100% (15-21 dpo); Specificity: 99.1% (Epitope IgG), 98.7% (Epitope IgM), 99.6% (Ragon/MGH IgG and Roche), 99.1% (Simoa)","68 positive & 232 negative samples","","no","","2021-05-27 09:56:26",
"313","Evaluation of WHO listed COVID-19 qPCR primers and probe in silico with 375 SERS-CoV-2 full genome sequences","10.1101/2020.04.22.20075697","NucleicAcid-PCR based","In_silico","all WHO methods","Primers/probes in silico evaluation","3 nucleotides mismatches in Chinese CDC N gene primers on 5 viral genome strains","Not specified","Not specified","","no","","2021-05-27 09:49:37",
"1156","Evaluation on testing of deep throat saliva and lower respiratory tract specimens with Xpert Xpress SARS-CoV-2 assay","10.1016/j.jcv.2020.104593","NucleicAcid-PCR based","PCR_KIT","E, N2","kit (Xpert)","Xpert Xpress SARS-CoV-2 assay results were compared to those by the TIB-Molbiol LightMix SarbecoV E-gene assay.","PPA:  98.86% (Deep Throat Saliva), 100% (Lower Respiratory Tract); NPA: 100% (both)","162 samples","","yes","","2021-05-27 10:14:54",
"63","Evaluation the auxiliary diagnosis value of antibodies assays for detection of novel coronavirus (SARS-Cov-2) causing an outbreak of pneumonia (COVID-19)","10.1101/2020.03.26.20042044","ImmunoAssay-Antibody"," ","IgM/IgG","GICA individual-kit","Kit: Innovita Biological Technolog","Sensitivity: 23.0% (IgM, 0-8 dpo), 53.8% (IgG, 0-8 dpo), 50.0% (IgM, 8-15 dpo), 92.1% (IgG, 8-15 dpo), 52.2% (IgM, 15+ dpo), 91.3% (IgG, 15+ dpo)","38 patients","","no","","2021-05-27 09:43:58",
"999","Evaluation under field conditions of a rapid test for detection of IgM AND IgG antibodies against SARS-CoV-2 ","10.17843/RPMESP.2020.372.5534","ImmunoAssay-Antibody","LFIA","IgM, IgG","COVID -19 IgG/IgM Rapid Test Cassette (wholeblood/serum/Plasma. Zhejang Orient Gene, Biotech Co LTD, China)","","sensitivity: 43.8% ; specificity: 98.9%","144 patients","","yes","","2021-05-27 10:10:01",
"64","Evaluations of serological test in the diagnosis of 2019 novel coronavirus (SARS-CoV-2) infections during the COVID-19 outbreak","10.1101/2020.03.27.20045153","ImmunoAssay-Antibody"," ","IgM/IgG on N-protein","In-house method and individual kit","Kit: Daraui Biotech","Sensitivity: 81.25% (IgM in house), 97.5% (IgG in house)","159 patients","","no","","2021-05-27 09:44:00",
"670","Evaluations of the serological test in the diagnosis of 2019 novel coronavirus (SARS-CoV-2) infections during the COVID-19 outbreak","10.1007/s10096-020-03978-6","ImmunoAssay-Antibody"," ","IgM, IgG vs N","in house","chemiluminescence immunoassay method compared to commercial ELISA kit (Darui Biotech, China)","sensitivity:  60.76% (IgM), 92.25% (IgG); specificity: 82.28% (IgM), 97.5% (IgG)","159 samples","","yes","","2021-05-27 10:00:09",
"444","Evolution and molecular characteristics of SARS-CoV-2 genome","10.1101/2020.04.24.058933","Others","In_silico","/","sequencing","genomic analysis of viral strains","/","/","","no","","2021-05-27 09:53:18",
"434","EXPLAINABLE-BY-DESIGN APPROACH FOR COVID-19 CLASSIFICATION VIA CT-SCAN","10.1101/2020.04.24.20078584","Others","In_silico","/","CT scan","use of AI on CT scan for diagnosis","F1 score: 97.31%","2482","","no","","2021-05-27 09:52:57",
"579","Exploring alternative swabs for use in SARS-CoV-2 detection from the oropharynx and anterior nares","10.1016/j.jviromet.2020.113948","NucleicAcid-PCR based","PCR_KIT","ORF1a, E","kit","Cobas Roche kit","LOD: below 1 copy/mL. Remark: Performance of non-flocked swabs in PBS is similar to that of previously-validated swabs; sensitivity not impacted by transport media.","15 patients","","yes","","2021-05-27 09:57:24",
"933","Extracting Possibly Representative COVID-19 Biomarkers from X-ray Images with Deep Learning Approach and Image Data Related to Pulmonary Diseases","10.1007/s40846-020-00529-4","Imaging-X-ray","Other","x-rays images","in silico","Convolutional Neural Network used to distinguish x-rays betwen different classes","Accuracy: 99.18% ; sensitivity: 97.36% ; specificity: 92.42%","455 x-rays images","","yes","","2021-05-27 10:08:23",
"141","Extraction-free COVID-19 (SARS-CoV-2) diagnosis by RT-PCR to increase capacity for national testing programmes during a pandemic","10.1101/2020.04.06.028316","NucleicAcid-PCR based","Other PCR method(s)","N-gene","In-house method","","Sensitivity: 98% ; Specificity: 100% ; Accuracy: 98.8%","Not specified","","no","","2021-05-27 09:45:28",
"936","Extraction-free SARS-CoV-2 detection by rapid RT-qPCR universal for all primary respiratory materials","10.1016/j.jcv.2020.104579","NucleicAcid-PCR based","RT-PCR","E gene","PrimeDirect™ Probe RT-qPCR Mix (TaKaRa","To establish a rapid RT-qPCR protocol for the detection of SARS-CoV-2 without the need of RNA extraction suitable for all respiratory materials.","Detection rate: 95.8%; ct values: <35","91 specimens","","yes","","2021-05-27 10:08:27",
"298","FACT- Frankfurt adjusted COVID-19 testing- a novel method enables high-throughput SARS-CoV-2 screening without loss of sensitivity","10.1101/2020.04.28.20074187","NucleicAcid-PCR based","PCR_KIT","ORF, E","Kit","FACT protocol (pooling swabs in a single tube) on Cobas Roche","Not specified","150 samples","","no","","2021-05-27 09:49:06",
"294","Failure of the cobas(R) SARS-CoV-2 (Roche) E-gene assay is associated with a C-to-T transition at position 26340 of the SARS-CoV-2 genome","10.1101/2020.04.28.20083337","NucleicAcid-PCR based","PCR_KIT","orf1ab, E","Kit","Cobas Roche kit","Not specified","Not specified","","no","","2021-05-27 09:48:58",
"243","False-negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: Rather than recurrence","10.1002/jmv.25855","Others","In_silico","","","","","","","yes","","2021-05-27 09:47:52",
"191","False-negative results of initial RT-PCR assays for COVID-19: a systematic review","10.1101/2020.04.16.20066787","Others","In_silico","","","","","","","no","","2021-05-27 09:46:44",
"65","False-Negative Results of Real-Time Reverse-Transcriptase Polymerase Chain Reaction for Severe Acute Respiratory Syndrome Coronavirus 2: Role of Deep-Learning-Based CT Diagnosis and Insights from Two Cases","10.3348/kjr.2020.0146","NucleicAcid-PCR based","Mixed","Not specified","Not specified","","Not reported","2 patients","","yes","","2021-05-27 09:44:02",
"142","Fast SARS-CoV-2 detection by RT-qPCR in preheated nasopharyngeal swab samples","10.1101/2020.04.08.20058495","NucleicAcid-PCR based","PCR_KIT","E-gene","Multiple-kits","Kits: Wuhan CoV E-gene, Roche","Sensitivity: 87.8% ; Specificity: 100% ; Accuracy: 99.9%","90 samples","","no","","2021-05-27 09:45:30",
"984","Fast SARS-CoV-2 detection by RT-qPCR in preheated nasopharyngeal swab samples","10.1016/j.ijid.2020.05.099","NucleicAcid-PCR based","RT-PCR","E gene","RT-PCR","performance of three protocols to rapidly detect SARS-CoV-2 bypassing RNA extraction","sensitivity: 87.8% ; specificity: 100% ; accuracy: 99.9% ; remarks: performances of the direct method","90 patients","","yes","","2021-05-27 10:09:32",
"420","Fast SARS-CoV-2 detection protocol based on RNA precipitation and RT-qPCR in nasopharyngeal swab samples","10.1101/2020.04.26.20081307","NucleicAcid-PCR based","Mixed","N1, N2, N3 (kit); S, E, N (qPCR with green dye)","kit & in house","use of two methods (2019-nCoV CDC qPCR Probe Assay , qPCR with intercalating gree dye) to assess an extraction free protocol","Sensitivity: 91%; Specificity: 90%; Remark:sensitivity and specificity of the extraction free protocol","165 samples","","no","","2021-05-27 09:52:30",
"1138","Fecal specimen diagnosis 2019 novel coronavirus-infected pneumonia","10.1002/jmv.25742","NucleicAcid-PCR based","","Not specified","Nucleic acid test (not specified)","","/","14 patients","","yes","","2021-05-27 10:14:21",
"1066","First confirmed detection of SARS-CoV-2 in untreated wastewater in Australia: A proof of concept for the wastewater surveillance of COVID-19 in the community","10.1016/j.scitotenv.2020.138764","NucleicAcid-PCR based","Mixed","N gene","RT-PCR & sequencing","Recently published RT-qPCR assays were used for the detection of SARS-CoV-2 RNA in wastewater samples (Corman et al., 2020; Shirato et al., 2020): Sarbeco & NIID_2019-nCOV_N. Sequencing","LOD: 8.3 copies/reaction (N_Sarbeco assay), not known (NIID_2019-nCOV_N assay). Remark: two (22.2%) samples collected from WWTP B on two separate sampling events were positive for SARS-CoV-2 using the N_Sarbeco assay.","9 wastewater samples","","yes","","2021-05-27 10:11:52",
"385","First Data-Set on SARS-CoV-2 Detection for Istanbul Wastewaters in Turkey","10.1101/2020.05.03.20089417","NucleicAcid-PCR based","PCR_KIT","RdRP","/","diagnostic panel validated by US ","/","9 wastewater samples","","no","","2021-05-27 09:51:18",
"793","First detection of SARS-CoV-2 in untreated wastewaters in Italy","10.1016/j.scitotenv.2020.139652","NucleicAcid-PCR based","Other PCR method(s)","RdRp, S, ORF1ab genes","WHO-5 and in house assays","three assays were tested for detecting virus in wastewaters. WHO-5 and ORF1ab in house nested PCR were more sensitive than the S-targeting PCR","","","","yes","","2021-05-27 10:04:14",
"585","Four point-of-care lateral flow immunoassays for diagnosis of COVID-19 and for assessing dynamics of antibody responses to SARS-CoV-2","10.1016/j.jinf.2020.06.023","ImmunoAssay-Antibody"," ","IgG. IgM vs N or S","Kits (LFIA)","point-of-care (POC) lateral flow immunoassays (LFIA) (ALLTEST 2019-nCoV IgG/IgM Rapid Test, Dynamiker 2019-nCoV IgG/IgM Rapid Test, ASK COVID-19 IgG/IgM Rapid Test, and Wondfo SARS-CoV-2 Antibody Test)","Sensitivity: 100% (overall, >21 dpo), 50% (ALLTEST 1-14 dpo), 97.5% (ALLTEST 15-21 dpo), 41.3% (Dynamiker 1-14 dpo), 87%  (Dynamiker 15-21 dpo), 47.8% (ASK 1-14 dpo), 87%  (ASK 15-21 dpo), 52.2% (Wondfo 1-14 dpo), 91.3%  (Wondfo 15-21 dpo); Specificity: 100% (overall, >21 dpo); 100% (overall, 1-14dpo), 100% (overall, 15-21 dpo) ","16 PCR positive 58 PCR negative patients","","yes","","2021-05-27 09:57:34",
"393","Fully automatic deep convolutional approaches for the analysis of Covid-19 using chest X-ray images","10.1101/2020.05.01.20087254","Others","In_silico","chest x-ray","convolutional network architecture","deep convolutional approach for covid analysis using x-ray ","/","/","","no","","2021-05-27 09:51:34",
"12","Generation of antibodies against COVID-19 virus for development of diagnostic tools","10.1101/2020.02.20.20025999","ImmunoAssay-Antibody"," ","Unclear","ELISA in-house-method","","not reported","None","","no","","2021-05-27 09:42:39",
"789","Genetic diversity among sars-cov2 strains in South America may impact performance of molecular detection","10.3390/pathogens9070580","Others","In_silico","whole genomes","in silico","review all available primer-probe sets targeting the E, N, and RdRp genes against available South American SARS-CoV-2 genomes checking for nucleotide variations in annealing sites","remark: no nucleotide variations on the E-gene target region, in contrast to the N and RdRp genes","300 genomes","","yes","","2021-05-27 10:04:05",
"426","Genetic structure of SARS-CoV-2 in Western Germany reflects clonal superspreading and multiple independent introduction events","10.1101/2020.04.25.20079517","NucleicAcid-Others","NGS","whole genome","whole genome sequencing","Artic protocol on Oxford Nanopore platform and Illumina platform","/","55 isolates","","no","","2021-05-27 09:52:40",
"705","Genetics of Severe Acute Respiratory Syndrome Coronavirus-2 and Diagnosis of Coronavirus Disease-2019: An Overview","10.1177/0972063420935548","Review"," ","review","review on different validated methodologies with indication of interpretation of the results","","","","","yes","","2021-05-27 10:01:19",
"244","Genome Detective Coronavirus Typing Tool for rapid identification and characterization of novel coronavirus genomes","10.1093/bioinformatics/btaa145","Others","In_silico","","","","","","","yes","","2021-05-27 09:47:54",
"770","Genome sequencing and the diagnosis of novel coronavirus (SARS-COV-2) in Africa: how far are we?","10.11604/pamj.2020.36.80.23723","Review","In_silico","","","review","remark: review on diagnostic test and relevance for Africa","/","","yes","","2021-05-27 10:03:28",
"927","Genomic variations of SARS-CoV-2 and molecular diagnosis","10.7652/jdyxb202004001","review","In_silico","","","","","","","yes (paper not in English)","","2021-05-27 10:08:12",
"455","Genomic, geographic and temporal distributions of SARS-CoV-2 mutations","10.1101/2020.04.22.055863","Others","In_silico","whole genomes","/","evaluation of genomic, geographic and temporal mutation distribution","/","1932 genomes","","no","","2021-05-27 09:53:36",
"428","Global health security capacity against COVID-19 outbreak and its association with the case fatality rate: an analysis of annual data from 210 countries and territories","10.1101/2020.04.25.20079186","Others","In_silico","/","/","Global Health Security Index association with fatality rate","/","/","","no","","2021-05-27 09:52:45",
"110","Global profiling of SARS-CoV-2 specific IgG/ IgM responses of convalescents using a proteome microarray","10.1101/2020.03.20.20039495v1","ImmunoAssay-Antibody"," ","IgM/IgG","Proteome microarray in-house-method","","Not reported","50 patiens","","no","","2021-05-27 09:44:51",
"285","Group testing for SARS-CoV-2 allows for up to 10-fold efficiency increase across realistic scenarios and testing strategies","10.1101/2020.04.30.20085290","NucleicAcid-PCR based","PCR_KIT","","Multiple kits","Sample pooling strategy for PCR testing","Not specified","Not specified","","no","","2021-05-27 09:48:40",
"838","Group testing-based robust algorithm for diagnosis of COVID-19","10.3390/diagnostics10060396","Others","In_silico"," ","Group Testing-Based Robust Algorithm","Algorithm is used to find a small set of confirmed cases out of a large population, simulation results only","/","/"," ","yes","","2021-05-27 10:05:38",
"1201","Head-to-Head Accuracy Comparison of Three Commercial COVID-19 IgM/IgG Serology Rapid Tests","10.3390/jcm9082369","ImmunoAssay-Antibody","Mixed","S protein"," Three comercial avaible kits:   i) NTBIO DiagnosticsInc. (Surrey, British Columbia, Canada) (ii) Zhejiang Orient-Gene Biotech Co. Ltd.(Huzhou, China) (iii) MEDsan GmbH, Biological Health Solutions (Hamburg,Germany)","Comparison of Three Commercial COVID-19 IgM/IgG Serology Rapid Tests","i) NTBIO DiagnosticsInc Specificity Whole Blood: 98%;  Specificity plasma: 96%; Sensitivity Whole Blood: 92%; Sensitivity Plasma 92%; Positive Predicted Value (PPV) Whole Blood: 97%; PPV Plasma: 95%; Negative predicted Value (NPV) Whole Blood: 95%; NVP Plasma: 94%; ii)  Zhejiang Orient-Gene Biotech Co. Ltd. Specificity Whole Blood: 100%; Specificity Plasma 98%; Sensitivity Whole Blood: 92%; Sensitivity Plasma: 100%; PPV Whole Blood: 100%; PPV Plasma: 97%; NPV Whole Blood: 95%; NPV Plasma: 100%; iii) EDsan GmbH, Biological Health Solutions, Specificity Whole Blood: 96%, Specificity Plasma: 96%; Sensitivity Whole Blood: 100%, Sensitivity Plasma: 100%; PPV Whole Blood: 95%; PPV plasma: 95%; NPV Whole Blood: 100%; NPV plasma: 100%","91 samples ","","yes","","2021-05-27 10:16:22",
"648","Head-to-head comparison of four antigen-based rapid detection tests for the diagnosis of SARS-CoV-2 in respiratory samples ","10.1101/2020.05.27.119255","ImmunoAssay-Antigen"," ","Not specified","kits","Immunochromatographic SARS-CoV-2 assays from RapiGEN, Liming bio, Savant, and Bioeasy compared to RT-PCR","Ssensitivity: 62.0% (RapiGEN), 84.9% (RapiGEN, samples with high viral load), 16.7% (Liming bio), 85.0% (Bioeasy), 100% (Bioeasy, samples with high viral load); specificity: 100% (all).","111 samples","","no","","2021-05-27 09:59:25",
"1239","Head-to-Head Comparison of Rapid and Automated Antigen Detection Tests for the Diagnosis of SARS-CoV-2 Infection.","10.3390/jcm10020265","ImmunoAssay-Antigen","Other Immuno assay","nucleocapside","Biotical SARS-CoV-2 Ag card (Biotical Health, Madrid, Spain), Panbio™ COVID-19 Ag Rapid Test Device (Abbott, Chicago, IL, USA), Coronavirus Ag Rapid Test Cassette (Healgen Scientific, Houston, TX, USA), Roche SARS-CoV-2 Rapid Antigen Test (Roche Diagnostics, Basel, Switzerland) and VITROS Immunodiagnostic Products SARS-CoV-2 Antigen test (Ortho Clinical Diagnostics, Raritan, NJ, USA)","comparison of 5 antigen tests against LightMix® (Roche Diagnostics®) Modular SARS-CoV E-gene test results","Sensitivity: 66.7% (Biotical), 67.7% (Panbio), 72.9% (Healgen), 69.8% (Roche), 83.3% (Ortho) ; Specificity: 83.1% (Ortho), 91.5% (Roche), 87.7% (Healgen), 91.5% (Panbio, Biotical) ; PPV: 87.3% (Biotical), 96.6% (Panbio), 84.2% (Healgen), 96.7% (Roche), 100% (Ortho) ; NPV: 92.4% (Biotical), 93.7% (Panbio), 96.2% (Healgen), 94.4% (Roche), 100% (Ortho) ; Accuracy: 91.3% (Biotical), 94.3% (Panbio), 93% (Healgen), 94.9% (Roche), 100% (Ortho) ; Remarks: more values are available for sensitivity and specificity at different Ct values and reading times considered. More PPV, NPV and accuracy values are available at different disease prevalence %.","188 samples","","yes","","2021-05-27 10:17:38",
"1177","Head-to-Head Comparison of Two SARS-CoV-2 Serology Assays","10.1093/jalm/jfaa125","ImmunoAssay-Antibody","Other Immuno assay","IgG","DiaSorin Liaison SARS-CoV-2 S1/S2 IgG and Roche Diagnostics Elecsys Anti-SARS-CoV-2 assays","","Roche: sensitivity 64.8% ; specificity 100.0%. Diasorin: sensitivity 57.4%; specificity 98.9% ","228 samples","","yes","","2021-05-27 10:15:35",
"893","Heat inactivation decreases the qualitative real-time RT-PCR detection rates of clinical samples with high cycle threshold values in COVID-19","10.1016/j.diagmicrobio.2020.115109","NucleicAcid-PCR based","PCR_KIT","ORF1, N genes","COVID-19 Qualitative Real Time PCR Kit (Da An Gene, China)","heat inactivation treatment before detection would reduce detection rates of SARS-CoV-2 in weakly positive clinical samples by qualitative real-time RT-PCR","","46 patients","","yes","","2021-05-27 10:07:13",
"792","Heat Inactivation of Different Types of SARS-CoV-2 Samples: What Protocols for Biosafety, Molecular Detection and Serological Diagnostics?","10.3390/v12070735","Mixed","Mixed","N gene (RT-PCR); IgG (ELISA)","kits","effect of 3 heat inactivation protocols on qRT-PCR EXPRESS One-Step Superscript, ThermoFisher Scientific, Waltham, Massachusetts & anti-SARS-CoV-2 ELISA for immunoglobulin class G (EI 2606-9601 G, Euroimmun AG, Lübeck, Germany)","remark: Regardless of the inactivation protocol and the type of samples, a 4 Log10 TCID50 reduction was observed. The protocols 56 °C-30 min and 60 °C-60 min had little influence on the RNA copies detection, whereas 92 °C-15 min drastically reduced the limit of detection. 56 °C-30 min treatment of serum specimens had a negligible influence on the results of IgG detection using a commercial ELISA test","spiked samples","","yes","","2021-05-27 10:04:12",
"114","Heat inactivation of serum interferes with the immunoanalysis of antibodies to SARS-CoV-2","10.1101/2020.03.12.20034231","ImmunoAssay-Antibody"," ","IgM/IgG","Individual-kit","Kit: KingFocus Biomedical engineering","Not reported ","34 samples","","no","","2021-05-27 09:44:58",
"1228","Herd immunity is not a realistic exit strategy during a COVID-19 outbreak","10.21203/rs.3.rs-25862/v1","ImmunoAssay-Antibody","ELISA","total antibody","SARS-CoV-2 total antibody ELISA (Wantai Biological Pharmacy Enterprise Co., China)","prevalence and distribution of antibodies to SARS-CoV-2 in a healthy adult population is established","/","7514 samples"," ","yes","","2021-05-27 10:17:18",
"1089","High resolution computed tomography for the diagnosis of 2019 novel coronavirus (2019-nCoV) pneumonia: a study from multiple medical centers in western China","10.21037/atm-20-5731","Imaging-CT scan","Other","","High Resolution CT scans","HRCT findings and comparison with four RT-PCR tests (targets not available)","Accuracy: 80.56% (HRCT combined with epydemiolgical history), 88.89% (one RT-PCR test), 91.67% (combination of two RT-PCR tests), 97.22% (combination of three RT-PCR tests), 100% (combination of four RT-PCR tests).","72 patients","","yes","","2021-05-27 10:12:40",
"67","High sensitivity detection of coronavirus SARS-CoV-2 using multiplex PCR and a multiplex-PCR-based metagenomic method","10.1101/2020.03.12.988246","NucleicAcid-PCR based","Other PCR method(s)","S-gene, N-gene","Other method","","LOD: 2.8 cpr","Not reported","","no","","2021-05-27 09:44:04",
"1254","High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea Massachusetts.","10.1093/infdis/jiaa579","ImmunoAssay-Antibody","LFIA","IgM, IgG vs RBD","kit (Biomedocmics)","BioMedomics SARS-CoV-2 (IgM/IgG) lateral flow immunoassay (LFA) point-of-care (POC) as a laboratory-developed test ","sensitivity: 80% (IgM), 85% (IgG), and 90% (combined IgM or IgG >14 dpo); Specificity: >99%","57 samples (validation), 374 (pre-covid samples for specificity)","","yes","","2021-05-27 10:18:09",
"964","High-resolution computed tomography finding in 552 patients with symptomatic COVID-19: first report from north of Iran","10.1007/s10140-020-01819-9","Imaging-CT scan","Other","CT scans","CT scans","","CT scan findings distribution available in tables","552 patients","","yes","","2021-05-27 10:08:58",
"143","High-surety isothermal amplification and detection of SARS-CoV-2, including with crude enzymes","10.1101/2020.04.13.039941","NucleicAcid-Others","LAMP","ORF1ab-gene, N-gene, S-gene","Other method","","LOD: 100 cpr","Not reported","","no","","2021-05-27 09:45:32",
"1214","High-throughput immunoassays for SARS-CoV-2 – considerable differences in performance when comparing three methods","10.1101/2020.05.22.20106294","ImmunoAssay-Antibody","Other","IgM and IgG","1) Abbott SARS-CoV-2 IgG on the ARCHITECT i2000 (Abbott, Illinois, USA); 2) Elecsys Anti-SARS-CoV-2 on the Cobas 8000 e801 (Roche Diagnostic Scandinavia AB, 80 Solna, Sweden);  3) LIAISON SARS-CoV-2 S1/S2 IgG on the LIAISON XL (DiaSorin, 81 Saluggia, Italy); 4) the lateral flow test 2019-nCOV IgG/IgM Rapid Test (Dynamiker 82 Biotechnology Co., Tianjin, China)","Performances opf three different comercially available high-throughput antibody assay and one rapid immunochromatographic test ","1) Abbott Sensitivity: 85%; Specificity: 100%; 2) Roche Sensitivity: 100%; Specificity: 98% 3) DiaSorin Sensitivity: 77.8%; Specificity: 96.9%; 4) Dynamiker Sensitivity: 75%; Specificity: 98%","133 patients","","no","","2021-05-27 10:16:49",
"245","High-throughput sequencing for confirmation of suspected 2019-nCoV infection identified by fluorescence quantitative polymerase chain reaction","10.1097/CM9.0000000000000792","NucleicAcid-PCR based","PCR_KIT","ORF1ab-gene, N-gene","Individual-kit","Kit: FQ-PCR kit","Not reported","3 samples (1 patient)","","yes","","2021-05-27 09:47:56",
"591","High-Throughput Transcription-mediated amplification on the Hologic Panther is a highly sensitive method of detection for SARS-CoV-2","10.1016/j.jcv.2020.104501","NucleicAcid-PCR based","PCR_KIT","not specified","kit","Hologic Panther APTIMA transcription-mediated amplification platform","Sensitivity: 98%; Specificity: 100%","116 samples","","yes","","2021-05-27 09:57:45",
"68","Highly accurate and sensitive diagnostic detection of SARS-CoV-2 by digital PCR","10.1101/2020.03.14.20036129","NucleicAcid-PCR based","WHO method(s)","ORF1ab-gene, N-gene","WHO-1, multiple-kits","Kits: Shanghai Huirui Biotechnology, Shanghai BioGerm Medical Biotechnology, and Daan","Specificity: tested ; LOD: 2 cpr (ORF1ab and N)","194 patients","","no","","2021-05-27 09:44:06",
"868","Highly sensitive detection of SARS-CoV-2 RNA by multiplex rRT-PCR for molecular diagnosis of COVID-19 by clinical laboratories","10.1016/j.cca.2020.04.023","NucleicAcid-PCR based","RT-PCR","N gene","in house","Highly sensitive detection of SARS-CoV-2 RNA by multiplex rRT-PCR for molecular diagnosis of COVID-19","LOD: 25 copies/reaction, Detectability: 100% . LOD: 21 copies/reaction, Detectability: 95%","30 sputum","","yes","","2021-05-27 10:06:29",
"702","Homogeneous circle-to-circle amplification for real-time optomagnetic detection of SARS-CoV-2 RdRp coding sequence","10.1016/j.bios.2020.112356","NucleicAcid-PCR based","Other PCR method(s)","","in house "," the proposed method was specific to distinguish SARS-CoV and SARS-CoV-2 sequences with high similarity. ","Remark: Detection limit of 0.4 fM with a dynamic detection range of 3 orders of magnitude and a total assay time of ca. 100 min.","","","yes","","2021-05-27 10:01:13",
"976","Hospital indoor air quality monitoring for the detection of SARS-CoV-2 (COVID-19) virus","10.1016/j.scitotenv.2020.141324","NucleicAcid-PCR based","RT-PCR","N, ORF1ab genes","Sansure Biotech Inc. kit (Changsha, China) ","virus detection in aerosol in indoor hospital air","","","","yes","","2021-05-27 10:09:18",
"1137","Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium","10.1001/jama.2020.11160","ImmunoAssay-Antibody","LFIA","IgM/IgG vs N","LFIA","COVID-19 IgG/IgM Rapid Test Cassette; Multi-G","specificity: 91.3% (IgM), 92.2% (IgG); sensitivity: 57.9% (IgM), 97% (IgG).","191 samples (90 PCR positive cases and 101 biobanked samples)","","yes","","2021-05-27 10:14:19",
"447","How fast does the SARS-Cov-2 virus really mutate in heterogeneous populations?","10.1101/2020.04.23.20076075","Others","PCR_KIT","all","genomic analysis","mutational landscape estimation","/","/","","no","","2021-05-27 09:53:24",
"835","How should diagnostic kits development adapt quickly in COVID 19-like pandemic models? Pros and cons of sensory platforms used in COVID-19 sensing","10.1016/j.talanta.2020.121534","Review","Mixed"," ","review","review of the current developed diagnostic tools, mentions (general) performance for several of categories of methods","/","/"," ","yes","","2021-05-27 10:05:32",
"1003","Human virus detection with graphene-based materials.","10.1016/j.bios.2020.112436","Others","Biosensor","mixed","graphene based biosensor","overview of graphene based biosensors for detecting virusses ","Table 1 lists virus biosensors and their LOD","/"," ","yes","","2021-05-27 10:10:03",
"399","Humoral immune response and prolonged PCR positivity in a cohort of 1343 SARS-CoV 2 patients in the New York City region","10.1101/2020.04.30.20085613","ImmunoAssay-Antibody","Mixed","IgG","Cobas RT-PCR, ELISA","RT-PCR Cobas Roche, ELISA Mount Sinai","Sensitivity: 92% (IgG)","1343","","no","","2021-05-27 09:51:47",
"374","Hybridization chain reactions targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","10.3390/ijms21093216","NucleicAcid-PCR based","LAMP","N1, N2, N3, RNAse P","In house  ","Design of hybridization chain reactions (HCRs)","Not specified","Not specified","","yes","","2021-05-27 09:50:57",
"392","Identification of IgG antibody response to SARS-CoV-2 spike protein and its receptor binding domain does not predict rapid recovery from COVID-19","10.1101/2020.05.01.20087684","ImmunoAssay-Antibody"," ","IgG vs RBD, S","in house ELISA","study on antibodies and association with protection from COVID-19 disease","/","20 patients & 79 controls","","no","","2021-05-27 09:51:32",
"381","Identification of novel mutations in RNA-dependent RNA polymerases of SARS-CoV-2 and their implications","10.1101/2020.05.05.079939","Others","In_silico","/","/","identification of RNA mutations affecting protein structure and function","/","/","","no","","2021-05-27 09:51:10",
"759","Identification of nsp1 gene as the target of SARS-CoV-2 real-time RT-PCR using nanopore whole-genome sequencing","10.1002/jmv.26140","NucleicAcid-PCR based","RT-PCR","nsp1 gene","in house ","","Sensitivity: 93.1% ; Specificity: 100%","101 specimens","","yes","","2021-05-27 10:03:06",
"1134","Imaging features of the initial chest thin-section CT scans from 110 patients after admission with suspected or confirmed diagnosis of COVID-19","10.1186/s12880-020-00464-5","Imaging-CT scan","In_silico","The characteristics, positions, and distribution of intrapulmonary lesions were analyzed. Moreover, interstitial lesions, pleural thickening and effusion, lymph node enlargement, and other CT abnormalities were reviewed."," "," ","/","110 patients"," ","yes","","2021-05-27 10:14:12",
"672","Imaging in corona virus disease 2019 (COVID-19) A Scoping review","10.1016/j.ejro.2020.100237","Imaging-Others"," ","","","Comparison of different tecniques of imaging for detection Covid-19 ","","","","yes","","2021-05-27 10:00:14",
"1064","Imaging manifestations and diagnostic value of chest CT of coronavirus disease 2019 (COVID-19) in the Xiaogan area","10.1016/j.crad.2020.03.004","Imaging-CT scan","Other","CT scan","CT scan","","Remark: : Spiral CT is a sensitive examination method, with a diagnostic sensitivity and accuracy better than that of nucleic acid detection","114 patients","","yes","","2021-05-27 10:11:48",
"1205","Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19","10.1101/2020.03.12.20035048","ImmunoAssay-Antibody","Other","IgG and IgM","Human SARS-CoV-2 IgG and IgM Chemiluminescence Analysis (CLIA) Assays panel (Shenzhen YHLO Biotech Co.,Ltd., Shenzhen, China)","Investigation of disease severity due to robust antibodies production","Severe cases were found in: Neutrophil-to-lymphocytes ratio (NLR) NLR high and IgG high: 72.3%; NLR high and IgG low: 48.5%; NLRlow and IgG high: 33.3%, NLR low and IgG low: 15.6% ","222 patients","","yes","","2021-05-27 10:16:30",
"1059","Immune response to SARS-CoV-2 in health care workers following a COVID-19 outbreak: A prospective longitudinal study","10.1016/j.jcv.2020.104575","ImmunoAssay-Antibody","Other","IgG, IgA vs S (Euroimmun); IgG, IgM, IgA vs N (Roche)","Prospective longitudinal study ","prospective study usign data provided by Ab kits: the Anti-SARS-CoV-2 IgG and IgA ELISA (EUROIMMUN AG, Lübeck, Germany) and the Elecsys Anti-SARS-CoV-2 (Roche Diagnostics, Rotkreuz, Switzerland)","Remark: immune response after a COVID-19 outbreak increases significantly over time but still approximately 22% of COVID-19 patients did not mount a measurable serologic immune response within 60 days after symptoms have occurred. Exposed co-workers did not develop any relevant IgG antibody levels over time.","166 subjects","","yes","","2021-05-27 10:11:38",
"246","Immunoassay of cooked wild rat meat by ELISA with a highly specific antibody targeting rat heat-resistant proteins","10.1080/09540105.2020.1740180","ImmunoAssay-Antibody"," ","Cooked rat meat antigens","ELISA in-house-method, QWM in-house-method","","Specificity: high (both methods) ; Remarks: that's how it is stated in the publication ","Not reported","","yes","","2021-05-27 09:47:58",
"640","Immunological assays for SARS-CoV-2: an analysis of available commercial tests to measure antigen and antibodies","10.1101/2020.04.10.20061150","Review","In_silico","","","Review on serological assays","Remark: review on different serological assays reporting performances; data available in supplementary material","/","","yes","","2021-05-27 09:59:10",
"584","Immunological detection of serum antibodies in pediatric medical workers exposed to varying levels of SARS-CoV-2","10.1016/j.jinf.2020.07.023","ImmunoAssay-Antibody"," ","IgG, IgM","kits","colloidal gold-based detection (Vazyme, Nanjing, China), enzyme-linked immunosorbent assay (ELISA) (Zhu Hai Livzon Diagnostics Ins, Zhu Hai, China), and dual-target immuno-fluorescence assay (DTFA) (NZK-LK-S0002, NZK Biotech Co., Wuhan, China) ","Remark: colloidal gold detection kit used in this research is not sensitive enough to be useful in accurate antibody detection","325 samples","","yes","","2021-05-27 09:57:32",
"822","Impact of heat-inactivation on the detection of SARS-CoV-2 IgM and IgG antibody by ELISA","10.1016/j.cca.2020.06.032","ImmunoAssay-Antibody","ELISA","IgM and IgG","in house ELISA","Unluckily paper in chinese all information extracted from the english abstract","IgM Positive coincidence rate: 100% (55/55), IgM negative coincidence rate: 96% (24/25), IgM total coincidence rate: 98.75% (79/80)  IgG Positive coincidence rate: 98.21% (55/56), IgG negative coincidence rate: 91.67% (22/24), IgG total coincidence rate: 98.75% (79/80) ","80 ","","yes (paper not in English)","","2021-05-27 10:05:09",
"638","Implementation of rapid SARS-CoV-2 antigenic testing in a laboratory without access to molecular methods: Experiences of a general hospital","10.1016/j.jcv.2020.104472","ImmunoAssay-Antigen"," ","Not specified","kit","RAD (rapid antigen detection) COVID-19 Ag Respi-Strip assay","Sensitivity: 30%; Specificity: 100%; PPV: 100%","774 patients","","yes","","2021-05-27 09:59:08",
"1056","Implications of SARS-CoV-2 genetic diversity and mutations on pathogenicity of the COVID-19 and biomedical interventions","10.1016/j.jtumed.2020.06.005","review","In_silico","","review","","Remark: SARS-CoV-2 has undergone significant mutations in various parts of its non-structural proteins (NSPs) especially NSP2 and NSP3, S protein, and RNA-dependent RNA polymerase (RdRp). In particular, the S protein could be a potential target for vaccine development. Additionally, RdRp could be a major target in the development of antivirals for the treatment of COVID-19.","/","","yes","","2021-05-27 10:11:32",
"1273","Improved Molecular Diagnosis of COVID-19 by the Novel Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR","10.1128/JCM.00310-20","NucleicAcid-PCR based","RT-PCR","(RdRp)/helicase (Hel), spike (S), and nucleocapsid (N)","in house","developed novel, highly sensitive and specific real-time RT-PCR assays for COVID-19 and compared their performances with that of the established RdRp-P2 assay using both in vitro and patient specimens","LOD with in vitro viral RNA transcripts: 11.2 RNA copies/reaction; Confidence interval: 95%;?copies/reaction RNA:  7.2 to 52.6 ","273 speciemens ","","yes","","2021-05-27 10:18:48",
"247","Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-polymerase chain reaction assay validated in vitro and with clinical specimens","10.1128/JCM.00310-20","NucleicAcid-PCR based","PCR_KIT","RdRp-region, Hel-region, S-gene, N-gene ","Multiple-kits and in-house-methods","Kits: LightMix Modular SARS, Wuhan CoV E-gene and 3 in-house-methods","LOD: 11.2 cpr (RdRp/Hel),  21.3 cpr (N gene) ; Specificity:  100% (RdRp/Hel)","37 patients","","yes","","2021-05-27 09:48:00",
"193","Improving Coronavirus (COVID-19) Diagnosis using Deep Transfer Learning","10.1101/2020.04.11.20054643","Others","In_silico","","","","","","","no","","2021-05-27 09:46:46",
"302","In silico analysis of RT-qPCR designs recommended by WHO for detection of SARS-CoV-2 and a commercial kit validated following UNE/EN ISO 17025:2005 and two reference laboratories","10.1101/2020.04.27.065383","NucleicAcid-PCR based","PCR_KIT","regions of 63 SARS-131 CoV-2 strains","Kit","Test validation according to guidelines of the UNE/EN ISO/IEC 17025:2005 and ISO/IEC 15189:2012","LOD 10cpr","275 samples","","no","","2021-05-27 09:49:15",
"14","In silico approach to accelerate the development of mass spectrometry-based proteomics methods for detection of viral proteins: Application to COVID-19","10.1101/2020.03.08.980383","Others","In_silico","","","","","","","no","","2021-05-27 09:42:41",
"248","In Silico assessment of the impact of 2019 novel coronavirus (2019-nCoV) genomic variation on published real-time quantitative polymerase chain reaction detection assays","10.1097/CM9.0000000000000817","NucleicAcid-PCR based","Other PCR method(s)","ORF1ab-gene, Hel-region, S-gene, E-gene, N-gene ","Not specified","","Remark: Analysis of 13 RT-qPCR primers sets ","Not reported","","yes","","2021-05-27 09:48:03",
"1264","In silico detection of SARS-CoV-2 specific B-cell epitopes and validation in ELISA for serological diagnosis of COVID-19.","10.1038/s41598-021-83730-y","ImmunoAssay-Others","In_silico"," S, nsp3, N and nsp12","in silico prediction and ELISA ","in silico prediction of epitopes and validation by testing with ELISA","Sensitivity: 92.3% (S-RBD), 87.2% (N-Nterm), 93.8% (mix) ; Specificity: 100% (S-RBD, N-Nterm), 97.2% (mix)","80 patients","","yes","","2021-05-27 10:18:30",
"657","In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19","10.1038/s41379-020-0595-z","Others","Mixed","","","CT-scan, Immunohistochemistry (IHC)","","7 patients","","yes","","2021-05-27 09:59:43",
"698","In vitro diagnostics of coronavirus disease 2019: Technologies and application","10.1016/j.jmii.2020.05.016","Review","Mixed","review","review on different metodologies on the market with performance indicators","","","","","yes","","2021-05-27 10:01:07",
"144","Increasing testing throughput and case detection with a pooled-sample Bayesian approach in the context of COVID-19","10.1101/2020.04.03.024216","Others","In_silico","","","","","","","no","","2021-05-27 09:45:34",
"1260","Independent Side-by-Side Validation and Comparison of 4 Serological Platforms for SARS-CoV-2 Antibody Testing.","10.1093/infdis/jiaa656","ImmunoAssay-Antibody","Mixed","IgG vs S, IgG vs N, IgA vs S (Euroimmun); IgA, IgM vs N (Roche); IgM, IgG vs S, N (Snibe/Medac); IgG vs N (Abbott)","kits (Euroimmun, Snibe/Medac, Roche and Abbott)","Chemiluminescent microparticle assay (Abbott); Chemoluminescence immunoassay platform (Snibe/Medac) ; Electrochemiluminescence immunoassay (Roche); Enzyme-linked immunosorbent assay (Euroimmun)","Sensitivity: 81.5% (Abbott), 95% (Roche), 91.6% (Euroimmun IgG-S), 79.8% (Euroimmun IgA), 86.6% (Euroimmun IgG-N), 56.9% (Snibe/Medac IgG), 25.9% (Snibe/Medac IgM); Specificity: 100% (Abbott), 100% (Roche), 100% (Euroimmun IgG-S), 93.6% (Euroimmun IgA), 97.3% (Euroimmun IgG-N), 100% (Snibe/Medac IgG), 97.2% (Snibe/Medac IgM); PPV: 100% (Abbott), 100% (Roche), 100% (Euroimmun IgG-S), 93.1% (Euroimmun IgA), 97.2% (Euroimmun IgG-N), 100% (Snibe/Medac IgG), 88.2% (Snibe/Medac IgM); NPV: 83.3% (Abbott), 94.8% (Roche), 91.7% (Euroimmun IgG-S), 81.1% (Euroimmun IgA), 87% (Euroimmun IgG-N), 74.2% (Snibe/Medac IgG), 61.9% (Snibe/Medac IgM)","229 samples","","yes","","2021-05-27 10:18:21",
"676","Inf-Net: Automatic COVID-19 Lung Infection Segmentation From CT Images","10.1109/TMI.2020.2996645","Imaging-CT scan","In_silico","","deep learning","Deep learning and Machin learning (AI)","","1600 images ","","yes","","2021-05-27 10:00:22",
"452","Inf-Net: Automatic COVID-19 Lung Infection Segmentation from CT Scans","10.1101/2020.04.22.20074948","Others","In_silico","chest CT","Lung Infection Segmentation Deep Network","COVID-19 Lung Infection Segmentation Deep Network (Inf-Net) is proposed to automatically identify infected regions from chest CT slices","/","/","","no","","2021-05-27 09:53:32",
"1209","Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event","10.1101/2020.05.04.20090076","ImmunoAssay-Antibody","ELISA","IgA and IgG","Anti-SARS-CoV-2 IgA and Anti-SARS-CoV-2 IgG (ELISA) EUROIMMUN","The study was designated to determine the total number of infected and the Infection Fatality Rate (IFR)","Infection Fatality Rate: 0.36%; Specificity: 99.1%; Sensitivity: 90.9%","600 patients","","yes","","2021-05-27 10:16:39",
"719","Influence of different inactivation methods on severe acute respiratory syndrome coronavirus 2 RNA copy number","10.1128/JCM.00958-20","NucleicAcid-PCR based","dPCR","ORF1ab, N","dPCR","effect of inactivation on SARS-CoV-2 nucleic acid detection kit (digital PCR method) (TargetingOne, Beijing, China) and a TD-1 Droplet Digital PCR system (TargetingOne; licensed in China under registration numbers 20170025, 20190065, and 20192220517)","Remark: inactivation reduced the quantity of detectable viral RNA and may cause false-negative results, especially in weakly positive cases","63 samples","","yes","","2021-05-27 10:01:44",
"761","Influence of Storage Conditions on SARS-CoV-2 Nucleic Acid Detection in Throat Swabs","10.1093/infdis/jiaa272","NucleicAcid-PCR based","PCR_KIT","ORF1ab, N","kit","2019 Novel Coronavirus (2019-nCoV) Detection Kit (Sansure Biotech). Effect of sample inactivation, storage temperature, and storage time ","Remark: storage conditions led to misclassification of at least 10.2% of positive cases. importance of immediate testing of samples","88 samples","","yes","","2021-05-27 10:03:10",
"424","Informative Ranking of Stand Out Collections of Symptoms: A New Data-Driven Approach to Identify the Strong Warning Signs of COVID 19","10.1101/2020.04.25.20079905","Others","In_silico","/","/","use of a Conditional Predictive Informativity ranking to predict diagnosis","/","/","","no","","2021-05-27 09:52:38",
"1119","Inhale, then exhale: start afresh to diagnose Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by non-invasive face-mask sampling technique","10.1016/j.cmi.2020.06.034","Others","Other","mixed","sampling strategy","letter to the editor, proposed to obtain samples from masks worn by patients rather than using swabs","/","/"," ","no","","2021-05-27 10:13:42",
"678","Initial success in the identification and management of the coronavirus disease 2019 (Covid-19) indicates human-to-human transmission in wuhan, china","10.7150/ijbs.45018","Others","Mixed","","","Review: good summary of all the tecniques and methods for detecting COvid-19","","","","yes","","2021-05-27 10:00:26",
"703","Intelligent Diagnosis System Based on COVID-19 CT Images ","10.13203/j.whugis20200225","Imaging-CT scan","In_silico","Lung","","Paper in chinese however information extract from abstract in english","accuracy: 89.65%","491 CT scan","","yes","","2021-05-27 10:01:15",
"744","International external quality assessment for SARS-CoV-2 molecular detection and survey on clinical laboratory preparedness during the COVID-19 pandemic, April/May 2020","10.2807/1560-7917.ES.2020.25.27.2001223","NucleicAcid-PCR based"," ","E, N, ORF1ab, RdRp genes","kits","proficiency test","correctly reported qualitative results: 98.3% (E gene), 93.3% ( N gene), 96.3% (ORF1ab gene), 95.6% (RdRP gene), 93.9% (S gene)","","","yes","","2021-05-27 10:02:35",
"745","Interpret with caution: An evaluation of the commercial AusDiagnostics versus in-house developed assays for the detection of SARS-CoV-2 virus","10.1016/j.jcv.2020.104374","NucleicAcid-PCR based","qPCR","E, RdRp, N, ORF1b, ORF1ab and M gene","in-house RT-PCR ( WHO)","Use the in-house assays as the “gold standard” to test the sensitivity, specificity, positive and negative predictive values of the AusDiagnostics assay","sensitivity: 100 %; specificity: 92.16 %; PPV:55.56%; NPV: 110% ","52 specimens, respiratory tract","","yes","","2021-05-27 10:02:37",
"442","Introductions and early spread of SARS-CoV-2 in France","10.1101/2020.04.24.059576","Others","In_silico","/","sequencing ","genomic analysis of viral strains from France","/","/","","no","","2021-05-27 09:53:13",
"547","Investigation of Compatibility of SARS-CoV-2 RT-PCR Kits Containing Different Gene Targets During COVID-19 Pandemic","10.1101/2020.06.17.20133967","NucleicAcid-PCR based"," ","RdRp-region, E-gene","kit","Bio-Speddy (RdRp gene) and Diagnovital (RdRp+E genes)","/","96 patients","","no","","2021-05-27 09:56:31",
"1161","Kinetics and performance of the Abbott Architect SARS-CoV-2 IgG antibody assay","10.1016/j.jinf.2020.07.031","ImmunoAssay-Antibody","Other Immuno assay","IgG","kit (Abbott)","Abbott Architect SARS-CoV-2 IgG assay","Sensitivity: 44.4% (hospitalised PCR positive cases, <5 dpo), 12.5% (hospitalised PCR negative cases, < 5dpo), 32.6% (hospitalised PCR positive cases, 5-9 dpo), 28.6% (hospitalised PCR negative cases, 5-9 dpo), 65.2% (hospitalised PCR positive cases, 10-14 dpo), 80% (hospitalised PCR negative cases, 10-14 dpo), 66.7% (hospitalised PCR positive cases, 15-20 dpo), 50% (hospitalised PCR negative cases, 15-20 dpo), 100% (hospitalised PCR positive cases, >20 dpo), 83.3% (hospitalised PCR negative cases, >20dpo), 85.1% (healthcare workers, >20dpo)","241 subjects","","yes","","2021-05-27 10:15:04",
"1262","Kinetics of Nucleo- and Spike Protein-Specific Immunoglobulin G and of Virus-Neutralizing Antibodies after SARS-CoV-2 Infection.","10.3390/microorganisms8101572","ImmunoAssay-Antibody","Mixed","IgG vs N protein (Abbott, Epitope, Mikrogen, Roche) , S protein (Virion-Serion),  S1 domain alone (Euroimmun) or together with the S2 domain (DiaSorin); S1, S2, N (Virachip)","kits","7 SARS-CoV-2 IgG assays (Abbott SARS-CoV-2 IgG, Wiesbaden, Germany; DiaSorin Liaison SARS-CoV-2 S1/2 IgG, DiaSorin, Dietzenbach, Germany; Epitope EDI Novel Coronavirus COVID-19 IgG ELISA Kit, Epitope Diagnostics, San Diego, CA, USA; Euroimmun Anti-SARS-CoV-2 ELISA (IgG), EUROIMMUN AG, Lübeck, Germany; Mikrogen recomWell SARS-CoV-2 IgG, Mikrogen GmbH, Neuried, Germany; SARS-CoV-2 ViraChip IgG Test, Viramed Biotech AG, Planegg, Germany; and SERION ELISA agile SARS-COV-2 IgG, Institute Virion-Serion GmbH, Würzburg, Germany), as well as 1 total SARS-CoV-2 antibody test (Roche Elecsys Anti-SARS-CoV-2, Roche Diagnostics, Mannheim, Germany)","Sensitivity vs PCR: 96.2% (Abbott), 84.6% (Diasorin), 80.8% (Epitope), 80.8% (Euroimmun), 88.5% (Mikrogen), 88.5% (Roche), 88.5% (Viramed), 96.2% (Virion-Serion); Sensitivity vs PRNT: 96.3% (Abbott), 88.9% (Diasorin), 92.6% (Epitope), 88.9% (Euroimmun), 96.3% (Mikrogen), 96.3% (Roche), 96.3% (Viramed), 96.3% (Virion-Serion); Specifiicty: 99% (Abbott), 96% (Diasorin), 100% (Epitope), 97% (Euroimmun), 98% (Mikrogen), 99% (Roche), 99% (Viramed), 100% (Virion-Serion)","37 samples","","yes","","2021-05-27 10:18:26",
"372","Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients","10.1080/22221751.2020.1762515","ImmunoAssay-Antibody"," ","IgM, IgG on N and S","ELISA","Evaluation of kinetic of IgG and IgM with ELISA test","Seropositive rate: 58.3% (N-IgG and N-IgM, <7dpo), 66.7% (S-IgG and S-IgM, <7dpo), 75% (N+S IgG and IgM, <7dpo), 73.7% (N-IgM, <14dpo), 68.4% (S-IgM, <14dpo), 84.2% (N-IgG, <14dpo), 78.9% (S-IgG, <14dpo), 84.2% (N-IgM+S-IgM, <14dpo), 94.7% (N-IgM?+?N-IgG, N-IgG?+?S-IgG, <14dpo), 73.7% (N-IgM, S-IgM, <21 dpo), 100% (N-IgG, S-IgG, <21dpo)","38 patients & 16 controls","","yes","","2021-05-27 09:50:53",
"486","Label-Free Electrochemical Detection of DNA Hybridization: A Method for COVID-19 Diagnosis","10.1007/s41403-020-00103-z","NucleicAcid-Others"," ","Viral RNA-c-DNA","label-free electrochemical transduction ","immobilization of the single-stranded probe nucleotide on to the biosensor ","/","/","","yes","","2021-05-27 09:54:38",
"15","Laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections","10.1101/2020.02.11.20021493","NucleicAcid-PCR based","PCR_KIT","Not specified","Individual-kit","Kit: GeneoDX Co. Ltd., Shanghai, China (CFDA approved)","Sensitivity: 74.4%-88.9% (Sputum),  53.6%-73.3% (Nasal swabs)","213 patients","","no","","2021-05-27 09:42:43",
"608","Laboratory diagnosis of coronavirus disease-2019 (COVID-19)","10.1016/j.cca.2020.06.045","Others","Mixed","","","Review on diagnostic tests","Remark: review on different methods reporting performances for serological tests","/","","yes","","2021-05-27 09:58:15",
"948","Laboratory diagnosis of emerging human coronavirus infections - the state of the art.","10.1080/22221751.2020.1745095","review","Mixed","mixed","multiple","paper gives an overview of diagnostic devices cleared for laboratory use on the Chinese market","table 3 lists  Diagnostic devices with target, performance","/"," ","yes","","2021-05-27 10:08:47",
"836","Laboratory diagnosis of SARS-CoV-2 - A review of current methods","10.1016/j.jiph.2020.06.005","Review","Mixed"," ","review","updated information about selection of specimens and availability of various diagnostic methods and their utility","/","/"," ","yes","","2021-05-27 10:05:34",
"778","Laboratory management for SARS-CoV-2 detection: a user-friendly combination of the heat treatment approach and rt-Real-time PCR testing","10.1080/22221751.2020.1775500","NucleicAcid-PCR based","PCR_KIT & other","N1, N2, RP (in house); N, E (kit)","in house & kit","in-house rt-Real-time PCR through the LC480 II instrument (Roche) using reagents and protocol from CDC (Division of Viral Diseases, Centers for Disease Control and Prevention-USA) and 2019-nCoV TaqMan RT-PCR Kit (Norgen Biotek Corp., Canada)","Sensitivity: 100%(in house, heat-treated samples), 100% (commercial kit, with extraction), 86.7% (commercial kit, heat protocol); specificity: 100% (in house, heat-treated samples), 100% (commercial kit, with extraction), 100% (commercial kit, heat protocol)","90 samples","","yes","","2021-05-27 10:03:43",
"852","Laboratory markers included in the Corona Score can identify false negative results on COVID-19 RT-PCR in the emergency room","10.11613/BM.2020.030402","Mixed","In_silico"," "," ","Algorithm combines chest images-relative score and several laboratory parameters to classify emergency room patients"," sensitivity of the Corona-score appears to exceed the sensitivity of the initial COVID-19 RT-PCR","240 patients"," ","yes","","2021-05-27 10:06:01",
"872","Laboratory Testing Methods for Novel Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)","10.3389/fcell.2020.00468","review","Other","","different methods are reviewed","review describes the available testing methods for SARS-CoV-2","remark: LOD and specificity reported for different methods","","","yes","","2021-05-27 10:06:38",
"884","Laboratory verification of an RT-PCR assay for SARS-CoV-2","10.1002/jcla.23507","NucleicAcid-PCR based","RT-PCR","RdRP, N, E","Novel Coronavirus Real?Time RT?PCR Kit (Liferiver)","Evaluation of the new Real-TIME RT_PCR kit","LOD: 1000 copies/ml; SPecificity: 100%; Accuracy: 86.7-100%","30 patients","","yes","","2021-05-27 10:06:56",
"988","Lack of sensitivity of an IVD/CE-labelled kit targeting the S gene for detection of SARS-CoV-2","10.1016/j.cmi.2020.06.036","NucleicAcid-PCR based","PCR_KIT","S gene","VIASURE SARS-CoV-2 S gene RT-PCR test and cobas 6800 SARS-CoV-2 RT-PCR assay","","","101 patients","","yes","","2021-05-27 10:09:39",
"1121","LAMP Assay: Could it be a Boon for the Molecular Diagnosis of COVID-19?","10.1007/s12291-020-00915-4","Others","LAMP","N/A","N/A","letter to the editor, highlighting the advantages of LAMP","/","/"," ","no","","2021-05-27 10:13:46",
"194","LAMP-Seq: Population-Scale COVID-19 Diagnostics Using a Compressed Barcode Space","10.1101/2020.04.06.025635","NucleicAcid-Others","LAMP","Provided in supplementary material","Other method","","Not reported","Not reported","","no","","2021-05-27 09:46:48",
"747","Large-scale implementation of pooled RNA extraction and RT-PCR for SARS-CoV-2 detection","10.1016/j.cmi.2020.06.009","NucleicAcid-PCR based","RT-PCR","","pooling strategies that increase testing throughput while maintaining high sensitivity","","sensitivity: 100%; remark: efficency higher 4.5 times than single sample assay","2168 samples  and 26 576 samples","","yes","","2021-05-27 10:02:41",
"400","Large-scale, in-house production of viral transport media to support SARS-CoV-2 PCR testing in a multi-hospital healthcare network during the COVID-19 pandemic","10.1128/JCM.00913-20","Others"," ","/","/","evaluation of peformance of VTM produced in-house in support of diagnostic testing","/","/","","yes","","2021-05-27 09:51:49",
"491","Letter of concern re: Comparison of seven commercial RT-PCR Diagnostic kits for COVID-19","10.1016/j.jcv.2020.104536","NucleicAcid-PCR based","PCR_KIT","Not specified","COVID-19 genesis Real-Time PCR","Evaluation conducted by Foundation for Innovative New Diagnostics at University of Geneva","Sensitivity: 100%; Specificity: 100%; LOD: 1-10 copies per reaction","50 positive & 100 negative samples","","yes","","2021-05-27 09:54:48",
"966","LIPS method for the detection of SARS-CoV-2 antibodies to spike and nucleocapsid proteins","10.1002/eji.202048715","ImmunoAssay-Antibody","Other Immuno assay","antibodies to N and S proteins","luciferase IP system (LIPS) assay","development of LIPS assay using S1, S2 and N antigens compared to ELISA test","sensitivity: 100% (all antigens)","26 patients","","yes","","2021-05-27 10:09:02",
"1227","Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents","10.1101/2020.08.05.20169128","ImmunoAssay-Antibody","Mixed","IgG, total antibody","Abbott SARS-CoV-2 IgG, DiaSorin SARS-CoV-2 IgG,  Roche Anti-SARS-CoV total antibody, Siemens SARS-CoV-2 total antibody"," longitudinal analysis of a COVID19 case cohort . ","sensitivity: 95-100% (Abbott, Roche, Siemens, all 21-40 dpo), 85% (Diasorin 21-40 dpo, Abbott  61-80 dpo), 71% (Abbott >81 dpo)","97 patients"," ","no","","2021-05-27 10:17:16",
"1230","Longitudinal Change of SARS-Cov2 Antibodies in Patients with COVID-19","10.1093/infdis/jiaa229","Others","In_silico"," "," ","retrospective study of medical records","/","112 patients"," ","yes","","2021-05-27 10:17:22",
"1061","Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients","10.1016/j.cell.2020.06.044","ImmunoAssay-Antibody","ELISA","IgG","ELISA","","Remark: SARS-CoV-2-neutralizing antibodies are readily generated from a diverse pool of precursors, fostering hope for rapid induction of a protective immune response upon vaccination.","4313 S-protein-reactive memory B cells from 12 patients","","yes","","2021-05-27 10:11:42",
"1176","Longitudinal Monitoring of SARS-CoV-2 IgM and IgG Seropositivity to Detect COVID-19","10.1093/jalm/jfaa079","ImmunoAssay-Antibody","Other Immuno assay","IgM and IgG  ","Diazyme SARS-CoV-2 IgM/IgG serology assays","kinetics of IgM and IgG seroconversion ","Sensitivity for the ? 7?d from symptoms:  IgM: 58.3%; IgG : 69.4%;  IgM/IgG: 69.4%;between 8–14?d: IgM: 87.0%; IgG: 95.7%; IgM/IgG: 95.7%;  ? 15?d:IgM: 89.5%; IgG: 94.7%; IgM/IgG: 100%.","54 positive +235 others","","yes","","2021-05-27 10:15:33",
"1067","Loop mediated isothermal amplification (LAMP) assays as a rapid diagnostic for COVID-19","10.1016/j.mehy.2020.109786","review","LAMP","not specified","LAMP","Penn-RAMP strategy employed by El-Tholoth et al","Remark:  success rate of 100% at 7–10 copies of viral RNA per reaction. the authors ocnsider that this strategy should be applied rapidly, and confirmed for viability with clinical samples, before being rolled out for mass-diagnostic testing","/","","yes","","2021-05-27 10:11:54",
"467","Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan","10.1016/j.jmii.2020.03.032","NucleicAcid-PCR based"," ","E/RdRp1/RdRp2/N genes","/","comparison of Oropharyngeal swabs and sputum samples and LPV/r treatment","/","5 cases","","yes","","2021-05-27 09:54:01",
"594","Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis","10.1016/j.jcv.2020.104455","ImmunoAssay-Antigen"," ","nucleoprotein antigen","kit ","RAD (rapid antigen detection) Coris COVID-19 Ag Respi-Strip ","specificity: 100%; sensitivity: 30.2%","148 samples","","yes","","2021-05-27 09:57:51",
"842","Lower cost alternatives for molecular diagnosis of COVID-19: conventional RT-PCR and SYBR Green-based RT-qPCR","10.1007/s42770-020-00347-5","NucleicAcid-PCR based","PCR_KIT","(E-Sarbeco F1 and R2","QuantiFast SYBR Green RT-PCR kit (QIAGEN, Hilden, Germany), Pyromark OneStep RT-PCRkit (QIAGEN, Hilden,Germany) ","standardize lower cost molecular methods for SARS-CoV-2 identification. E gene primers previously determined for TaqMan assays by Colman et al. (2020) were adapted in SYBR Green assay and RT-PCR conventional"," SYBR Green Sensitivity: 95%, specificity: 100%;Conventional PCR Sensitivity: 92%, specificity: 100%","63 samples","","yes","","2021-05-27 10:05:42",
"902","Lower nasopharyngeal viral load during the latest phase of COVID-19 pandemic in a Northern Italy University Hospital","10.1515/cclm-2020-0815","NucleicAcid-PCR based","PCR_KIT","ORF-1a/b, E-gene","Cobas SARS-CoV-2 Test (Roche)","comparison of average viral load between patients in May and April","Cq values: 31.85 (ORF 1a/b, May), 28.37  (ORF 1a/b, April), 33.76 (E gene, May), 29.79 (E gene, April)","200 patients"," ","yes","","2021-05-27 10:07:29",
"441","Lung injury in patients with or suspected COVID-19 : a comparison between lung ultrasound and chest CT-scanner severity assessments, an observational study","10.1101/2020.04.24.20069633","Others"," ","/","chest CT scans and Lung Ultrasound","comparison between CT scans and LU","/","/","","no","","2021-05-27 09:53:11",
"1099","Lung ultrasound as diagnostic tool for SARS-CoV-2 infection","10.1007/s11739-020-02512-y","Imaging-Others","Other","Lung Ultrasound","lung ultrasound","Lung Ultrasound (LUS) is a useful tool for the early detection of SARS-CoV-2 infection and for the evaluation of the disease severity","Sensibility: 73%; Sensitivity: 89%","53 patients","","yes","","2021-05-27 10:13:00",
"801","Lung ultrasound for early diagnosis and severity assessment of pneumonia in patients with coronavirus disease 2019","10.3904/KJIM.2020.180","Imaging-Others","Other","","","manual evaluation of lung ultrasound for early detection of pneumonia and for assessment of respiratory failure","/","6 patients","","yes","","2021-05-27 10:04:30",
"1133","Lung ultrasound in the frontline diagnosis of COVID-19 infection","10.1016/j.medcli.2020.06.001","mixed","Mixed"," ","RT-PCR performed at early onset of symptoms with lung ultrasonography, then RT-PCR performed after one week"," ","Remark: lung ultrasonography (LUS) helps the treating clinician to raise suspicion of the disease in the current pandemic context.","1 patient"," ","yes","","2021-05-27 10:14:10",
"1098","Lung ultrasound is a reliable diagnostic technique to predict abnormal CT chest scan and to detect oxygen requirements in COVID-19 pneumonia","10.18632/aging.104150","Imaging-Others","Other","Lung Ultrasound","lung ultrasound","Lung ultrasonography diagnostic performance","Sensitivity: 89% (prediction of CT scan abnormalities), 95% (detection of oxygen requirements) ; specificity: 100% (prediction of CT scan abnormalities), 67% (detection of oxygen requirements)","50 patients","","yes","","2021-05-27 10:12:58",
"1096","Machine learning for coronavirus covid-19 detection from chest x-rays","10.1016/j.procs.2020.09.258","Imaging-X-ray","Other","Chest Xray","in-house supervised machine learning techniques","Machine learning for coronavirus covid-19 detectionfrom chest x-rays","Avarage precision recall: 0.965","85 chest images","","yes","","2021-05-27 10:12:54",
"1258","Magnetic Bead-Based Immunoassay Allows Rapid Inexpensive and Quantitative Detection of Human SARS-CoV-2 Antibodies.","10.1021/acssensors.0c02544","ImmunoAssay-Antibody","ELISA",""," indirect chromogenic ELISA: Recombinant 6xHis-tagged SARS-CoV-2 Nucleocapsid protein was mobilized on the surface of Ni2+ magnetic beads","chromogenic magnetic bead-based immunoassay which allows quantitative detection of human antibodies against SARS-CoV-2 in serum, plasma, or blood","sensitivity: 97%, specificity: 100%","165 samples (46 positive)","","yes","","2021-05-27 10:18:17",
"195","Mass Spectrometric Identification of SARS-CoV-2 Proteins from Gargle Solution Samples of COVID-19 Patients","10.1101/2020.04.18.047878","ImmunoAssay-Antigen"," ","N-protein","","","None tested","3 samples","Mass spectrometry","no","","2021-05-27 09:46:50",
"196","Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-qPCR","10.1101/2020.04.17.20067348","NucleicAcid-PCR based","Other PCR method(s)","RdRp-region, N-gene","Not specified","","Accuracy: 94% ; Sensitivity: 91% ; Specificity: 97%","85 patients","","no","","2021-05-27 09:46:53",
"1136","Meta-analysis of the clinical performance of commercial SARS-CoV-2 nucleic acid, antigen and antibody tests up to 22 August 2020","10.1101/2020.09.16.20195917","review","Mixed","mixed targets","mixed","Meta-analysis of the clinical performance of commercial SARS-CoV-2 nucleic acid, antigen and antibody tests","/","/","","no","","2021-05-27 10:14:17",
"816","Metagenomic Analysis Reveals Clinical SARS-CoV-2 Infection and Bacterial or Viral Superinfection and Colonization","10.1093/clinchem/hvaa106","NucleicAcid-Others","NGS"," ","metagenomic sequencing","using metagenomics allows for the detection of superinfection in patients","/","8 patients"," ","yes","","2021-05-27 10:04:57",
"1077","Method comparison of SARS-CoV-2 serology assays involving three commercially available platforms and a novel in-house developed enzyme-linked immunosorbent assay","10.1016/j.clinbiochem.2020.08.004","ImmunoAssay-Others","Other Immuno assay","N protein, Spike, RDB","UMN (Spike RBD, Total Ab); Siemens (Spike RBD, Total Ab); Roche (Nucleocapsid, Total Ab); Abbott (Nucleocapsid, IgG)","Comparison of four available kits","1) UMN (Spike RBD, Total Ab) Positive Antibody Results/ Confirmed Positive PCR: 25/28; Negative Antibody Results/ Prepandemic or Negative PCR: 28/28; Sensitivity (95% CI): 89.3%; Specificity (95% CI): 100% ; 2) Siemens (Spike RBD, Total Ab) Positive Antibody results/ Confirmmed Positive PCR: 24/28; Negative Antibody Results/ Prepandemic or Negative PCR: 28/28; Sensitivity(95% CI): 85.7%; Specificity(95% CI): 100%; 3) Roche (Nucleocapsid, Total Ab) Positive Antibody Results/ Confirmed Positive PCR: 25/28; Negative Antibody Results/ Prepandemic or Negative PCR: 28/28; Sensitivity (95% CI): 89.3%; Specificity (95% CI): 100%; 4) Abbott (Nucleocapsid, IgG) Positive Antibody Results/ Confirmed Positive PCR: 24/28; Negative Antibody Results/ Prepandemic or Negative PCR: 28/28; Sensitivity (95% CI): 85.7%; Specificity (95% CI): 100% ","28 patients","","yes","","2021-05-27 10:12:15",
"446","Metropolitan Wastewater Analysis for COVID-19 Epidemiological Surveillance","10.1101/2020.04.23.20076679","NucleicAcid-PCR based","PCR_KIT","N gene (CDC)","CDC RT-PCR kit","analysis of waste waters","/","/","","no","","2021-05-27 09:53:22",
"573","Microfluidic Immunoassays for Sensitive and Simultaneous Detection of IgG/IgM/Antigen of SARS-CoV-2 within 15 min.","10.1021/acs.analchem.0c01635","ImmunoAssay-Antibody","Mixed","IgG, IgM, Antigen","in house","portable microfluidic immunoassay system ","Remark: The assay demonstrated high sensitivity and specificity ","26 patients & 28 controls","","yes","","2021-05-27 09:57:12",
"435","Modeling serological testing to inform relaxation of social distancing for COVID-19 control","10.1101/2020.04.24.20078576","Others","In_silico","/","/","use of transmission model to examine how serology can be implemented for distancing rules","/","/","","no","","2021-05-27 09:52:59",
"436","Modelling the impact of control measures against the COVID-19 pandemic in Viet Nam","10.1101/2020.04.24.20078030","Others","In_silico","/","/","use of modelling methods to estimate impacts of mitigation measures on the COVID-19 pandemic","/","/","","no","","2021-05-27 09:53:01",
"784","Molecular analysis of several in-house rRT-PCR protocols for SARS-CoV-2 detection in the context of genetic variability of the virus in Colombia","10.1016/j.meegid.2020.104390","NucleicAcid-PCR based","PCR_KIT & other","whole genome; E, RdRP","NGS and RT-PCR","NGS (Illumina & Nanopore) and PCR (Thermo Fisher Scientific, Waltham, MA, USA), following the Charité-Berlin protocol (Corman et al, 2020)","remark: Colombian SARS-CoV-2 sequences displayed genetic variability in some target regions used for COVID-19 diagnosis. Mismatches in critical primer regions could impact their performance and the rate of false-negative results","30 cases","","yes","","2021-05-27 10:03:55",
"600","Molecular and Immunological Diagnostic Tests of COVID-19: Current Status and Challenges","10.1016/j.isci.2020.101406","Others","Mixed","","","Review on diagnostic tests","Remark: review on different methods reporting performances","/","","yes","","2021-05-27 09:57:59",
"334","Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes","10.1080/22221751.2020.172907","Others","Mixed","S gene, IgG, IgM","qPCR and in house ELISA","Oral and anal swabs and blood samples","Not specified","178 patients","","yes","","2021-05-27 09:50:14",
"103","Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes","10.1080/22221751.2020.1729071","ImmunoAssay-Antibody"," ","IgM/IgG on N-protein","In-house method","","Remark: Dilution assay","39 patients","","yes","","2021-05-27 09:44:47",
"650","Molecular and Serological Tests for COVID-19. A Comparative Review of SARS-CoV-2 Coronavirus Laboratory and Point-of-Care Diagnostics","10.3390/diagnostics10060434","Review"," ","","","Review on diagnostic tests","Remark: review on different methods reporting performances","/","","yes","","2021-05-27 09:59:29",
"375","Molecular detection of SARS-CoV-2 in formalin fixed paraffin embedded specimens","10.1172/jci.insight.139042","ImmunoAssay-Antigen","Mixed","S, N protein","immunofluorescence assay (IFA), RNAscope in situ hybridization (ISH), multiplex FISH","Detection of SARS-CoV-2 in FFPE tissues","Not reported ","Not reported","","yes","","2021-05-27 09:50:59",
"197","Molecular Detection of SARS-CoV-2 in Formalin Fixed Paraffin Embedded Specimens","10.1101/2020.04.21.042911","ImmunoAssay-Antigen"," ","Mouse ab, Rabbit abS","","","None tested","Not reported","Not reported","no","","2021-05-27 09:46:55",
"1022","Molecular Detection of SARS-CoV-2 Infection in FFPE Samples and Histopathologic Findings in Fatal SARS-CoV-2 Cases","10.1093/ajcp/aqaa091","NucleicAcid-PCR based","WHO method(s)","N genes","WHO-1","","","","","yes","","2021-05-27 10:10:24",
"293","Molecular detection of SARS-CoV-2 using a reagent-free approach","10.1101/2020.04.28.20083626","NucleicAcid-PCR based","PCR_KIT","N","Multiple kits","1 kit ABI, 2 kits Meridian Bioscience, 1 in house, 1 Quantabio, 1 Promega","LOD: 364 cpm (ddPCR, ABI); Sensitivity: 73% (heat treated-no extraction), 95.2% (removing samples inhibited)","68 samples","","no","","2021-05-27 09:48:56",
"72","Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia","10.1093/clinchem/hvaa029","NucleicAcid-PCR based","WHO method(s)","ORF1b-gene, N-gene","WHO-3","","Specificity: tested ; LOD: 10 cpr ; PCR Efficiency: tested","No clinical samples","","yes","","2021-05-27 09:44:08",
"929","Molecular diagnosis of COVID-19 in different biologic matrix, their diagnostic validity and clinical relevance: A systematic review","10.1016/j.lfs.2020.118207","review","Other","","different methods reviewed","systematic review to evaluate the effectiveness of the molecular detection techniques in COVID-19. 6 literature databases (PubMed, EMBASE, OVID, Web of Science, Scopus and Google Scholar)","sensitivity and specificity reported for different methods","/","","yes","","2021-05-27 10:08:16",
"330","Molecular immune pathogenesis and diagnosis of COVID-19","10.1016/j.jpha.2020.03.001","Others"," ","Not specified","Not specified","Review on pathogenesis and diagnostics","Not specified","Not specified","","yes","","2021-05-27 09:50:10",
"737","Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence","10.1515/cclm-2020-0722","Review","Mixed","","review","","Remark: review on different methods reporting performance","/","","yes","","2021-05-27 10:02:21",
"495","Monitoring antibody response following SARS-CoV-2 infection: Diagnostic efficiency of four automated immunoassays","10.1016/j.diagmicrobio.2020.115140","ImmunoAssay-Antibody"," ","IgM, IgG, IgA","CLIA, ELISA, ELFA","kits: Elecsys (Roche), Liaison S1/S2 IgG (Diasorin), IgG and IgA (Euroimmun), VIDAS IgG and IgM","Sensitivity: 81.1% (Elecsys), 70.3% (Liaison), 86.5% (Euroimmun IgA+IgG), 78.4% (VIDAS IgG+IgM); Specificity: 100% (Elecsys), 100% (VIDAS); PPV: 100% (Elecsys), 100% (VIDAS)","111 patients & 96 controls","","yes","","2021-05-27 09:54:57",
"811","Multi-center evaluation of cepheid xpert® xpress SARS-CoV-2 point-of-care test during the SARS-CoV-2 pandemic","10.1016/j.jcv.2020.104426","NucleicAcid-PCR based","qPCR","E-gene and N2 gene","Xpert Xpress SARS-CoV-2","","LOD: 8.26 copies/ml","86 patients","","yes","","2021-05-27 10:04:49",
"1107","Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation","10.1016/j.eclinm.2020.100651","ImmunoAssay-Antibody","Other Immuno assay","","ARCHITECT SARS-CoV-2 N IgG Immunoassay (Abbot, Illinois, U.S.A), LIAISON SARS-CoV-2 S1/S2 IgG (Diasorin, Saluggia,Italy), Elecsys N Anti-SARS-CoV-2 (Roche, Mannheim, Germany), VIDAS SARS-COV-2 RBD IgG (BioMérieux, Marcy-l'Etoile, France), Siemens SARS-CoV-2 RBD Total (COV2T) (Siemens, NY, USA), Access SARS-CoV-2 RBD IgG assay (Beckman-Coulter, CA, U.S.A.) and in house RBD ELISA test","","Specificity: 99.5% (Abbott), 98.7% (Diasorin), 98.9% (VIDAS IgG), 100% (Roche and Beckman), 97.7% (ELISA), 98.8% (siemens) ; Sensitivity: 84.7% (Abbott), 82.4% (Diasorin), 89.3% (VIDAS IgG), 89% (Roche), 89.4% (ELISA), 81.5% (Beckman), 85.9% (Siemens)","3089 samples","","yes","","2021-05-27 10:13:17",
"1181","Multi-platform Comparison of SARS-CoV-2 Serology Assays for the Detection of COVID-19","10.1093/jalm/jfaa139","ImmunoAssay-Antibody","Other Immuno assay","IgM and IgG","Diazyme, Roche, and Abbott SARS-CoV-2 serology assays","comparison of  the performance of the Diazyme, Roche, and Abbott SARS-CoV-2 serology assays","sensitivity ?7-day: Diazyme IgM: 58.1%; Diazyme IgG: 67.4%; Diazyme IgM/IgG panel: 69.8%; Roche total Ig: 67.4%; Abbott IgG: 67.4%. 8–14-day: Diazyme IgM: 93.5%; Diazyme IgG: 96.8%; Diazyme IgM/IgG panel: 96.8%; Roche total Ig: 100.0%; Abbott IgG: 100.0%. ?15-day: Diazyme IgM: 92.0%; Diazyme IgG:  96.0%;  Roche total Ig: 96%;  Diazyme IgM/IgG panel: 100%; Abbott IgG assay: 100%.","66 positive, 179 negative","","yes","","2021-05-27 10:15:43",
"1217","Multi-site Validation of a SARS-CoV-2 IgG/IgM Rapid Antibody Detection Kit","10.1101/2020.05.25.20112227","ImmunoAssay-Antibody","LFIA","IgG, IgM","in house LFIA"," ","specificity: 97.9–100% (IgM), 99.7–100% (IgG); sensitivity: 45.6%–77.4% (1-14 dpo), 94.1–100% (>14 dpo)","1,892 patients"," ","no","","2021-05-27 10:16:55",
"1154","Multicenter comparison of the Cobas 6800 system with the RealStar RT-PCR kit for the detection of SARS-CoV-2","10.1016/j.jcv.2020.104573","NucleicAcid-PCR based","PCR_KIT","ORF1ab , E (Cobas); E, S (Altona)","kits (Roche and Altona)","comparison of the Cobas (Roche) and the RealStar assay (Altona).","overall agreement: 76%; Concordance: 99% (when CT values for E gene for Cobas is <35)","170 samples","","yes","","2021-05-27 10:14:49",
"1188","Multicenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 Assay for the Detection of SARS-CoV-2 in Oropharyngeal Swab Specimens","10.1128/JCM.01288-20","NucleicAcid-PCR based","PCR_KIT","E gene, N2 genes","Cepheid Xpert Xpress SARS-CoV-2 assay (Cepheid, Sunnyvale, CA)","Comparison of performances of Cepheis test and other commercially available real-time reverse transcription-PCR (RT-PCR) assays approved by the National Medical Products Administration (NMPA)","PPA: 96.1% ; NPA: 96.2% ; Kappa coefficient: 0.92","285 samples","","yes","","2021-05-27 10:15:55",
"373","Multicenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 Test","10.1128/JCM.00926-20","NucleicAcid-PCR based","PCR_KIT","E, N2, RdRP","Kit","Multicenter Evaluation of the Cepheid Xpert Xpress","LOD: 0.01 plaque forming units (PFU)/mL; Positive agreement: 99.5%; negative agreement: 95.8%","85 samples","","yes","","2021-05-27 09:50:55",
"774","Multicenter evaluation of the NeuMoDx SARS-CoV-2 Test","10.1016/j.jcv.2020.104583","NucleicAcid-PCR based","PCR_KIT","N1, N2, S, E","kit","NeuMoDx SARS-CoV-2 assay","PPA: 99%; NPA: 91.5 %; LOD: 1267 copies/ mL (N1), 1392 copies/ mL (N2)","212 specimens","","yes","","2021-05-27 10:03:37",
"1267","Multicenter evaluation of the Panbio COVID-19 rapid antigen-detection test for the diagnosis of SARS-CoV-2 infection.","10.1016/j.cmi.2021.02.001","ImmunoAssay-Antigen","Other","not specified","kit","Panbio COVID-19 Ag Rapid Test Device (PanbioRT) (Abbott)","sensitivity: 90.5% (overall), 99.5% (in patients with PCR Ct<25), 91.8% (< 5 dpo); specificity: 98.8%; agreement with PCR: 95.7%; NPV: 94.6%; PPV: 97.8%","958 patients","","yes","","2021-05-27 10:18:36",
"688","Multicentre comparison of quantitative PCR-based assays to detect SARS-CoV-2, Germany, March 2020","10.2807/1560-7917.ES.2020.25.24.2001057","NucleicAcid-PCR based","RT_PCR","","","Comparison 11 different RT-PCR test systems used in seven diagnostic laboratories in Germany","","","","yes","","2021-05-27 10:00:46",
"989","Multiple assays in a real-time RT-PCR SARS-CoV-2 panel can mitigate the risk of loss of sensitivity by new genomic variants during the COVID-19 outbreak","10.1016/j.ijid.2020.06.027","NucleicAcid-PCR based","In_silico","N, E, RdRp, genes","WHO-5, WHO-3, WHO-7, WHO-1, QIAstat-Dx Respiratory SARS-CoV-2 Panel","evaluation of five SARS-CoV-2 PCR assay panels against the accumulated genetic variability of the virus to assess the effect on sensitivity of the individual assays","","more than 33000 sequences","","yes","","2021-05-27 10:09:41",
"998","Multiple-centre clinical evaluation of an ultrafast single-tube assay for SARS-CoV-2 RNA","10.1016/j.cmi.2020.05.007","NucleicAcid-Others","Other","ORF1ab","reverse transcription recombinase–aided amplification (RT-RAA) assay","","sensitivity: 97.63% ; specificity: 97.87% ; PPV: 96.21% ; NPV: 98.68%","947 patients","","yes","","2021-05-27 10:09:59",
"912","Multiplex detection and dynamics of IgG antibodies to SARS-CoV2 and the highly pathogenic human coronaviruses SARS-CoV and MERS-CoV","10.1016/j.jcv.2020.104521","ImmunoAssay-Antibody","Other","IgG","","Multiplex detection and dynamics of IgG antibodies to SARS-CoV2 and the highly pathogenic human coronaviruses SARS-CoV and MERS-CoV","Accuracy Spike antigen: 100%; Accuracy Nucleocapsid: 99%; Accuracy S and Nc: 100%; Sensitivity S antigen: 100%; Sensitivity Nc antigen: 100%; Sensitivity S and NC antigens: 100%; Specificity S antigen: 100%, Specificity Nc antigen: 98,7%; SpecificityS and Nc antigens: 100%","167 sera","","yes","","2021-05-27 10:07:45",
"550","Multiplex Isothermal Amplification Coupled with Nanopore Sequencing for Rapid Detection and Mutation Surveillance of SARS-CoV-2","10.1101/2020.06.12.20129247","NucleicAcid-Others","NGS","N, S, ORF1ab, ORF8","in house","NIRVANA (Nanopore sequencing of Isothermal Rapid Viral Amplification for Near real-time Analysis)","LOD: 10 copies ","/","","no","","2021-05-27 09:56:37",
"723","Multiplex reverse transcription loop-mediated isothermal amplification combined with nanoparticle-based lateral flow biosensor for the diagnosis of COVID-19","10.1016/j.bios.2020.112437","NucleicAcid-PCR based","LAMP","ORF1ab, N ","in house","multiplex reverse transcription loop-mediated isothermal amplification (mRT-LAMP) coupled with a nanoparticle-based lateral flow biosensor (LFB) assay (mRT-LAMP-LFB) for diagnosing COVID-19.","LOD: 12 cpr; Sensitivity: 100%; Specificity: 100%","129 samples","","yes","","2021-05-27 10:01:52",
"847","Multiplexing primer/probe sets for detection of SARS-CoV-2 by qRT-PCR","10.1016/j.jcv.2020.104499","NucleicAcid-PCR based","qPCR","N1 and N2","in house","Multiplexing primer/probe sets for detection of SARS-CoV-2 by qRT-PCR","Positive identification: 98.4%, Negative identification : 100% (170/170)","356 patients","","yes","","2021-05-27 10:05:52",
"1040","Nanopore target sequencing for accurate and comprehensive detection of SARS-CoV-2 and other respiratory viruses","10.1101/2020.03.04.20029538","NucleicAcid-Others","NGS","12 targets on viral genomes","Nanopore Targeted Sequencing","NTS of 12 amplicons compared to RT?qPCR kit (Huirui, China) and 2019?nCoV RT?qPCR kit (BioGerm, China)","LoD: 10 copies/reaction (after 1h sequencing)","45 samples","","yes","","2021-05-27 10:10:59",
"724","Nanopore Targeted Sequencing for the Accurate and Comprehensive Detection of SARS-CoV-2 and Other Respiratory Viruses","10.1002/smll.202002169","NucleicAcid-Others","NGS","ORF1ab","sequencing","nanopore targeted sequencing (NTS) ","LOD: 10 standard plasmid cpr; Specificity: 100%","61 samples","","yes","","2021-05-27 10:01:54",
"1102","Nanozyme chemiluminescence paper test for rapid and sensitive detection of SARS-CoV-2 antigen","10.1016/j.bios.2020.112817","ImmunoAssay-Antigen","Other Immuno assay","S-spike protein","nanozyme chemiluminescence paper test","Co–Fe@hemin-peroxidase nanozyme which combines traditional CLIA with lateral flow assay","LOD: 360 TCID50/ml","","","yes","","2021-05-27 10:13:06",
"1020","Nasopharyngeal Swabs Are More Sensitive Than Oropharyngeal Swabs for COVID-19 Diagnosis and Monitoring the SARS-CoV-2 Load","10.3389/fmed.2020.00334","NucleicAcid-PCR based","WHO method(s)","N, ORF1ab","WHO-1","Detection of SARS-CoV-2 by oropharyngeal swabs (OPS) and nasopharyngeal swabs (NPS) by WHO-1 method","sensitivity: 98.3% (NPS), 21.1% (OPS)","120 patients","","yes","","2021-05-27 10:10:22",
"763","No evidence of SARS-CoV-2 RNA among blood donors: A multicenter study in Hubei, China","10.1111/trf.15943","NucleicAcid-PCR based","RT-PCR","N and ORF1ab genes","China CDC RT-qPCR","CDC China NAT method tested on plasma","LOD: 62.94 copies/ml (N gene, pooled samples), 33.14 copies/ml (ORF1ab gene, pooled samples), 3.87 copies/ml (N gene, individual samples), 4.85 copies/ml (ORF1ab gene, individual samples) ; remarks: plasma samples","","","yes","","2021-05-27 10:03:14",
"198","No test is better than a bad test: Impact of diagnostic uncertainty in mass testing on the spread of Covid-19","10.1101/2020.04.16.20067884","Others","In_silico","","","","","","","no","","2021-05-27 09:46:57",
"199","Noisy Pooled PCR for Virus Testing","10.1101/2020.04.06.026765","Others","In_silico","","","","","","","no","","2021-05-27 09:46:59",
"905","Non-Invasive Technique-Based Novel Corona(COVID-19) Virus Detection Using CNN","10.1007/s40009-020-01009-8","Imaging-CT scan","In_silico"," ","CT scan evaluation by Deep Convolution Neural Network (D-CNN)"," ","accuracy: 95.09%; specificiy: 81.89%; sensitivity: 100%","Kaggles CT dataset"," ","yes","","2021-05-27 10:07:33",
"200","Non-specific Primers Reveal False-negative Risk in Detection of COVID-19 Infections","10.1101/2020.04.07.20056804","NucleicAcid-PCR based","WHO method(s)","Unclear","WHO-1","","Remark: Review on non-specific results of WHO1 ","Not reported","","no","","2021-05-27 09:47:01",
"660","Novel coronavirus disease (Covid-19) in children","10.3906/SAG-2004-174","Review"," ","","","Review: collecting information of pediatric reports ","","","","yes","","2021-05-27 09:59:49",
"923","Novel One-Step Single-Tube Nested Quantitative Real-Time PCR Assay for Highly Sensitive Detection of SARS-CoV-2","10.1021/acs.analchem.0c01884","NucleicAcid-PCR based","RT-PCR","ORF1ab and N genes","in house method","one-step single-tube nested quantitative real-time PCR (OSN-qRT-PCR) assay for the highly sensitive detection of SARS-CoV-2 ","sensitivity: 100%; specificity: 100% compared to standard method RT PCR","181 patients","","yes","","2021-05-27 10:08:04",
"1275","Novel rapid identification of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by real-time RT-PCR using BD Max Open System in","10.7717/peerj.9318","NucleicAcid-PCR based","RT-PCR","E and RdRp genes ","in-house method using the Max Open system","Novel rapid identification by real-time RT-PCR using BD Max Open System in Taiwan","In-house method detect 28 samples positve out of 272 in 100% accordance with th BD MAX System. Spearman coefficients of In-house method: 0.96; Spearman coefficients BD Max System: 0.91","400 specimens","","yes","","2021-05-27 10:18:52",
"201","One-pot Detection of COVID-19 with Real-time Reverse-transcription Loop-mediated Isothermal Amplification (RT-LAMP) Assay and Visual RT-LAMP Assay","10.1101/2020.04.21.052530","NucleicAcid-Others","LAMP","N-gene","Other method","","LOD: 6 cpu; Remark: method development","Not reported","","no","","2021-05-27 09:47:03",
"1038","One-step RNA extraction for RT-qPCR detection of 2019-nCoV","10.1101/2020.04.02.022384","NucleicAcid-PCR based","PCR_KIT","N gene","CDC 2019-nCoV Real-Time Diagnostic assay","direct lysis of respiratory samples in place of RNA extraction kits","Sensitivity:  100 copies of input (direct lysis)","not specified","","no","","2021-05-27 10:10:54",
"203","Optimal Allocation of COVID-19 Test Kits Among Accredited Testing Centers in the Philippines","10.1101/2020.04.14.20065201","Others","In_silico","","","","","","","no","","2021-05-27 09:47:05",
"900","Optimization of a fluorescent qPCR detection for RNA of SARS-CoV-2 ","10.13345/j.cjb.200088","NucleicAcid-PCR based","qPCR","N gene; ORF1a gene","in house qPCR"," ","LOD: 1/10000; Cq value: lower than 35 or 40; results consistent with kits"," "," ","yes (paper not in English)","","2021-05-27 10:07:25",
"887","Optimization of primer sets and detection protocols for SARS-CoV-2 of coronavirus disease 2019 (COVID-19) using PCR and real-time PCR","10.1038/s12276-020-0452-7","NucleicAcid-PCR based","Other PCR method(s)","","Conventional, RT and multiplex PCR detection protocols","guidelines for designing and optimizing primer sets for the development of detection protocols for SARS-CoV-2 utilizing both traditional and real-time PCR; extension to multiplex PCR as well as multiplex real-time PCR to provide multiple options for the selection of detection protocols suitable for various experimental environments","","","","yes","","2021-05-27 10:07:02",
"146","Optimization of SARS-CoV-2 detection by RT-QPCR without RNA extraction","10.1101/2020.04.06.028902","NucleicAcid-PCR based","PCR_KIT","E-gene, S-gene, N-gene, RdRp-region","Multiple-kits","Kits: Altona Diagnostics, SeeGene","Remark: Efficiency of the two kits is similar","88 samples","","no","","2021-05-27 09:45:36",
"204","Optimize Clinical Laboratory Diagnosis of COVID-19 from Suspect Cases by Likelihood Ratio of SARS-CoV-2 IgM and IgG antibody","10.1101/2020.04.07.20053660","ImmunoAssay-Antibody"," ","IgM/IgG","Not specified","","Sensitivity: 86.26%( IgG), 90.18% (IgM), 99.15%(IgG+IgM)","284 samples","","no","","2021-05-27 09:47:07",
"322","Optimized qRT-PCR approach for the detection of intra- and extracellular SARS-CoV-2 RNAs","10.1101/2020.04.20.052258","NucleicAcid-PCR based","Other PCR method(s)","M gene","in house RT-PCR","","","viral strains isolated from 7 patients","","no","","2021-05-27 09:49:56",
"728","Optimized qRT-PCR approach for the detection of intra-and extra-cellular SARS-CoV-2 RNAs","10.3390/ijms21124396","NucleicAcid-PCR based","Other PCR method(s)","M gene, RdRP","in house","alternative RT-PCR using a low-cost SYBR green method","remark:M-gene-based qRT-PCR detection of SARS-CoV-2 RNA was at least as specific asthe RdRP PCR (WHO), but showed higher sensitivity","cell cultures","","yes","","2021-05-27 10:02:02",
"1042","Optimizing diagnostic strategy for novel coronavirus pneumonia, a multi-center study in Eastern China","10.1101/2020.02.13.20022673","mixed","Mixed","","CT scans, RT-PCR, multiplex PCR, rapid antigen test, mNGS","the study suggests that a combination of RT-PCR and CT-scan should be used for virus detection","","53 patients","","no","","2021-05-27 10:11:03",
"147","Optimizing RT-PCR detection of SARS-CoV-2 for developing countries using pool testing","10.1101/2020.04.15.20067199","NucleicAcid-PCR based","PCR_KIT","ORF1ab-gene","Individual-kit","Kit: TaqMan 2019-nCoV Assay Kit v1 for the Orf1ab gene (Thermofisher)","Remark: focus on sample pooling strategies for developing countries","31 sample pools","","no","","2021-05-27 09:45:38",
"1238","Overcoming Supply Shortage for SARS-CoV-2 Detection by RT-qPCR.","10.3390/genes12010090","NucleicAcid-PCR based","RT-PCR","N1","RT-qPCR","compare results with saliva instead of nasopharingeal swabs, lower primer/probe concentration and thermocycling time, 0.45% saline instead of guanidine hydrochloride transport media","LOD: 7.3 cp/reaction (regular RT-qPCR), 23.7 cp/reaction (primer/probe lower concentration),44 cp/reaction (lower thermocycling time) ; remarks: saliva is not an appropriate substitute for nasopharyngeal swabs, saline and guanidine hydrochloride have similar diagnostic capabilities and detection is possible after 10 days storage in both media (for these Ct values are compared)","10 Patients","","yes","","2021-05-27 10:17:36",
"766","Overcoming the bottleneck to widespread testing: A rapid review of nucleic acid testing approaches for COVID-19 detection","10.1261/rna.076232.120","Review","","","","review on nucleic acid testing","Remark: review of nucleic acid testing","/","","yes","","2021-05-27 10:03:20",
"874","Overview of COVID-19 testing and implications for otolaryngologists","10.1002/hed.26213","review","mixed","","","A good review of different testing methods PCR, CT scan and sierological assay ","","","","yes","","2021-05-27 10:06:40",
"489","P-FAB: A Fiber-Optic Biosensor Device for Rapid Detection of COVID-19","10.1007/s41403-020-00122-w","ImmunoAssay-Antigen"," ","N protein","label-free or labelled bioassays","plasmonic fiber-optic absorbance biosensor (P-FAB) ","remark: LOD of technique: 10 ^-18 M","/","","yes","","2021-05-27 09:54:44",
"653","Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms","10.1016/j.jcv.2020.104659","ImmunoAssay-Antigen"," ","","kit","Panbio™ COVID-19 AG Rapid Test Device","sensitivity: 73.3% (overall), 86.5% (<7 dpo), 53.8% (>7 dpo); Specificity: 100%","255 samples","","yes","","2021-05-27 09:59:35",
"892","Past, present, and future of COVID-19: A review","10.1590/1414-431x202010475","review","PCR_KIT & other","","kits","review reporting performances of PCR-based kits","","","","yes","","2021-05-27 10:07:10",
"704","Pathogenesis and transmission of SARS-CoV-2 in golden hamsters","10.1038/s41586-020-2342-5","Mixed","Mixed","N protein and gene","kits","research on hamster","","3 hamsters","","yes","","2021-05-27 10:01:17",
"205","Patient-collected tongue, nasal, and mid-turbinate swabs for SARS-CoV-2 yield equivalent sensitivity to health care worker collected nasopharyngeal swabs","10.1101/2020.04.01.20050005","Others","In_silico","","","","","","","no","","2021-05-27 09:47:09",
"303","Performance & Quality Evaluation of Marketed COVID-19 RNA Detection Kits","10.1101/2020.04.25.20080002","NucleicAcid-PCR based","PCR_KIT","ORF1a/b","Kits","","LoD Sansure Biotech Co., Ltd and BGI can achieve 1 cpr, Bio-Germ, LiveRiver and Maccura  10 Cpr, and the rest were not reactive at or below 10 cpr","7 samples","","no","","2021-05-27 09:49:17",
"1190","Performance characteristics of a high throughput automated transcription mediated amplification test for SARS-CoV-2 detection","10.1128/JCM.01669-20","NucleicAcid-PCR based","RT-PCR","ORF1ab gene","in house","in house developed and validated a high-throughput, fully automated nucleic acid amplification test (NAAT) for direct amplification and detection of SARS-CoV-2 RNA from specimens of infected individuals comparated with other NAAT (EUA Panther Fusion SARS-CoV-2 reverse transcription-PCR (RT-PCR) assay (Hologic, Inc.))","LoD: 25 copies/ml ; PPA: 100% ; NPA: 98.7% ; overall agreement: 99.3%","140 patients","","yes","","2021-05-27 10:15:59",
"1084","Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison","10.1016/S1473-3099(20)30634-4","ImmunoAssay-Antibody","Other Immuno assay","IgG","1)SARS-CoV-2 IgG assay (Abbott, Chicago, IL, USA), 2) LIAISON SARS-CoV-2 S1/S2 IgG assay (DiaSorin, Saluggia, Italy), 3) Elecsys Anti-SARS-CoV-2 assay (Roche, Basel, Switzerland), 4) SARS-CoV-2 Total assay (Siemens, Munich, Germany), and 5)novel 384-well ELISA (the Oxford immunoassay)","comparison of 5 commercially available kits","1) Abbott Sensitivity: 92.7%; Specificity: 99.9%; 2)DiaSorin Sensitivity: 96.2%; Specificity: 98.9%; 3)Oxford Sensitivity: 99.1%; Specificity: 99%; 4) Roche Sensitivity: 97.2%; Specificity: 99.8%; 5) Siemens Sensitivity: 98.1%; Specificity: 99.9%","1502 blood","","yes","","2021-05-27 10:12:29",
"709","Performance characteristics of four high-throughput immunoassays for detection of igg antibodies against sars-cov-2","10.1128/JCM.01243-20","ImmunoAssay-Antibody"," ","IgG vs S (Euroimmun, Ortho-Clinical); IgG vs N (Epitope, Abbott)","kits","four high-throughput serologic tests for detection of anti-SARS-CoV-2 IgG antibodies, CMIA Abbott Laboratories (Abbott Park, IL), ELISA Epitope Diagnostics, Inc. (San Diego, CA), ELISA Euroimmun (Lubeck, Germany), and CLIA Ortho-Clinical Diagnostics (Rochester, NY)","sensitivity: 92.9% (Abbott, >14dpo), 88.1% (Epitope, >14dpo), 97.6% (Euroimmun, >14dpo), 98.8% (Ortho-Clinical, >14dpo); Specificity: 99.6%(Abbott), 99.6% (Epitope), 98.0% (Euroimmun), 99.6% (Ortho-Clinical); PPV: 92.8% (Abbott), 90.6%(Epitope), 71.2% (Euroimmun), 92.5% (Ortho-Clinical)","224 samples","","yes","","2021-05-27 10:01:28",
"377","Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho","10.1128/JCM.00941-20","ImmunoAssay-Antibody"," ","IgG on N protein","chemiluminescent microparticle immunoassay ","Abbott SARS-CoV-2 IgG test","specificity: 99.90%; sensitivity: 53.1% (7 dpo), 82.4% (10 dpo), 96.9% (14 dpo),100% (17 dpo), 88.7% (7 days post PCR positivity), 97.2% (10 days post PCR positivity), 100% (>14 days post PCR positivity)","6001 samples (1145 for validation, 4856 for seroprevalence survey)","","yes","","2021-05-27 09:51:03",
"300","Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence Testing in Idaho","10.1101/2020.04.27.20082362","ImmunoAssay-Antibody"," ","IgG  ","Chemiluminescent microparticle immunoassay kit","Abbott SARS-CoV-2 IgG","Specificity: 99.9% (1020 samples); Sensitivity: 100% (17dpo), 96.9% (14dpo), 82.4% (10dpo), 53.1% (7dpo), 100% (14 days post PCR positivity), 97.2% (10 days post PCR positivity), 88.7% (7 days post PCR positivity)","5901 samples (1020 serum samples before covid circulation, 125 positive, 4856 from another study)","","no","","2021-05-27 09:49:11",
"997","Performance evaluation and clinical application of three antibody test kits for novel coronavirus ","10.3760/cma.j.cn112309-20200303-00097","","","","","","","","","yes (paper not in English)","","2021-05-27 10:09:57",
"1072","Performance evaluation of Abbott ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect immunofluorescence and virus microneutralization test","10.1016/j.jcv.2020.104539","ImmunoAssay-Antibody","Other Immuno assay","IgG ","Abbott ARCHITECT SARS-CoV-2 IgG","Comparison of Abbott ARCHITECT SARS-CoV-2 IgG vs immunoflourescence  IFA ","Positivity after 7days: 8.3%; Positivity after 14 days: 61.9%; Positivity after >14 days: 100%; Sensitivity 14 days post-symptoms: 100%;  Sensitivity 10 days post-symptoms: 82.7%; Sensitivity vs. microneutralization was 94.4 %.","18 patients","","yes","","2021-05-27 10:12:05",
"1070","Performance evaluation of Panther Fusion SARS-CoV-2 assay for detection of SARS-CoV-2 from deep throat saliva, nasopharyngeal, and lower-respiratory-tract specimens","10.1002/jmv.26574","NucleicAcid-PCR based","PCR_KIT","not specified","kit","performance evaluation of the Panther Fusion severe acute respiratory syndrome coronavirus 2 (SARS?CoV?2) assay (PF assay) (Hologic, Inc.) in comparison to the TIB?Molbiol LightMix SarbecoV E?gene assay (TIB?Molbiol assay) (TIB?Molbiol) using deep throat saliva (DTS), nasopharyngeal (NP) and lower respiratory tract (LRT) specimens.","PPA: 96.43% (NP), 100% (LRT), 96% (DTS), 97.53% (overall); NPA: 100% (NP), 100% (LRT), 100% (DTS), 100% (overall)","158 samples (142 patients)","","yes","","2021-05-27 10:12:00",
"883","Performance evaluation of serological assays to determine the immunoglobulin status in SARS-CoV-2 infected patients","10.1016/j.jcv.2020.104589","ImmunoAssay-Antibody","ELISA","IgA, IgM and IgG targeting S spike","in-house","we have evaluated an in-house developed ELISA for the detection of the immunoglobulin classes A, G and M directed against the full-length spike glycoprotein from SARS-CoV-2","Sensitivity values: of 98, 94, 98, 100 and 100 %, respectively. Specificity values: 78, 100, 83, 97 and 93 %","110 sera","","yes","","2021-05-27 10:06:54",
"679","Performance evaluation of the NASnet convolutional network in the automatic identification of COVID-19","10.18517/ijaseit.10.2.11446","Imaging-X-ray"," ","chest X-ray","deep learning","Neural Architecture Search Network (NASNet) in the automatic detection of COVID-19 (Coronavirus Disease 2019) from chest Imaging-X-ray","accuracy: 97%","240 images","","yes","","2021-05-27 10:00:28",
"1215","Performance evaluation of the point-of-care SAMBA II SARS-CoV-2 Test for detection of SARS-CoV-2","10.1101/2020.05.24.20100990","NucleicAcid-Others","Other sequencing method(s)","ORF1ab and Nucleocapsid protein (region 2)","SAMBA II SARS-CoV-2 Test for detection of SARS-CoV-2","Performance evaluation of the SAMBA II SARS-CoV-2 test detecxtion of SARS-CoV-2","LOD: 250 cp/mL; Sensitivity: 98.9%; Specificity: 100%; PPV: 100%; NPV: 98.78%","172 clinical samples","","yes","","2021-05-27 10:16:51",
"651","Performance of a novel diagnostic assay for rapid SARS-CoV-2 antigen detection in nasopharynx samples","10.1016/j.cmi.2020.09.030","ImmunoAssay-Antigen"," ","not specified","kit","STANDARD F COVID-19 Ag fluorescent immunoassay (FIA) (SD Biosensor, Suwon, South Korea)","PPA: 47.1% (vs RT-PCR); NPA: 98.4% (vs RT-PCR); LOD: 2 × 10^6 RNA copies/mL","359 samples","","yes","","2021-05-27 09:59:31",
"1155","Performance of a qualitative rapid chromatographic immunoassay to diagnose COVID-19 in patients in a middle-income country","10.1016/j.jcv.2020.104592","ImmunoAssay-Antibody","Mixed","IgM, IgG (Wondfo); IgG, IgA (ELISA)","kits (EuroImmun, Wondfo)","ELISA (Euroimmun-Lübeck, Germany) that detects anti-SARS-CoV-2 IgA and IgG antibodies, as well as an RCI (Wondfo-China) that detects anti-SARS-CoV-2 IgG/IgM.","Sensitivity:  85.8%;  94.9% (>14 dpo); Specificity: 100%","122 subjects","","yes","","2021-05-27 10:14:52",
"535","Performance of Abbott Architect, Ortho Vitros, and Euroimmun Assays in Detecting Prior SARS-CoV-2 Infection","10.1101/2020.07.29.20164343","ImmunoAssay-Antibody"," ","IgG vs S or N","ELISA kits","kits: Ortho-Clinical Diagnostics Vitros, and Euroimmun, Abbott Architect,Yale-developed anti-spike ELISA test.","Sensitivity: 86% (Abbott Architect), 94% (Ortho Vitros), 86% (Euroimmmun), 94% (Yale assay)","36 samples","","no","","2021-05-27 09:56:06",
"1253","Performance of Abbott ID Now COVID-19 Rapid Nucleic Acid Amplification Test Using Nasopharyngeal Swabs Transported in Viral Transport","10.1128/JCM.01136-20","NucleicAcid-PCR based","PCR_KIT","RdRP (Abbott ID Now), N2, E (Cepheid Xpert)","kits (Abbot ID Now, Cepheid Xpert)","Comparisons between Abbott ID Now COVID-19 and Cepheid Xpert Xpress SARS-CoV-2 ","PPA: 54.8% (using dry nasal swabs fro ID Now); NPA: 98.6% (using dry nasal swabs fro ID Now); overall agreement: 85.1%; PPV:94.4%; NPV: 83.1%","101 samples","","yes","","2021-05-27 10:18:07",
"1251","Performance of SARS-CoV-2 serology tests: Are they good enough?","10.1371/journal.pone.0245914","ImmunoAssay-Antibody","Other Immuno assay","IgG","Epitope Diagnostics Inc. (EDI, San Diego, CA, USA), EuroImmun UK ITC (UK), Abbott Diagnostics (Maidenhead, UK), DiaSorin (London, UK), SARS-CoV-2 IgG/IgM rapid test from Healgen (Houston, TX, USA)","comparison of different immunoassays","Specificity: 81% (EDI, Euroimmun, Abbott), 100% (Healgen), 71% (Diasorin) ; Specificity: (EDI, Abbott), 92% (Euroimmun), 96% (Diasorin) ; remarks: sensitivity is for positive samples at all time points, specificity is on pre-pandemic controls. more values are available at different time points and for different sample sets","up to 50 samples","","yes","","2021-05-27 10:18:03",
"1174","Performance of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Assays in Different Stages of Infection: Comparison of Commercial Enzyme-Linked Immunosorbent Assays and Rapid Tests","10.1093/infdis/jiaa305","ImmunoAssay-Antibody","Other Immuno assay","Euroimmun: S1; Wantai: spike; ","Euroimmun SARS-CoV-2 IgA and IgG ELISAs (Euroimmun),  Wantai SARS-CoV-2 IgM and total antibody ELISAs (Beijing Wantai Biological Pharmacy), Wantai SARS-CoV-2 Ab Rapid Test (Beijing Wantai), 2019-nCoV IgG/IgM Rapid Test (Hangzhou AllTest Biotech) ","Comparison of performance among 2 ELISA: Euroimmun SARS-CoV-2 IgA and IgG ELISAs (Euroimmun),  Wantai SARS-CoV-2 IgM and total antibody ELISAs (Beijing Wantai Biological Pharmacy); and 2 rapid tests  the Wantai SARS-CoV-2 Ab Rapid Test (Beijing Wantai), and the 2019-nCoV IgG/IgM Rapid Test (Hangzhou AllTest Biotech) ","Sensitivity: the Euroimmun IgA and IgG ELISAs tested positive in 9 (30%) and 1 (3.3%) of the 30 individuals in group tested at < 5 d from symptoms, in 21 (84%) and 10 (40%) of the 25 at d 6-10, in all 22 patients (100%) at d>21. The Wantai IgM and total antibody ELISAs tested positive in 8 (26.7%) and 11 (36.7%) of the 30 individuals tested at <5d from symptoms. Both tests provided positive results in 23 of 25 patients (92%) at d 6-10 and in all 22 (100%) at d>21. The Wantai rapid test tested positive in 6 of 30 individuals (20%) tested at <5d from symptoms, in 20 of 25 (80%) at d 6-10, and in all 22 (100%) at d>21. The 2019-nCoV IgG/IgM Rapid Test tested 6 of the 30 (20%) patients positive IgM at < 5 d from symptoms and 4/30 (13.3%) a positive IgG band. At d 6-10 5 (20%) displayed weakly positive IgM and 12 (48%) clearly positive IgG bands. At d >21, 10 (45.5%) showed a weakly positive IgM band, and all 22 (100%) displayed a clearly positive IgG band. Specificity: Euroimmune IgA 83%; Euroimmune IgG 98%; Wantai IgM and total Ab: 97%; Wantai rapid test: 98%; 2019-nCoV IgG/IgM Rapid Test IgM 99%;  IgG 100% .","77 positive. 100 negative","","yes","","2021-05-27 10:15:29",
"341","Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation","10.1101/2020.05.18.20101618","ImmunoAssay-Antibody"," ","IgG, IgA, IgM ","Multiple-kits","Abbott SARS-COV-2 IgG (CE marked), Diasorin Liaison SARS-CoV-2 S1/S2 IgG (research use only), Euroimmun SARS-CoV-2 IgG and IgA (CE marked), 2 rapid lateral flow (immunocromatographic) tests :Acro Biotech 2019-nCoV IgG/IgM (CE marked) and Xiamen Biotime Biotechnology SARS-CoV-2 IgG/IgM (CE marked) in comparison with a microneutralisation test (MNT)","Specificity, Sensitivity: 95.1%, 80.5% (Abbott Architect SARS-CoV-2 IgG); 94.9%, 43.8% (Diasorin Liaison SARS-CoV-2 IgG); 68.3%, 87.8% (Euroimmun SARS-CoV-2 IgA), 86.6%, 70.7% (Euroimmun SARS-CoV-2 IgG), 74.4%, 56.1% (Acro 2019-nCoV IgG), 69.5%, 46.3% (Acro 2019-nCoV IgM), 97.5%, 71.9% (Xiamen Biotime SARS-CoV-2 IgG), and 88.8%, 81.3% (Xiamen Biotime SARS-CoV-2 IgM)","62 patients & 53 controls","","no","","2021-05-27 09:50:29",
"689","Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation","10.1016/j.jcv.2020.104512","ImmunoAssay-Antibody"," ","IgG, IgA, IgM","kits","four automated assays [Abbott SARS-COV-2 IgG (CE marked), Diasorin Liaison® SARS-COV-2 S1/S2 IgG (research use only, RUO), and Euroimmun SARS-COV-2 IgG and IgA (CE marked)], and two rapid lateral flow (immunocromatographic) tests [Acro Biotech 2019-nCoV IgG/IgM (CE marked) and Xiamen Biotime Biotechnology SARS-COV-2 IgG/IgM (CE marked)] and a microneutralisation test (MNT). ","specificity: 95.1% (Abbott Architect SARS-CoV-2 IgG), 94.9% (Diasorin Liaison SARS-CoV-2 IgG, RUO), 68.3% (Euroimmun SARS-CoV-2 IgA), 86.6% (Euroimmun SARS-CoV-2 IgG), 74.4% (Acro 2019-nCoV IgG), 69.5% (Acro 2019-nCoV IgM), 97.5% (Xiamen Biotime SARS-CoV-2 IgG), 88.8% (Xiamen Biotime SARS-CoV-2 IgM); Sensitivity: 80.5 % (Abbott Architect SARS-CoV-2 IgG), 43.8% (Diasorin Liaison SARS-CoV-2 IgG, RUO), 87.8% (Euroimmun SARS-CoV-2 IgA), 70.7% (Euroimmun SARS-CoV-2 IgG), 56.1% (Acro 2019-nCoV IgG), 46.3% (Acro 2019-nCoV IgM), 71.9% (Xiamen Biotime SARS-CoV-2 IgG), 81.3 % (Xiamen Biotime SARS-CoV-2 IgM).","62 patients","","yes","","2021-05-27 10:00:48",
"624","Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department","10.1002/jmv.25800","ImmunoAssay-Antibody"," ","IgM/IgG","kit","VivaDiag COVID?19 IgM/IgG Rapid Test lateral flow immunoassay (LFIA)","Sensitivity: 18.4%; specificity: 91.7%; NPV: 26.2%; PPV: 87.5% ","110 subjects","","yes","","2021-05-27 09:58:44",
"301","Performance verification of detecting COVID-19 specific antibody by using four chemiluminescence immunoassay systems","10.1101/2020.04.27.20074849","ImmunoAssay-Antibody"," ","IgM/IgG","Immunochemioluminescence","","Kit D: 92% sensitivity and 99.23% specificity), others kits sensitivity <90%, specificity <97.7%","180 samples","","no","","2021-05-27 09:49:13",
"1245","Point of Care Nucleic Acid Testing for SARS-CoV-2 in Hospitalized Patients: A Clinical Validation Trial and Implementation Study.","10.1016/j.xcrm.2020.100062","NucleicAcid-PCR based","PCR_KIT","ORF1, E","SAMBA II SARS-CoV-2 test POC (Point of Care)","evaluation of POC test vs RT-PCR","correlation: 0.96 (POC vs RT-PCR); Sensitivity: 96.9%; Specificity: 100%","149 patients (Validation study)","","yes","","2021-05-27 10:17:51",
"1043","Point-of-Care Diagnostics of COVID-19: From Current Work to Future Perspectives.","10.3390/s20154289","review","Mixed","","","Comparison and performances of some testing methods are reported in the text and in tables","","","","yes","","2021-05-27 10:11:05",
"1163","Point-of-care serological assays for delayed SARS-CoV-2 case identification among health-care workers in the UK: a prospective multicentre cohort study","10.1016/S2213-2600(20)30315-5","ImmunoAssay-Antibody","LFIA","IgG","kits (CTK Biotech, Zhuhai Encode)","two point-of-care lateral flow serological assays, the Onsite CTK Biotech COVID-19 split IgG/IgM Rapid Test (CTK Biotech, Poway, CA, USA) and the Encode SARS-CoV-2 split IgM/IgG One Step Rapid Test Device (Zhuhai Encode Medical Engineering, Zhuhai, China), were evaluated for performance against a laboratory immunoassay (EDI Novel Coronavirus COVID-19 IgG ELISA kit [Epitope Diagnostics, San Diego, CA, USA]) ","Sensitivity: 93.4% (Encode), 88.2% (Onsite); Specificity: 99% (Encode), 94% (Onsite); Agreement with PCR:  94% (Encode), 84.7% (Onsite)","400 samples","","yes","","2021-05-27 10:15:08",
"206","Pooled RNA extraction and PCR assay for efficient SARS-CoV-2 detection","10.1101/2020.04.17.20069062","Others","In_silico","","","","","","","no","","2021-05-27 09:47:11",
"795","Pooled RNA sample reverse transcriptase real time PCR assay for SARS CoV-2 infection: A reliable, faster and economical method","10.1371/journal.pone.0236859","NucleicAcid-PCR based","RT-PCR","RdRP, E gene "," LightMix Modular SARS-CoV-2 RdRP (TIB MOLBIOL); LightMix SarbecoV E-gene (TIB MOLBIOL)","paper focusses on sample pooling strategy","sensitivity: 95.4%; specificity: 100%; positive predicitive value: 100%; negative predicitive value: 92.86%","280 samples","","yes","","2021-05-27 10:04:18",
"304","Pooled RNA sample reverse transcriptase real time PCR assay for SARS CoV-2 infection: a reliable, faster and economical method","10.1101/2020.04.25.20079095","NucleicAcid-PCR based","PCR_KIT","E gene","Pool of 8 samples","Positive samples assessed also for RdRP gene","Overall pooled samples: sensitivity 95.4%, specificity 100%,","280 samples","","no","","2021-05-27 09:49:19",
"621","Pooling of nasopharyngeal swab specimens for SARS-CoV-2 detection by RT-PCR","10.1002/jmv.25971","NucleicAcid-PCR based","PCR_KIT","E, RdRP","pooling strategy for RT-PCR","pooling strategy on RT?PCR (REALQUALITY RQ?2019?nCoV from AB ANALITICA","/","/","","yes","","2021-05-27 09:58:38",
"449","Pooling of Nasopharyngeal Swab Specimens for SARS-CoV-2 detection by RT-PCR","10.1101/2020.04.22.20075598","NucleicAcid-PCR based","PCR_KIT","E, RdRP","kit","pooling strategy","Remark: LOD reported by manufacturer 125 (E) and 150 (RdRP) copies/ml","20 pools","","no","","2021-05-27 09:53:28",
"1263","Pooling of Upper Respiratory Specimens Using a SARS-CoV-2 Real-time RT-PCR Assay Authorized for Emergency Use in Low-Prevalence","10.1093/ofid/ofaa466","NucleicAcid-PCR based","RT-PCR","N1, N3","RT-PCR","evaluation of the performance of  RT-PCR test authorized by the US Food and Drug Administration (FDA) for emergency use for pooled testing of upper respiratory specimens","PPA: 100% (between pooled and single samples); NPA: >99%","101 specimens","","yes","","2021-05-27 10:18:28",
"207","Pooling RT-PCR or NGS samples has the potential to cost-effectively generate estimates of COVID-19 prevalence in resource limited environments","10.1101/2020.04.03.20051995","Others","In_silico","","","","","","","no","","2021-05-27 09:47:13",
"382","Pooling RT-PCR test of SARS-CoV-2 for large cohort of 'healthy' and infection-suspected patients: A prospective and consecutive study on 1,000 individuals","10.1101/2020.05.04.20088146","NucleicAcid-PCR based","PCR_KIT","N1, N2","National Institute of Infectious Diseases (NIID) Japan protocol","pooling strategy","/","1000","","no","","2021-05-27 09:51:12",
"415","Population-scale testing can suppress the spread of COVID-19","10.1101/2020.04.27.20078329","Others","In_silico","/","/","population scale testing: test everyone, repeatedly, and isolate the infected individuals","/","/","","no","","2021-05-27 09:52:20",
"148","Portable and accurate diagnostics for COVID-19: Combined use of the miniPCR thermocycler and a well-plate reader for SARS-CoV-2 virus detection","10.1101/2020.04.03.20052860","NucleicAcid-PCR based","WHO method(s)","Multiple targets on N-gene","WHO-7","","Detection range: 625 to 2 x10^5 copies","Synthetic control","","no","","2021-05-27 09:45:41",
"76","Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020","10.1016/j.cca.2020.03.009","NucleicAcid-PCR based","PCR_KIT","ORF1ab-gene, N-gene","Individual-kit","kit: provided  by  Shanghai  Huirui Biotechnology Co.,Ltd.","Not reported","4480 samples","","yes","","2021-05-27 09:44:10",
"1113","Positive virus detection in patients who recovered from COVID-19 during quarantine period between discharge and home: a two-center experience in Wuhan, China","10.1007/s10096-020-03918-4","NucleicAcid-PCR based","RT-PCR","ORF1ab and N genes","RT-PCR","virus detection by RT-PCR tests of patients before and after hospital discharge","","193 patients","","yes","","2021-05-27 10:13:29",
"815","Potential False-Negative Nucleic Acid Testing Results for Severe Acute Respiratory Syndrome Coronavirus 2 from Thermal Inactivation of Samples with Low Viral Loads","10.1093/clinchem/hvaa091","NucleicAcid-PCR based","RT-PCR"," ","primer and probe were generated following Chinese national guidelines","effect of thermal inactivation on the sensitivity of the RT-PCR","Mean Cq: 33.07 (thermal inactivation), 32.69 (no thermal inactivation)","23 samples"," ","yes","","2021-05-27 10:04:55",
"897","Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review.","10.3390/jcm9030623","review","Mixed","mixed","multiple","paper gives an overview of current an potential detection methods.","tables 1 & 2 list current and potential detection methods and their performance (if available)","/"," ","yes","","2021-05-27 10:07:21",
"408","Pre-test probability for SARS-Cov-2-related Infection Score: the PARIS score","10.1101/2020.04.28.20081687","Others","In_silico","/","PARIS (pre-test probability) score","PARIS score is based on demographic characteristics, clinical symptoms, and results of blood tests (complete white blood cell count, serum electrolytes and CRP)","Sensitivity: 80.3%; PPV: 92.3%; NPV:99.5%","400","","no","","2021-05-27 09:52:05",
"277","Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal","10.1136/bmj.m1328","Others","In_silico","","","","","","","yes","","2021-05-27 09:48:23",
"414","Predictive value of sudden olfactory loss in the diagnosis of COVID-19","10.1101/2020.04.27.20081356","Others"," ","/","/","predictive value of smell loss fo covid","specificity: 97%; sensitivity: 65%; PPV: 63%; NPV: 97%","500","","no","","2021-05-27 09:52:18",
"799","Preliminary Analysis of B- and T-Cell Responses to SARS-CoV-2","10.1007/s40291-020-00486-3","ImmunoAssay-Antibody","Mixed","IgM, IgG","LFIA and MCLIA","LFIA and MCLIA, were supplied by Beier Bioengineering Co. Ltd (Beijing, China)","sensitivity: 94.48% (LFIA-IgM), 95.28% (LFIA-IgG), 92.13% (MCLIA-IgM), 90.55% (MCLIA-IgG); specificity: 100% (LFIA-IgM), 100% (LFIA-IgG), 100% (MCLIA-IgM), 100% (MCLIA-IgG)","129 patients","","yes","","2021-05-27 10:04:26",
"401","Preliminary Results of Seroprevalence of SARS-CoV-2 at Community Clinics in Tokyo","10.1101/2020.04.29.20085449","ImmunoAssay-Antibody"," ","IgG","kit","SARS-CoV-2 Antibody Testing Kit IgG RF-NC002","Remark: limitation on antibody tests includes low sensitivity and potentcross-reactivity with the previous coronavirus","202","","no","","2021-05-27 09:51:51",
"729","Presence of mismatches between diagnostic PCR assays and coronavirus SARS-CoV-2 genome: Sequence mismatches in SARS-CoV-2 PCR","10.1098/rsos.200636rsos200636","NucleicAcid-PCR based","In_silico","WHO-1,2,3,4,5,6,7","all WHO methods and other published PCR assays","in silico comparison of 17 027 viral sequences to determine the sequence variability in the primer/probe binding regions","","17027 viral sequences, 27 PCR methods","","yes","","2021-05-27 10:02:04",
"512","Prevalence of Sars-Cov-2 Infection in Health Workers (HWs) and Diagnostic Test Performance: The Experience of a Teaching Hospital in Central Italy","10.3390/ijerph17124417","NucleicAcid-PCR based","Mixed","RT-PCR target not specified; IgM, IgG","RT-PCR and CLIA","RT-PCR: AllplexTM 2019-nCoV Assay, Seegene Inc., Seoul, Korea; CLIA: Medical Systems, 2019-nCoV IgM/IgG, Genova, Italy","sensitivity: 0% (IgM), 50% (IgG), 80% (14 days post diagnosis), 100% (20 days post diagnosis); specificity: 98.99% (IgM), 99.1% (IgG). Remark: study on health workers","1084 samples","","yes","","2021-05-27 09:55:29",
"1211","Prevalence of SARS-CoV-2 infection in the Luxembourgish population: the CON-VINCE study.","10.1101/2020.05.11.20092916","ImmunoAssay-Antibody","ELISA","IgA and IgG ","Anti-SARS-CoV-2 IgA and IgG Euroimmun ","Better understan of the dynamics of the pandemic and improve measures to confine spread of SARS-CoV-2 ","IgA Specificity: 89.2%; IgG Specificity: 97.8%; IgA Sensitivity: 92.9%; IgG Sensitivity: 85.7%","1820 patients","","no","","2021-05-27 10:16:43",
"667","Prior-Attention Residual Learning for More Discriminative COVID-19 Screening in CT Images","10.1109/TMI.2020.2994908","Imaging-CT scan"," ","3D chest CT images","","novel multi-task prior-attention residual learning strategy for one-stage lesion-aware COVID-19 screening in CT images. ","remark: this method surpassed other state-of-the-art COVID-19 screening methods. Accuracy: 89.7% (PA-66-M model)","4657 images","","yes","","2021-05-27 10:00:03",
"1168","Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","10.1093/cid/ciaa489","ImmunoAssay-Antibody","Other Immuno assay","IgM, IgG vs N, S","kit (iFlash)","iFlash-SARSCoV-2 IgG/IgM chemiluminescent immunoassay C86095G/C86095M, YHLO BIOTECH, Shenzhen)","/","41 patients","","yes","","2021-05-27 10:15:17",
"1158","Profile of Specific Antibodies to SARS-CoV-2: The First Report.","10.1016/j.jinf.2020.03.012","ImmunoAssay-Antibody","Other Immuno assay","IgM, IgG","kit (Shenzhen)","chemiluminescent immunoassay (Shenzhen Yahuilong Biotechnology Co., Ltd).","Remark: dynamic profile of Ab","34 patients","","yes","","2021-05-27 10:14:58",
"561","Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)","10.1093/cid/ciaa310","ImmunoAssay-Antibody"," ","IgM. IgA, IgG vs NP","ELISA","","Remark: detection efficiency by IgM ELISA is higher than that of qPCR (>5.5 dpo); Positive detection rate is significantly increased (98.6%) when combining IgM ELISA assay with PCR for each patient compared with a single qPCR test (51.9%).","208 samples","","yes","","2021-05-27 09:56:51",
"468","Prolonged viral shedding in feces of pediatric patients with coronavirus disease 2019","10.1016/j.jmii.2020.03.021","NucleicAcid-PCR based","PCR_KIT","ORF1ab, N","RT-PCR Kit China FDA","RNA detectable in stool for longer than 4 weeks","Remark: fecal specimens","3","","yes","","2021-05-27 09:54:03",
"324","Promising methods for detection of novel coronavirus SARS-CoV-2","10.1002/viw2.4","Others","Other PCR method(s)","","","","Comparison of 6 different methods: whole-genome sequencing, RT-PCR, nanopore target sequencing, antibody-based immunoassay techniques, use of paper-based biomolecular sensors, and the clustered regularly interspaced short palindromic repeats-Cas system-based technology","Not specified","","yes","","2021-05-27 09:49:58",
"855","Proposal of a low-dose, long-pitch, dual-source chest CT protocol on third-generation dual-source CT using a tin filter for spectral shaping at 100 kVp for CoronaVirus Disease 2019 (COVID-19) patients: a feasibility study","10.1007/s11547-020-01179-x","Imaging-CT scan","Other"," ","low-dose, long-pitch dual-source chest CT","evaluation of feasibility and diagnostic reliability of LDCT for covid detection"," study demonstrated the feasibility of LDCT","10 patients"," ","yes","","2021-05-27 10:06:07",
"643","Proposal of De Novo Antigen Test for COVID-19: Ultrasensitive Detection of Spike Proteins of SARS-CoV-2","10.3390/diagnostics10080594","ImmunoAssay-Antigen"," ","Spike Proteins","in house","ultrasensitive ELISA coupled with thio-NAD cycling","LOD:1.8 pg/mL; LOQ: 5.9 pg/mL","/","","yes","","2021-05-27 09:59:16",
"1118","Protein based biomarkers for non-invasive Covid-19 detection","10.1016/j.sbsr.2020.100362","review","Biosensor","mixed","multiple biosensor systems","focus on protein based biomarkers and their biosensors","Table 1 lists recently develop biosensor and their parameters","/"," ","yes","","2021-05-27 10:13:39",
"210","Proteome-wide analysis of differentially-expressed SARS-CoV-2 antibodies in early COVID-19 infection","10.1101/2020.04.14.20064535","ImmunoAssay-Antibody"," ","IgM/IgG on S-protein","Proteome microarray in-house-method","","Remark: Unclear","40 patients","","no","","2021-05-27 09:47:15",
"211","Proteomic and Metabolomic Characterization of COVID-19 Patient Sera","10.1101/2020.04.07.20054585","Others","In_silico","","","","","","","no","","2021-05-27 09:47:17",
"1220","Pushing beyond specifications: Evaluation of linearity and clinical performance of a fully automated SARS-CoV-2 RT-PCR assay for reliable quantification in blood and other materials outside recommendations","10.1101/2020.05.28.20115469","NucleicAcid-PCR based","PCR_KIT","RdRp & E-Gene","SARS-CoV-2 IVD (cobas6800/8800 system)","fully automated sample-to-result platform, test for E-gene and RdRp are compared","Positive agreement 95.7%, negative agreement 98.9%","235 samples"," ","no","","2021-05-27 10:17:01",
"616","Qualitative assessment of SARS-CoV-2-specific antibody avidity by lateral flow immunochromatographic IgG/IgM antibody assay","10.1002/jmv.26344","ImmunoAssay-Antibody"," ","IgM/IgG","kit","LFIC ALLTEST 2019?nCoV IgG/IgM Rapid Test Cassette (Hangzhou ALLTEST Biotech Co., Ltd. Hangzhou, China)","Remark: Sera losing IgG reactivity after urea treatment were drawn significantly earlier after onset of symptoms than those which preserved it. This assay may be helpful to estimate the time of acquisition of infection in patients with mild to severe COVID?19.","76 samples","","yes","","2021-05-27 09:58:30",
"788","Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays","10.1016/j.jcv.2020.104540","ImmunoAssay-Antibody","Mixed","IgM, IgG, total Ab","kits (ELISA; CLIA; LFIA)","3 different IgG-ELISAs (EUROIMMUN IgG and NCP-IgG ELISA, Wantai ELISA), 2 CLIA (Elecsys, LIAISON) and 2 lateral flow tests (MEDsan IgM/IgG-Rapid-Test, Wantai Rapid Test) and subsequently correlated to neutralization titers.","Sensitivity: 99% (NT), 	98% (Wanati ELISA), 92.86% (EI IgG ELISA), 88.89% (EI NCP ELISA), 94.95% (Elicsys), 84% (LIAISON), 88.78% (Wantai rapid T), 92.93% (MedSan rapid T)","100 samples","","yes","","2021-05-27 10:04:03",
"251","Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients","10.1093/cid/ciaa345","NucleicAcid-PCR based","PCR_KIT","ORF1ab-gene, N-gene","Individual-kit","Kit: TargetingOne, Beijin, China (ddPCR), Shanghai BioGerm Medical Technology Co. LTD, China (RT PCR)","LOD:  Cq <38 (qPCR),  10 cpr (ddPCR) ; Remark: Comparison of RT-PCR and ddPCR ","323 samples (76 patients)","","yes","","2021-05-27 09:48:05",
"532","R3T (Rapid Research Response Team) One-step RT-qPCR kit for COVID-19 diagnostic using in-house enzymes","10.1101/2020.07.31.20165704","NucleicAcid-PCR based","PCR_KIT","Multiple targets on N-gene","Individual-kit","Kit: CDC EUA IDT#10006606","LOD: 10 copies ","20 patients & 172 controls","","no","","2021-05-27 09:56:00",
"859","Raman spectroscopy-based detection of RNA viruses in saliva: A preliminary report","10.1002/jbio.202000189","Others","Other","","Raman spectroscopy","Proof of concept method using Raman spectroscopy to detect the RNA viruses in saliva","prediction accuracy: 91.6% ; sensitivity: 92.5% ; specificity: 88.8% ; ","","","yes","","2021-05-27 10:06:15",
"212","Rapid and accurate identification of COVID-19 infection through machine learning based on clinical available blood test results","10.1101/2020.04.02.20051136","Others","In_silico","","","","","","","no","","2021-05-27 09:47:19",
"213","Rapid and quantitative detection of COVID-19 markers in micro-liter sized samples","10.1101/2020.04.20.052233","ImmunoAssay-Antibody"," ","IgG, S1-protein antigen","Rapid microfluidic ELISA in-house-method","","LOD: 2 ng/mL (IgG in serum) ; LLOD: 0.4 ng/mL (SARS-CoV-2 S1 protein)","no","","no","","2021-05-27 09:47:21",
"576","Rapid and Sensitive Detection of COVID-19 Using CRISPR/Cas12a-based Detection with Naked Eye Readout, CRISPR/Cas12a-NER","10.1016/j.scib.2020.04.041","NucleicAcid-Others","CRISPR","Multiple targets ","CRISPR/Cas12a-NER","CRISPR/Cas12a-based-detection with naked eye readout (CRISPR/Cas12a-NER)","Agreement with PCR: 100%; LOD: 10 cpr (E gene)","31 samples","","yes","","2021-05-27 09:57:18",
"875","Rapid and sensitive detection of SARS-CoV-2 RNA using the Simplexaâ„¢ COVID-19 direct assay","10.1016/j.jcv.2020.104416","NucleicAcid-PCR based","RT-PCR","S gene and ORF1ab","SimplexaTM COVID-19 Direct assay","Comparison of the all-in -one method with the WHO pro0tocol","LOD S gene: 3.2 (CI: 2.9–3.8) log10 cp/ mL and 0.40 (CI: 0.2–1.5) TCID50/mL .   LOD ORF1ab: 3.2 log10 (CI: 2.9–3.7) log10 cp/mL and 0.4 (CI: 0.2–1.3) TCID50/mL","278 specimens","","yes","","2021-05-27 10:06:42",
"150","Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay","10.1016/j.cmi.2020.04.001","NucleicAcid-Others","LAMP","ORF1ab-gene, S-gene","Other method","","LOD: 20 (orf1ab-4), 200 cpr (S-123) ; Sensitivity: 100% ; Specificity: 100%","130 samples (58 positive)","","yes","","2021-05-27 09:45:43",
"1135","Rapid antibody testing for SARS-CoV-2 in asymptomatic and paucisymptomatic healthcare professionals in hematology and oncology units identifies undiagnosed infections","10.1097/HS9.0000000000000408","ImmunoAssay-Antibody","Other Immuno assay","IgG, IgM","PRIMA LAB SA, Switzerland"," ","Specificity: 98% (IgG), 96% (IgM); sensitivity: 100% (IgG), 85% (IgM); accuracy: 98.6% (IgG), 92.9% (IgM)","246 patients"," ","yes","","2021-05-27 10:14:14",
"79","Rapid colorimetric detection of COVID-19 coronavirus using a reverse tran-scriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic plat-form: iLACO","10.1101/2020.02.20.20025874","NucleicAcid-PCR based","PCR_KIT","ORF1ab","Individual-kit","Kits: Two kits were used in parallel to validate the positive samples  (BGI and Biotech & Biomedicine Science (Shenyang)","LOD: 10 cpr","43 samples","LAMP","no","","2021-05-27 09:44:12",
"1103","Rapid COVID-19 diagnosis using ensemble deep transfer learning models from chest radiographic images","10.1007/s12652-020-02669-6","Imaging-X-ray","In_silico","X-ray","X-ray","deep transfer learning models from chest radiographic images. Binary (covid positive and negative subjects) and multi classification (covid, normal and viral and bacterial pneumonia subjects) are used.","Accuracy: 99.21% (three class classification), 96.15% (binary classification)","more than 1203 chest x-ray scans","","yes","","2021-05-27 10:13:09",
"80","Rapid Detection of 2019 Novel Coronavirus SARS-CoV-2 Using a CRISPR-based DETECTR Lateral Flow Assay","10.1101/2020.03.06.20032334","NucleicAcid-Others","CRISPR","E-gene, N-gene","WHO-7, WHO-1","","Specificity: tested ; LOD: 10 cpu ; Sensitivity: 90%","23 samples","","no","","2021-05-27 09:44:14",
"570","Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based Biosensor","10.1021/acsnano.0c02823","Others"," ","S-protein ","FET","Field-effect transistor (FET)-based biosensing device","LOD: 1 fg/mL (in phosphate-buffered saline), 100 fg/mL (in clinical transport medium) ","/","","yes","","2021-05-27 09:57:06",
"697","Rapid Detection of IgM Antibodies against the SARS-CoV-2 Virus via Colloidal Gold Nanoparticle-Based Lateral-Flow Assay","10.1021/acsomega.0c01554","ImmunoAssay-Others","LFIA","IgM","in house","colloidal gold nanoparticle-based lateral-flow (AuNP-LF) assay","sensitivity: 100%; specificity: 93.3%","14","","yes","","2021-05-27 10:01:05",
"81","Rapid Detection of Novel Coronavirus (COVID-19) by Reverse Transcription-Loop-Mediated Isothermal Amplification","10.1101/2020.02.19.20025155","NucleicAcid-Others","LAMP","Not specified","Other method","","Specificity: tested ; LOD: 1.02 fg per reaction","208 Simulated Clinical Samples","","no","","2021-05-27 09:44:16",
"1028","Rapid detection of novel coronavirus/Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by reverse transcription-loop-mediated isothermal amplification","10.1371/journal.pone.0234682","NucleicAcid-PCR based","LAMP","NSP3, ORF1ab genes","in house LAMP","in house LAMP compared to fNxTAG CoV Extended Panel Assay or WHO-7","LOD: 304 viral copies  PPV: 95% ; NPV: 90%","60 samples","","yes","","2021-05-27 10:10:34",
"380","Rapid detection of SARS-CoV-2 by low volume real-time single tube reverse transcription recombinase polymerase amplification using an exo probe with an internally linked quencher (exo-IQ)","10.1093/clinchem/hvaa116","NucleicAcid-Others","RT_PCR","N gene","in house reverse transcription recombinase polymerase amplification","Generation of a suitable set of reverse transcription recombinase polymerase amplification (RT-RPA) primer and exonuclease probe, internally quenched (exo-IQ) probe sequences targeting the SARS-CoV-2 N gene","Sensitivity 100%, specificity: 100%","19 samples","","yes","","2021-05-27 09:51:08",
"536","Rapid detection of SARS-CoV-2 by pulse-controlled amplification (PCA)","10.1101/2020.07.29.20154104","NucleicAcid-Others"," ","E gene","PCA (pulse controlled amplification)","","/","83 positive & 40 negative samples","","no","","2021-05-27 09:56:08",
"82","Rapid Detection of SARS-CoV-2 Using Reverse transcription RT-LAMP method","10.1101/2020.03.02.20030130","NucleicAcid-Others","LAMP","ORF1b-gene, N-gene","Other method","","Specificity: tested ; LOD: 1000 cpm","5 samples","","no","","2021-05-27 09:44:18",
"1088","Rapid detection of SARS-CoV-2 with recombinase polymerase amplification Schnellnachweis von SARS-CoV-2 mit recombinase polymerase amplification","10.1007/s12268-020-1458-3","NucleicAcid-PCR based","Other PCR method(s)","","","","","","","yes (paper not in English)","","2021-05-27 10:12:38",
"288","Rapid development of COVID-19 rapid diagnostics for low resource settings: accelerating delivery through transparency, responsiveness, and open collaboration","10.1101/2020.04.29.20082099","ImmunoAssay-Antibody"," ","IgG, IgA, IgM on NP, S2","ELISA and LFA","Mologic","Sensitivity: 88%, 94% (ELISA IgG, 10 dpo), 96% (ELISA IgG, 14-21 dpo); Specificity: 97%","834 samples","","no","","2021-05-27 09:48:46",
"151","Rapid diagnosis of SARS-CoV-2 infection by detecting IgG and IgM antibodies with an immunochromatographic device: a prospective single-center study","10.1101/2020.04.11.20062158","ImmunoAssay-Antibody"," ","IgM/IgG","LFIA individual-kit","Kit: AllTest Biotech, Hangzhou, China","Specificity: 100% ; Sensitivity: 47.3% (11 dpo), 73.9% (14 dpo), 88.9% (17 dpo)","163 patients","","no","","2021-05-27 09:45:45",
"690","Rapid direct nucleic acid amplification test without rna extraction for sars-cov-2 using a portable pcr thermocycler","10.3390/genes11060664","NucleicAcid-PCR based"," ","ORF1ab, N (Chinese CDC)","in house","protocol for direct rapid extraction-free PCR (DIRECT-PCR) detection of SARS-CoV-2 without the need for nucleic acid purification","LOD: 6 cpr","synthetic RNA templates","","yes","","2021-05-27 10:00:51",
"214","Rapid direct nucleic acid amplification test without RNA extraction for SARS-CoV-2 using a portable PCR thermocycler","10.1101/2020.04.17.042366","NucleicAcid-PCR based","WHO method(s)","N-gene","WHO-1","","LOD: 12cpr (spiked sputum RT-PCR), 1200cpr (nasal exudate RT-PCR), 600cpr (spiked sputum FAST direct PCR), 60cpr (nasal exudate FAST direct PCR) ; Efficiency: 88.64% (spiked sputum RT-PCR), 77.45% (nasal exudate RT-PCR), 85.52% (spiked sputum FAST direct PCR), 81.08% (nasal exudate FAST direct PCR)","Not reported","","no","","2021-05-27 09:47:23",
"1062","Rapid establishment of laboratory diagnostics for the novel coronavirus SARS-CoV-2 in Bavaria, Germany, February 2020","10.2807/1560-7917.ES.2020.25.9.2000173","NucleicAcid-PCR based","PCR_KIT & other","E, RdRP ","kit & in-house","Comparison of two different one-step real-time RT-PCR systems (Qiagen and Invitrogen) with SARS-CoV-2 assays from Corman et al.  and a commercial test kit with kit-specific assays (RealStar SARS-CoV-2 RT-PCR kit 1.0, Altona)","LOD: 10 cpr (Altona), 50cpr (RT-PCR  with Invitrogen superMix); PCR efficiency: 95% (Invitrogen), 125% (Altona) ","675 samples","","yes","","2021-05-27 10:11:44",
"845","Rapid Gel Card Agglutination Assays for Serological Analysis following SARS-CoV-2 Infection in Humans","10.1021/acssensors.0c01050","ImmunoAssay-Antibody","Mixed","IgG","in house","a serology test to detect SARS-CoV-2 antibodies from human plasma using gel card agglutination tests","sensitivity and specificity: 100%","10 samples","","yes","","2021-05-27 10:05:48",
"321","Rapid identification of SARS-CoV-2-infected patients at the emergency department using routine testing","10.1101/2020.04.20.20067512","Others"," ","Not specified","Algorithm based on clinical parameters, CT scans and demographic data","","Not specified","592 patients","","no","","2021-05-27 09:49:54",
"726","Rapid identification of SARS-CoV-2-infected patients at the emergency department using routine testing","10.1515/cclm-2020-0593","Imaging-Others"," ","chest X-ray/CT and laboratory parameters","algorithm","corona-score model ","sensitivity:96%; specificity: 95%","592 patients","","yes","","2021-05-27 10:01:58",
"485","Rapid Implementation of a SARS-CoV-2 Diagnostic Quantitative Real-Time PCR Test with Emergency Use Authorization at a Large Academic Safety Net Hospital","10.1016/j.medj.2020.05.001","NucleicAcid-PCR based","PCR_KIT","N1, N2, RNase P","Kit","2019-nCoV kit from Integrated DNA Technologies (IDT: Cat No 10006606)","LOD: 10 copies/microliter","1045 samples","","yes","","2021-05-27 09:54:36",
"1256","Rapid Implementation of Severe Acute Respiratory Syndrome Coronavirus 2 Emergency Use Authorization RT-PCR Testing and Experience at an Academic Medical Institution","10.1016/j.jmoldx.2020.10.019","NucleicAcid-PCR based","RT-PCR","E, S","laboratory-developed real-time RT-PCR test","newly designed dual-target real-time RT-PCR (altona RealStar SARS-CoV-2 Reagent)","LOD:  2.7 cpr (nasopharyngeal ), 23.0 cpr (sputum); Specificity: 100%","174 samples","","yes","","2021-05-27 10:18:13",
"1048","Rapid Isothermal Amplification and Portable Detection System for SARS-CoV-2","10.1101/2020.05.21.108381","NucleicAcid-Others","LAMP","ORF1ab, S, ORF8, N","in house assay","RT-LAMP  isothermal  assay  for  the detection of SARS-CoV-2 virus with performance comparable to currently approved tests using RT-PCR. Introduction of swabs in virus spiked synthetic nasal fluids, moving the  swab  to  viral  transport  medium  (VTM),  and  using  a  volume  of  that  VTM  for  performing  the amplification without an RNA extraction kit. Use of  an  additively manufactured cartridge and a smartphone-based reader.","LOD: 50 RNA copies/µL  (viral  transport  medium VTM  solution  within  20  minutes),  5000  RNA  copies/µL  (nasal solution). Remark: Performance comparable to currently approved tests using RT-PCR. Detection  of SARS-CoV-2 virus  in less  than 40  minutes using  an  additively manufactured cartridge and a smartphone-based reader. ","","","yes","","2021-05-27 10:11:15",
"779","Rapid large-scale COVID-19 testing during shortages","10.3390/diagnostics10070464","NucleicAcid-PCR based","","E, RdRP","kit","holistic SARS-CoV-2 testing platform: RT-PCR: LightMix® SarbecoV E-gene plus EAV, TIB MOLBIOL, Berlin, Germany","sensitivity: 96.8%; specificity: 100%; intra-run and inter-run precision: <3%","17545 tests in 9720 individuals","","yes","","2021-05-27 10:03:45",
"84","Rapid Molecular Detection of SARS-CoV-2 (COVID-19) Virus RNA Using Colorimetric LAMP","10.1101/2020.02.26.20028373","NucleicAcid-Others","LAMP","ORF1b-gene, N-gene","Other method","","Specificity: tested","7 samples","","no","","2021-05-27 09:44:20",
"1162","Rapid point-of-care testing for SARS-CoV-2 in a community screening setting shows low sensitivity","10.1016/j.puhe.2020.04.009","ImmunoAssay-Antibody","GICA","IgM, IgG","rapid test (not specified)","The evaluated rapid test is an IgG/IgM–based test for SARS-CoV-2 with a time to result of 20 min. Two drops of blood are needed for the test performance.","sensitivity: 36.4%; specificity: 88.9%","49 patients","","yes","","2021-05-27 10:15:06",
"722","Rapid quantification of SARS-CoV-2-neutralizing antibodies using propagation-defective vesicular stomatitis virus pseudotypes","10.3390/vaccines8030386","ImmunoAssay-Antibody"," ","neutralizing antibodies","in house (psudotyped virus) and kits (Allplex SARS-CoV-2 specific RT-qPCR assay, Seegene; RealStar SARS-CoV-2 RT-PCR Kit, Altona Diagnostic Technologies; Euroimmun AG, Lübeck, Germany # EI 2606-9601 G and # EI 2606-9601 A)","The pseudotype virus neutralization dose 50% (PVND50) and the SARS-CoV-2 neutralizing dose 50% (ND50) determined in the sera from two independent cohorts of individuals that had been tested positive for SARS-CoV-2 infection by RT-PCR and/or ELISA show good coorelation","","29 samples","","yes","","2021-05-27 10:01:50",
"85","Rapid random access detection of the novel SARS-coronavirus-2 (SARS-CoV-2, previously 2019-nCoV) using an open access protocol for the Panther Fusion","10.1016/j.jcv.2020.104305","NucleicAcid-PCR based","WHO method(s)","RdRp-region, E-gene, N-gene, S-gene","WHO-5","","Specificity: tested","None","","no","","2021-05-27 09:44:22",
"1271","Rapid SARS-CoV-2 Detection Using Electrochemical Immunosensor.","10.3390/s21020390","ImmunoAssay-Antigen","Other Immuno assay","S","immunoassay","label-free electrochemical immunoassay for the rapid detection of SARS-CoV-2 virus via the spike surface protein. The assay consists of a graphene working electrode functionalized with anti-spike antibodies","Remark: The sensor was able to detect a specific signal above 260 nM (20 µg/mL) of subunit 1 of recombinant spike protein. Additionally, it was able to detect SARS-CoV-2 at a concentration of 5.5 × 105 PFU/mL","/","","yes","","2021-05-27 10:18:44",
"1206","Rapid serological tests have a role in asymptomatic health workers COVID-19 screening","10.1101/2020.04.15.20057786","ImmunoAssay-Antibody","Other","IgG and IgM","Viva-Diag Jiangsu Medomics Medical Technologies, Nanjing- China","Asymptomatic screening of antibodies against Covi-19 ","/","525 patients","","no","","2021-05-27 10:16:32",
"278","Rapid surveillance of COVID-19 in the United States using a prospective space-time scan statistic: Detecting and evaluating emerging clusters","10.1016/j.apgeog.2020.102202","Others","In_silico","","","","","","","yes","","2021-05-27 09:48:25",
"252","Rapid viral diagnosis and ambulatory management of suspected COVID-19 cases presenting at the infectious diseases referral hospital in Marseille, France, - January 31st to March 1st, 2020: A respiratory virus snapshot","10.1016/j.tmaid.2020.101632","NucleicAcid-PCR based","WHO method(s)","S-gene","WHO-5, in-house-method","","Not reported","280 patients ","","yes","","2021-05-27 09:48:07",
"152","Rapid, field-deployable nucleobase detection and identification using FnCas9","10.1101/2020.04.07.028167","NucleicAcid-Others","CRISPR","N-gene","Other method","","Not reported","Not reported","","no","","2021-05-27 09:45:47",
"215","Rapid, large-scale, and effective detection of COVID-19 via non-adaptive testing","10.1101/2020.04.06.028431","Others","In_silico","","","","","","","no","","2021-05-27 09:47:25",
"644","Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection","10.1002/14651858.CD013705","Review"," ","","","Review on serological assays (antigen, rapid and individual tests)","Remark: review on different serological assays reporting performances","/","","yes","","2021-05-27 09:59:19",
"630","Rapid, sensitive and high-throughput screening method for detection of SARS-CoV-2 antibodies by bio layer interferometry","10.1101/2020.08.15.20175851","ImmunoAssay-Antibody"," ","IgM, IgA, IgG vs S1, N","kit","Bio-layer interferometry (BLI) method: OnCovid total antibody assay ","Sensitivity: 100%; specificity: 100%","43 samples","","no","","2021-05-27 09:58:56",
"1159","Re: Profile of specific antibodies to SARS-CoV-2: The first report","10.1016/j.jinf.2020.03.052","ImmunoAssay-Antibody","ELISA","IgM, IgG","kits (Zhuhai Livzon Diagnostics INC.)","Two respective enzyme-linked immunosorbent assay kits (Zhuhai Livzon Diagnostics INC.) were adopted to test the levels of SARS-CoV-2 specific IgM and IgG","Remark: dynamic profile of Ab","27 patients & 36 controls","","yes","","2021-05-27 10:15:00",
"1243","Real-life validation of the Panbio COVID-19 antigen rapid test (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2","10.1016/j.eclinm.2020.100677","ImmunoAssay-Antigen","LFIA","nucleocapsid protein"," Panbio COVID-19 Ag rapid test device by Abbott (Lake Country, IL, U.S.A)","Evaluation of Panbio test compared with results from Allplex 19-nCoV multiplex platform for detection of SARS-CoV-2 (Seegene, South-Korea)","Specificity: 100% ; Sensitivity: 95.2% (Utrecht samples), 98.0% (Aruba samples) ; remarks: more sensitivity values are available for both sets of samples and for different Ct values","1575 samples","","yes","","2021-05-27 10:17:47",
"642","Real-life validation of the Panbio COVID-19 Antigen Rapid Test (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infection","10.1101/2020.10.16.20214189 ","ImmunoAssay-Antigen"," ","nucleocapsid  protein","kit (LFA immunochromatography assay)","Panbio™ COVID-19 Ag Rapid Test (Abbott)","specificity: 100%; sensitivity:  72.6% (NL), 81% (Aruba), >95%  (nasopharyngeal  samples) ","1367 (NL) & 208 (Aruba) samples","","no","","2021-05-27 09:59:14",
"493","Real-time diagnosis of reactive oxygen species (ROS) in fresh sputum by electrochemical tracing; correlation between COVID-19 and viral-induced ROS in lung/respiratory epithelium during this pandemic","10.1016/j.bios.2020.112435","Others"," ","Mitochondrial ROS","Electrochemical sensor","electrochemical ROS/H2O2 system (Patent pub. No: US, 2018/0299401 A1, Pub. Date: Oct. 18, 2018)","Accuracy: 97%; Sensitivity: 97%; Specificity: 91%","142 sputum samples","","yes","","2021-05-27 09:54:52",
"596","Real-time PCR-based SARS-CoV-2 detection in Canadian laboratories","10.1016/j.jcv.2020.104433","NucleicAcid-PCR based","PCR_KIT","multiple targets","in house & kits","Laboratory developed tests (LDTs) and kits comparison","Remark: LoD of the various LDTs were between 3.4 and 4.5 log10 copies/mL; Most commercial methods were equivalent to LDTs, with only a few assays that showed reduced sensitivity","/","","yes","","2021-05-27 09:57:55",
"856","Real-time RT-PCR diagnostics of virus causing COVID-19","10.17749/2070-4909.2020.13.1.52-63","NucleicAcid-PCR based","RT-PCR"," ","in house RT-PCR","article in Russian","sensitivity: 100%; specificity: 100%","440 samples"," ","yes (paper not in English)","","2021-05-27 10:06:09",
"996","Real-time RT-PCR for the detection of SARS-CoV-2 nucleic acid ","10.3760/cma.j.cn112309-20200318-00124","","","","","","","","","yes (paper not in English)","","2021-05-27 10:09:55",
"832","Real-world evaluation of a novel technology for quantitative simultaneous antibody detection against multiple SARS-CoV-2 antigens in a cohort of patients presenting with COVID-19 syndrome","10.1039/d0an01066a","ImmunoAssay-Antibody","Other Immuno assay","IgG, IgM, IgA"," gold nanoparticle array","simultanous detection of 3 antibodies against S1, S2, and N","sensitivity: 88% (+10dpo); specificity: 77% (+10 dpo)","74 patients"," ","yes","","2021-05-27 10:05:26",
"86","Recent advances and perspectives of nucleic acid detection for coronavirus","10.1016/j.jpha.2020.02.010","NucleicAcid-PCR based","Mixed","Unclear","Unclear","","Not reported","None","","yes","","2021-05-27 09:44:24",
"655","Recent progress on the diagnosis of 2019 Novel Coronavirus","10.1111/tbed.13620","Review","Mixed","","","Review on diagnostic tests","Remark: review on different methods reporting performances","","","yes","","2021-05-27 09:59:39",
"725","Recognition of COVID-19 disease from X-ray images by hybrid model consisting of 2D curvelet transform, chaotic salp swarm algorithm and deep learning technique","10.1016/j.chaos.2020.110071","Imaging-X-ray"," ","chest X-rays","deep learning","hybrid model consisting of two-dimensional (2D) curvelet transformation, chaotic salp swarm algorithm (CSSA) and deep learning technique","Accuracy: 95.24%-99.69%; Specificity: 96.05-99.81%; Precision: 92.22%-99.62%","2905 images","","yes","","2021-05-27 10:01:56",
"307","Reconstructed diagnostic sensitivity and specificity of the RT-PCR test for COVID-19","10.1101/2020.04.24.20078949","NucleicAcid-PCR based","Other PCR method(s)","","Diagnostic sensitivity and specificity of the RT-PCR test for COVID-19 were reconstructed from data on 1014 patients in Wuhan","","Sensitivity 95%, specificity 95%"," 1014 samples","","no","","2021-05-27 09:49:25",
"1160","Reliability and usefulness of a rapid IgM? IgG antibody test for the diagnosis of SARS-CoV-2 infection: a preliminary report","10.1016/j.jinf.2020.04.022","ImmunoAssay-Antibody","LFIA","IgM, IgG","kit (Beijing Diagreat Biotechnologies rapid test)","2019-nCoV IgG/IgM Antibody Rapid Test Kit (Beijing Diagreat Biotechnologies Co., Ltd)","sensitivity: 83%; specificity: 93%; concordance with PCR: 86.4%","30 patients & 7 controls","","yes","","2021-05-27 10:15:02",
"543","Reliability of serological tests for COVID-19: Comparison of three immunochromatography test kits for SARS-CoV-2 antibodies","10.1101/2020.06.28.20140475","ImmunoAssay-Antibody"," ","IgM, IgG","kits","2019-nCoV IgG/IgM Rapid Test Cassette (Hangzhou AllTest Biotech Co., Ltd., China), COVID-19 IgM/IgG Duo (SD BIOSENSOR, Korea), and 2019-nCoV IgG/IgM Detection Kit (Vazyme Biotech Co., Ltd., China)","specificity: 98.0% (IgM Hangzhou AllTest), 98.0% (IgM SD BIOSENSOR), 97.0% (IgM Vazyme Biotech), 99.0% (IgG all kits)","99 samples","","yes","","2021-05-27 09:56:22",
"387","Repeated seroprevalence of anti-SARS-CoV-2 IgG antibodies in a population-based sample from Geneva, Switzerland","10.1101/2020.05.02.20088898","ImmunoAssay-Antibody"," ","IgG on S1","ELISA","Euroimmun AG, Lubeck, Germany # EI 2606-9601 G","sensitivity: 86.2%; specificity: 100%","1335","","no","","2021-05-27 09:51:22",
"552","Resilient SARS-CoV-2 diagnostics workflows including viral heat inactivation","10.1101/2020.04.22.20074351","NucleicAcid-PCR based","PCR_KIT","N, RdRP gene (CDC)","WHO-7 (CDC), WHO-5 (Charitè)","","Remark: comparison of different RNA extraction methods and RT-PCR Mastemixes","/","","no","","2021-05-27 09:56:41",
"487","Response to correspondence received on our paper:Interpret with caution: an evaluation of the commercial AusDiagnostics versus in-house developed assays for the detection of SARS-CoV-2 virus","10.1016/j.jcv.2020.104484","Others"," ","","","","","","","","","2021-05-27 09:54:40",
"87","Reverse transcription loop-mediated isothermal amplification combined with nanoparticles-based biosensor for diagnosis of COVID-19","10.1101/2020.03.17.20037796","NucleicAcid-Others","LAMP","ORF1b-gene, N-gene","Other method","","Specificity: tested ; LOD: 12 cpr","129 samples","","no","","2021-05-27 09:44:26",
"574","Reverse-Transcription Recombinase-Aided Amplification Assay for Rapid Detection of the 2019 Novel Coronavirus (SARS-CoV-2)","10.1021/acs.analchem.0c01032","NucleicAcid-PCR based"," ","S, ORF1ab","RT-RAA","reverse-transcription recombinase-aided amplification (RT-RAA) assay","sensitivity: 10 cpr (S), 1 cpr (ORF1ab)","/","","Yes (full text NOT available)","","2021-05-27 09:57:14",
"1023","Review of Current Advances in Serologic Testing for COVID-19","10.1093/ajcp/aqaa112","review","Mixed","IgG, IgM, IgA","ELISA, CLIA, LFIA, PRNT","","","","","yes","","2021-05-27 10:10:26",
"1052","Review on machine and deep learning models for the detection and prediction of Coronavirus.","10.1016/j.matpr.2020.06.245","Imaging-Others","Other","CT scan and Xray ","","deep learning on different machine and deep learning models for the detection of coronavirus ","1) Transfer Deep Learning for automatically predicting COVID- 19; Type of data: Xray;  Accuracy: 98%; 2)Automated Technique for Detecting and Classifying Pneumonia-based using Deep Learning; Type of data: CT scan and Xray;  Accuracy: 96%; 3) Deep Learning for Screening COVID-19 pneumonia; Type of data: Ct scan; Accuracy: 86.7%; 4) Deep CNN; Type of data: X-ray; Accuracy: VGG19, DenseNet models f-scores = 0.89 ; 5) Automated Deep Convolutional Neural Network; Type of data: X-ray, 98%; 6) Support Vector Machine; Type of data: CT; Accuracy: 99,68%; 7) Support Vector Machine based on deep learning approach (Deep Features); Type of data: X-ray; Accuracy: SVM + ResNet50 (FPR = 95.52%, 1 score = 95.52%, MCC = 91.41% and Kappa = 90.76%)","/","","yes","","2021-05-27 10:11:23",
"421","Risk assessment via layered mobile contact tracing for epidemiological intervention","10.1101/2020.04.26.20080648","Others","In_silico","/","/","risk infection assessment via layered mobile contact tracing","/","/","","no","","2021-05-27 09:52:32",
"1093","Risk stratification through implementation and evaluation of a COVID-19 score: A retrospective diagnostic study Risikostratifizierung durch Implementierung und Evaluation eines COVID-19-Scores: Eine retrospektive Diagnostikstudie","10.1007/s00063-020-00754-4","Others","In_silico","","","","sensitivity: 98.4% ; specificity: 48.3%","697 patients","","yes (paper not in English)","","2021-05-27 10:12:48",
"1037","Room-temperature-storable PCR Mixes for SARS-CoV-2 Detection","10.1101/2020.04.07.029934","NucleicAcid-PCR based","RT-PCR","ORF1ab, N, S","rRT-PCR","optimized freeze-drying procedure that allows SARS-CoV-2 PCR mixes to be transported and stored at ambient temperatures, without loss of activity.","Sensitivity: 10^3 copies/mL (freez-dried and wet mixes); LoD95: 500 copies/mL (ORF1ab),   500 copies/mL (N), 200 copies/mL (S).","56 samples","","yes","","2021-05-27 10:10:52",
"941","RSNA Expert Consensus Statement on Reporting Chest CT Findings Related to COVID-19: Interobserver Agreement Between Chest Radiologists","10.1177/0846537120938328","Imaging-CT scan","Other","CT scans","CT scans","assessment of variability between chest radiologists in the interpretation of the expert guidelines in patients with suspected coronavirus disease pneumonia in a setting with limited reverse transcription polymerase chain reaction testing availability","remarks: tables with CT findings and agreement on reporting are available","303 patients","","yes","","2021-05-27 10:08:35",
"717","RT-LAMP for rapid diagnosis of coronavirus SARS-CoV-2","10.1111/1751-7915.13586","NucleicAcid-PCR based","LAMP","ORF1ab, S, N","in house LAMP","","Sensitivity: 80 copies of viral RNA/ml","16 samples","","yes","","2021-05-27 10:01:40",
"538","RT-PCR testing to detect a COVID-19 outbreak in Austria: rapid, accurate and early diagnosis in primary care (The REAP study)","10.1101/2020.07.13.20152439","NucleicAcid-PCR based","PCR_KIT","Not specified","In house","","Sensitivity: 100% (acute presenters), 50% (second half of outbreak); Specificity: 100%","73 patients","","No","","2021-05-27 09:56:12",
"88","RT-QPCR detection of SARS-CoV-2 RNA from patient nasopharyngeal swab using Qiagen Rneasy kits or directly via omission of an RNA extraction step","10.1101/2020.03.20.001008","NucleicAcid-PCR based","WHO method(s)","Multiple targets on N-gene","WHO-7","","Not reported","2 samples","","yes","","2021-05-27 09:44:28",
"527","Saliva as a Noninvasive Specimen for Detection of SARS-CoV-2","10.1128/jcm.00776-20","NucleicAcid-PCR based","PCR_KIT","Not specified","kit","AusDiagnostics, Mascot, Australia","Remark: saliva sensitivity is lower than swabs","522 saliva samples","","yes","","2021-05-27 09:55:51",
"1266","Saliva as a testing specimen with or without pooling for SARS-CoV-2 detection by multiplex RT-PCR test.","10.1371/journal.pone.0243183","NucleicAcid-PCR based","RT-PCR","N, E, ORF1ab genes","in house rRT-PCR and QuantiVirus™ Saliva Collection Kit (DiaCarta, Inc.)","saliva collection kit validated by in house rRT-PCR","LOD: 200 copies/ml ; sensitivity: 98.8% ; specificity: 100% ; PPV: 100% ; NPV: 98.9%","462 samples pooled","","yes","","2021-05-27 10:18:34",
"218","Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs","10.1101/2020.04.16.20067835","NucleicAcid-PCR based","WHO method(s)","Multiple targets on N-gene","WHO-7","","Not reported","142 patients","","yes","","2021-05-27 09:47:27",
"992","Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study","10.1016/j.cmi.2020.05.001","NucleicAcid-PCR based","PCR_KIT","ORF1ab, N gene","SARS-CoV-2 Nucleic Acid Diagnostic Kit (Sansure, Changsha, China)","","sensitivity: 84.2% (saliva) ; specificity: 98.9% (saliva)","200 patients","","yes","","2021-05-27 10:09:47",
"219","Saliva Sample as a Non-Invasive Specimen for the Diagnosis of Coronavirus Disease-2019 (COVID-19): a Cross-Sectional Study","10.1101/2020.04.17.20070045","NucleicAcid-PCR based","WHO method(s)","ORF1ab-gene, N-gene","WHO-1, individual-kit","Kit: Sansure Biotech","LOD: 200 copies (RT-PCR test) ; Specificity: 98.9% ; Sensitivity: 84.2%","200 patients","","yes","","2021-05-27 09:47:30",
"1277","Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19.","10.1101/2020.08.07.20170258","ImmunoAssay-Antibody","Other Immuno assay","IgA vs N, S","rapid immunoassay (Brevitest platform)","BRAVO (Brevitest IgA Salivary Mucosal Test)","PPV: 92%; NPV:97%","87 samples","","no","","2021-05-27 10:18:56",
"1083","Sample pooling is a viable strategy for SARS-CoV-2 detection in low-prevalence settings","10.1016/j.pathol.2020.09.005","NucleicAcid-PCR based","RT-PCR","RdRp, N, E","Pooling DNA","Pooling is a viable strategy for high-throughput testing of SARS-CoV-2 in low-prevalence settings.","","1000 patients","","yes","","2021-05-27 10:12:27",
"220","Sample-Efficient Deep Learning for COVID-19 Diagnosis Based on CT Scans","10.1101/2020.04.13.20063941","Others","In_silico","","","","","","","no","","2021-05-27 09:47:32",
"757","Sampling and detection of corona viruses in air: A mini review","10.1016/j.scitotenv.2020.140207","Review","Other PCR method(s)","","dPCR, LAMP, RT-qPCR","mini review with some performance data of detection methods used on air samples","","","","yes","","2021-05-27 10:03:02",
"962","SARS n-CoV2-19 detection from chest x-ray images using deep neural networks","10.1108/IJPCC-06-2020-0060","Imaging-X-ray","In_silico","X-rays","X-rays","use deep learning technique for automatic detection of COVID-19 using chest x-rays","Accuracy: 92.5-96%","1428 x-rays","","yes","","2021-05-27 10:08:53",
"634","SARS-Coronavirus-2 nucleocapsid protein measured in blood using a Simoa ultra-sensitive immunoassay differentiates COVID-19 infection with high clinical sensitivity","10.1101/2020.08.14.20175356","ImmunoAssay-Antigen"," ","N-protein","in house","single molecule array (Simoa) immunoassay on the automated HD-X platform","LOD: 0.2 pg/ml; specificity : 100%; sensitivity: 97.4%","100 samples","","no","","2021-05-27 09:59:02",
"1044","SARS-CoV-2 and the COVID-19 disease: a mini review on diagnostic methods.","10.1590/s1678-9946202062044","review","Mixed","","","Performances of few RT-PCR methods reported in a table","","","","yes","","2021-05-27 10:11:07",
"609","SARS-CoV-2 antibody characterization in emergency department, hospitalized and convalescent patients by two semi-quantitative immunoassays","10.1016/j.cca.2020.06.004","ImmunoAssay-Antibody"," ","IgM/IgG","kits","Pylon COVID-19 IgM and IgG assays :Cyclic enhanced fluorescence assay (CEFA);  SARS-CoV-2 MIA: microsphere immunoassay (MIA),","Sensitivity: 25% (CEFA, 0-3 dpo), 14.3 (MIA, 0-3 dpo), 21.2% (CEFA, 4-7 dpo), 25% (MIA, 4-7 dpo), 69% (CEFA, 8-14 dpo), 65% (MIA, 8-14 dpo), 93.3% (15-20 dpo), 93.3% (MIA, 15-20 dpo), 100% (CEFA, >21 dpo), 100% (MIA, >21 dpo) ","994 samples (916 patients)","","yes","","2021-05-27 09:58:17",
"727","SARS-CoV-2 antibody testing-questions to be asked","10.1016/j.jaci.2020.05.020","ImmunoAssay-Antibody"," ","","","review containing kits performance data and comparing 21 commercial SARS-CoV-2 immunoassays and 1 laboratory-developed assay detecting IgM and IgG antibodies plotted against various prevalence settings.","","","","yes","","2021-05-27 10:02:00",
"572","SARS-CoV-2 Coronavirus Nucleocapsid Antigen-Detecting Half-Strip Lateral Flow Assay Toward the Development of Point of Care Tests Using Commercially Available Reagents","10.1021/acs.analchem.0c01975","ImmunoAssay-Antigen"," ","N-protein","LFA","Half-strip Antigen detecting lateral Flow assay","LOD:  0.65 ng/mL ","/","","yes","","2021-05-27 09:57:10",
"597","SARS-CoV-2 detection by direct rRT-PCR without RNA extraction","10.1016/j.jcv.2020.104423","NucleicAcid-PCR based","PCR_KIT","E, S, RdRP","kit","comparison between direct PCR using SeeGene AllplexTM 2019-nCoV rRT-PCR with RealStar® SARS-CoV-2 rRT-PCR kit (Altona Diagnostics)","Reamrk: i) SeeGene and Altona kits provide similar efficiency, ii) direct rRT-PCR without RNA extraction is possible if samples are collected in UTM or molecular water; ii), specimens stored in water should be screened rapidly, iii) RNA extraction is necessary if samples are in saline water or Hanks medium.","95 samples","","yes","","2021-05-27 09:57:57",
"1039","SARS-CoV-2 detection from nasopharyngeal swab samples without RNA extraction","10.1101/2020.03.28.013508","NucleicAcid-PCR based","PCR_KIT","ORF1ab, N, S (Thermofisher); N1, N2 (IDT)","kits (direct detection)","direct SARSCoV-2 detection from nasopharyngeal swab samples with TaqMan™ 2019-nCoV Assay Kit v1 (ThermoFisher) and 2019-nCoV CDC qPCR Probe Assay (Integrated DNA Technologies).","remark: the kit from Thermo Fisher Scientific is fully compatible with an RNA extraction-free protocol with an efficiency comparable to that obtained using kit-extracted RNA","2 patients","","no","","2021-05-27 10:10:57",
"1125","SARS-CoV-2 detection in different respiratory sites: A systematic review and meta-analysis","10.1016/j.ebiom.2020.102903","review","Other","mixed","mixed","comparison of respiratory sampling strategies ","percentage of positive tests: 75% (oropharyngeal swab, 0–7 dpo), 35% (oropharyngeal swab, 8–14 dpo), 12% (oropharyngeal swab, +14 dpo), 80% (nasopharyngeal swabs, 0–7 dpo), 59% (nasopharyngeal swabs 8–14 dpo), 36% (nasopharyngeal swabs, +14 dpo), 98% (sputum, 0–7 dpo), 69% (sputum, 8–14 dpo), 46% (sputum, +14 dpo) ","/"," ","yes","","2021-05-27 10:13:54",
"254","SARS-CoV-2 detection in patients with influenza-like illness","10.1038/s41564-020-0713-1","NucleicAcid-PCR based","PCR_KIT","ORF1ab-gene, N-gene","Individual-kit","Kit: quantitative PCR assay (BioGerm) approved by the China CDC and National Medical Products Administration","Not reported","640 samples","","yes","","2021-05-27 09:48:09",
"820","SARS-CoV-2 detection in setting of viral swabs scarcity: Are MRSA swabs and viral swabs equivalent?","10.1371/journal.pone.0237127","NucleicAcid-PCR based","PCR_KIT","S, ORF1ab","Simplexa COVID-19 Direct Kit (DiaSorin)","comparison of results between  nasal MRSA swab and viral swabs","concordance: 80/81","81 samples"," ","yes","","2021-05-27 10:05:05",
"312","SARS-CoV-2 Detection Using an Isothermal Amplification Reaction and a Rapid, Inexpensive Protocol for Sample Inactivation and Purification","10.1101/2020.04.23.20076877","NucleicAcid-PCR based","LAMP","ORF1ab","In-house RT-LAMP","Combined with rapid inactivation and purification steps compatible with other tests","LOD: 5cpu (inactivation), 2cpu (purification)","Not specified","","no","","2021-05-27 09:49:35",
"90","SARS-CoV-2 detection using digital PCR for COVID-19 diagnosis, treatment monitoring and criteria for discharge","10.1101/2020.03.24.20042689","NucleicAcid-PCR based","WHO method(s)","ORF1ab-gene, N-gene, S-gene","WHO in ddPCR","","Sensitivity: tested ; LLOD: 10 fold lower than real time PCR","36 patients, 108 samples","","no","","2021-05-27 09:44:30",
"157","SARS-CoV-2 detection with CRISPR diagnostics","10.1101/2020.04.10.023358","NucleicAcid-Others","CRISPR","RdRp-region","WHO-5","","LOD: 10 cpm ; Specificity: 100%","Not reported","","no","","2021-05-27 09:45:49",
"685","SARS-CoV-2 diagnostic diary: From rumors to the first case. early reports of molecular tests from the military research and diagnostic institute of Rio de Janeiro","10.1590/0074-02760200200","NucleicAcid-PCR based","RT_PCR","N1 and n2","","First covid report in Brazil in military ","","1300","","yes","","2021-05-27 10:00:40",
"1208","SARS-CoV-2 genomes recovered by long amplicon tiling multiplex approach using nanopore sequencing and applicable to other sequencing platforms","10.1101/2020.04.30.069039","Others","Other","full genome SARS-CoV-2","in house","The usage of unique primer set designed to recover long reads of SARS-CoV-2 c","/","/","","no","","2021-05-27 10:16:37",
"583","SARS-CoV-2 IGM and IGG rapid serologic test for the diagnosis of COVID-19 in the emergency department","10.1016/j.jinf.2020.07.032","ImmunoAssay-Antibody"," ","IgG, IgM","kit","lateral flow immunoassay (LFI)","sensitivity: 75%; specificity: 80.3%; PPV: 35.7%; NPV: 95,7%","157 patients","","yes","","2021-05-27 09:57:30",
"720","SARS-CoV-2 infection serology: a useful tool to overcome lockdown?","10.1038/s41420-020-0275-2","ImmunoAssay-Antibody"," ","IgG/IgM vs N, S","kits","comparison of two different immunochromatographic cards (Card1: 2019-nCoV IgG/IgM Rapid Test Cassette, Hangzhou AllTest Biotech Co, Hangzhou, China); Card2: Cellex qSARS IgG/IgM Rapid Test, Cellex, Inc., NC, USA), an immunofluorescence chromatographic card (Card3: POCT-fluorescence Coronavirus IgG/IgM antibodies detection kit ,Sichuan Xincheng Biological Co., China), and a chemiluminescence-automated immunoassay (CLIA: Shenzhen Mindray Bio-Medical Electronics Co., Shenzen, China)","Sensitivity: 61.4% (IgM Card1),	84.3% (IgG Card1), 87.8% (IgM Card2), 89.6% (IgG Card2), 84% (IgM Card3), 93% (IgG Card3), 84% (IgM CLIA), 95% (IgG CLIA); Specificity: 100% (IgM Card1),	100% (IgG Card1), 100% (IgM Card2), 100% (IgG Card2), 100% (IgM Card3), 100% (IgG Card3), 94% (IgM CLIA), 100% (IgG CLIA)","83 samples","","yes","","2021-05-27 10:01:46",
"279","SARS-CoV-2 is not detectable in the vaginal fluid of women with severe COVID-19 infection","10.1093/cid/ciaa375","NucleicAcid-PCR based","WHO method(s)","Unclear","WHO not clearly specified","","Not reported","10 patients","","no","","2021-05-27 09:48:27",
"316","SARS-CoV-2 On-the-Spot Virus Detection Directly From Patients","10.1101/2020.04.22.20072389","NucleicAcid-PCR based","LAMP","N gene","In-house RT-LAMP","","Not specified","182 patients","","no","","2021-05-27 09:49:43",
"786","SARS-CoV-2 RNA detection in the air and on surfaces in the COVID-19 ward of a hospital in Milan, Italy","10.1016/j.scitotenv.2020.140540","NucleicAcid-PCR based","PCR_KIT","not specified (environmental kit)","kit","VETfinder “Detection of CoV-19 and SARS and Recovery control in environmental sample” detection kit (Generon s.r.l., San Prospero, Modena, Italy)","positivity rate: 41.7% (ICU), 0% (clean areas), 35% (contaminated area), 50% (semi-contaminated area)","42 samples (air and surface)","","yes","","2021-05-27 10:03:59",
"911","SARS-CoV-2 RNA Extraction Using Magnetic Beads for Rapid Large-Scale Testing by RT-qPCR and RT-LAMP","10.3390/v12080863","NucleicAcid-Others","PCR_KIT & other","N, E genes","WHO-5 E gene, RT-LAMP N gene","RNA extraction methods tested with different RT-PCR, LAMP assays","Sensitivity: 100% (RT-PCR, up to Ct35), 97% (RT-LAMP, Ct cutoff 30), 100% (RT-LAMP, time point 25 min) ; Specificity: 96% (RT-PCR), 100% (RT-LAMP)","82 samples","","yes","","2021-05-27 10:07:43",
"760","SARS-CoV-2 RNA in wastewater anticipated COVID-19 occurrence in a low prevalence area","10.1016/j.watres.2020.115942","NucleicAcid-PCR based","RT-PCR","N gene, three targets","US CDC qPCR kit","","LOD: 50gc ; theoretical limit of quantification: 4.45log10 gc/L (N1), 4.91log10 gc/L (N2), 4.75log10 gc/L (N3). Remarks: wastewater and effluent water samples","72 water samples","","yes","","2021-05-27 10:03:08",
"1223","SARS-CoV-2 sample-to-answer nucleic acid testing in a tertiary care emergency department: evaluation and utility","10.1101/2020.07.03.20145383","NucleicAcid-PCR based","PCR_KIT"," ","Cepheid Xpert ® Xpress SARS-CoV-2, Mobidiag Novodiag ® 25 Covid-19"," ","sensitivity: 100% (Xpert), 93.4% (Novodiag), specificity: 100% (both assays)","107 samples"," ","no","","2021-05-27 10:17:07",
"458","SARS-CoV-2 serological analysis of COVID-19 hospitalized patients, pauci-symptomatic individuals and blood donors","10.1101/2020.04.21.20068858","ImmunoAssay-Antibody"," ","IgG vs N,S (ELISA), S (S-Flow), S, N antigens (LIPS)","in-house ELISA & S-Flow assay & LIPS assay","S-Flow is based on recognition of S by flow citometry; LIPS recognizes antigens by immunoprecipitation","Remark: variations in sensitivity can be attributed to the technique and the antigen in use; graphs reported in supplementary material, but not clear indication of the values for each assay","951","","no","","2021-05-27 09:53:42",
"112","SARS-CoV-2 specific antibody responses in COVID-19 patients","10.1101/2020.03.18.20038059v1","ImmunoAssay-Antibody"," ","IgM/IgA","In-house method and individual kit","Kit: EUROIMMUN","Sensitivity: cross comparison","195 samples","","no","","2021-05-27 09:44:55",
"699","SARS-CoV-2-IgG response is different in COVID-19 outpatients and asymptomatic contact persons","10.1016/j.jcv.2020.104542","Mixed","Mixed","S1 spike protein","","In summary, our study shows that SARS-CoV-2-IgG antibodies arefound significantly less frequently in PCR-positive asymptomatic con-tactpersonscomparedtoPCR-positiveoutpatients.S","","137 patients","","yes","","2021-05-27 10:01:09",
"462","Scalable and Resilient SARS-CoV2 testing in an Academic Centre","10.1101/2020.04.19.20071373","NucleicAcid-PCR based","PCR_KIT","ORF1ab (N used for vaidation)","kit","validation of their kit (ORF1ab) versus Hologic kit (N)","Sensitivity: 92.86%; Specificity: 100%","94","","no","","2021-05-27 09:53:51",
"553","Scaling diagnostics in times of COVID-19: Colorimetric Loop-mediated Isothermal Amplification (LAMP) assisted by a 3D-printed incubator for cost-effective and scalable detection of SARS-CoV-2","10.1101/2020.04.09.20058651","NucleicAcid-PCR based","LAMP","N","in house","In house LAMP","LOD: 62 copies","Plasmid & 8 samples","","no","","2021-05-27 09:56:43",
"968","Scent dog identification of samples from COVID-19 patients - A pilot study","10.1186/s12879-020-05281-3","Others","Other","Scent identification from Detection dog","Detection dog","Eight detection dogs were trained for 1 week to detect saliva or tracheobronchial secretions of SARS-CoV-2 infected patients in a randomised, double-blinded and controlled study","Overall detection avarage: 94%; Avarage diagnostic sensitivity: 82.63% Confidence interval: 95%  [CI]: 82.02–83.24%;  Specificity: 96.35% Confidence interval: 95% [CI]: 96.31–96.39%","1012 samples","","yes","","2021-05-27 10:09:04",
"569","Selective Naked-Eye Detection of SARS-CoV-2 Mediated by N Gene Targeted Antisense Oligonucleotide Capped Plasmonic Nanoparticles","10.1021/acsnano.0c03822","NucleicAcid-Others"," ","N","AuNP-LF","colorimetric assay based on gold nanoparticles capped with antisense oligonucleotide","LOD: 0.18 ng/?L RNA","/","","yes","","2021-05-27 09:57:03",
"1060","Self-collection: An appropriate alternative during the SARS-CoV-2 pandemic","10.1016/j.jcv.2020.104417","NucleicAcid-PCR based","PCR_KIT","E/RdRP, N2","kit & in-house","comparison between performance of self collected nasal & throat swabs and health-workers collected swabs. analysis performed with CFX96 Touch RT-PCR Detection Systems (BioRad, Hercules, California USA), and in-house developed Taqman assay targeting the E gene","Remark: Self collection was highly concordant with Helath-care collection (??=?0.890)","236 patients","","yes","","2021-05-27 10:11:40",
"1116","Sensitive and Simultaneous Detection of SARS-CoV-2-Specific IgM/IgG Using Lateral Flow Immunoassay Based on Dual-Mode Quantum Dot Nanobeads","10.1021/acs.analchem.0c03484","ImmunoAssay-Antibody","LFIA","IgM, IgG","in house LFIA","dual-mode LFIA biosensor for rapid and sensitive detection of SARS-CoV-2-specific IgM/IgG in clinical samples. By taking advantages of SiO2@Au@QD labels in the LFIA system, it detects low concentrations of IgM/IgG (1:106 dilution) from 1 ?L of serum within 15 min","specificity: 100% ; sensitivity: 100%","57 samples","","yes","","2021-05-27 10:13:35",
"91","Sensitive one-step isothermal detection of pathogen-derived RNAs","10.1101/2020.03.05.20031971","NucleicAcid-Others","LAMP","RdRp-region, E-gene, N-gene, S-gene","WHO-5","","LOD: 60 cpm","No clinical samples","","no","","2021-05-27 09:44:33",
"894","Sensitivity assessment of droplet digital PCR for SARS-CoV-2 detection","10.3892/ijmm.2020.4673","NucleicAcid-PCR based","dPCR","N1 gene","WHO-7","comparison of performances of WHO-7 N1 assays in RT-qPCR and dPCR using TaqMan probe, EvaGreen or SYBRgreen chemistry","LOD: 0.00187ng (EvaGreen ddPCR), 0.0187ng (SYBRgreen and TaqMan RT-qPCR)","2 patients","","yes","","2021-05-27 10:07:15",
"282","Sensitivity assessment of SARS-CoV-2 PCR assays developed by WHO referral laboratories","10.1101/2020.05.03.20072207","NucleicAcid-PCR based","PCR_KIT","RpRP, N, E, ORF1ab, ORF1b","Multiple kits","SARS-CoV-2 RT-PCR tests developed by Charite (Germany), HKU (Hong-Kong), China  CDC  (China),  US  CDC  (United-States),  and  Institut  Pasteur,  Paris  (France)","LOD: 1.36 log10TCID50/mL (N China CDC), 0.44 log10TCID50/mL (N1 US CDC), 0.63 log10TCID50/mL (RdRp IP2)","56 samples","","no","","2021-05-27 09:48:33",
"291","Sensitivity evaluation of 2019 novel coronavirus (SARS-CoV-2) RT-PCR detection kits and strategy to reduce false negative","10.1101/2020.04.28.20083956","NucleicAcid-PCR based","PCR_KIT","ORF1ab, N, E, RdRP","Multiple kits","5 kits= 1 kit China's CDC, 2 kits WHO, 2 self designed","Remark: kit 1 more sensitive","110 samples (10 positive & 100 suspected)","","no","","2021-05-27 09:48:52",
"819","Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019","10.1093/infdis/jiaa273","ImmunoAssay-Antibody","Other Immuno assay","Antibodies vs S, Antibodies vs N","luciferase immunoprecipitation","Quantitative measurements of plasma or serum antibodies","sensitivity: 100% (Ab vs N, +14 dpo), 91% (Ab vs S, +14 dpo); specificity:  100% (Ab vs N, +14 dpo), 100% (Ab vs S, +14 dpo)","100 samples"," ","yes","","2021-05-27 10:05:03",
"560","Sensitivity of nasopharyngeal swabs and saliva for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","10.1093/cid/ciaa848","NucleicAcid-PCR based","PCR_KIT","RdRp-region, E-gene, N-gene","kit","Allplex 2019-nCoV Assay (100T) (Seegene Inc, Seoul, Korea)","Sensitivity: 89% (nasopharyngeal swabs), 72% (saliva) ","91 patients","","yes","","2021-05-27 09:56:49",
"1202","Sensitivity of the Wondfo One Step COVID-19 test using serum samples","10.6061/clinics/2020/e2013","ImmunoAssay-Antibody","Mixed","","Wondfo One Step COVID-19 rapid test kits (Guangzhou, China) ","Comparison of sensitivity performance of Wondfo kit versus Euroimmun IgG test","Sensitivity in capillary blood: 55% Sensitivity on serum: 96%","47 patients","","yes","","2021-05-27 10:16:24",
"578","Sequence mismatch in PCR probes may mask the COVID-19 detection in Nepal","10.1016/j.mcp.2020.101599","NucleicAcid-Others","In_silico","whole genomes","","","Remark: Mutations in probe binding sites were found which could impact PCR efficiency resulting in false negative results","93 patients","","yes","","2021-05-27 09:57:22",
"437","Sequential informed pooling approach to detect SARS-CoV2 infection","10.1101/2020.04.24.20077966","Others","In_silico","/","/","pooling strategy for RT-PCR tests","/","/","","no","","2021-05-27 09:53:03",
"1235","Serodiagnostics for Severe Acute Respiratory Syndrome-Related Coronavirus 2 : A Narrative Review.","10.7326/M20-2854","review","Other","Ab","review on serological assay","review reporting performances","/","/","","yes","","2021-05-27 10:17:30",
"735","Serologic Response to SARS-CoV-2 in COVID-19 Patients with Different Severity","10.1007/s12250-020-00270-x","ImmunoAssay-Antibody","Mixed","IgM, IgG; ORF1ab, N","kits","two commercial qPCR kits: (Daan Gene, Guangzhou, China and BGI, Shenzhen, China); semi-quantitative magnetic particle chemiluminescence immunoassays (M-CLIAs)","consistency rate: 48.86% (qPCR and Ab test)","88 patients","","yes","","2021-05-27 10:02:17",
"336","Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France","10.1101/2020.05.19.20101832","ImmunoAssay-Antibody"," ","RBD (rapid test), S (S-flow), IgG, IgM","rapid immunodiagnostic test, S-Flow assay","Rapid test developed by Biosynex® , S-flow based on flow-citometry","specificity: 99.4% (rapid test), 99% (S-flow); Sensitivity: 88.1% (IgM rapid test), 71.2% (IgG rapid test), 95.6% (IgM+IgG rapid test), 99.4% (S-flow)","162","","no","","2021-05-27 09:50:18",
"516","Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020","10.2807/1560-7917.es.2020.25.16.2000421","ImmunoAssay-Antibody"," ","IgG, IgM vs RBD of Spike protein","ELISA","Performance evaluation in combination with confirmatory microneutralisation (MN) and 90% plaque reduction neutralisation tests (PRNT90)","Remark: PRNT more sensitive than MN; using IgG ELISA on RBD of spike, plus confirmation with PRNT is a valid approach ","51 serum samples from 24 positive cases & serum samples from 200 controls","","yes","","2021-05-27 09:55:33",
"1019","Serological chemiluminescence immunoassay for the diagnosis of SARS-CoV-2 infection","10.1002/jcla.23466","ImmunoAssay-Antibody","Other Immuno assay","IgG, IgM","CLIA Shenzhen Yhlo Biotech Co., Ltd","","sensitivity: 60% (IgM), 86.67% (IgG) 93.33% (IgM, cutoff value reassessed); specificity: 100% (IgM, IgG), 98% (IgM, cutoff value reassessed) ; PPV: 100% (IgM, IgG), 93.33% (IgM, cutoff value reassessed) ; NPV: 89.29% (IgM), 96.15% (IgG), 98% (IgM, cutoff value reassessed)","65 patients","","yes","","2021-05-27 10:10:20",
"1240","Serological cross-reactivity using a SARS-CoV-2 ELISA test in acute Zika virus infection Colombia.","10.1016/j.ijid.2020.09.1451","ImmunoAssay-Antibody","ELISA","IgG IgA IgM","INgezim COVID 19 DR test","investigation on seroreactivity by using a commercial SARSCoV-2 ELISA test in samples collected from groups from different individuals, including patients diagnosed to have Dengue, Zika,and Chikungunya virus infection, between 2015 and 2019, in the Caribbean Colombian region","sensitivity: 90.1%","127 samples","","yes","","2021-05-27 10:17:40",
"601","Serological detection of 2019-nCoV respond to the epidemic: A useful complement to nucleic acid testing","10.1016/j.intimp.2020.106861","ImmunoAssay-Antibody"," ","IgM, IgG vs S1, N","kit","Chemiluminescence Detection Kit (Shenzhen Yahuilong Biotechnology Co. Ltd., Shenzhen, China)","Remark: areas under the ROC curves for IgM and IgG were 0.984 and 1.000, respectively","742 subjects","","yes","","2021-05-27 09:58:01",
"92","Serological detection of 2019-nCoV respond to the epidemic: A useful complement to nucleic acid testing","10.1101/2020.03.04.20030916","ImmunoAssay-Antibody"," ","IgM/IgG on N-protein, S-protein","Individual-kit","Kit: Shenzhen Yhlo Biotech","Specificity: 97% ; Sensitivity: 100%","736 but (only 3 + for Covid-19)","","no","","2021-05-27 09:44:35",
"93","Serological diagnostic kit of SARS-CoV-2 antibodies using CHO-expressed full-length SARS-CoV-2 S1 proteins","10.1101/2020.03.26.20042184","ImmunoAssay-Antibody"," ","IgM/IgG on S-protein","ELISA in-house-method","","Accuracy: 97.3% ; Sensitivity:  97.5%","412 patients, 257 negative controls","","no","","2021-05-27 09:44:37",
"827","Serological differentiation between COVID-19 and SARS infections","10.1080/22221751.2020.1780951","ImmunoAssay-Antibody","ELISA","IgM and IgG","capture ELISA","We developed and compared the performance of four different serological tests to comprehensively assess the cross-reactivity between COVID-19 and SARS patient sera","specificity: 100%; sensitivity: 96%","","","yes","","2021-05-27 10:05:20",
"17","Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients","10.1101/2020.03.13.20035428","ImmunoAssay-Antibody"," ","IgM/IgG","Individual-kit","Kit: Zhuhai Livzon Diagnositic Inc","Sensitivity: 11% (1-7 dpo), 96.8% (8-15 dpo)","134 patients","","no","","2021-05-27 09:42:45",
"587","Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients","10.1016/j.jinf.2020.03.051","ImmunoAssay-Antibody"," ","IgG, IgM","kit","colloidal gold-based immunochromatographic (ICG) strip","Sensitivity: 11.1% (1-7 dpo), 92.9% (8-14 dpo), 96.8% (>15 dpo)","134 samples","","yes","","2021-05-27 09:57:38",
"362","Serological tests facilitate identification of asymptomatic SARS-CoV-2 infection in Wuhan, China","10.1002/jmv.25904","ImmunoAssay-Antibody"," ","IgG, IgM","Kits","Beijing Innovita Biological Technology Co., Ltd., 2019-nCoV Ab Test (Colloidal Gold) and RT-PCR method (reported in Clin Chim Acta. Jun 2020;505:172-175)","Not specified","1402 patients","","yes","","2021-05-27 09:50:37",
"1192","Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset","10.1183/13993003.00763-2020","ImmunoAssay-Antibody","Other Immuno assay","IgG and IgM, N and ORF1ab genes","commercial ELISA, LFIA, CMIA, RT-PCR","three enzyme-linked immunosorbent assays (ELISA-Ab, ELISA-IgM and ELISA-IgG), three colloidal-gold lateral-flow immunoassays (LFIA-Ab, LFIA-IgM and LFIA-IgG) (Beijing Wantai Biological Pharmacy Enterprise Co., Ltd, Beijing, China) and two chemiluminescence microparticle immunoassays (CMIA-Ab and CMIA-IgM) (Xiamen InnoDx Biotech Co., Ltd, Xiamen, China), commercial one-step real-time reverse transcriptase polymerase chain reaction (RT-PCR) assay (Bio-Germ, Shanghai, China) ","Sensitivity: 97.5% (ELISA-Ab, LFIA-Ab), 96.3% (CMIA-Ab), 92.5% (ELISA-IgM), 86.3% (CMIA-IgM, LFIA-IgG), 88.8% (LFIA-IgM, ELISA-IgG) ; Specificity: 100% (ELISA-Ab, IgM, IgG), 99.3% (CMIA-Ab, IgM), 95.2% (LFIA-Ab), 98.1% (LFIA-IgM), 99.5% (LFIA-IgG)","80 patients","","yes","","2021-05-27 10:16:04",
"549","Seroprevalence and epidemiological characteristics of immunoglobulin M and G antibodies against SARS-CoV-2 in asymptomatic people in Wuhan, China","10.1101/2020.06.16.20132423","ImmunoAssay-Antibody"," ","IgM, IgG","in house","colloidal gold antibody method","Remark: seroprevalence study","18712","","no","","2021-05-27 09:56:35",
"411","Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital","10.1101/2020.04.27.20082289","ImmunoAssay-Antibody","Mixed","N1, N2 (RT-PCR); Ab versus RDB","RT-PCR CDC ","CDC-006-00019 (RT-PCR), Luminex (Ab)","Sensitivity: 97% (IgA,IgG,>10dpo), 75% (IgM, >10dpo); Specificity: 100% (IgM,IgG,>10dpo), 98% (IgA, >10dpo)","578","","no","","2021-05-27 09:52:11",
"422","Seroprevalence of COVID-19 virus infection in Guilan province, Iran","10.1101/2020.04.26.20079244","ImmunoAssay-Antibody"," ","IgG, IgM","kit","","Remark: data according to the manufacturer; Sensitivity: 97.1% (11-14dpo), 81.25% (4-10dpo); Remark: data measured; Sensitivity:63.3% (IgG, IgM); Specificity: 100% (IgG, IgM)","552","","no","","2021-05-27 09:52:34",
"417","Severe Acute Respiratory Syndrome Coronavirus 2 Serology in Asymptomatic Healthcare Professionals: Preliminary Experience of a Tertiary Italian Academic Center","10.1101/2020.04.27.20073858","ImmunoAssay-Antibody"," ","IgM, IgG","chemiluminescence immunoassay system","MAGLUMI 2019-nCoV IgM/IgG kit","Remark: provided by manufacturers; Sensitivity: 78.65% (IgM), 91.21% (IgG); Specificity: 97.5 (IgM), 97.33 (IgG)","133","","no","","2021-05-27 09:52:24",
"280","Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients","10.3201/eid2607.200841","ImmunoAssay-Antibody"," ","IgG, IgA on N-protein, S-protein","ELISA multiple-kits","ELISA in-house-method and beta-versions of two commercial kits from EUROIMMUN Medizinische Labordiagnostika AG","Remark: In-house-method ELISA RBD and N more sensitive than S1, ELISA kits S1 IgG more specific than IgA , but IgA higher Sensitivity: than IgG - dpo between 13-21--possible crossreactivity with other viruses","198 samples (only 3 covid19)","","no","","2021-05-27 09:48:29",
"416","Shedding of infectious SARS-CoV-2 in symptomatic neonates, children and adolescents","10.1101/2020.04.27.20076778","Others"," ","","/","cell culture and virus isolation (upper respiratory tract)","/","23","","no","","2021-05-27 09:52:22",
"1173","Side by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity","10.1093/clinchem/hvaa198","ImmunoAssay-Antibody","Other Immuno assay","Abbot: nucleocapside protein;Diasorin: spike protein; Roche:nucleocapside protein","Abbott, Diasorin, and Roche assays for the detection of anti-SARS-CoV-2 antibodies.","Comparison of performance  Abbott, Diasorin, and Roche assays for the detection of anti-SARS-CoV-2 antibodies.","Specificity: Abbott 99.2%; Roche 99.7% ; Diasorin 98.3%","1154 negative, 65 positive","","yes","","2021-05-27 10:15:27",
"95","Simple Strategy for Rapid and Sensitive Detection of 2019 novel coronavirus Based on Antibody","10.21203/rs.3.rs-16761/v1","ImmunoAssay-Antibody"," ","Unclear","LFIA individual-kit","Kit: Zhu Hai Livzon Diagnositics","Sensitivity: 63.4%","41 samples","","no","","2021-05-27 09:44:39",
"96","Simultaneous Detection of 2019 Novel Coronavirus and Influenza Virus by Double Fluorescent RT-PCR","10.21203/rs.3.rs-18989/v1","NucleicAcid-PCR based","PCR_KIT","RdRp-region, E-gene, N-gene, S-gene","Multiple-kits","Kits: Shanghai BioGerm Medical Biotechnology Co, Shuoshi novel coronaviruskit","LOD: 1000 cpm (kits)","3000 samples","","no","","2021-05-27 09:44:41",
"319","Smart Pooled sample Testing for COVID-19: A Possible Solution for Sparsity of Test Kits","10.1101/2020.04.21.20044594","NucleicAcid-PCR based","PCR_KIT","Not specified","Sample pooling strategy for PCR testing","Not specified","Not specified","Not specified","","no","","2021-05-27 09:49:50",
"423","Specific mutations in SARS-CoV2 RNA dependent RNA polymerase and helicase alter protein structure, dynamics and thus function: Effect on viral RNA replication","10.1101/2020.04.26.063024","Others","In_silico","/","/","structural analysis of SARS-CoV2. effect of mutation of RdRp on the protein structure","/","/","","no","","2021-05-27 09:52:36",
"1226","Specificity and Performance of Nucleocapsid and Spike-based SARS-CoV-2 Serologic Assays","10.1101/2020.08.05.20168476","ImmunoAssay-Antibody","ELISA","IgA, IgG","3 in house ELISA; Kits: EDI™ Novel Coronavirus COVID-19 ELISA IgG and IgM, Euroimmun Anti-SARS-CoV-2 ELISA IgG and IgA, lateral flow assay, DPP® COVID-19 IgM/IgG System (Chembio)","comparison of 3 in-house ELISA and 4 commercial ELISA kits","sensitivity: 90% (in-house trimer spike IgA), 90% (in-house trimer spike IgG), 89% (in-house nucleocapsidIgG), 73.7% (EDI nucleocapsid IgM), 84.5% (EDI nucleocapsid IgG), 95% (Euroimmun S1 IgA), 82.8% (Euroimmun S1 IgG), 82.0% (Chembio nucleocapsid IgM), 92% (Chembio nucleocapsid IgG); specificity: 100% (in-house trimer spike IgA), 99.3% (in-house trimer spike IgG), 98.3% (in-house nucleocapsid IgG), 100% (EDI nucleocapsid IgM), 95.1% (EDI nucleocapsid IgG), 93.7% (Euroimmun S1 IgA), 99.7% (Euroimmun S1 IgG), 91.7% (Chembio nucleocapsid IgM), 93.3% (Chembio nucleocapsid IgG).","400 samples"," ","no","","2021-05-27 10:17:14",
"1248","Specificity testing by point prevalence as a simple assessment strategy using the Roche Elecsys(R) Anti-SARS-CoV-2 immunoassay.","10.1016/j.ijid.2021.02.024","ImmunoAssay-Antibody","Other Immuno assay","IgG, IgA, IgM","e Roche Elecsys Anti-SARS-CoV2","strategy for validation and performance verification of serological assays without biobanking and standard clinical samples","Specificty: 99.84% ; NPV: 99.98%","627 patients","","yes","","2021-05-27 10:17:57",
"937","Spectrum of chest computed tomographic (CT) findings in coronavirus disease-19 (COVID-19) patients in India","10.1016/j.ejrad.2020.109147","Imaging-CT scan","Other","CT scans","CT scans","analysys of CT scans of positive RT-PCR symptomatic patients","Remarks: 34.7% of cases have lung abnormalities, table with distribution of lung findings in CT scans is available","147 patients","","yes","","2021-05-27 10:08:29",
"687","Spectrum of neuropsychiatric manifestations in COVID-19","10.1016/j.bbi.2020.06.020","Others"," ","neuropsychiatric symptoms","","Investigation of neuropsychiatric manifestations in COVID-19","","40469 patients","","yes","","2021-05-27 10:00:44",
"257","Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19","10.1002/jmv.25786","NucleicAcid-PCR based","Other PCR method(s)","Not specified","Not specified","","Not reported","610 patients","","yes","","2021-05-27 09:48:11",
"1244","Strand-Specific Reverse Transcription PCR for Detection of Replicating SARS-CoV-2.","10.3201/eid2702.204168","NucleicAcid-PCR based","RT-PCR","E gene (minus strand)","in house rRT-PCR","evaluation of in house rRT-PCR test compared to Panther Fusion SARS-CoV-2 Assay (Hologic Inc., https://www.hologic.com), the Panther Aptima SARS-CoV-2 Assay (Hologic Inc.), or the in-house rRT-PCR specific to the SARS-CoV-2 envelope gene","LOD: 5 cp/reaction ; remarks: comparison of Ct values for different RT-PCR tests is available","146 patients","","yes","","2021-05-27 10:17:49",
"1112","Streamlined inactivation, amplification, and Cas13-based detection of SARS-CoV-2","10.1038/s41467-020-19097-x","NucleicAcid-Others","CRISPR","","SHINE","SHINE (Streamlined Highlighting of Infections to Navigate Epidemics), RPA-based amplification and Cas13-based detection in a single step","Specificity: 100% ; sensitivity: 90%","50 samples","","yes","","2021-05-27 10:13:27",
"419","Structure of replicating SARS-CoV-2 polymerase","10.1101/2020.04.27.063180","Others","In_silico","/","/","microscopic structure of the SARS-CoV-2 RdRp","/","/","","no","","2021-05-27 09:52:28",
"1101","Structured reporting in portable chest radiographs: An essential tool in the diagnosis of COVID-19","10.1016/j.ejrad.2020.109414","Imaging-X-ray","Other","X-ray","X-ray","chest radiography compared with RT-PCR results","specificity: 98% ; sensitivity: 43% ; accuracy: 85% ; PPV: 88% ; NPV: 85% ; remarks: values when compared with RT-PCR results","582 patients","","yes","","2021-05-27 10:13:04",
"1213","Study on the expression levels of antibodies against SARS-CoV-2 at different period of disease and its related factors in 192 cases of COVID-19 patients","10.1101/2020.05.22.20102525","ImmunoAssay-Antibody","Other Immuno assay","IgM and IgG","Shenzhen New Industries Biomedical Engineering Co.,Ltd [Snibe], China","Describing the kinetics prodfile of antibodies against SARS-CoV-2 and explore the related factor of antibodies expression against SARS-CoV-2 in covid-19 patients","Positive test rate <7 days symptoms onset IgM: 14.7%, Positive test rate <7 days symptoms onset IgG: 26.4%; Positive test rate 8-14 days symptoms onset IgM: 56.6%; Positive test rate 8-14 days symptoms onset IgG: 66.5%; Positive test rate 15-21 days symptoms onset IgM: 82.8%; Positive test rate 15-21 days symptoms onset IgG: 91%; Positive test rate 22-28 days symptoms onset IgM: 84.9%; Positive test rate 22-28 days symptoms onset IgG: 94.8%; Positive test rate 29-35 days symptoms onset IgM: 75.5%; Positive test rate 29-35 days symptoms onset IgG: 93.5%; Positive test rate 36-42 days symptoms onset IgM: 67.4%;  Positive test rate 36-42 days symptoms onset IgG: 94.9%;  Positive test rate 43-49 days symptoms onset IgM: 62.5%;  Positive test rate 43-49 days symptoms onset IgG: 92.3%;  Positive test rate 50-56 days symptoms onset IgM: 58.7%; Positive test rate 50-56 days symptoms onset IgG: 96%; Positive test rate >56 days symptoms onset IgM: 41.2%;  Positive test rate >56 days symptoms onset IgG: 92.2%","192 patients","","no","","2021-05-27 10:16:47",
"471","Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin","10.1186/s12941-020-00358-y","NucleicAcid-Others","Mixed","","RT-PCR Charite","one case study","/","1 patient","","yes","","2021-05-27 09:54:09",
"1128","Supersensitive Multifluorophore RNA-FISH for Early Virus Detection and Flow-FISH by Using Click Chemistry","10.1002/cbic.202000081","Others","Other","m-RNA","in house probe for flow cytometry","Method for the detection of RNA transcripts in live cells. Multiple?fluorophore?containing oligonucleotide probes that hybridize to the mRNA  allow reliable detection and direct visualization of mRNA with only a very small number (5–10) of probe strands. The new method enabled the in?situ detection of viral transcripts as early as 4 hours after infection. A potential application could be the monitoring of leukemia therapy by flow?FISH to prevent dangerous relapse cases or the very early detection of virus infections now needed for the detection of the Corona virus to reduce the diagnostic gap and prevent uncontrolled propagation of the disease.","Remark: probes tested by targeting a ?1?kb RNA viral transcript of the rotavirus A (RVA) gene segment?7. After 4?hours post infection RVA, transcripts could be readily detected. The 15×3 probe set with only 0.05?ng?DNA/?L provides a clear shift in fluorescence compared to the negative control."," "," ","yes","","2021-05-27 10:14:00",
"614","Systematic review with meta-analysis of the accuracy of diagnostic tests for COVID-19","10.1016/j.ajic.2020.07.011","Others"," ","","","Review on diagnostic tests","Remark: review on different methods reporting performances","/","","yes","","2021-05-27 09:58:25",
"445","Tapestry: A Single-Round Smart Pooling Technique for COVID-19 Testing","10.1101/2020.04.23.20077727","Others","In_silico","N gene (CDC)","pooling strategy for RT-PCR","/","/","/","","no","","2021-05-27 09:53:20",
"160","Temporal detection and phylogenetic assessment of SARS-CoV-2 in municipal wastewater","10.1101/2020.04.15.20066746","NucleicAcid-PCR based","PCR_KIT","Multiple targets on N-gene","Individual-kit","Kit: CDC EUA IDT#10006606","LOD: 10 cpr ; remark: on plasmid","Not reported","","no","","2021-05-27 09:45:51",
"472","Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study","10.1016/S1473-3099(20)30196-1","NucleicAcid-Others","Mixed","RdRp, E genes; NP and RBD proteins","in house RT-PCR, EIA and Nanopore sequencing","/","/","23 patients","","yes","","2021-05-27 09:54:11",
"281","Test Agreement Between Roche Cobas 6800 and Cepheid GeneXpert Xpress SARS-CoV-2 Assays at High Cycle Threshold Ranges","10.1101/2020.05.05.078501","NucleicAcid-PCR based","PCR_KIT","ORF1, E (Cobas) N2, E (GeneXpert)","Multiple kits","Roche cobas 6800 SARS-CoV-2 , Cepheid GeneXpert Xpress SARS-CoV-2 assay, and a laboratory developed test (LDT) based on a modified CDC protocol","LOD: 100 cpml (Cobas), 250 cpml (GeneXpert)","35 samples","","no","","2021-05-27 09:48:31",
"1186","Test Agreement between Roche Cobas 6800 and Cepheid GeneXpert Xpress SARS-CoV-2 Assays at High Cycle Threshold Ranges","10.1128/JCM.01187-20","NucleicAcid-PCR based","PCR_KIT & other","E gene","Roche Cobas 6800 SARS-CoV-2 assay, the Cepheid GeneXpert Xpress SARS-CoV-2 assay, and a laboratory-developed test (LDT) based on a modified CDC protocol","the Cepheid GeneXpert Xpress SARS-CoV-2 assay and the Roche Cobas 6800 SARS-CoV-2 assay showed a high level of agreement among patients with high CT values","LoD: 100 copies/ml (Roche) 250 copies/ml (Cepheid)","35 samples","","yes","","2021-05-27 10:15:53",
"305","Test performance evaluation of SARS-CoV-2 serological assays","10.1101/2020.04.25.20074856","ImmunoAssay-Antigen"," ","IgM and IgG","ELISA LFA","Comparisons of percent positivity by time interval","Specificity greater than 95% for the majority of tests evaluated and >99% for 2 LFAs (Wondfo, Sure Biotech)","238 samples","","no","","2021-05-27 09:49:21",
"504","Testing for COVID-19: A few points to remember","/","ImmunoAssay-Antibody","ELISA","ELISA","","SARS-CoV-2 from Euroimmun (Germany)","Remark: full text available upon login at https://www.prolekare.cz/casopisy/casopis-lekaru-ceskych/2020-2-6/testovani-covid-19-co-bychom-meli-mit-na-pameti-122277","269 subjects","","yes","","2021-05-27 09:55:15",
"708","Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays","10.1016/j.rbmo.2020.06.001","Review"," ","","","review","remark: review on diagnostic assays reporting performance","/","","yes","","2021-05-27 10:01:26",
"824","Testing For SARS-CoV-2: The Day the World Turned its Attention to the Clinical Laboratory","10.1111/cts.12828","Review","Mixed","","NAAT assays, serological and antigen tests","availability of diagnostic tests","remark: sensitivity and specificity reported for all the methods discussed","","","yes","","2021-05-27 10:05:14",
"1236","Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with","10.1016/j.bios.2021.113008","ImmunoAssay-Antibody","Other Immuno assay","Ig","Roche Elecsys Anti-SARS-CoV-2 assay and Testing-on-a-probe (TOP) SARS-CoV-2 total RBD antibody (TAb) and Surrogate Neutralysing Antibody (SNAb)","Testing-on-a-probe assay compared to Cobas RT-PCR ","Sensitivity: 61.5% (TAb), 33.3% (Roche) ; LOD: 5RFU (TAb), 96% (SNAb) ; Specificity: 99.6% (TAb), 96.6% (SNAb)","120 patients","","yes","","2021-05-27 10:17:32",
"861","The Allplex 2019-nCoV (Seegene) assay: which performances are for SARS-CoV-2 infection diagnosis?","10.1007/s10096-020-03930-8","NucleicAcid-PCR based","PCR_KIT","E, N, RdRP genes","Allplex 2019-nCoV (Seegene), GeneFinder COVID-19 plus (Elitech)","Evaluation of performance of Allplex 2019-nCoV test compared with the GeneFinder COVID-19 plus assay and the diagnosis of the infectious disease specialist of the hospital","rate of agreement: 100% (clinical diagnosis) ; 92.7%(GeneFinder COVID-19 plus kit)","41 samples","","yes","","2021-05-27 10:06:19",
"696","The association of lung ultrasound images with COVID-19 infection in an emergency room cohort","10.1111/anae.15175","Imaging-Others"," ","lung","Imaging-Others","Imaging-Others for the triage of patients with suspected COVID?19 infection","sensitivity: 97% (83–100%); specificity: 62% (50–74%); positive predictive value: 54% (41–98%); negative predictive value: 98% (88–99%)","100 patients (31 positive)","","yes","","2021-05-27 10:01:03",
"684","The clinical characteristic of eight patients of COVID-19 with positive RT-PCR test after discharge","10.1002/jmv.26017","Others","Mixed","","","8 patients re-admitted to hospital after discharging with postive PCR but not syntoms and normal level of IL-6 and CT scan","","8 patients","","yes","","2021-05-27 10:00:38",
"98","The comparative superiority of IgM-IgG antibody test to real-time reverse transcriptase PCR detection for SARS-CoV-2 infection diagnosis","10.1101/2020.03.28.20045765","ImmunoAssay-Antibody"," ","IgM/IgG","Unclear","Kit: YHLO biotech?","Sensitivity: 78.4% (IgM), 96.8% (IgG)","133 patients","","no","","2021-05-27 09:44:43",
"1075","The contribution of acute phase reaction proteins to the diagnosis and treatment of 2019 novel coronavirus disease (COVID-19)","10.1017/S095026882000165X","Others","Other","complement 3 (C3), complement 4 (C4), C-reactive protein (CRP), serum amyloid A (SAA) and prealbumin (PA)","","acute-phase reaction proteins to the diagnosis and treatment","CRP and SAA in the COVID-19 group (including mild, moderate and severe patients) had increased significantly (P < 0.01), whereas the mean values of C3, C4 and PA decreased (P < 0.01)","102 patients","","yes","","2021-05-27 10:12:11",
"1184","The Detection of SARS-CoV-2 using the Cepheid Xpert Xpress SARS-CoV-2 and Roche 2 cobas SARS-CoV-2 Assays","10.1128/JCM.00772-20","NucleicAcid-PCR based","PCR_KIT","Chepeid: E gene, N gene; Roche: ORF1 E gene)","Cepheid Xpert Xpress SARS-CoV-2 assay and e Roche cobas SARS-CoV-2 assay","comparison of results from specimens tested with both assays","agreement of 99% for both kits","103 specimens","","yes","","2021-05-27 10:15:49",
"1008","The diagnosis of pandemic coronavirus pneumonia: A review of radiology examination and laboratory test.","10.1016/j.jcv.2020.104396","review","Mixed","mixed","qPCR, CT imaging","comparison of qPCR and CT imaging for COVID diagnosis","detection rate of CT is higher than qPCR","/"," ","yes","","2021-05-27 10:10:10",
"539","The diagnostic accuracy of nucleic acid point-of-care tests for human coronavirus: A systematic review and meta-analysis","10.1101/2020.07.09.20150235","NucleicAcid-Others","Mixed","","Multiple kits","LAMP, CRISPR and SAMBA-II Point of Care tests,","remark: review and metanalysis on POC tests","/","","no","","2021-05-27 09:56:14",
"1006","The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients.","10.1016/j.intimp.2020.106504","Others","Other"," 5 blood bio-markers","serological analysis","neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, platelet-to-lymphocyte ratio , and C-reactive protein","specificity: 63.6% (NLR), 55% (d-NLR), 44% (PLR); sensitivity: 88% (NLR), 84% (d-NLR), 77% (PLR)","93 patients"," ","yes","","2021-05-27 10:10:07",
"520","The diagnostic value of rapid anti IgM and IgG detecting tests in the identification of patients with SARS CoV-2 virus infection","10.1556/650.2020.31859","ImmunoAssay-Antibody"," ","IgG, IgM","kit","Anhui and Clungene rapid tests","Sensitivity: 33.3% (Anhui), 35.48% (Clungene); Specificity: 85.02% (Anhui),72.85% (Clungene). Remark: the authors conclude that these tests should NOT be used in differential diagnosis of infection","625 (anhui) & 1029 (Clungene)","","yes (paper not in English)","","2021-05-27 09:55:41",
"508","The different tests for the diagnosis of COVID-19 - A review in Brazil so far","10.5935/1518-0557.20200046","Others","Mixed","","","Review on diagnostic tests commercially available","Remark: review on different serological methods reporting performances","/","","yes","","2021-05-27 09:55:23",
"459","The impact of changes in diagnostic testing practices on estimates of COVID-19 transmission in the United States","10.1101/2020.04.20.20073338","Others","In_silico","R0, Rt","simulations","changes in test practice and delay in reporting can result in biased estimate of R0 and Rt","/","/","","no","","2021-05-27 09:53:44",
"376","The Impacts of Viral Inactivating Methods On Quantitative RT-PCR for COVID-19","10.1016/j.virusres.2020.197988","NucleicAcid-PCR based","Other PCR method(s)","N-gene, ORF1ab gene","RT-PCR","Evaluation of the effect of four virus inactivation methods","Not reported ","2 patients","","yes","","2021-05-27 09:51:01",
"837","The outlook for diagnostic purposes of the 2019-novel coronavirus disease","10.1002/jcp.29804","Review","Mixed"," ","review","overview of the different types of Clinical and Para?clinical diagnostic methods","/","/"," ","yes","","2021-05-27 10:05:36",
"221","The Potential Use of Unprocessed Sample for RT-qPCR Detection of COVID-19 without an RNA Extraction Step","10.1101/2020.04.06.028811","NucleicAcid-PCR based","WHO method(s)","Multiple targets on N-gene","WHO-7","","Not reported","Not reported","","no","","2021-05-27 09:47:34",
"461","The production of antibodies for SARS-CoV-2 and its clinical implication","10.1101/2020.04.20.20065953","ImmunoAssay-Antibody"," ","IgM, IgG vs N, S","MCLIA","Magnetic Chemiluminescence Enzyme Immunoassay","Sensitivity: 70.24% (IgG), 96.10% (IgM); Remark: upward trend in detection rate after sympthoms onset: 73.6% (IgM 13-15dpo), 97-8% (IgG 16-18 dpo)","221 patients","","no","","2021-05-27 09:53:49",
"707","The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients","10.1126/sciimmunol.abc8413","ImmunoAssay-Antibody"," ","Ig(tot), IgM vs RBD","in house ELISA","In-house RBD Ig and IgM ELISA","Sensitivity: 98% (Igtot, >9 dpo), 81% (IgM, >9 dpo), 57% (Igtot, <9 dpo), 43% (IgM, <9 dpo); Specificity: 100%","63 patients & 71 controls","","yes","","2021-05-27 10:01:24",
"430","The role of asymptomatic SARS-CoV-2 infections: rapid living systematic review and meta-analysis","10.1101/2020.04.25.20079103","Others","In_silico","/","/","review and meta-analysis on asympthomatic infections","/","/","","no","","2021-05-27 09:52:49",
"1036","The role of procalcitonin in early differential diagnosis of suspected children with COVID-19","10.1101/2020.04.07.20057315","Others","Other","procalcitonin","procalcitonin concentration in blood","","sensitivity: 65.9%;  specificity,: 78.6%; PPV: 82.9%; NPV: 59.2% ","72 patients","","no","","2021-05-27 10:10:50",
"973","The strategic alliance between clinical and molecular science in the war against sars-cov-2, with the rapid-diagnostics test as an indispensable weapon for front line doctors","10.3390/ijms21124446","ImmunoAssay-Others","Other Immuno assay","","rapid tests","comprison of performances of rapid tests vs RT-PCR","","","","yes","","2021-05-27 10:09:14",
"384","The UCSC SARS-CoV-2 Genome Browser","10.1101/2020.05.04.075945","Others","In_silico","genome","sequencing","UCSC genome browser for SARS-CoV-2","/","/","","no","","2021-05-27 09:51:16",
"287","The Utility of rRT-PCR in Diagnosis and Assessment of Case-fatality rates of COVID-19 In the Iranian Population. Positive Test Results are a Marker for Illness Severity","10.1101/2020.04.29.20085233","Others"," ","","","Clinical assessment of PCR positive cases","Not specified","96103 patients","","no","","2021-05-27 09:48:44",
"163","Time course quantitative detection of SARS-CoV-2 in Parisian wastewaters correlates with COVID-19 confirmed cases","10.1101/2020.04.12.20062679","NucleicAcid-PCR based","Other PCR method(s)","E-gene","Reference to other paper","See doi:10.1101/2020.03.29.20045880","Remark: focus on wastewater ; LOQ: 10^3 equivalent viral genomes per liter","31 samples","","no","","2021-05-27 09:45:53",
"853","Time-dependent changes in the seroprevalence of COVID-19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID-19","10.1111/hepr.13551","ImmunoAssay-Antibody","Other Immuno assay","IgG"," electrochemiluminescence immunoassay using Elecsys Anti-SARS-CoV-2 (S300) assay","study focus on asymptomatic liver disease outpatients","specificity: 98% (immunochomatography), 100% (Elecsys)","100 patients"," ","yes","","2021-05-27 10:06:03",
"260","Timely Diagnosis and Treatment Shortens the Time to Resolution of Coronavirus Disease (COVID-19) Pneumonia and Lowers the Highest and Last CT Scores From Sequential Chest CT","10.2214/AJR.20.23078","Others","In_silico","","","","","","","yes","","2021-05-27 09:48:13",
"164","Toilets dominate environmental detection of SARS-CoV-2 virus in a hospital","10.1101/2020.04.03.20052175","NucleicAcid-PCR based","PCR_KIT","Not specified","Individual-kit","Kit: Shanghai Chromysky Medical Research, China","Not reported","157 samples","","no","","2021-05-27 09:45:55",
"311","Towards the next phase: evaluation of serological assays for diagnostics and exposure assessment","10.1101/2020.04.23.20077156","ImmunoAssay-Antibody"," ","IgG, IgM, IgA","ELISA , CLIA, rapid antibody test","PRNT50 as reference","Specificity: wantai IgG 99%, IgG 99%, Euroimmune IgG 99%, IgA 94%, liaison 98%,","147 samples","","no","","2021-05-27 09:49:33",
"396","TRACKING AND PREDICTING COVID-19 RADIOLOGICAL TRAJECTORY USING DEEP LEARNING ON CHEST X-RAYS: INITIAL ACCURACY TESTING","10.1101/2020.05.01.20086207","Others","In_silico","chest x-ray","deep learning","ability of a deep learning algorithm at extracting features from chest x-rays to track and predict radiological evolution","accuracy: 82.7% (predict outcome between Worse and Improved cases)","224316 chest Imaging-X-ray","","no","","2021-05-27 09:51:41",
"919","Trends and Innovations in Biosensors for COVID-19 Mass Testing","10.1002/cbic.202000250","review","Other","","diffennt methods are reviewed","This work surveys the landscape of available and emerging biosensor technologies for COVID?19 testing","LOD and specificity reported for different methods","","","yes","","2021-05-27 10:07:56",
"806","Trends in the prevalence of COVID-19 infection in Rio Grande do Sul, Brazil: Repeated serological surveys ","10.1590/1413-81232020256.1.09632020","ImmunoAssay-Antibody","","IgM, IgG","WONDFO SARS-CoV-2","","Sensitivity: 86.4%, Specificity: 99.6%","596 patients","","yes","","2021-05-27 10:04:40",
"668","Triplex Real-Time RT-PCR for Severe Acute Respiratory Syndrome Coronavirus 2","10.3201/eid2607.201285","NucleicAcid-PCR based","RT_PCR","N2, E, Rnase P","triplex in house","internally controlled triplex SARS-CoV-2 rRT-PCR that targets the N and E genes. The N2 and E-gene targets have proven to be sensitive in singleplex formats","specificity 100%, LOD triplex 45cpm, LOD singleplex 5cp/microL","42 patients with other visures, 27 patients (10 positive sars-cov-2)","","yes","","2021-05-27 10:00:05",
"706","Two Detailed Plaque Assay Protocols for the Quantification of Infectious SARS-CoV-2","10.1002/cpmc.105","Others"," ","replication?competent lytic virions","Others","protocols of two quantitative methods to measure infectious SARS?CoV?2 by quantifying the plaques formed in cell culture upon infection with serial dilutions of a virus specimen","","","","yes","","2021-05-27 10:01:21",
"1148","Two serological approaches for detection of antibodies to SARS-CoV-2 in different scenarios: a screening tool and a point-of-care test","10.1016/j.diagmicrobio.2020.115167","ImmunoAssay-Antibody","Mixed","total Ab vs N","in house: DR-ELISA (INgezim COVID 19 DR), DR-LFA (INgezim COVID 19 CROM)","Two serological tools based on a double recognition assay: enzyme-linked immunosorbent assay (DR-ELISA) and lateral flow assay (DR-LFA)","sensitivity: 91.2% (DR-LFA), 100% (DR-ELISA); specificity: 100% (DR-LFA), 98.2% (DR-ELISA)","1065 samples","","yes","","2021-05-27 10:14:39",
"390","Ultra-fast and onsite interrogation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in environmental specimens via surface enhanced Raman scattering (SERS)","10.1101/2020.05.02.20086876","Others"," ","RBD of S1 (Raman); ORF1, N (RT-PCR)","Raman; RT-PCR kit","surface enhanced Raman scattering (SERS) ","Remark: environmental samples; Accuracy: 93.33% (1189/1182 ratio), 93.33% (LD1 scores); false positive rate: 10% (1189/1182 ratio), 0% (LD1 scores); false negative rate: 0% (1189/1182 ratio), 20% (LD1 scores)","17 water samples","","no","","2021-05-27 09:51:28",
"99","Ultra-Low-Cost Integrated Silicon-based Transducer for On-Site, Genetic Detection of Pathogens","10.1101/2020.03.23.002931","NucleicAcid-PCR based","Mixed","Not specified","PCR on Integrated Silicon-based Transducer","","Not reported","None","","no","","2021-05-27 09:44:45",
"906","Ultra-sensitive and high-throughput CRISPR-p owered COVID-19 diagnosis","10.1016/j.bios.2020.112316","NucleicAcid-Others","CRISPR","ORF1ab, N genes (WHO-1)","in house CRISPR based assay","","Specificity: 71.4% ; sensitivity: 100% ; LOD 2copies/samples","29 specimens","","yes","","2021-05-27 10:07:35",
"292","Ultra-Sensitive High-Resolution Profiling of Anti-SARS-CoV-2 Antibodies for Detecting Early Seroconversion in COVID-19 Patients","10.1101/2020.04.28.20083691","ImmunoAssay-Antibody"," ","IgG/IgM/IgA on Spike Protein/S1/RBD/N","Single molecule array assay","","Sensitivity: 86% (IgG+IgA) (7dpo); Specificity: 100% (IgG+IgA)","81 samples","","no","","2021-05-27 09:48:54",
"1242","Ultrarapid On-Site Detection of SARS-CoV-2 Infection Using Simple ATR-FTIR Spectroscopy and an Analysis Algorithm: High Sensitivity and","10.1021/acs.analchem.0c04608","Others","Other","","ATR-FTIR Spectroscopy","a superfast, reagent-free, and nondestructive approach of attenuated total reflection Fourier-transform infrared (ATR-FTIR) spectroscopy with subsequent chemometric analysis toward the prescreening of virus-infected samples","sensitivity: 95%; specificity: 89%","61 negatives and 20 positives","","yes","","2021-05-27 10:17:44",
"1053","Ultrasensitive detection of pathogenic viruses with electrochemical biosensor: State of the art.","10.1016/j.bios.2020.112431","review","Biosensor","mixed","multiple published biosensor systems","overview of biosensors technology for virus detection","tables 1-3 list virus biosensors and their performace","/"," ","yes","","2021-05-27 10:11:25",
"1127","Understanding, verifying, and implementing emergency use authorization molecular diagnostics for the detection of sars-cov-2 RNA","10.1128/JCM.00796-20","review","Other","N/A","N/A","commentary, general guidance for the verification of assays with  emergency use authorization","/","/"," ","no","","2021-05-27 10:13:58",
"1076","Unexpected diagnosis of COVID-19-associated disorders by SARS-CoV-2-specific serology","10.1016/j.jcv.2020.104568","ImmunoAssay-Antibody","Other Immuno assay","N protein","CE IVD-labeled Abbott SARS-CoV-2 IgG assay","Evaluation the analytical performances of the CE IVD-labeled Abbott SARS-CoV-2 IgG assay (Des Plaines, IL, USA) carried out with the automated Abbott Architect™ i2000","Sensitivity: 94%; Specificity: 100%; ","117 sera","","yes","","2021-05-27 10:12:13",
"631","Universal PCR and antibody testing demonstrate little to no transmission of SARS-CoV-2 in a rural community","10.1101/2020.08.15.20175786","ImmunoAssay-Antibody","Mixed","IgG vs N (Abott), IgG vs RBD (ELISA)","Multiple kits and in house","Abbott ARCHITECT and in-house ELISA","PPV: 99.11% (both tests), 44.19%-63.32% (only one test). Remark: cross-sectional survey of the prevalence and cumulative incidence of SARS-CoV-2 infection ","1891","","no","","2021-05-27 09:58:58",
"427","Unraveling the Myths of R0 in Controlling the Dynamics of COVID-19 Outbreak: a Modelling Perspective","10.1101/2020.04.25.20079319","Others","In_silico","/","/","use of modelling and dynamical systems techniques on epidemiological model","/","/","","no","","2021-05-27 09:52:42",
"641","Urgent need of rapid tests for SARS CoV-2 antigen detection: Evaluation of the SD-Biosensor antigen test for SARS-CoV-2","10.1016/j.jcv.2020.104654","ImmunoAssay-Antigen"," ","nucleoprotein","kit","STANDARD Q COVID-19 Ag (SD-Biosensor, RELAB, I)","Sensitivity: 70.6% (vs RT-PCR), 72.1% (diagnostic samples), 40% (screening samples); specificity: 100%; NPV: 87.4% (Vs RT-PCR); PPV: 100% (vs RT-PCR); concordance with RT-PCR: 90.3%","330 patients","","yes","","2021-05-27 09:59:12",
"388","Urine Proteome of COVID-19 Patients","10.1101/2020.05.02.20088666","Others"," ","proteome","LC-MS/MS","urine proteomic profile","/","6 patients & 32 controls","","no","","2021-05-27 09:51:24",
"740","US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2","10.3201/eid2608.201246","NucleicAcid-PCR based","RT-PCR","3 targets on N genes (CDC method)","validation in house","N3 false positives with SARS-CoV","efficiency: 101,2% (N1), 99,4% (N2), 102,6% (N3); LOD: 5copies/reaction, 1 × 10?1.5 TCID50/mL (extracted RNA), 1.0 × 10?1.5 TCID50/mL (N1 and N2, spiked material), 1.0 × 10?1 TCID50/mL (N3, spiked material); ","2437 specimens","","yes","","2021-05-27 10:02:27",
"790","Use of Machine Learning and Artificial Intelligence to predict SARS-CoV-2 infection from Full Blood Counts in a population","10.1016/j.intimp.2020.106705","Others","In_silico","blood counts","machine learning & AI","random forest and Lasso based regularized generalized linear models and artificial neural network","AUC: 94% (complete blood count), 84% (monocytes-leukocytes-eosinophils variable)","598 blood counts","","yes","","2021-05-27 10:04:07",
"765","Use of Whole Genome Sequencing Data for a First in Silico Specificity Evaluation of the RT-qPCR Assays Used for SARS-CoV-2 Detection","10.3390/ijms21155585","Others","In_silico","whole genome","in silico","bio-info analysis of publicly available genomes to evaluate the specificity of 12 RT-qPCR tests (consisting of a total of 30 primers and probe sets) ","Remark: good specificity of the assays. An exception is the first method developed by the China CDC, which exhibits three primer mismatches present in 358 SARS-CoV-2 genomes sequenced mainly in Europe from February 2020 onwards. The best results were obtained for the assay of Chan et al. (2020) targeting the gene coding for the spiking protein (S)","4755 genomes","","yes","","2021-05-27 10:03:18",
"1090","Using Artificial Intelligence to Detect COVID-19 and Community-acquired Pneumonia Based on Pulmonary CT: Evaluation of the Diagnostic accuracy","10.1148/radiol.2020200905","Imaging-CT scan","Other","CT scan","COVID-19 detection neural network (COVNet","retrospective and multicenter study.Deep learning model:  COVID-19 detection neural network (COVNet), was developed to extract visual features from volumetric chest CT scans for the detection of COVID-19"," sensitivity: 90%; specificity: 96% ","4352 chest CT scans from 3322 patients.","","yes","","2021-05-27 10:12:42",
"1086","Using machine learning of clinical data to diagnose COVID-19: A systematic review and meta-analysis","10.1186/s12911-020-01266-z","Others","Other","CRP, lymphocytes, neutrophils","machine learning XGBoost ","computational methods trained on large clinical datasets could yield ever more accurate COVID-19 diagnostic models to mitigate the impact of lack of testing.","Sensitivity: 92.5%; Specificity: 97.9%","546 patients","","yes","","2021-05-27 10:12:33",
"1246","Using Prenatal Blood Samples to Evaluate COVID-19 Rapid Serologic Tests Specificity.","10.1007/s10995-020-02981-9","ImmunoAssay-Antibody","LFIA","IgM, IgG","rapid LFIA kits: RDT#1: Hightop COVID-19 IgM/IgG Ab Rapid Test Kit (Qingdao Hantang Biological Technology Co., Ltd., Qingdao, China); RDT#2: COVID-19 IgG/IgM Rapid Test Kit (Nantong Egens Biotechnology Co. Ltd., Nantong, China); RDT#3: Orient Gene COVID-19 IgG/IgM Rapid Test (Zhejiang Orient Gene Biotech Co. Ltd, Huzhou, China). RDT#4: Standard Q COVID-19 IgM/IgG Duo Test (SD Biosensor, Gyeonggi-do, Republic of Korea).","evaluation of specificity of rapid serologic tests in stored serum samples from 2018","Specificity: 100% (RDTs #1, IgM and IgG), 100% (RDTs #2, IgM and IgG), 98.9% (RDTs #3, IgM),  94.4% (RDTs #3, IgG), 88.9% (RDTs #4, IgM),  100% (RDTs #4, IgG)","120 samples (RDTs #1), 80 samples (RDTs #2), 90 samples (RDTs #3 and #4)","","yes","","2021-05-27 10:17:53",
"1034","Using X-ray images and deep learning for automated detection of coronavirus disease","10.1080/07391102.2020.1767212","Imaging-X-ray","In_silico","X-ray and CT scan","deep learning","This paper conducts a comparative study of the use of the recent deep learning models to deal with detection and classification of coronavirus pneumonia","Inception_Resnet_V2 pre-trained model: accuracy: 92.18%; sensitivity: 92.11%; specificity: 96.06%; precision: 92.38%. DensNet201 model: accuracy: 88.03%; sensitivity: 87.94%; specificity: 93.97%; precision: 88.30%.","6087 images ","","yes","","2021-05-27 10:10:46",
"734","Utility of available methods for diagnosing SARS-CoV-2 in clinical samples","10.5812/pedinfect.103677","Review","Mixed","","review","","Remark: review on different methods reporting performance","/","","yes","","2021-05-27 10:02:15",
"752","Utility of lateral flow tests in SARS-CoV-2 infection monitorization ","10.37201/req/052.2020","ImmunoAssay-Antibody"," ","IgM , IgG","kit","We analyzed the usefulness of the SARS-CoV-2 rapid test of Autobio and tried to correlate its pattern with the severity of COVID19 infection.","specificity: 100% (IgG), 74% (IgM)","40 samples","","yes","","2021-05-27 10:02:52",
"863","Validation and performance comparison of three SARS-CoV-2 antibody assays","10.1002/jmv.26341","ImmunoAssay-Antibody","Mixed","IgM, IgG","Abbott COVID?2 IgG, STANDARD Q [SQ] IgM/IgG Duo and Wondfo total antibody test","Validation of two lateral flow assays (Wondfo Total Antibody and SQ IgM/IgG combo) and one chemiluminescent assay (Abbott IgG)","Specificity: 100% (SQ IgG, Wondfo Total), 99.62% (Abbott IgG), 98.87% (SQ IgM) ; sensitivity: 87.5% (SQ IgM) ; agreement: 8.5% (SQ IgM/IgG and Wondfo Total), 94.6% (SQ IgG and Abbott IgG)","1300 samples","","yes","","2021-05-27 10:06:23",
"926","Validation and verification of the Abbott RealTime SARS-CoV-2 assay analytical and clinical performance","10.1016/j.jcv.2020.104474","NucleicAcid-PCR based","RT-PCR","N1 and N2","RealTime SARS-CoV-2 assay EUA","Evaluation analytical and clinical performance of the RealTime SARS-CoV-2 assay compared to the SARS-CoV-2 CDC-based laboratory developed test","LOD: 50 copies/ml; Sensitivity: 93%; Specificity: 100%","24 patients","","yes","","2021-05-27 10:08:10",
"920","Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody","10.1515/cclm-2020-0594","ImmunoAssay-Antibody","Other Immuno assay","IgG","LIAISON SARS-CoV-2 from DiaSorin","A retrospective validation study was conducted including the serum of 125 patients in order to determine the analytical and clinical performances of the LIAISON®SARS-CoV-2 from DiaSorin® detecting anti-SARS-CoV-2 IgG and to compare its clinical performance with the enzyme-linked immunosorbent assay (ELISA) test from Euroimmun®","sensitivity: 100%; specificity: 99% compared to RTq PCR; sensitivity: 100%; specificity: 96% compared to ELISA","125 patients","","yes","","2021-05-27 10:07:58",
"283","Validation of a commercially available SARS-CoV-2 serological Immunoassay","10.1101/2020.05.02.20080879","ImmunoAssay-Antibody"," ","IgG and IgA on Spike Protein S1 (ELISA); IgG on Spike Protein (rIFA)","ELISA and recombinant  immunofluorescence  assay  (rIFA)","Euroimmun assay (ELISA), in house developed rIFA","Specificity:  97.3% (IgG, EI cutoff),  86.4%  (IgA, EI cutoff), 100% (IgG cutoff>1.5), 87% (IgG cutoff<0.5); PPV: 100% (IgG cutoff>1.5), 86% (IgG cutoff <0.5); Sensitivity: 97% (IgG cutoff <0.5), 86% (IgG cutoff>1.5), 91% (cutoff1.1, <21 dpo); NPV: 97% (IgG cutoff <0.5), 89% (IgG cutoff>1.5), 62% (cutoff1.1, <21 dpo)","181 cases & 176 controls","","no","","2021-05-27 09:48:36",
"977","Validation of a commercially available SARS-CoV-2 serological immunoassay","10.1016/j.cmi.2020.06.024","ImmunoAssay-Antibody","ELISA","IgG and IGA","Euroimmun AG, Lübeck, Germany, # EI 2606-9601 G and # EI 2606-9601 A","","AUC: 99% (IgG), 97.8% (IgA) ; Specificity: 100% ; Sensitivity: 94% ; PPV: 100% ; NPV: 97%","506 patients","","yes","","2021-05-27 10:09:20",
"1284","Validation of a duplex PCR technique using the gen E and RNase P for the diagnosis of SARS-CoV-2.","10.1016/j.eimc.2020.12.014","NucleicAcid-PCR based","RT-PCR","E, RNase P","RT-PCR & kit","comparison of the duplex PCR technique (E gene and RNase P) against the monoplex standard (Charite, E gene)","Sensitivity: 90%; specificity: 87%","88 samples","","yes","","2021-05-27 10:19:11",
"537","Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan","10.1101/2020.07.16.20155796","ImmunoAssay-Antibody"," ","IgM, IgG vs N, S","CLIA","iFlash3000 CLIA analyzer","Remark: concordance rates of the antibody test with the PCR test were 98.1% (IgM) and 100% (IgG) among PCR-negative cases and 30.8% (IgM) and 73.1% (IgG) among PCR-positive cases ","199 samples","","no","","2021-05-27 09:56:10",
"310","Validation of a SARS-CoV-2 spike ELISA for use in contact investigations and serosurveillance","10.1101/2020.04.24.057323","ImmunoAssay-Antigen"," ","spike protein","ELISA","","Specificity 99.3% , sensitivity 96%","618 samples","","no","","2021-05-27 09:49:31",
"299","Validation of a Single-step, Single-tube Reverse Transcription-Loop-Mediated Isothermal Amplification Assay for Rapid Detection of SARS-CoV-2 RNA","10.1101/2020.04.28.067363","NucleicAcid-PCR based","LAMP","N1 ","Commercial RT-LAMP ","Single Tube OptiGene Ltd Mastemix and CDC N1 primers (N1-STOP LAMP)","Sensitivity: 87%; Specificity: 100%; LOD: 54 TCID50 mL-1; PPV: 100%; NPV: 78%","157 samples","","no","","2021-05-27 09:49:08",
"286","Validation of an extraction-free RT-PCR protocol for detection of SARS-CoV2 RNA","10.1101/2020.04.29.20085910","NucleicAcid-PCR based","Other PCR method(s)","N","In-house extraction free RT-PCR protocol","RT-PCR protocol Grant et al 2020","Sensitivity: 93% (overall), 100% (high viral titre)","136 samples","","no","","2021-05-27 09:48:42",
"881","Validation of SARS-CoV-2 detection across multiple specimen types","10.1016/j.jcv.2020.104438","NucleicAcid-PCR based","RT-PCR","N1 and N2","","evaluate the accuracy and sensitivity of a laboratory modified CDCbased SARS-CoV-2 N1 and N2 assay across a range of sample types."," CT cut-off: 33.8–35.7 LOD: 10–20 copies/reaction (N1) CT cut-off: 34.0–36.2 LOD: 1–10 copies/reaction (N2). ","2600 specimens","","yes","","2021-05-27 10:06:50",
"1285","Validation of self-collected buccal swab and saliva as a diagnostic tool for COVID-19.","10.1016/j.ijid.2020.12.080","NucleicAcid-PCR based","RT-PCR","E","RT-PCR (Corman)","Validation of self-collected buccal swab and saliva as a diagnostic tool for COVID-19","PPA: 66.7% (saliva vs NPS), 56.7% (buccal swab vs NPS); NPA: 91.7%(saliva vs NPS), 100% (buccal swab vs NPS); Overall Agreement: 69.0%(saliva vs NPS), 73.8% (buccal swab vs NPS)","42 patients","","yes","","2021-05-27 10:19:13",
"1250","Validation of the GeneXpert Xpress SARS-CoV-2 PCR assay using saliva as biological specimen.","10.1016/j.bjid.2021.101543","NucleicAcid-PCR based","RT-PCR","E and N2 genes","Xpert Xpress SARS-CoV-2 (Cepheid, Sunnyvale, California, USA)","Xpert Xpress assay compared to Charitè-Berlin assay targetin E and ORF1ab","remarks: 100% agreement between the two assays. more info about Ct values are available","40 samples","","yes","","2021-05-27 10:18:01",
"1183","Validation of the Hologic Aptima Unisex and Multitest Specimen Collection Kits Used for Endocervical and Male Urethral Swab Specimens (Aptima Swabs) for Collection of Samples from SARS-CoV-2-Infected Patients","10.1128/JCM.00753-20","Others","Other","/","system for collection of samples from SARS -CoV -2 infected patients","validation of the Hologic Aptima Unisex and Multitest Specimen collection device using RT-PCR reaction using Thermo-Fisher TaqPath COVID-19 Combo Kit on QuantStudio 12K Flex instrument","/","16 Positive, 19 Negative","","yes","","2021-05-27 10:15:47",
"1252","Validation of the STANDARD Q COVID-19 antigen test in Vojvodina Serbia.","10.1371/journal.pone.0247606","ImmunoAssay-Antigen","LFIA","","STANDARD Q COVID-19 Ag Test (SD Biosensor, Gyeonggi-do, South Korea)","Comparison of chromatographic antigen assay with Argene, SARS-COV-2 R-GENE assay (bioMerieux, Marcy-l’Etoile, France) and COVID-19 Genesig Real-Time PCR Kit (Primerdesign Ltd, Chandler’s Ford, UK)","Sensitivity: 58.1% ; Specificity: 100% ; PPV: 100% ; NPV: 81.1% ; Accuracy: 85% ; remarks: more values are available for sample subsets","120 patients","","yes","","2021-05-27 10:18:05",
"1261","Variable Performance in 6 Commercial SARS-CoV-2 Antibody Assays May Affect Convalescent Plasma and Seroprevalence Screening.","10.1093/ajcp/aqaa228","ImmunoAssay-Antibody","Mixed","IgG (Beckman); Total Ab (Roche, Siemens); IgA, IgG (Euroimmun)","kits","6 SARS-CoV-2 antibody assays: Beckman Coulter SARS-CoV-2 IgG (AU5800 analyzer; Beckman Coulter), Roche Elecsys Anti–SARS-CoV-2 Total (ecobas 400 analyzer; Roche), Siemens SARS-CoV-2 Total (Centaur XP analyzer; Siemens-C), and Siemens SARS-CoV-2 Total Antibody (Vista 1500 analyzer; Siemens-V), Euroimmun Anti–SARS-CoV-2 IgA and Euroimmun Anti–SARS-CoV-2 IgG.","Specificity : >99% (Beckman Coulter, Roche, Siemens-C, and Siemens-V),  98.9% (Euroimmun IgG), 4.6% (Euroimmun IgA); Sensitivity at >21 dpo: 84% (Beckman Coulter), 95% (Centaur), 72% (Vista), 98% (Roche), 67% (Euroimmun IgA), 84% (Euroimmun IgG); Sensitivity compared with clinical status, >14 dpo: 86% (Beckman Coulter), 95% (Siemens-C), 78% (Siemens-V), 90% (Roche), 73% (Euroimmun IgA), 96% (Euroimmun IgG); concordance between assays: 97% (Beckman Coulter), 97% (Siemens-C), 86% (Siemens-V), 85% (Roche), 82% (Euroimmun IgA), 99% (Euroimmun IgG)","184 samples (specificity), 154 samples (sensitivity)","","yes","","2021-05-27 10:18:24",
"932","Variplexâ„¢ test system fails to reliably detect SARS-CoV-2 directly from respiratory samples without RNA extraction","10.1007/s10096-020-03983-9","NucleicAcid-PCR based","LAMP","","Variplex","test the possibility of isothermal amplification directly from respiratory samples without RNA extraction","Sensitivity:17%; Specificity: 88.7%","109 patients","","yes","","2021-05-27 10:08:20",
"971","Viral and bacterial pneumonia diagnosis via deep learning techniques and model explainability","10.14569/IJACSA.2020.0110780","Imaging-X-ray","In_silico","X-ray","x-ray","CNN-based method to distinguish between bacterial and viral pneumonia, stratify healthy samples and patients.","average accuracy: 95.8%","5856 images","","yes","","2021-05-27 10:09:10",
"111","Viral Kinetics and Antibody Responses in Patients with COVID-19","10.1101/2020.03.24.20042382","ImmunoAssay-Antigen"," ","Multiple","","","Not reported","67 patients","transmission electron microscopy","no","","2021-05-27 09:44:53",
"907","Viral loads in throat and anal swabs in children infected with SARS-CoV-2","10.1080/22221751.2020.1771219","NucleicAcid-PCR based","WHO method(s)","ORF1ab","WHO-1","RT-PCR-testing on throat and anal swabs correlation with different immune state in paediatric patients and SARS-CoV2 infections","","2138 patients","","yes","","2021-05-27 10:07:37",
"1013","Viruses in wastewater: occurrence, abundance and detection methods.","10.1016/j.scitotenv.2020.140910","NucleicAcid-PCR based","Mixed","mixed","RT-PCR, qPCR","overview of methods for dection of virusses in wates water","table 3 lists available methods for detection of virusses in waste water","/"," ","yes","","2021-05-27 10:10:12",
"1283","Visual Detection of SARS-CoV-2 RNA by Conventional PCR-Induced Generation of DNAzyme Sensor.","10.3389/fmolb.2020.586254","NucleicAcid-Others","Other PCR method(s)","N","visual detection assay","simple visual detection assay for SARS-CoV-2 RNA using a conventional thermal cycler by the PCR-induced generation of DNAzyme sensor","Sensitivity: 100%; Specificity: 100%; LOD: 1000 copies of viral RNA","34 samples","","yes","","2021-05-27 10:19:09",
"834","Weakly Supervised Deep Learning for COVID-19 Infection Detection and Classification from CT Images","10.1109/ACCESS.2020.3005510","Imaging-CT scan","In_silico"," ","CT scan evaluation by Weakly Supervised Deep Learning","design and evaluation of several CT scan evaluation algorithms","accuracy: 84.3% (covid19), 83.2% (community acquired pneumonia), 80.1% (non pneumonia); precision: 72.4% (covid19), 70.7% (community acquired pneumonia), 66.7% (non pneumonia); sensitivity: 76.4% (covid19), 74.5% (community acquired pneumonia), 73.8% (non pneumonia); specificity: 89.8% (covid19), 89% (community acquired pneumonia), 89.6% (non pneumonia)","60 images"," ","yes","","2021-05-27 10:05:30",
"771","Within the lack of chest COVID-19 X-ray dataset: A novel detection model based on GAN and deep transfer learning","10.3390/SYM12040651","Imaging-X-ray","In_silico","X-rays","deep learning","GAN with deep transfer learning for coronavirus detection in chest X-ray images","testing accuracy: 80.6% (Googlenet), 85.2% (Alexnet),  100% (Googlenet including two classes COVID-19, and normal); validation accuracy: 99.9% (Googlenet including two classes COVID-19, and normal)","307 images","","yes","","2021-05-27 10:03:30",